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ABSTRACT
The dietary recommendation to replace saturated fat with carbohydrate as a means of 
reducing cardiovascular risk, has been hindered by the adverse effect of dietary extrinsic 
sugars on plasma lipids. The project described in this thesis, formed part of a BBSRC- 
funded trial to examine the impact of dietary extrinsic sugars on lipoprotein kinetics. A 
key objective of this project was to design and deliver two diets, high and low in extrinsic 
sugars, to test the hypothesis of the main trial; that dietary sugars influence plasma 
lipids, via differential effects on the kinetics of plasma lipoproteins, in groups with 
moderately raised and low liver fat.
This thesis presents the results from five experimental Chapters (2-6): i) An independent, 
systematic review and meta-analysis of the relationship between dietary sugars and 
plasma lipids (Chapter 2), that confirmed significant positive and negative associations 
between dietary sugars, especially fructose, with plasma TAG and HDL-cholesterol, 
respectively; ii) the development of two experimental diets, high and low in sugars, 
based on the exchange of starch and sugars, using supermarket foods (Chapter 3). The 
exchange achieved, and came close to achieving, target intakes for sugar, that were 
representative of the upper 95**^  and lower 5*^  percentile of sugar intake in the UK; iii) a 
study of the impact of these two diets on plasma lipids and lipoproteins, in groups with 
raised and low liver fat (Chapters 4 & 5). The high sugar diet was accompanied by 
significant increases in plasma TAG, apoproteins (CHI & E), and liver fat, and decreases 
in HDL-cholesterol, and lipoprotein particle size. In contrast, the low sugar diet was 
associated with opposite changes in all of these variables. The effects of both diets were 
shown to be more pronounced in the group with moderately raised liver fat (> 4.2%), and 
were largely unaltered by the re-analysis of sugar intake by three different methods 
(Chapter 6).
These findings provide evidence for the practical feasibility, and experimental utility of 
exchanging starch and sugars in real foods. They also provide further support for the 
recommendation to restrict the intake of dietary extrinsic sugars, especially in individuals 
with moderately raised liver fat.
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Chapter 1 
INTRODUCTION
1.1 General introduction
The death rate from cardiovascular diseases (CVD) in the UK has been falling since 
the 1970s. In the last 10 years, the rate of premature death (death before age of 75) 
from CVD has decreased by 44% [1]. This decline, has been more substantial among 
those aged 55 and above, as compared to the younger age group. Despite this falling 
trend, CVD is still a major cause of death in the UK, and accounts for one in three of 
all deaths or almost 191,000 deaths per year [1].
There are numerous risk factors contributing to CVD, including obesity, type 2 
diabetes (T2DM), hypertension, dyslipidaemia, and metabolic syndrome [1, 2]. The 
metabolic syndrome, which is a cluster of abnormalities that includes, disturbed 
glucose and insulin metabolism, obesity and abdominal fat distribution, dyslipidaemia 
and hypertension, has increased in importance through its association with the 
development of T2DM and CVD, particularly in middle-aged men [3, 4]. It has also 
now widely recognised that the highest prevalence of this group is found in people 
with intra-abdominal obesity, and raised liver fat [5-7]. A key underlying defect in 
metabolic syndrome is insulin resistance, a condition that has been implicated in pro- 
atherogenic changes in plasma lipids, hypertension and pro-coaguable, and 
inflammatory states, that collectively confer what is known as cardio-metabolic risk 
[4]. An atherogenic lipoprotein phenotype (ALP) is a dyslipidaemia that is 
characterised by three principal lipid abnormalities; moderately increased plasma 
triacylglyceroi (TAG), reduced high-density lipoprotein-cholesterol (HDL-C) and a 
predominance of small, dense low density lipoprotein (sdLDL) [8-11]. Correction of 
these lipid abnormalities have been associated with reduced CVD mortality and 
morbidity [12]. As such, these biomarkers of CVD risk have become important 
therapeutic targets for dietary and lifestyle modification [13,14].
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1.2 Historical perspective on the roie of dietary carbohydrates and CVD
In the early 1950s, Dr. Ancel Keys, an American physiologist was the first to propose 
an association between dietary saturated fats and coronary heart disease (CHD) [15]. 
This positive association was subsequently confirmed and found to be mediated 
through the cholesterol-raising effects of saturated fatty acids (SFA) [16]. This led to 
worldwide nutritional advice to reduce intake of saturated fats. Soon after, in the 
1960s, Keys speculated about the potentially harmful effect of trans fatty acids on 
heart disease and became one of the first to warn against the adverse effect of trans 
fatty acids and the need to reduce intake of certain vegetable oils and margarine [16, 
17]. However, it was discovered subsequently that vegetable oils were not associated 
with high blood cholesterol levels, whilst saturated fatty acids frequently increased 
LDL-cholesterol (LDL-C) [16]. In later work. Keys proposed that saturated fatty acids 
from animal sources were associated with raised blood cholesterol, whilst 
polyunsaturated fatty acids had the opposite effect [16, 17]. His most frequently cited 
study. The  Seven Countries study’ [18, 19], fuelled a wealth of research in this area, 
especially in relation to the links between dietary fats, saturated fat, LDL-C and CVD. 
There after, the National Cholesterol Education Program, Adult Treatment Therapy III 
(NCEP-ATP III) guideline focused on reducing fats to lower LDL-C and total 
cholesterol (TC) to reduce CVD risk [20]. Dietary recommendations at the time, 
emphasized the importance of replacing fat with carbohydrates (CHOs). However, in 
the late 1950s, this theory was challenged by Professor John Yudkin, a British 
physiologist and nutritional scientist who claimed that sugars harboured greater risk 
than fats. Yudkin, who became internationally renowned for his book ‘Pure, White and 
Deadly’, first published in 1972 [21], proposed that sugar and refined sweeteners 
were associated with CHD and T2DM, mainly by increasing plasma TAG and insulin 
levels [21-23]. Dietary sugars were ‘out lawed’ as ‘the killer whites’ for their potentially 
adverse effects on CHD risk. Yudkin, who originally had been an advocate of the 
adverse effects to cardiovascular health of CHO-based diets, was largely responsible 
for stimulating interest in the association between dietary sugars and CVD risk [22]. In 
agreement with Yudkin, more recent meta-analysis by Katan et al. has demonstrated 
the potential adverse effects of dietary CHOs on CVD risk factors; plasma TAG and 
HDL-C (Fig. 1.1) [24]. Mozaffarian at al. also has confirmed that a higher intake of 
dietary CHOs, especially when the glycémie index is high, was associated with an
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increased progression of coronary atherosclerosis in post-menopausal women (Fig. 
1.2) [25].
Figure 1.1: Effects of a diet high in monounsaturated fat (MUFA) as compared 
with a diet high in CHO on piasma TAG and HDL-C
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Triglycerides -100
o------
-75
0 .8 -
504030200 10
C Q
Day
Straight line, high CHO diet; dotted line, high MUFA diet. Data are in mean. Adapted
from Katan et al. [24]
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Previous to this, there was universal agreement that a low fat diet, which was 
generally high in CHO, was an essential dietary modification to improve lipid 
abnormalities and reduce CVD morbidity. However, there was growing evidence to 
suggest that high CHO diets may be associated with adverse changes in plasma 
lipids, especially hypertriacylglycerolaemia [24, 26], the formation of sdLDL and 
reduction of plasma HDL-C [27]. There is now evidence to suggest that these effects 
are exacerbated by insulin resistance and by the accumulation of fat in the liver [28, 
29].
The following introduction will summarise the prevalence, incidence, and 
pathophysiology of CVD and dyslipidaemia, and the inter-relationships between 
metabolic syndrome, abdominal obesity, insulin resistance, fatty liver and other 
cardio-metabolic risk factors. It will also address the classification and metabolism of 
CHO, and review the available literature concerning the effects of a high CHO and 
sugar diets on lipid and lipoprotein abnormalities. A more detailed account of the 
effects of a high sugar diet on plasma lipids, is presented in a systematic review in 
Chapter 2.
1.3 Dietary CHOs; classification and metabolism
Dietary carbohydrates (CHOs) are the major substrate for energy metabolism in a 
typical human diet; and generally contribute «45 to 55% of total energy [30]. In 
addition, CHOs influence satiety, blood glucose and insulin, lipid metabolism and, via 
fermentation, exert a major influence on colonic function, including bowel habit, 
transit, the metabolism and balance of the commensal flora and large bowel epithelial 
cell health, immune modulation and calcium absorption [31-33]. These effects may 
have substantial implications for human health, particularly for obesity and CVD risk.
According to Yudkin’s original work, CHOs are classified as ‘available/digestible’ and 
‘unavailable/indigestible’ [21]. The ‘available/digestible’ CHOs refers to two main 
components, based on their chemical structure i.e. complex (starch) and simple or 
refined (sugars), whereas the ‘unavailable/indigestible’ CHOs refer to the dietary 
fibre. The term CHOs was originally derived from the general empirical formula of the 
carbon, oxygen and hydrogen molecules Cm(H20)n. In chemical terms, CHOs are also 
known as saccharides which are divided into three chemical groups; sugars
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(monosaccharides and disaccharides), oligosaccharides and polysaccharides (Table 
1.1) [31, 34]. The word saccharides originated from the Greek word ‘sakkharon’ which 
means ‘sugar’. Terminologies like complex CHO, starches, resistant starch, dietary 
fibre and glycaemic CHO are terms that relate to the physiological attributes of CHOs 
and thus reflect the associations between CHOs health and disease.
Table 1.1 : Primary classification of dietary CHOs based on chemistry including 
character of individual monomers, degree of polymerisation (DP) and type of
linkage (a or p)
Class (DP) Subgroup Principal components
Sugars (1-2) Monosaccharides Glucose, fructose, galactose
Disaccharides Sucrose, lactose, maltose, 
trehalose
Polyols (sugar alcohols) Sorbitol, mannitol, lactitol, xylitol, 
erythritol, isomalt, maltitol
Oligosaccharides 
(3 -9) (short-chain 
carbohydrates)
Malto-oligosaccharides («- 
glucans)
Maltodextrins
Non-ot-glucan
oligosaccharides
Raffinose, stachyose, fructo and 
galacto oligosaccharides, 
polydextrose, inulin
Polysaccharides
( > 10)
Starch («-glucans) Amylose, amylopectin, modified 
starches
Non-starch
polysaccharides
(NSPs)
Cellulose, hemicellulose, 
pectin, arabinoxylans, P- 
glucan, glucomannans, 
plant gums and mucilages, 
hydrocolloids
Non-starch polysaccharides 
(NSPs)
DP, degree of polymerisation or number of monomeric (single sugar) units. Figure 
structure of dietary mono- and disaccharides (Figs. 1.3 and 1.4). Adapted from 
Cummings & Stephen [31] which was based FAO/WHO ‘Carbohydrates in Human 
Nutrition’ report [32] and Cummings etal. [35].
1.3.1 Polysaccharides (starches)
Polysaccharides are a major component of CHOs, and consist of a mixture of long 
straight (amylase) and branching chains (amylopectins) of glucose units, which are
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synthesised and utilised by plants as their energy store [31]. Animals and humans are 
able to synthesise long and branched glucose chains known as glycogen which is 
stored in the body and skeletal muscle. This provides a readily available, but 
relatively small and short-term, source of energy. The major energy store in tissues is 
fat, but the breakdown of fat to provide energy is more complex and requires more 
energy than CHOs [32]. Polysaccharides can be found in plant-based food such as 
bread, rice, potatoes, cereals and cereal products. Polysaccharides and 
disaccharides, such as sucrose, and are digested in the intestine to be absorbed in 
the simplest unit as monosaccharides before being metabolised to energy [36].
1.3.2 Mono- and disaccharides (sugars)
Mono- and disaccharides are typically referred to as sugars (Figs. 1.3 and 1.4). 
Sugars play an important role in a human diet, mainly as a sweetener in foods and 
beverages to increase palatability. Because of their physical properties and functional 
characteristics and capacity, sugars are widely used in food manufacturing for food 
preservation and as moisturising agents [31]. The three principal monosaccharides, 
glucose, fructose and galactose, form the building blocks of oligosaccharides and 
polysaccharides. Free glucose and fructose occur naturally in fruits and honey. 
Amongst all types of sugar, fructose is the sweetest, and high fructose corn syrup 
(HFCS), produced by the hydrolysis of corn starch, containing glucose:fructose 
(45:55), has been increasingly used in foods and beverages for its sweetness, and is 
cheaper compared to other type of sugars. The consumption of sugar from HFCS has 
been associated with increasing rates of obesity and T2DM [37, 38] mainly in the US 
and especially among children [39]. However, there is an embargo on the use of 
HFCS in the UK and Europe [40].
Figure 1.3: Chemical structure of monosaccharides
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The principal disaccharides are sucrose and lactose (Fig. 1.4). Sucrose, commonly 
known as table sugar, which contains glucose:fructose (50:50), is the most abundant 
sugar and is widely used as an added sweetener in tea, coffee and cooking [31]. It is 
extracted from cane and beet. The increasing intake of sucrose has also been 
associated with adverse effects on CVD risk factors, including raised plasma TAG, 
low HDL-C [41] and hyperglycaemia [42]. Lactose is milk sugar, containing 
glucose:galactose (50:50). Maltose, the least abundant disaccharide, is derived from 
the starch which occurs in sprouted wheat and barley. Another less well known 
disaccharide, trehalose, which is found in yeast and fungi and small amounts in bread 
and honey, is used in the manufacture of foods and beverages as a replacement for 
sucrose, since it provides similar technological properties, but a less sweet taste in 
the final product [31].
Figure 1.4: Chemical structure of disaccharides
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In addition to classifications based on chemical structure, sugars have also been 
categorised by other terms, like total sugar, added sugar, free sugars, refined sugars, 
discretionary sugar, intrinsic, extrinsic and milk sugars which are used to denote their 
origin, and for labelling, educational and research purposes. Total sugars’: a term 
generally used for labelling purposes mainly on food packaging which includes all 
sugars (all mono- and disaccharides except polyols) from any source in a food [43]. 
This term is established in many countries, including the European Union, Australia 
and New Zealand. Similar to total sugars, the term ‘free sugars’ has been used to 
describe any sugars which occur in any foods that are free or extrinsic (outside of the
31
food matrix) [44], which includes all mono- and disaccharides including lactose [45]. 
In analytical terms, ‘free sugar’ has been used to describe hydrolysed CHO in a food 
where the component has been identified by chromatography and colorimetric 
methods [45]. However, in more recent years, this term has been used to describe all 
monosaccharides and disaccharides added to foods, by the manufacturer or 
consumer, in addition to the sugar naturally occurring in such foods as honey, syrups 
and fruit juices. The term ‘free’ sugar is used internationally and preferred by the 
WHO/FAO panel relative to its synonym, non-milk extrinsic sugar (NMES) (described 
below) which was only adopted in the UK [46]. The term ‘added sugars’ is commonly 
used in the US to refer to sugars and syrups that are added to foods and beverages 
during processing and preparation [47]. These foods include honey, molasses, fruit 
juice concentrate, brown sugar, corn sweetener, HFCS, sucrose, lactose, glucose, 
corn syrup and malt syrup. ‘Natural sugar’ is a term used in the food manufacturing 
industry to distinguish between the naturally occurring sugar in food and added sugar 
[48]. Terminologies like ‘discretionary sugar’, refined sugars’ and ‘total available 
sugars’ are also in use on food labels to describe the content of sucrose [48].
Sugars can also be subdivided into categories of intrinsic and extrinsic, terms that 
originated in the UK, on the basis of their physical location in foods [36]. intrinsic 
sugars are sugars that are located inside the cellular matrix and form the integral part 
of certain foodstuffs, such as whole fruits and vegetables, these are namely fructose, 
glucose and sucrose, and are naturally occurring and always accompany other 
micronutrients [31, 34]. Extrinsic sugars, are generally defined as sugars that are 
located outside the cellular structure of foods. They are found in processed foods and 
fruits, including fruit juices and fruit products. For example, lactose in milk is an 
extrinsic sugar as it is not found within the cellular matrix. However, due to its 
nutritional properties, lactose forms a separate group which is known as ‘milk sugar’ 
to distinguish it from other extrinsic sugars which are non-milk extrinsic sugars 
(NMES), and have less nutritional value [31, 36].
Non-milk extrinsic sugars (NMES). This term was first introduced in the UK in 
response to concern over oral health. NMES were considered to be harmful through 
their association with dental caries [36], but whilst this term is not well understood by 
the public, it is useful from a nutritional perspective to help consumers choose 
between healthy and unhealthy sugars with respect to oral health, and has often been
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used in dietary surveys [49-51]. NMES includes sugars in fruit juices, honey, and 
those added to foods and beverages as a sweetener (i.e. recipe/table sugar and high- 
fructose corn syrup) during processing and preparation. Recipe sugars include 
sugars that are added to composite dishes and confections. Recipes and 
formulations have a characteristic content of sugars. The quantity of sugar in different 
recipes and products, ranges from negligible to 100% of the food energy. Foods 
which are high in sugar include preserves, soft drinks, sugar confectionery, biscuits, 
cakes and desserts. In comparison, table sugars are sugars that are pure and 
reinforced with non-nutritive sweeteners, which an individual may choose to add to 
food or drink [31, 36]. The latter are thought to exert deleterious effects on health. In 
addition to dental caries, NMES have also been associated with adverse effects on 
CVD risk [52].
1.3.3 Non-starch polysaccharides
Non-starch polysaccharides (NSPs) are more commonly known as dietary fibre, and 
are contained in such foods as fruits, vegetables and whole grain cereal-based foods. 
Soluble fibre is contained in oats, barley and rye, and insoluble fibre is found in 
wheat, maize and rice. NSPs-rich foods are generally less energy dense, but provide 
more bulk than other foods, as for example vegetables compared to the same weight 
of rice. This property of NSPs may contribute to its ability to increase satiety [53], 
making it a favoured a component of weight-losing diets [54-56]. NSP is thought to 
influence CHO metabolism, but the mechanism is unknown. Oats and beans have 
been associated with a lowering of LDL-C through their (3-glucan content, but exert no 
effect on plasma TAG [57].
1.3.4 Dietary intake of the UK population from the National Dietary and 
Nutrition Survey (NDNS)
Data from NDNS showed the average intake of energy from CHO to be 48%  and 
49% in men and women, respectively, whilst the energy intake from NMES was 14%  
and 12% in men and women, respectively (Table 1.2). Although the total intake of 
CHOs (NDNS) is close to the Dietary Recommended Value (DRV) (50% of energy) 
[58], the current intake of NMES exceeds the WHO recommendation of free sugars
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i.e. <10% of energy [52]. Nonetheless, the intake of NMES was shown to be reduced 
as age increased in both genders [30].
The main sources of intake of total CHO in the UK population according to NDNS [30] 
are cereals and cereal products (45%), potatoes (11%), drinks (10%) and sugar, 
preserves and confectionery (9%). There were differences in the contributions from 
these foods groups across age groups. The main sources of dietary sugars in the 
younger UK population were soft drinks (57%); sugar, preserves and confectionery 
(24%), whereas the main sources in older groups were sugar (mainly table sugar), 
preserves and confectionery, providing just over a third of total intake (34%), followed 
by soft drinks (27%). It is possible that the high intake of sugars may have an 
influence in lowering the average intake of dietary fibre below the current DRV of 
16g/day, particularly in the younger age groups (< 35 years old) [58].
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Table 1.2: Average daily intake of energy and macronutrients of UK adults
Men Mean Women Mean
Age IQ- 25- 35- 50- IQ- 25- 35- 50-
(year) 24 34 49 64 24 34 49 64
Energy (MJ) 9.44 9.82 9.93 9.55 9.72 7 6.61 6.96 6.91 6.87
Protein (g) 77.8 90.6 90.1 88.8 88.2 59.9 58.7 65.1 67.4 63.7
CHO (g) 273 277 279 269 275 206 196 206 203 203
% of food 49 47.7 47.5 47.4 47.7 49.1 48.7 48.6 48.1 48.5
energy 
NMES (g) 96 80 78 70 79 60 49 51 48 51
% of food 17.4 13.9 13.1 12.2 13.6 14.2 11.8 11.8 11 11.9
energy 
NSP (g) 12.3 14.6 15.7 16.4 15.2 10.6 11.6 12.8 14 12.6
% with 94 77 70 61 72 96 92 85 80 87
intakes
Fat (g) 85.8 87.1 88.3 84.5 86.5 63.9 59.8 61.9 61.2 61.4
% of food 36 35.8 35.9 35.6 35.8 35.5 35.4 34.7 34.5 34.9
energy 
Sat. fat (g) 32.3 32.2 33.4 32 32.5 23.5 22.4 23.6 23.7 23.3
% of food 13.5 13.2 13.5 13.4 13.4 12.9 13.2 13.2 13.3 13.2
energy
CHO, carbohydrate; NMES, non-milk extrinsic sugars; NSP, non-starch 
polysaccharides; Sat. fat, saturated fat. National Dietary and Nutrition Survey (NDNS) 
[30].
1.4 Prevalence of cardiovascular disease (CVD)
Cardiovascular disease (CVD) represents a number of diseases which include 
coronary heart disease (CHD), cerebrovascular disease, peripheral arterial disease, 
rheumatic heart disease, congenital heart disease and deep vein thrombosis, and 
pulmonary embolism. The most prevalent forms of CVD worldwide are CHD and 
cerebrovascular disease or stroke [1]. In 2008, an estimated 17.3 million people died 
from CVD, worldwide, representing 30% of all global deaths [59]. In the US alone, an 
estimated 71.3 million people, or one in three adults, have some form of CVD and the 
prevalence is well known to increase with age [60]. While in the UK, the incidence of 
death from CVD has fallen over the last 30 years by 60%, it is still the main cause of
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premature death [1]. The World Health Organization (WHO) has forecast, that by 
2030 over 23 million people across the globe will die from CVD, and the prevalence 
will increase substantially in South-East Asia [59, 61]. According to WHO, CVD 
underlies 10% of disability-adjusted life years lost (defined as ‘healthy years of life 
lost’) in low- and middle-income countries, and 18% in high-income countries [62]. 
The economic burden of CVD is considerable. In 2006, it has been estimated that 
CVD cost the NHS in the UK over £14 billion, with 72% of this cost being for hospital 
care and 20% for the cost of medication [1].
1.5 Cardio-metabolic risk
Cardio-metabolic risk describes a collection of related CVD risk factors with a 
common metabolic origin (Fig. 1.5). A conventional approach of medical practice, has 
been to lower CVD morbidity by treating smoking, hypertension and dyslipidaemia. 
However, as the prevalence of obesity and the risk of diabetes has increased, focus 
has shifted to the treatment of cardio-metabolic risk, which may represent the 
greatest underlying source of CVD risk worldwide.
Figure 1.5: Characteristics of cardio-metaboiic risk [63]
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1.5.1 Metabolic syndrome
The clustering of metabolic abnormalities that are known today as metabolic 
syndrome, have been recognised since the 1920s. Metabolic syndrome is 
phenotypically heterogeneous and presents as a variable expression of metabolic
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defects, that increase CVD risk by approximately two-fold [64]. Kyi in was one of the 
first to recognise this collection of abnormalities as a clustering of hypertension, 
hyperglycaemia and gout in the 1920s [65]. Two decades later, abdominal obesity 
had been detected as the most common type of obesity associated with the metabolic 
abnormalities seen in patients diagnosed with CVD and T2DM [66]. In the late 1980s, 
Reaven introduced the term ‘Syndrome X ’, and proposed insulin resistance to be a 
key pathophysiological feature in T2DM, hypertension and CHD [67]. Since then, the 
concept of insulin resistance and associated metabolic disturbances leading to 
increased CVD risk, have become known by a variety of names, including 
dysmetabolic syndrome. Syndrome X, cardio-metabolic syndrome, insulin resistance 
syndrome and metabolic syndrome [68].
Metabolic syndrome has been defined by a number of clinical bodies. The first official 
definition was provided by W HO in 1999 [69]. This was followed by other definitions 
from the European Group for the Study of Insulin Resistance (EGIR 1999) [70], the 
National Cholesterol Education Program-Adult Treatment Therapy III (ATP III 2001) 
[20] and the International Diabetes Federation (IDF 2006) [71, 72] (Table 1.3). Of 
these definitions, the ATP III criteria has been the most widely used in both clinical 
practice and epidemiological studies. In general, metabolic syndrome is defined as a 
group of metabolic disturbances, which may include combinations of abdominal 
obesity, an ALP (elevated plasma TAG, reduced HDL-C and predominance of 
sdLDL), raised blood pressure, insulin resistance, with or without glucose intolerance, 
and pro-thrombotic and pro-inflammatory states [4].
The prevalence of the metabolic syndrome has increased dramatically in the last 
decade, perhaps, in part, because of an increased awareness of the condition. In the 
US between 1999-2002, the prevalence of metabolic syndrome was 39% where 
almost 40% of those cases were in men and 38% were in women [73]; whereas in the 
UK, this syndrome has been reported to affect up to 25% of middle-aged, otherwise 
healthy men [74]. Metabolic syndrome more than doubles the risk of CHD mortality 
[3], predisposes to the development of T2DM [75], and is increasing in parallel with 
the pandemic of obesity [76]. In addition to those who are clinically diagnosed with 
metabolic syndrome, there is a substantial number of free-living and otherwise 
healthy individuals who are ‘at risk’ of developing the metabolic syndrome. While this
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group will be at increased susceptibility to CVD, their relatively moderate risk is more 
likely to be modifiable and responsive to early dietary and lifestyle modification [77].
Table 1.3: Definitions of the metabolic syndrome by different institutions
WHO 1999 EGIR 1999 NCEP ATP-III 2001 IDF 2006
Diabetes or impaired Insulin resistance or Any three of the Central obesity:
glucose tolerance or hyperinsulinaemia following WC>94cm for
insulin resistance plus (only non-diabetics components:- European S\ >90cm
two or more of the subjects) plus two or •  Fasting plasma for South Asians &
following more of the following glucose>6.1mmol/L Chinese S', >85 for
components:- components:- • Hypertriglyceridae Japanese S,
• Central obesity: •  Fasting plasma mia: WC>80cm
BMI>30kg/m^ glucose>6 .1mmol/ TAG>1.7mmol/L European/South
and/or WHR>0.9 L • Low HDL- Asians/Chinese $;
{S), WHR>0.85 (?) • Dyslipidaemia: C <1.0mmol/L {S), >90 for Japanese $,
• Dyslipidaemia: TAG>2.0mmol/L HDL-C<1.3mmol/L plus two of the
TAG>1.7mmol/L and/or HDL- (?) following
and/or HDL- C<1.0mmol/L • Hypertension: components:-
C<0.9mmol/L {S), •  Arterial arterial •  Hypertriglyceridae
HDL-C<1.0mmol/L pressure>140mmH press ure>130/85m mia:
(?) g mHg TAG>1.7mmol/L
• Arterial • Central obesity: • Central obesity: •  Low HDL-
pressure>140/90m WC>94cm {S), WC>102cm (6'), C<1.03mmol/L [S),
mHg WC>80cm (?) W C>88cm (?) HDL-
• Microalbuminuria>2 C<1.29mmol/L (?)
Opg/min or •  Raised arterial
albumin:creatinin pressure: systolic
ratio>30mg/g BP>130mmHg or 
diastolic 
BP>85mmHg 
•  Fasting plasma 
glucose>5.6mmol/ 
L or T2DM
WHR: waist:hip ratio, WC: waist circumference, 6': male, $: female
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1.5.2 Abdominal obesity
Thirty years ago, the greatest world health issue related to nutrition, was malnutrition, 
whereas today, W HO finds itself dealing with a pandemic of obesity and its co­
morbidities. Since the 1980s, worldwide obesity has created a ‘double burden’ of 
disease that and is linked to a lifestyle that is inappropriate for cardiovascular health, 
and which threatens to overwhelm the health services globally [78-81]. Obesity has 
become a common medical condition, increasing the likelihood of various chronic 
diseases including T2DM, CVD and some forms of cancer. In 2008, an estimated 1.5 
billion adults or 65% of the world’s population were overweight, and more than one in 
ten were obese [78]. In 2003-2004, 32% of the US population were identified as 
obese [82], which increased to 34% in 2010. In 2009, almost a quarter of adults in the 
UK, were classified as obese [83], of which at least 2.8 million were predicted to die 
each year [78]. In simple terms, obesity is an excessive storage of body fat that 
occurs when energy intake exceeds energy expenditure [83]. Although the aetiology 
of obesity is complex [84], its high prevalence across the globe has been attributed, 
to a major extent to an increased intake of energy-dense foods, that are high in fats, 
salt and sugars, but low in other micronutrients such as vitamins and minerals, and 
decreased physical activity [84, 85].
Obesity is defined clinically by body mass index (BMI) = kg/m^ [86]. Individuals with 
BMI > 25 kg/m^ are classified as being overweight, BMI 30 to 34.9 kg/m^ are obese 
type 1, BMI 35 to 39.9 kg/m^ are obese type 2 , whilst those with BMI > 40 kg/m^ are 
morbidly obese. Despite the fact that BMI is a predictor of disease morbidity and 
mortality, abdominal or central obesity, as assessed by waist circumference (> 102 
cm in men; > 88 cm in women), is known to be an even stronger marker of obesity- 
related health risk [87] than BMI, and is inextricably linked to T2DM, hypertension and 
CVD [88-90]. In addition, abdominal obesity, especially an excess of intra-abdominal 
or visceral adipose tissue (VAT), has been identified as the most prevalent 
anthropometric feature of these metabolic abnormalities [4]. It has been proposed 
that an accumulation of VAT may reflect the failure of subcutaneous adipose tissue to 
act as a protective reservoir or ‘sink’ for the storage of excess fat derived from food. 
When this ‘sink’ over flows, this can lead to the deposition of ectopic fat in skeletal 
muscle, heart and critically the liver [4]. The accumulation of visceral and ectopic fat 
has been implicated as a possible cause and/or effect of the metabolic abnormalities
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found in insulin resistant states. As individuals become obese, their tissues are likely 
to become resistant to the actions of insulin [91]. This may be due to, in part, to an 
increase in intra-cellular lipolysis that is associated with increased abdominal fat 
which, in turn, elevates the plasma concentration of non-esterified fatty acid (NEFA) 
[92]. Elevated plasma NEFA has the ability to interfere with the cellular mechanisms 
of insulin signalling and to suppress the sensitivity of cells to insulin [92, 93]. Even 
though central obesity and insulin resistance frequently co-exist, each may make 
independent and distinct contributions to cardio-metabolic risk [94].
1.5.3 Metabolic effects of insulin resistance
A quarter of the world’s adults are suspected to express insulin resistance [95, 96]. 
Insulin resistance or a decreased biological response to insulin is associated with 
central obesity and T2DM, and can result in a compensatory hyperinsulinaemia, 
which has now been recognised as a key underlying feature of metabolic syndrome 
[91, 97]. The exact molecular and cellular events that give rise to insulin resistance 
are still unclear. Insulin resistance is primarily observed in muscle and adipose tissue. 
In muscle, insulin insensitivity impairs glucose uptake which leads to increased 
plasma glucose levels, whilst in adipose tissue, insulin does not fully suppress 
hormone sensitive lipase (HSL) to inhibit intra-cellular lipolysis and the release of 
non-esterified fatty acid (NEFA), which ‘spill-over’ into the systemic circulation and 
increases delivery of NEFA to the liver [98]. This represents one mechanism by which 
insulin resistance can promote the accumulation of fat (TAG) in the liver [7, 99].
Excess VAT and intra-hepatic fat have been associated with hepatic insulin 
resistance [100-102]. Whether fat accumulation in the liver is a cause or an effect of 
insulin resistance remains unclear. Irrespective of this, fasting serum insulin 
concentration has been previously related to the amount of liver fat, in both men and 
women [103]. Insulin resistance has also been associated with an atherogenic lipid 
profile, most notably hypertriacylglycerolaemia, due to increased very-low density 
lipoprotein (VLDL) (both increased synthesis and reduced clearance) [104] and 
reductions in HDL-C [67]. There is evidence to suggest that the latter process may 
promote the progressive elimination of lipid and apolipoproteins from VLDL particles, 
leading to an increased formation of intermediate-density (IDL) and LDL, which under 
certain circumstances, can become sdLDL [104]. Moreover, hyperinsulinaemia may
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directly promote hepatic VLDL production even when there is resistance to the 
glucose-lowering effect of insulin [67]. This may also result in increased hepatic 
glucose production which could lead to hyperglycaemia, especially in patients with 
T2DM [104]. In addition, insulin resistance and hyperinsulinaemia have been 
associated with hypertension [105]. Through these effects, insulin resistance has 
been implicated as a causal factor for the development of four major related 
diseases; T2DM [104], metabolic syndrome [106], fatty liver [100] and CVD [104, 
107, 108].
1.5.4 Fatty liver disease
The accumulation of TAG in hepatocytes, in the absence of alcohol overconsumption, 
can lead to non-alcoholic fatty liver disease (NAFLD). NAFLD (liver fat > 5%) is 
considered when alcohol is consumed at less than 20g/day for women and 40g/day 
for men [109]. While an increased concentrations of liver enzymes; alanine 
transaminase (ALT) and aspartate transaminase (AST) (or AST/ALT ratio less than 1) 
may provide a crude indication of possible NAFLD, further more definitive 
investigations are required to diagnose the condition. These include proton magnetic 
resonance spectroscopy (HMRS), ultrasound, computerised tomography (CT) scan or 
an ultimately liver biopsy [110]. NAFLD is probably the most common condition of 
liver disease, and was observed in nearly 25% of Europeans with a spectrum of 
pathology that includes steatosis and liver cirrhosis, ranging from mild to severe 
[111]. Steatosis, the first stage of NAFLD, represents fat accumulation in liver tissue 
without inflammation. In some cases, NAFLD can progress to non-alcoholic 
steatohepatitis (NASH), which is characterised by steatosis and inflammation, with or 
without fibrosis. The former condition is usually benign while the latter has a higher 
risk of CVD and progression to severe liver disease, including cirrhosis. In the US, the 
prevalence of NAFLD was estimated to be 30% as measured by HMRS [112]. It is 
mostly detected in obese individuals, diabetics and patients diagnosed with metabolic 
syndrome and dyslipidaemia [110], and has been found to be positively associated 
with BMI and abdominal obesity [113]. In addition, NAFLD has been associated with 
peripheral and hepatic insulin resistance [5, 114], increased fasting plasma insulin 
concentration [103], decreased insulin clearance [115] and dyslipidaemia [103]. The 
hallmark feature of the pathogenesis of fatty liver disease is the accumulation of TAG  
in the liver, with hepatic insulin resistance as the key underlying metabolic defect (Fig.
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1.6). There is also evidence to suggest that in NAFLD, insulin fails to suppress 
adipose tissue lipolysis to the same extent as in healthy individuals, which further 
exacerbates the accumulation of TAG in the liver [114].
Figure 1.6: Schematic for the pathogenesis of fatty iiver disease
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TNF-a, tumor necrosis factor. Insulin resistance, the most antecedent metabolic 
abnormality associated with fatty liver disease (with/without other abnormalities) leads 
to hepatic fat accumulation which later predisposes to the hepatocelullar injury. This 
is also associated with the direct cellular toxicity caused by excess free fatty acids, 
oxidant stress and lipid peroxidation. Hepatocelullar injury leads to an inflammatory 
response. These effects are dependent on a variety of environmental and genetic 
influences, including high CHO intake. Adapted from Chronic Liver Disease 
Foundation (CLDF) Slide Collection courtesy of Neushwander-Tetri & Caldwell [116].
Stable isotope tracers have been used to identify possible sources of fat that may 
contribute to fatty liver (Fig. 1.7). These include fat from the periphery, and 
specifically NEFA released from adipose tissue that overflows into the liver via the 
hepatic portal vein (Pathway 1 and 3); new fatty acids via DNL (Pathway 2); and
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dietary fatty acids which can enter the liver through the uptake of intestinally derived 
chylomicron remnants (Pathway 4) [117].
Figure 1.7: A mechanistic diagram of iipid fiux through the iiver
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technique. DNL, 6e novo lipogenesis] FA, fatty acids; NEFA, non-esterified fatty 
acids; TAG, triacylglycerol. Adapted from Donnelly etal. [117].
Fatty liver has been previously shown to be four-fold higher in individuals with 
metabolic syndrome compared to individuals without metabolic syndrome, 
independently of age, gender and BMI [103]. Liver fat has also been linked with all 
components of the metabolic syndrome, especially waist circumference and fasting 
serum insulin, in both men and women [103]. Insulin resistance produced by fatty 
liver has been linked to increase glucose, VLDL, G-reactive protein (GRP) and 
coagulation factors, all of which increase GVD risk [6]. Effective treatment for NAFLD, 
through weight loss and pharmacotherapy, has been shown to be effective, if the 
condition is at a reversible stage [118].
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One of the environmental predisposing factors associated with NAFLD is an 
excessive intake of dietary CHO and sugar. A survey conducted by Zelber-Sagi et al. 
has shown that NAFLD patients had a higher intake of soft drinks relative to healthy 
individuals, and that the risk of NAFLD was associated with the consumption of soft 
drinks independently of age, gender, BMI and total energy intake [119]. Increased 
liver fat was also associated with increased DNL [114, 120]. As already mentioned, 
insulin resistance may contribute to the increase in fatty acid flux from the adipose 
tissue to the liver, which promotes the accumulation of fat in the liver [121].
1.6 Lipoproteins; structure and metabolism
Lipoproteins are macromolecular complexes of lipids and proteins. A typical 
lipoprotein particle has a highly hydrophobic, interior core of lipid, which consists of 
TAG and cholesterol ester (CE), and a relatively hydrophilic outer surface monolayer 
of free cholesterol and phospholipid; each of these particles is associated with one or 
more apolipoproteins that weave in and out of the hydrophobic core and hydrophilic 
coat (Fig. 1.8) [91]. Lipoproteins are heterogeneous with respect to their physical, 
structural and metabolic characteristics (Fig. 1.9) [98]. This heterogeneity is due, in 
part, to their different physiological roles as transport vehicles for plasma lipids [91, 
98]. Lipoproteins have been traditionally defined into four classes, according to their 
hydrated density [122]; chylomicron, very low-density lipoprotein (VLDL), LDL and 
HDL (Table 1.4) [91, 98]. Chylomicron and VLDL particles are relatively rich in TAG, 
therefore they are often referred to as TAG-rich lipoproteins and are mainly 
responsible for the delivery of TAG to tissues, whilst LDL and HDL particles have 
roles as transport vehicles of cholesterol to and from cells, respectively [91].
Lipoprotein metabolism is co-ordinated by the apolipoproteins (apo); apo Al, All, AIV, 
B (48 and 100), Cl, Cll, CHI, D and E (Table 1.5) [91]. All apolipoproteins, except apo 
B, are soluble, thus may present in lipid-free form in the plasma and may exchange 
between lipoprotein particles [98]. In general, these apolipoproteins play an important 
role in stabilising the structure of the lipoprotein, acting as ligands for specific 
receptors and co-factors for enzymes, thus determining the physiological behaviour of 
the associated lipoproteins [123].
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Figure 1.8: Structure of a lipoprotein particle
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Figure 1.9: The diameter, density and subclasses of lipoproteins
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Table 1.5; Features and functions of the major human plasma apolipoproteins
Apolipoprotein Associated Moiecular Specific function in
(origin) iipoprotein mass
(Da)
lipoprotein metabolism
Al (intestine. HDL, chylomicrons 28,000 Activator for LCAT. Ligand for
liver) HDL receptor.
All HDL, chylomicrons 17,000 Possible inhibitor of LCAT.
AIV Secreted with 
chylomicrons but 
transfers to HDL
46,000 Associated with the formation 
of TAG-rich lipoproteins and 
appetite regulation.
B100 (liver) LDL, VLDL, IDL 550,000 Ligand for VLDL & LDL 
receptor.
B48 (intestine) Chylomicrons,
chylomicron
remnants
260,000 Ligand for chylomicrons.
Cl VLDL, HDL, 
chylomicrons
7,600 Possible activator of LCAT.
Cll (liver) VLDL, HDL, 
chylomicrons
8,916 Activator of LPL.
CHI (liver) VLDL, HDL, 
chylomicrons
8,750 Inhibitor of hepatic uptake of 
TAG-rich lipoprotein particles & 
LPL.
D Component of HDL 20,000 Unknown
E (liver) VLDL, HDL, 
chylomicrons, 
chylomicron 
remnants
34,000 Ligand for chylomicron, VLDL 
and HDL. Major vehicle for 
cholesterol transport in brain.
LCAT, lechitin-cholesterol acyl transferase; LPL, lipoprotein lipase
Adapted from Advance Nutrition and Human Metabolism textbook by Gropper et al.
[98] and Metabolic Regulation. A Human Perspective textbook by Frayn [91].
Lipoprotein metabolism is essential for the transport and lipolysis of TAG, via the 
endogenous and exogenous pathways. The process of deposition of TAG in the 
adipocytes begins with two major routes; i) uptake of TAG from plasma, and ii) DNL, 
the synthesis of TAG from other sources in the liver, particularly glucose and fructose 
[91, 98, 125]. The exogenous pathway describes the synthesis and catabolism of
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chylomicrons. Following a meal, the products of fat digestion are absorbed (fatty 
acids, monoacylglycerol, diacylglycerol and cholesterol) and re-esterified in the 
enterocyte and combined with apolipoprotein (notably B48) to form a chylomicron 
which are secreted in the blood via the lymph. There is one molecule of apo B48 per 
chylomicron particle. After having entered the blood circulation, chylomicrons rapidly 
attain apo Cll from FIDL, which renders them substrates for lipolysis via the action of 
endothelial bound lipoprotein lipase (LPL) enzyme. In this process, they lose TAG 
and acquire CE from other lipoproteins via the action of cholesteryl ester transfer 
proteins (CETP), whilst at the same time, shedding unesterified cholesterol and 
phospholipid, and some apolipoproteins which are taken-up by other particles such 
as FIDL (Fig, 1.10) [125]. Once the TAG are hydrolysed, the chylomicron particles 
shrink (these smaller, TAG-depleted particles are called chylomicron remnants), and 
the apo Cll will return to FIDL. The chylomicron remnants are relatively enriched in 
CE and are potentially atherogenic [126-128]. Linder conditions of health, chylomicron 
remnants are removed from the circulation via specific receptors in the liver which are 
maintained in a high state of activity and recognise apo E. In contrast to the 
exogenous pathway, the endogenous pathway describes the production of VLDL 
from the liver and its catabolism to intermediate-density lipoproteins (IDL) and LDL 
[91]. The apo B100, E and Cll containing VLDL particles are produced in the liver 
and, like apo B48 in chylomicrons, each of these particles carries a single apo B100 
polypeptide. Like chylomicrons, the TAG in VLDL is also a substrate for lipoprotein 
lipase (LPL), an endothelial lipase tethered to endothelial lining of blood vessel walls. 
The hydrolysis of TAG from these particles, leads to excess surface material that is 
passed to other lipoproteins, mainly FIDL from VLDL particles, which become 
relatively enriched with CE (via the action of CETP). These particles are either taken- 
up directly by the liver and other tissues, as VLDL remnants, or alternatively they may 
remain in the circulation, having been reduced in size through the action of LPL until 
they are depleted of all surface components, except apo B100, phospholipid and free 
cholesterol, though enriched with CE and become LDL particles [91, 98,125].
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Figure 1.10: The exogenous and endogenous lipoprotein metabolism pathways
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LDLR, LDL receptor; CE, cholestryl ester; LPL, lipoprotein lipase; FFA, free fatty acid; 
FIL, hepatic lipase. Adapted from Flarrison’s Principles of Internal Medicine textbook 
by Kasper & Flarrison [125].
1.7 Atherogenic lipoprotein phenotype
An atherogenic lipoprotein phenotype (ALP) or so called ‘lipid triad’ are terms which 
have been frequently used to described a common, pro-atherogenic form of 
dyslipidaemia, characterised by three lipid abnormalities: raised plasma TAG levels, 
decreased FIDL-C concentrations and a predominance of sdLDL particles. While 
each of these features predispose an individual to increased CVD risk on its own, in 
combination they have been associated with a three-fold increased risk of CHD [129]. 
This risk can be further exacerbated by insulin resistance and/or the metabolic 
syndrome [27, 130, 131]. An ALP has been referred to as diabetic dyslipidaemia, as it 
is commonly observed in patients with T2DM, which accounts for nearly 50-75%  of 
cases [132, 133]. An overproduction of apo B, leading to raised number of LDL
49
particles and plasma apo B (> 1.3g/L), increase CVD risk, and has also been 
associated with an ALP [8 , 134, 135]. In theory, the key underlying defect for the 
development of ALP, is an alteration of TAG-rich lipoproteins, and more specifically 
an increased secretion of larger TAG-rich lipoproteins (VLDL-TAG) and decreased 
clearance of VLDL (Fig. 1.11). The reduced clearance of VLDL results in its increased 
residence time in plasma and competition with partially lypolised chylomicrons 
remnants, which, together with the cholesterol-enriched IDLs, may be particularly 
atherogenic [132, 136]. This perturbation of TAG metabolism also results in an 
increased production of precursors of small dense LDL (sdLDL) and HDL (sdHDL) 
particles via a series of steps, that includes LPL-mediated lipolysis [132, 136]. The 
production of sdLDL particles is increased through further TAG enrichment of the 
lipolytic products by the action of CETP and by the hydrolysis of TAG and 
phospholipid via the action of hepatic lipase [27, 132]. The reduction in HDL, mainly 
in HDL2, results from the remodelling of HDL into smaller and denser particles via the 
action of CETP. TAG-rich HDL particles are substrates for hydrolysis by hepatic 
lipase which are then rapidly catabolised and cleared from the plasma [132].
Figure 1.11: Hypothetical mechanism for the development of an atherogenic 
lipoprotein phenotype in association with altered metabolism of TAG-rich 
lipoproteins.
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TG, triglyceride; LPL, lipoprotein lipase; LDLR, LDL receptor; CETP, cholestryl ester 
transfer protein; Choi, cholesterol; HL, hepatic lipase. Adapted from Krauss [132].
Insulin resistance may play an important role in the development of an ALP by 
increasing the size of the TAG pool in the liver. As already mentioned, insulin 
resistance can promote the efflux of NEFA from adipose tissue and influx into the 
liver and increases the accumulation of fat (TAG) in this organ (Fig. 1.12) [132]. Many
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studies have demonstrated a relationship between insulin resistance and plasma 
NEFA [137-140]. Clearance of postprandial TAG is usually reduced in insulin 
resistant states. Nonetheless, insulin resistance also promotes hepatic lipase activity 
which is responsible for the hydrolysis of phospholipids in LDL and HDL particles, 
leading to the formation of sdLDL and a decrease in HDL2 [141, 142].
Figure 1.12: Mechanism for the formation of an ALP (raised plasma TAG, 
reduced plasma HDL-C and production of small, dense LDL and small, dense 
HDL) in relation to insulin resistance.
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IR, insulin resistance; NEFA, non-esterified fatty acids; GETP, cholesteryl-ester 
transport protein; CE, cholesteryl ester; FIL, hepatic lipase; LPL, lipoprotein lipase; 
TAG, triacylglycerol. Adapted from Ginsberg [107].
1.8 Relationship between elevated TAG, low HDL-C, sdLDL, CVD risk and
dietary intake
It has been well documented that elevated plasma TAG, especially when 
accompanied by low plasma HDL-C, is associated with increased CVD risk. Despite 
its contribution to the development of ALP, plasma TAG has re-emerged as an 
independent risk factor of CHD [143]. An increase in the concentration of plasma 
TAG by 1 mmol/L is associated with increased risk of 30% and 75% in men and 
women respectively, independent of HDL-C concentration [143]. A moderate rise in
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plasma TAG > 1.5mmol/L also influences LDL size and density, particularly when 
insulin resistance is present [27]. In contrast, CVD and HDL share an inverse 
relationship. Low HDL-C level has been associated with increased CHD risk in 
population studies [144, 145]. An increase in plasma HDL-C concentration by 
0.03mmol/L was associated with a reduction in CHD events by 3% in a previous 
study [146]. Like LDL, HDL particles are typically heterogeneous. The reduction in 
plasma HDL, mainly in metabolic syndrome and T2DM, is associated with a reduction 
in the larger HDL subclass (HDL2b) relative to the smaller HDL subclasses (HDLsb and 
HDLsc). The HDL2 subclass has also been inversely associated with abdominal 
obesity, plasma insulin concentration, glucose intolerance [147] and sdLDL [148]. The 
weaker relationship between HDL3 and CVD risk has been ascribed to the shorter 
half-life, lower TAG:CE ratio and reduced anti-oxidative potential of this subclass 
[149]. In individuals with insulin resistance, plasma HDL-C and apo AI are reduced, 
as a result of the action of CETP-mediated transfer of CE from HDL to TAG-rich 
lipoproteins [150]. In addition, the non-HDL-C particle (TC -  HDL-C) has been shown 
to be another useful predictor of CVD, most notably in patients with T2DM [151].
Evidence from cross-sectional, prospective cohort and clinical intervention studies 
has revealed an emerging relationship between sdLDL and CVD [9, 27, 122, 130, 
145, 152, 153], and a predominance of these particles has been associated with a 
three-fold to four-fold increase in risk of acute myocardial infarction [129, 130]. The 
distribution of LDL particle size has been categorised into two subclass phenotypes 
or patterns, known as pattern ‘A’ and ‘B’. Pattern ‘B’ consists of predominantly sdLDL 
and has been associated with increased CHD risk via several inter-related 
mechanisms; 1) greater infiltration of the artery wall by virtue of its smaller size [154], 
2) increased affinity for arterial proteoglycans [154, 155], 3) increased susceptibility to 
undergo oxidative modification in the arterial wall (subendothelial space in arterial 
intima) [156], 4) lower affinity for the LDL receptor which is resulted in an increased 
residence time in plasma (Fig. 1.13). In addition, the phenomenon of enhanced post­
prandial lipaemia (TAG-'intolerance') has also been recognised to be a major risk 
factor for CVD, through the direct effects of raised plasma CM-remnants, and indirect 
effects in promoting the formation of an ALP (sdLDL, low HDL) [157].
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Figure 1.13: Distribution profiies of LDL subclasses representative of subclass 
pattern A, I and B.
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Pattern A, large, buoyant LDL subclass; Pattern I, intermediate LDL subclass; Pattern
B, small, dense LDL subclass. Adapted from Griffin etal. [158].
Recent findings have indicated that plasma ape B may be a better predictor of CVD, 
relative to LDL-0 concentration, as raised apo B provides a marker of an increased 
number of circulating LDL-0 particles [159]. While the ratio of LDL-C:apo B may be 
useful in detecting an ALP, the ratio of apo B:HDL-C has been shown to discriminate 
dyslipidaemia in individuals with diabetes [160]. Even though raised plasma apo B (>
1.3 g/L) is associated with an abundance of sdLDL, a predominance of sdLDL (> 50%  
phenotype B) describes the proportion of sdLDL, and as such, may not necessarily 
be associated with a raised plasma apo B [158].
Knowledge of the relationship between lifestyle factors and CVD was advanced 
considerably by the work of Ancel Keys in the 1960s [16]. Since then, a host of 
studies have established the relationship between dietary fats, principally saturated 
fat and dietary cholesterol, and CVD risk factors, mainly raised plasma TC and LDL-
C. The American Heart Association (AHA) together with W HO are now focusing in 
reducing dietary fat intake, mainly saturated fat, in the effort to reduce both the 
morbidity and mortality of CHD [20, 46]. However, even though the intake of dietary 
fat has been reduced and is currently close to the recommended level of intake in the
53
UK, the incidence of cardio-metaboiic may be unaffected, quite possibly because 
saturated fat is being replaced by an inappropriate substitute in the form of dietary 
CHO, and more specifically extrinsic sugars [22, 23, 146, 161]. There is strong 
evidence to suggest that the replacement of dietary fat with high CHO diets produces 
adverse effects on CVD risk, and that these effects may be more pronounced than 
the effect of high fat diet [24]. It has also been speculated that the adverse effect of 
CHO may be exaggerated when the diet is high in dietary sugars, and when other 
underlying metabolic disorders, such as elevated liver fat and insulin resistance, are 
present [121].
1.9 Carbohydrate-induced dyslipidaemia
There is growing evidence to suggest that high CHO diets (> 55% of total energy) are 
associated with raised plasma TAG [162, 163], which is consistent with an increased 
risk of CHD [164]. The increase in plasma TAG that may be induced by dietary CHO  
is often accompanied by a reduction in plasma HDL-C and the formation of sdLDL 
[27, 165-167]. The plasma lipid response to dietary CHO is highly variable between 
individuals and also dependent on the amount of CHO, NSP, fat, and proportion of 
extrinsic sugars (mainly fructose and sucrose), the latter of which appears to exert its 
effect through increased DNL in the liver (Fig. 1.14) [168, 169]. When dietary sugar, 
mainly as fructose, is available, it is rapidly taken-up by the liver and converted into 
glycerol-3-phosphate, favouring estérification of free fatty acids (FFA) to form TAG 
[170]. Fructose, the most lipogenic sugar, is the major contributor to this effect [29, 
42, 171]. In contrast to glucose, high fructose intake is not regulated by insulin or the 
energy status of cells. Dietary fructose by-passes a critical step in glycolysis 
controlled by phosphofructokinase (PFK), an allosteric enzyme that is up-regulated by 
insulin, whilst down-regulated by fatty acids and adenosine tri-phosphate (ATP) (Fig. 
1.15) [172, 173]. This induces a high flux of fructose to the liver which leads to 
significantly increased DNL and TAG synthesis by the increased flux of glycerol and 
acyl-coA [174]. In agreement with these metabolic effects, studies by Sobrecas et at. 
and Le et al. showed that short-term overfeeding of fructose increased the hepatic 
deposition of lipid [29, 175]. Increased liver fat caused by overfeeding of fructose also 
appeared to increase liver fat, in association with insulin resistance and the 
overproduction of large TAG-rich VLDL [121].
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Figure 1.14: De novo lipogenesis pathway associated with metabolism of 
dietary carbohydrates in the liver.
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FFA, free fatty acid; TG, triglyceride; LPL, lipoprotein lipase; Sc, subcutaneous; FA, 
fatty acid. Adapted from Fried & Rao [170].
Figure 1.15: Pathway of fructose and triacylglycerol biosynthesis
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1.10 Relationships between dietary carbohydrates, cardio-metaboiic risk, 
and an ALP
There is evidence to suggest that when a high percentage of dietary energy is 
supplied in the form of CHOs, particularly as sugars, DNL is increased by 12.8±1.4%  
to 13±5.1% depending on body weight [169, 176], and that lipid oxidation is reduced, 
leading to an increased deposition of lipid in the form of TAG in the liver [29]. In 
situations where abdominal obesity has been related to hepatic and peripheral insulin 
resistance, raised liver fat has been positively associated with elevated fasting serum 
insulin [103]. On the basis of this evidence, we postulate that the type of dietary CHO, 
in combination with insulin resistance, as indicated by increased liver fat, elevates 
plasma TAG, reduces plasma HDL-C and promotes the formation of both sdLDL and 
possibly apo B, and thus the expression of an ALP (Fig. 1.16).
Figure 1.16: Possible metabolic routes of impact of dietary carbohydrates in the 
liver, leading to the formation of an ALP and increase CVD risk
VLDL
Ü  Liver fat
► tr  DNL ÏÏTA  
^  Insu
Dietary
CHO
VLDL
resistance
ALP
CVD
risk
Ü
CHO, carbohydrate; DNL, de novo lipogenesis; TAG, triacylglycerol; ALP, 
atherogenic lipoprotein phenotype; CVD, cardiovascular disease; VLDL, very-low 
density lipoprotein; apo, apolipoprotein.
1.11 A low fat, high carbohydrate diet; a conventional dietary strategy for 
reducing CVD risk
Low fat diets are advocated to reduce weight [177] and treat dyslipidaemia [20]. The 
substitution of fat for CHO can increase CVD risk, especially when there is a high 
amount of CHO (> 55% of total energy intake) and/or a high ratio of sugar to complex 
CHO (> 1:4). Previous studies have also suggested that low fat diets (20% to 30%  
dietary fat) that are enriched with CHO are not associated with a decrease in CHD  
incidence, possibly because the decrease in LDL is counterbalanced by an adverse
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fall in plasma HDL and increase in TAG (see Fig. 1.1) [26, 178, 179]. Recent 
evidence suggests that this adverse effect of dietary CHO on CHD risk factors can be 
reduced by controlling for the type of CHO, which can be achieved by limiting the 
intake of extrinsic sugars, such as sucrose and fructose, and increasing dietary fibre. 
The majority of previous intervention studies have provided data on the effects of total 
CHO intake on plasma lipids, whilst the effects of the quality of CHO in real foods 
have been relatively under studied. Evidence from cross-sectional studies suggests 
that dietary CHO exerts significant effects on plasma TAG. A higher intake of dietary 
CHO has been positively linked to increased fasting plasma TAG [180, 181]. In 
addition, a few prospective studies have found that a high CHO diet, as determined 
by glycaemic index (Gl), was a better predictor of CHD risk factors [182, 183]. There 
is growing experimental evidence to show that total dietary CHO exerts adverse 
affects on lipid metabolism. High CHO diets have been shown to increase plasma 
TAG, especially in hypercholesterolaemic and hyperlipidaemic groups [184, 185]. 
High CHO diets (> 55% of total energy intake) have been shown to increase plasma 
TAG by «40% from baseline compared to high fat diets [162, 186, 187]. These diets 
also increase the particle size of VLDL, and VLDL-TAG production rate, and 
decrease the VLDL-TAG clearance rate [188]. A raised fasting plasma TAG, which 
has been induced by a high CHO diet has also been associated with chylomicrons 
remnants that compete with VLDL for lipolysis, and can provide an additional source 
of fatty acids for hepatic VLDL-TAG synthesis [188-191]. Hudgins et al. [192] 
examined a diet low in fat (10% fat) and high in CHO (75% CHO) and reported higher 
concentrations of plasma TAG (50 to 60%) on the high CHO diet. Chong et al. [191] 
examined high sugar test meals (glucose and fructose) in 14 healthy participants and 
found a significant difference between glucose and fructose in plasma TAG and 
VLDL-TAG. A study examining two diets in 42 patients with T2DM found that high 
CHO diets increased plasma TAG and that the effects persisted for 14 weeks [187]. 
Dallongeville et al. [193] compared 11 lean and 8 obese women on either CHO or fat 
load diets for seven days, and showed that plasma TAG increased post-prandially in 
women after high CHO load diet. A recent intervention by Frisch et al. [194], studied 
200 overweight participants who were randomly assigned to either a low CHO (< 40%  
CHO of total energy) or low fat diet (> 55% CHO of total energy) for 12 months. The 
reduced CHO diet produced beneficial effects with respect to CHD risk factors, such 
as lower TAG levels (reduced by 14% after 6 months; 7% after 12 months from
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baseline) [194]. A summary of these and other studies on the effects of dietary CHOs 
on plasma lipids is shown in Table 1.6.
Existing evidence supports a strong association between high CHO and increased 
plasma TAG and other lipid markers (VLDL-TAG). However, the majority of previous 
studies were conducted over a short period of time and the findings were ascribed to 
the rapid ingestion of CHO [189, 195-197]. Furthermore, the majority of available 
studies incorporated high CHO test meals into the diets that were unrepresentative of 
real foods consumed by populations. Dietary sugars have been strongly implicated in 
the development of dyslipidaemia. To investigate this further, a systematic review of 
studies on the effects of dietary sugars on plasma TAG and HDL-C was undertaken, 
the results of which are presented in Chapter 2 .
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1.12 Overall aims
1. To acquire independent evidence for the reciprocal relationship between 
dietary sugars and plasma TAG and HDL-C.
2. To design and implement two iso-energetic diets, which could deliver high 
and low intakes of dietary sugar that were representative of the upper 95^ 
and lower 5^ *^  percentile of sugar intake in the UK population.
3. To determine the effects of high and low sugar diets on plasma lipids, 
lipoproteins, cardio-metaboiic risk factors and liver fat, and to determine 
how the percentage of liver fat influences the plasma lipid response to 
these diets.
4. To evaluate the effects of high and low sugar diets on plasma LDL and 
HDL subclasses and apolipoproteins.
5. To re-examine the effects of a high and low sugar diets on plasma lipids, 
when the intake of sugar (NMES) has been determined by several 
different methods.
6 . Discuss and draw final conclusions from study aims 1-5.
1.13 Overall objectives
Aims 1-5 were achieved by the following objectives:
1. Conduct an independent systematic review on the effect dietary sugars on 
plasma TAG and HDL-C (Chapter 2).
2 . Develop a dietary exchange model that was based on NDNS data and the 
manipulation of the sugar to starch ratio (Chapter 3).
3. Apply and test the efficacy of the two diets, high and low in sugars, on 
plasma lipids in a dietary intervention study in volunteers at increased 
cardio-metaboiic risk (Chapter 4).
4. To separate LDL and HDL subclasses by gradient gel electrophoresis and 
quantify the plasma concentrations of apolipoproteins using commercially 
available assays (Chapter 5).
5. Re-analyse NMES intakes by three other published methods (Chapter 6).
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1.14 Hypotheses
A dietary exchange model based on the manipulation of the ratio of starch to sugars 
in a variety of supermarket foods, will be a feasible method for delivering two diets, 
high and low in extrinsic sugars. A high sugar diet will be associated with adverse 
changes in plasma lipids, relative to a low sugar diet, with respect to cardio-metaboiic 
risk. The plasma lipid response to a high sugar diet will be more pronounced in the 
presence of a moderately raised percentage of liver fat.
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Chapter 2
SYSTEMATIC REVIEW AND META-ANALYSIS ON THE EFFECT OF DIETARY 
SUGARS ON PLASMA TRIACYLGLYCEROL AND HDL-CHOLESTROL
2.1 Introduction
An estimated 55 kg per capita of dietary sugars («25%E) was consumed in North 
America in 1970, which increased to 68 kg per capita in 1995 [201]. In 2004, the 
average Canadian was reported to be consuming 110 g of sugars (21 %E) every day 
[202]. While dietary fats and saturated fat have experienced a long standing 
relationship with CVD through raised blood cholesterol, a high intake of sugars has 
been associated with CVD for at least 50 years [23]. One of the earliest reports 
(1954-1969) of an association between high sugar consumption and increased CHD  
mortality came from a study of 20 economically advanced countries, including the US, 
Canada, Japan, Australia, New Zealand, UK and several European countries [203]. 
More recent epidemiological studies also reported an association between an intake 
of sugars mainly from soft drinks with T2DM, hypertension and obesity leading to 
CVD [37, 204].
While the National Cholesterol Education Program in the Adult Treatment Panel III 
guidelines (NCEP-ATP III) focused on decreasing LDL-C as the most atherogenic 
lipid fraction in efforts to reduce CVD risk by reducing dietary fat intake [20], there is a 
substantial body of evidence to support a relationship between non-LDL cholesterol 
and CVD risk through diet. The latter is mediated through the formation of a 
dyslipidaemia known as an ALP, as described in Chapter 1. In recent years, there 
has been an expanding literature on the unfavourable effects of dietary CHO in 
raising plasma TAG, reducing HDL-C and increasing CVD risk [179].
Previous meta-analysis has shown that dietary fructose increases the concentration 
of plasma TAG in individuals with T2DM [205]. However, the effects of dietary sugars 
and fructose in healthy humans, with or without developed features of metabolic 
syndrome have not been extensively evaluated. This chapter presents a systematic 
review of the existing literature on human studies on the effects of sugars on plasma 
lipids.
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2.2 Study aim
To demonstrate the relationships between a high intake of sugar and fructose on 
plasma lipids in normal, healthy participants, for the purpose of providing support and 
scientific rationale for studying the impact of extrinsic sugars on an ALP.
2.3 Study objective
To undertake an independent, systematic review of cross-sectional, prospective 
cohort and intervention studies on the effects of dietary sugars, including glucose, 
sucrose and fructose, on plasma lipids (primarily plasma TAG and HDL-C) in healthy 
participants. To perform a meta-analysis on the selected data using software from the 
Cochrane Handbook for Systematic Reviews of Interventions [206].
2.4 Study hypothesis
A high intake of dietary sugar, especially in the form of fructose, will be significantly 
associated with a moderately raised concentration of plasma TAG (> 1.7mmol/L) and 
low HDL-C (< 1 .Ommol/L) in non-patient participants, as defined according to the 
NCEP-ATP III classification for metabolic syndrome [20].
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2.5 Methods and materials
The methods for the planning, literature searches, protocol and analysis were based 
on the Cochrane Handbook for Systematic Review of Intervention [206], and adapted 
from a previous meta-analysis on T2DM [205] and systematic review of the effects of 
sugar-sweetened beverages on weight gain [38].
2.5.1 Systematic search for publications
i) Inclusion criteria for studies
i) Year of publication: This analysis included studies published from any year up 
until September 2011. ii) Study location: This analysis included studies conducted in 
any country, iii) Duration of study: This analysis included prospective cohort studies 
with any duration of follow-up, and intervention studies with any duration intervals,
iv) Study participants: This analysis included studies conducted in healthy human 
adult participants, aged > 19 years, men and women. Healthy in this context was 
defined as being without disease (such as T2DM and hypertension) or taking any 
lipid-lowering medication (e.g. statins and fibrates). However, this analysis did include 
participants at increased CVD risk or manifesting any features of the metabolic 
syndrome (such as obese participants or participants with hyperinsulinaemia). v) 
Lipid measurements: Plasma lipid concentrations (plasma or serum TAG and/or 
HDL-C) as endpoint measures, vi) Study designs: Cross-sectional and prospective 
cohort studies, and randomised controlled trials that employed a dietary intervention 
with either a cross-over or parallel design, vii) Study methods: Studies that 
measured dietary sugar intake using appropriate tools (such as FFQ and diet-recall) 
and measured plasma lipids using validated assays and analysers and considered 
analytical performance in terms of accuracy, precision and % confidence of variance 
(%CV).
ii) Exclusion criteria for studies
i) Studies that did not include the above, ii) Studies that contained confounding 
factors that might affect lipid metabolism, such as lipid-lowering medications (e.g. 
statins and fibrates), high fibre and high fat diets, iii) Studies that did not provide full
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text and/or data, or that were in some way inaccessible or could not be retrieved via 
intra-library loan, iv) Animal studies, v) Studies conducted in children.
iii) Search strategy
Studies satisfying the above criteria, from all health and nutrition journals in the 
Bioscience online databases, were targeted in the literature. Language was restricted 
to English. Study identification included both manual (from citations) and electronic 
searching (using three main databases as described below). The initial selection 
criteria was broad to ensure that as many studies as possible were assessed in 
relation to their relevance to the analysis. Any studies that did not meet the inclusion
criteria on the basis of abstracts and titles presented in electronic catalogues, were
excluded at a preliminary screen. The next decision to exclude or include a study was 
made after reviewing the full paper. The number of studies included and excluded at 
the various stages was documented. The manual search was restricted to papers that 
had been cited in other studies. A schematic flow of the literature search is shown in 
Figure 2.1.
iv) Electronic search strategy
The following online databases; ISI Web of Science, SCOPUS and Medline, were the 
primary sources of papers. These databases were accessed via the George Edwards 
Library at the University of Surrey.
v) Search terms for electronic databases
The following terms were used for searching the electronic databases. The basic 
search terms used were;
• Dietary (sugar OR sucrose OR fructose)
And
• Triglyceride OR triacylglycerol OR plasma lipid OR lipid 
These basic research terms were refined as the searching progressed.
6 8
Figure 2.1 : Schematic fiow diagram of study selection procedure.
Manual SearchElectronic Search
Citations excluded from 
electronic search
Synthesis of all studies included in systematic
Full text for related studies retrieved 
for more detailed evaluation
Relevant studies included in the 
systematic review
Studies excluded after 
evaluation from 
systematic review with 
reasons
Full text for related studies 
retrieved for more detailed 
evaluation
Manual search/trace from 
references and citations of 
available study
Studies excluded after 
evaluation from 
systematic review with 
reasons
Potentially relevant citations 
identified after liberal screening on 
the electronic search
2.5.2 Methods for the meta-analysis
Thirty-six studies were included in the meta-analysis. These studies included a 
comparison of the effects of high sucrose and high fructose diets, and low sucrose 
and low fructose diets on plasma TAG, Studies of sucrose and fructose were 
analysed separately. Meta-analysis was conducted using the Review Manager 
(RevMan) software 4.2.10 by the Cochrane Collaboration [207]. This software is used 
for preparing and maintaining Cochrane Reviews for publication within the Cochrane 
Group. However, it also allows public usage solely for educational purposes, and in 
this case was used to develop forest plots and to calculate the effect size of the meta­
analysis. The studies that were included in the meta-analysis were selected on the
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basis of data that were available in the original papers, which consisted of the mean 
outcomes in terms of plasma TAG, with standard deviation (SD) or standard error 
(SE), and the number of participants (n). Since the RevMan software required SD to 
perform the analysis, SE was converted to SD using the formula of SD = SExVN. In 
general, this meta-analysis involved several stages including; i) An assessment of 
the heterogeneity and quality o f studies; II) Evaluation of the risk of bias; III) A 
sensitivity analysis; and Iv) A total and subgroups meta-analyses.
i) Assessments for heterogeneity and quality of studies
There was substantial variation in the studies included in the meta-analysis. The 
studies varied in their subject characteristics (e.g. male vs female, normal vs 
overweight BMI, or pre- vs post-menopausal), design (e.g. cross-over or parallel, 
duration) and nature of dietary intervention (e.g. sugar format and dose/level of 
intake). To make allowance for the variable magnitude of outcomes (in terms of effect 
size) introduced by this heterogeneity, three different analytical approaches were 
taken. Firstly, the quality of studies was assessed using the Jadad Scale [208] to 
ensure that all included studies were equivalent in their statistical power. This scale, 
which has been recommended by the British Medical Journal (BMJ) [209], is based 
on a score of 0 -  5 that is derived from the consideration of three methodological 
factors; randomisation, blinding and withdrawal or drop-out [208]. While a score of 3 - 
5 is considered as high quality, all the studies included in this analysis scored 1 - 2 
which was considered as low quality. Secondly, to make allowance for the impact of 
heterogeneity in study design on the effect size, parallel studies were excluded from 
the analysis. While in principle, it is acceptable to combine cross-over studies with 
parallel studies, a recommendation has been made to avoid combining different study 
designs in a meta-analysis, to prevent the confounding effects of variable 
characteristics of the two types of study [206]. There is also a recommendation to 
undertake an analysis of subgroups for parallel studies, though this was not possible 
in this case, due to the relatively few selected studies with this design. Thirdly, the 
degree of heterogeneity was calculated by Cochrane’s Q (ChP) statistic for both 
sucrose and fructose intervention studies, at a significance level of p<0 .10, and 
quantified by 1^ , where 1^ is interpreted as follows: 0%-40% might not be important; 
30%-60% may represent moderate heterogeneity; 50%-90% may represent 
substantial heterogeneity; and 70%-100% represent considerable heterogeneity
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[206]. The method used in the meta-analysis i.e. random- or fixed-models was 
determined by the degree of heterogeneity.
ii) Assessment of risk of bias
In contrast to parallel studies, cross-over studies allocate each subject to all of the 
interventions. In this case, each subject acts as his or her own control, limiting within- 
subject variation, and thus reducing the number of participants required to achieve 
the desired statistical power. Since every subject receives every intervention, this 
allows the determination of the real effect of an intervention [210]. Nevertheless, 
meta-analysis for cross-over studies is associated with risk of bias. The principal 
problem inherent in cross-over studies is that of carry-over, when the effects of an 
intervention in one period persist into a subsequent period, thus interfering with the 
effects of the second intervention [211]. This carry-over effect is reduced with an 
appropriate wash-out period. The studies included in this meta-analysis all employed 
wash-out periods of between 2 to 6 weeks, and none reported any carry-over or order 
effect in their papers. Another problem associated with cross-over studies is the risk 
of drop-out due to extended study duration. This issue was underreported in most 
papers. To further reduce bias, only randomised cross-over studies were included in 
the meta-analysis.
iii) Sensitivity analysis
This systematic review also involved an ‘indirect’ sensitivity analysis from the outset 
of the systematic search. While no specific questions were developed to conduct this 
sensitivity analysis as recommended by the Cochrane Handbook [206], the inclusion 
criteria in this meta-analysis were highly selective and inadvertently answered the 
questions that were supposed to be in the sensitivity analysis. The sensitivity analysis 
was important to insure robustness of the final conclusion, and involved a decision­
making process to include or exclude the studies. The tight eligibility criteria that were 
pre-specified in the protocol of this analysis, such as characteristics of participants, 
type of intervention, outcomes, study design and type of data, also helped to increase 
the strength of this meta-analysis.
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iv) Subgroup analyses
Subgroup analyses were required to determine the influence of established 
covariates of plasma TAG on the effect size or the magnitude of effect of the dietary 
intervention. Biological factors such as BMI, gender and menopausal status, and 
methodological factors, such as the duration of intervention, dose and format of 
sugars, all of which have been previously identified as potential determinants of 
variation in the response of plasma TAG [205], and thus were examined by subgroup 
analysis. Studies were stratified on the basis of subcategories in each subgroup (i.e., 
men and women, normal body weight and overweight/obese, pre- and post­
menopausal, short-, intermediate- and long-term intervention, liquid and solid format, 
and < 20%E, 20%E - 40% E and > 40% E of sucrose or fructose), and an inter-study 
test of heterogeneity (Chi^) was calculated for each subcategory and subgroup.
2.5.3 Analytical methods
There was evidence of substantial heterogeneity in terms of the available data
associated with total groups, subgroup and subcategories. For this reason, when
there was significant heterogeneity, a random-model was used instead of a fixed-
model [211]. The meta-analysis only involved continuous outcomes with the same 
endpoint measure of plasma TAG, when the conclusion was based on effect size. 
Effect size was determined by the standardised mean difference (SMD) which was 
calculated by the difference in mean outcome between groups (MD) divided by the 
pooled standard deviation (SD) of measurements [SMD = MD/SDpooled]. This 
represents the most appropriate method for the meta-analysis of cross-over studies 
[212]. The data was computed and SMD calculated using RevMan software [207].
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2.6 Results
A preliminary screen identified a total of 506 citations. After this initial screen, and 
exclusion of reviews and inclusion of healthy participants and appropriate lipid 
measurements, 182 citations remained. From these 182 studies, a further 113 were 
excluded on the basis of their title and abstract (71 duplicate studies, 28 did not 
assess sugar consumption or report any lipid measurements, 9 had confounding 
factors, such as a high intake of fat or fibre, exercise and/or weight loss, 1 included 
an individual with diabetes and 4 used enteral products). From 69 abstracts, 27 
citations could not be retrieved online or had limited access, thus were excluded from 
the analysis. Further evaluation identified 42 studies as being acceptable for the 
analysis. Of these, five were cross-sectional studies [41, 183, 213-215], one was a 
prospective study [216], and 36 were interventions (16 were sugar interventions [163, 
171, 192, 217-228] and 20 were fructose interventions [29, 175, 186, 191, 229-244]). 
Figure 2.2 shows the stages of this inclusion and exclusion process.
Figure 2.2: Flow diagram of inclusion and exclusion process.
506 citations identified
113 abstracts excluded 
(duplicates/no dietary or 
sugar intake or lipid 
data/contain confounding 
factors)
182 abstracts saved
324 irrelevant citations 
excluded 
(reviews/animal 
study/non-adult 
population)
69 abstracts eligible
27 studies excluded 
(could not be retrieved 
via intra-library loan/no 
full data available)
42 studies included 
(5 cross-sectional, 1 prospective & 36 intervention)
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2.6.1 Findings from cross-sectionai and prospective studies
There are a limited number of cross-sectional and prospective studies on the impact 
of dietary sugar on plasma lipid concentrations, and particularly on plasma TAG in 
healthy or ‘at risk’ adult participants. All cross-sectional studies included in this 
analysis presented their data and results differently in terms of sugar intakes, 
therefore, only data from the two largest cross-sectional studies are presented in 
graphic form (Figs. 2.3 and 2.4). For a full description of all studies, see Table 2.1. Of 
the six studies included in this review, five involved men and women, and one 
involved post-menopausal women. Out of these five, one compared ethnicity in men 
and women. Three studies used 24-hour diet recall and three studies used Food 
Frequency Questionnaires (FFQ) as dietary assessment tools. For the assessment of 
sugar intake, one study calculated soft drink intake, another measured added sugar 
intake. Two studies measured total sugar intake and two others measured sugar 
intake using glycaemic load (GL). In relation to outcomes, three studies measured 
plasma TAG and HDL-C, whilst two studies only measured plasma TAG and one 
study only plasma HDL-C.
Of the cross-sectional studies included in this analysis, 80% demonstrated a 
significant positive relationship between sugar consumption and plasma TAG [41, 
183, 214, 215], whilst 67% found a significant inverse relationship between sugar 
consumption and plasma HDL-C [41, 215]. Only one study failed to find a positive 
association between sugar intake and plasma TAG [213] (Table 2 .1). Figure 2.3 
shows data from the largest cross-sectional study to be included in the analysis, the 
Framingham Heart Study (n«9,000). The figure shows evidence of a strongly positive 
association between the concentration of plasma TAG with daily intake of soft drinks
(p<0 .001).
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Figure 2.3: A cross-sectionai study on the association between numbers of soft 
drink consumed per day with piasma TAG concentration (the Framingham
Heart study).
I . /u n
1.65-
1.60-
§  1.55-
1.50-
1.45-
1.40
<1 (n=5840) 1 (n=1918) >2 (n=1239)
Number of soft drink/day
TAG, triacylglycerol. n=8,997. Values are mean±SEM. OR, 1.25; 95 percent Cl (1.04- 
1.51). *Mean values of plasma TAG concentration increased significantly with the 
number of soft drinks (p<0.001). Please note: statistical significance was obtained 
from the original paper [214].
Data from the second largest cross-sectional study to be included in this analysis, 
NHANES 1999-2006 [41] (n>6,000), was in complete accordance with this finding 
from Framingham, with plasma TAG being positively associated with increased 
percentage of energy (%E) from added sugar (Fig. 2.4). In contrast, plasma HDL-C  
was found to be significantly decreased as energy intake from added sugar 
increased. Regression analyses revealed significantly positive and negative 
associations between the proportion of energy from added sugar and plasma TAG (r  ^
= 0.76) and plasma HDL-C (r^  = -0.98). The findings from NHANES, with respect to 
HDL-C, were further supported by the only prospective cohort study included in this 
analysis, which found that energy intake from sucrose was inversely associated with 
plasma HDL-C in both cross-sectional (at baseline and year 7) and longitudinal 
analyses (from baseline to year 7) [216]. This study also examined the impact of race 
and gender on these associations, both cross-sectionally and over time. This 
revealed significant inverse cross-sectional associations, at baseline in black men, 
white men and white women (p<0.01), and at year 7 in white men and black women 
(p<0.01), and in white men, white women and black women over time (p<0.05). The
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overall findings from both the cross-sectional and prospective studies, provide 
evidence to support the existence of positive and inverse relationships between the 
intake of sugar an plasma concentration of TAG and HDL-C, respectively.
Figure 2.4: A cross-sectional study on the association between %E from added 
sugar per day with plasma TAG and HDL-C (NHANES 1999-2006).
1.8-,
O Geometric mean TAG 
□  Adjusted mean HDL-C^  1.6-
1.4-
r^=0.76’
1.2-
<5 5-<10 10-<17.5 17.5-<25 >25
% Energy from added sugar
TAG, triacylglycerol; HDL-C, HDL-cholesterol; %E, percent of total energy; NHANES, 
National Health and Nutrition Examination Survey. The solid line represents linear 
regression for TAG, the dotted line represents linear regression for HDL-C. n=6,113. 
Error bars indicate 95% confidence interval. ^Geometric mean of TAG significantly 
increased with %E from added sugar (p<0.001). **Adjusted mean of HDL-C  
significantly decreased with %E from added sugar (p=0 .02). Please note: statistical 
significance was obtained from the original paper [41].
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2.6.2 Findings from dietary sugars intervention studies
From a total of 36 intervention studies that modified intake of sugar, five examined 
short-term (< 1 day), nine examined intermediate-term (> 1 day to < 2 weeks) and two 
examined the long-term effects of sugar consumption on plasma TAG (> 2 weeks) (Fig. 
2.5). For a full description of studies, see Table 2 .2 . Overall, 80% from the short-term 
studies [171, 220, 221, 224], and 89% from the intermediate-term studies [163, 192, 
217, 218, 223, 226-228] observed significant increases in plasma TAG by (mean±SD)
0.46±0.3mmol/L after sugar consumption. Both long-term studies [219, 222] included in 
this analysis reported increases of 0.49±0.46mmol/L (mean ± SD) in plasma TAG. Only 
one study reported a fall in plasma HDL-C of 0.13±0.18mmol/L after sugar 
consumption, but this was also non- significant [222].
The effects of different types of sugars on plasma TAG are shown in Figure 2.5. Three 
out of seven sucrose studies [28-30], including one long-term study which found 
positive, but non-significant effects on plasma TAG and HDL [222]. Nonetheless, three 
studies reported decreases in plasma TAG after sucrose feeding, including one study 
in a cohort at high risk of GHD [220, 225, 236], and one showed no change following 
sucrose consumption [220]. In one study that compared HFOS and sucrose, both 
sugars increased plasma TAG significantly from baseline, with the greater effect being 
ascribed to sucrose [171]. The outcome of the studies that examined the effects of 
glucose on plasma TAG were equivocal, with 50% indicating an increase [220, 240, 
242] and 50% indicating a decrease in plasma TAG [220, 221, 225]. The effects of 
dietary sugars on plasma TAG in overweight and obese participants were variable, 
whilst in two short-term studies, the effects of sugars in subjects with normal body 
weight produced contradictory findings [221, 225].
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Figure 2.5: Intervention studies on the effect of dietary sugar consumption on 
plasma TAG and HDL-C.
Duration of Intervention
1.5n
1.0-
0.5
0.0
5  
<  -0 .5 -
-1.0-
-1 .5
-2.0J
< 1 day > 1 day < 2 
weeks
> 2 weeks o Sucrose 
□ Glucose 
A  HFOS
□
%
O
© -
o  
study
A
Cross-over
Study design
Parallel
TAG, triacylglycerol; HDL-C, HDL-cholesterol; A, absolute change. Grey filled symbol 
denotes plasma HDL-C. Symbols with blue outline represent studies conducted in 
participants with normal body weight; symbols with red outline represent studies 
conducted in overweight/obese participants. Values are mean±SD. *Mean values were 
significantly different between sources (p<0.05). **Mean values were significantly 
different from baseline values (p<0.001). Please note: p values were obtained from the 
statistical analysis in each individual study. All studies in this graph are described in 
Table 2.2 except studies 6 , 9 and 10 which are described in Table 2.3 (Fructose 
intervention studies).
Key numbering:-
1 : n=6 , 85g sucrose/glucose [221]
2: n=10, healthy, 75g sucrose/glucose [220]
3: n=10, with CHD risk, 75g sucrose/glucose [220]
4: n=34, 25%E sucrose/HFCS [171]
5: n=11, 75g gIucose+7.5g fructose vs 75g glucose [225]
6 : n=11, +3.5g/kg FFM/d glucose, three days [240]
7&8: n=290, -t-7%E added sugar, six months [222]
9: n=15, 25%E requirement, 10 weeks [242]
10: n=17, 70g sucrose [236]
80
2.6.3 Findings from fructose feeding intervention studies
The greatest proportion of studies in this analysis examined the effect of fructose 
feeding. In cross-over studies that compared high and low intakes of fructose, 95%  
intervened with a fructose formula which consisted of fructose dissolved in water as 
their test meals. There were six short-term (< 1 day), five intermediate (< 1 day < 2 
weeks) and eight long-term (> 2 weeks) studies included in this analysis. Overall, all 
short-term, 86% of intermediate-term and 70% of the long-term studies showed 
significant increases in plasma TAG (Fig. 2.6 and Table 2.3).
Over 75% of studies demonstrated positive effects following fructose feeding on 
plasma TAG concentration (Fig. 2.6). Two studies, one short-term and one long-term, 
in obese men and women found decreases in plasma TAG after fructose feeding [236, 
237]. Plasma TAG increased significantly from baseline in nearly 71% of studies 
conducted in men. Interestingly, studies which were conducted in both men and 
women, and analysed independently, showed greater elevations in plasma TAG in men 
relative to women, that were on average 0.30mmol/L higher in men compared to 
women [237, 238]. More surprisingly, three studies showed non-significant effects of 
fructose feeding on plasma TAG, all of which were conducted in overweight (BMI 25- 
29.9kg/m^) and obese participants (BMI > 30kg/m2) [233, 237, 242]. Only one 
intermediate-term study showed a non-significant negative effect of fructose feeding on 
plasma HDL-C in overweight men [229].
In summary, findings from the intervention studies on the effects of dietary sugars on 
plasma TAG and HDL-C were variable and inconclusive. In contrast, high fructose 
feeding was more consistently associated with increased plasma TAG in 17 out of 20 
studies.
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Figure 2.6: intervention studies on the effect of fructose formula feeding on 
plasma TAG.
Duration o f intervention
< 1 day
_ _ A _ _
2 .0-1
1 .5 -
1.0-
I  0.5-1
r
> 1 day < 2  ^ 2 weeks 
weeks
r
0.0-
-0 .5
-1.0^
** Û Î
o Men-i-Women 
□ Men 
A  Women
B
study
□  -T -
TAG, triacylglycerol. A, absolute change. Blue symbols represent studies conducted in 
participants with normal body weight; symbols with red outline represent studies 
conducted in overweight/obese participants. Studies 1-4, 6 and 7 employed randomise 
cross-over study design; studies 5 and 8-12 employed parallel study design. Values 
are mean±SD. *Mean values of plasma TAG concentration were significantly increased 
from baseline (p<0.05), **Mean value of plasma TAG concentration was significantly 
increased from baseline (p<0.001), ***Mean value was significantly different from low 
fructose feeding (p<0.05). ^Mean value was significantly different between genders. 
Note: p values were obtained from the statistical analysis in each individual study.
Key numbering:-
1. n=12, 30%E fructose [235]
2 . n=16 (8 men, 8 women), 25%E fructose [238]
3. n=6 (3 men, 3 women), 0.75g/kg BW fructose [186]
4. n=T7 (9 men, 8 women), 30%E fructose [237]
5. n=11, +3.5g/kg FFM/d fructose [240]
6 . n=6 , +3.0g/kg BW fructose [239]
7. n = 7 ,18%E fructose [232]
8 . n=7 (Post-menopausal), 25% energy requirement fructose [233]
9. n=17 (9 men, 8 women), 25% energy requirement fructose [242]
10. n=15 (7 men, 8 women), 25% energy requirement glucose [242]
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2.6.4 Meta-analysis for dietary sucrose intervention studies
Out of 16 cross-over studies that intervened with dietary sugars, seven studies (total 
n=92) were included in the meta-analysis (Fig. 2.7). Only studies that compared high 
sucrose with low sucrose diets were included. Meta-analyses were undertaken to 
examine both total and subgroup effects, the results of which are presented 
separately. All subgroups in the sucrose intervention showed non-significant 
heterogeneity among studies (p>0.10) and were considered to be unimportant (1^ = 
0% to 40%) [211]. Since there was no evidence of heterogeneity, the analyses of the 
total group and subgroups were conducted using a fixed-model. All seven studies 
showed significant positive associations between a high intake of dietary sucrose and 
plasma TAG. The ‘effect size’ of sucrose on plasma TAG was significantly moderate, 
at 0.58 (95% Cl; 0.28, 0.88; p=0.0002; n=92).
Figure 2.7: Forest plot of total effect of isoenergetic high sucrose diet vs low 
sucrose diet on piasma TAG in 92 participants reported in seven studies.
Study
or sub-category
Hgh sucrose diet 
W Mean(SD)
L
N
)w sucrose cf et 
Mean(SD)
SMD (fixed) 
95% Cl
Weight
%
SMD (fixed) 
95% Cl
Brynesetal2002 10 1.10(0 .10) 10 0 .98(0 .10) — Ê— 9.71 1.15 [0 .19 ,  2.111
Cuing et al 2009 8 1.33(0 .68) 8 1 .11(0 .68) : 9.22 0.31 [ -0 .6 8 ,  1.29]
Hudgins et ai 2000 19 1 .83(0 .87) 19 1 .15(0 .40) - E - 19.60 0.98 [0 .31 ,  1.66]
Marckmannetal2000 20 0.96(1 .30) 20 0.81(0 .22) 23.34 0 .16 [ - 0 .4 6 ,  0.78]
Moore et ai 2000 11 1.06(0 .30) 11 0.96(0 .50) w 12.77 0.23 [ - 0 .6 1 ,  1 .07]
Partis et al 2008 6 1.22(0 .56) 6 0 .61(0 .05) - - - - - - E- - - - - - 5.07 1.44 [0 .11 ,  2.77]
Rabenetal2001 18 0.95(0 .30) 18 0 .81(0 .21) - i - 20.28 0 .53 [ - 0 .1 4 ,  1.19]
TÉ ! (95% Cl) 92 92 ♦ 100.00 0 .58 [0 .28 ,  0.88]
Test for heterogeneiy; ChF=7.06, df=6 (P=0,31), F =15.1%
Test for overall effect: Z = 3.79 (P=0.0002)
-4 ■2 2 4
Paired analysis was applied to all studies [212]. Data are SMDs with 95% 01, where 
SMD is interpreted as follows: < 0.4 represents a small effect size; 0.4 -  0.7 
represents a moderate effect size; and > 0.7 represents a large effect size [205]. P 
value is for generic inverse variance fixed-model. Interstudy heterogeneity was tested 
by Cochrane’s Q (Chi^) at significance level of p<0.10 and quantified by I , where 1^ is 
interpreted as follows: 0%-40% might not be important; 30%-60% may represent 
moderate heterogeneity; 50%-90% may represents substantial heterogeneity; and 
70%-100% represents considerable heterogeneity [211]. Study quality was assessed 
by the Jadad Scale, where score 3-5 is considered high quality (range 0-5) [208]. SD, 
standard deviation; SMD, standardised mean difference; Cl, confidence interval; df, 
degree of freedom; n, number of participants.
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2.6.5 Subgroup meta-analyses for dietary sucrose intervention studies
A subgroups analysis was performed on the basis of significant covariates of the 
association between dietary sucrose and plasma TAG, including the duration of 
intervention, BMI of participants, sucrose dose, and format employed [205] (Fig. 2.8). 
Three short-term studies (< 1 day) (n=27) [220, 221, 225], and four intermediate-term 
studies (> 1 day < 2 weeks) (n=65) [192, 217, 228, 245] were included in the 
subgroup analysis of duration of intervention (Fig. 2.8(A)). None of the long-term 
studies were included in this analysis, as they were all of parallel design. Shorter-term 
studies showed a significantly large effect size of a high sucrose diet on plasma TAG, 
[effect size 0.78 (95% Cl; 0.21, 1.35; p=0.008)], whilst intermediate-term studies 
showed a significantly moderate effect size of high sucrose diet, [effect size 0.50 
(95% Cl; 0.15, 0 .86; p=0.005)].
Figure 2 .8B shows the subgroup analysis based on BMI. Six studies, with a total of 
75 subjects of normal body weight [192, 217, 221, 225, 228, 245] and two studies 
with 17 overweight or obese participants [192, 220]. As expected, high sucrose diets 
were associated with greater effects in overweight/obese participants, with an effect 
size of 1.03 (95% Cl; 0.30, 1.75; p=0.006) as compared to participants of normal 
body weight who showed a significantly moderate effect on plasma TAG, [effect size 
0.49 (95% Cl; 0.16, 0.82; p=0.004)].
Studies were also sub-grouped according to the percentage of sucrose, expressed as 
proportion of total energy intake (%E) (Fig. 2.8C). Four studies (n=54) [220, 221, 228, 
245] intervened with 20%E to 40%E of sucrose, whilst two studies (n=27) [192, 217] 
intervened with greater than 40%E of sucrose. The studies with a higher contribution 
of energy from sucrose were accompanied by a greater effect on plasma TAG, [effect 
size 0.77 (95% Cl; 0 .21, 1.33; p=0.007)] compared to the studies with a lower 
contribution of energy from sucrose, which showed a moderate effect on plasma 
TAG, [effect size 0.56 (95% Cl; 0.17, 0.96; p=0.005)]. One study was excluded 
because total energy intake was not reported in the original paper [225].
A subgroup analysis was conducted to address the possible effects of the form of 
sugar (liquid or solid. Fig. 2.8(D)). Three studies (n=27) [220, 221, 225] incorporated 
sucrose in liquid beverages, whilst four studies (n=65) [192, 217, 228, 245]
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intervened with sucrose in a solid food. Figure 2 .8D illustrates that the studies using a 
liquid form of sucrose were associated with significantly greater effects on plasma 
TAG, [effect size 0.78 (95% 01; 0.21, 1.35; p=0.008] than the studies using sucrose in 
a solid diet [effect size 0.50 (95% Cl; 0.15, 0 .86; p=0.005)]. Interestingly, all the 
studies that used a liquid form of sucrose were short-term, experimental feeding 
studies, whilst all studies that used solid test meals were all intermediate-term 
studies.
Overall, the sucrose intervention studies showed a positive, significantly moderate 
effect on plasma TAG (effect size 0.4-0.7). Subgroup analyses revealed that the 
shorter-term studies had a greater ‘effect size’ on plasma TAG than the intermediate- 
term studies. A larger ‘effect size’ of dietary sucrose on plasma TAG was evident in 
overweight or obese participants, at higher intake of sucrose (%E), and when the 
sucrose was in a liquid form.
92
Figure 2.8: Forest plots of subgroup analyses of the effect of Isoenergetic high 
sucrose vs low sucrose diet on plasma TAG (A-D). (See next page for footnote)
(A) Effect of duration of dietary sucrose Intervention on plasma TAG
study
or sub-category
Higli sucrose diet 
N Mean(SD)
Low sucrose diet 
N Mean(SD)
St® (fixed) 
95% a
Weigtrt S I®  (fixed)
01 Stiort-term
Brynes et al 2002 10 1 .1 0 (0 .1 0 ) 10 0 .9 8 (0 .1 0 )
Moore et al 2000 11 1 .0 6 (0 .3 0 ) 11 0 .9 6 (0 .5 0 )
Parks et al 2008 6 1 .2 2 (0 .5 5 ) 6 0 .6 1 (0 .0 5 )
Subtotal (95% CD 27 27
Test for heterogeneiy: ChF=3.14, df = 2 (P= 021), F = 36.4%
Test for overall effect 2  = 2.67 (P ■= 0.008)
02 Intermediate-term
Culingetal2009 8 1 .3 3 (0 .6 8 ) 8 1 .1 1 (0 .6 8 )
Hudgins et al 2000 19 1 .8 3 (0 .8 7 ) 19 1 .1 5 (0 .4 0 )
Marckmannetal2000 20 0 .9 6 (1 .3 0 ) 20 0 .8 1 (0 .2 2 )
Rabenetal2001 18 0 .9 5 (0 .3 0 ) 18 0 .8 1 (0 .2 1 )
Subtcial(95%CI) 65 65
Test for tieterogeneity; O f =3^8, d f=3 (P=0.35), F =8.5% 
Test for overal effect 2  = 2.80 (P=0.005)
Total (95% 0 )  92
Test for heterogeneity; ChF=7.06, df = 8 (P = 0.31), F = 15.1%
Test for overall effect 2=3.79 (P = 0.0002)
9 .7 1
1 2 .77
S.07
27 .59
1 00 .00
1 .1 5  [0 .1 9 , 2 .1 1 ]  
0 .2 3  [ - 0 .6 1 ,  1 .0 7 ]  
1 .4 4  [0 .1 1 , 2 .7 7 ]  
0 .7 8  [0 .2 1 , 1 .3 5 ]
9 .2 2 0 .3 1 [ -0 .6 8 ,. 1 .2 9 ]
19 .60 0 .9 8 [0 .3 1 , 1 .6 6 ]
23 .34 0 .1 6 [ -0 .4 6 , , 0 .7 8 ]
20 .28 0 .5 3 [ - 0 .1 4 ,, 1 .1 9 ]
72 .45 0 .5 0 [0 .1 5 , 0 .8 6 ]
0 .5 8  [0 .2 8 , 0.
(B) Impact of participants' BMI on the effects of dietary sucrose on plasma TAG
Study
or sub-category N
High sucrose diet 
Mean(SD) N
Low sucrose diet 
Mean(SD)
01 Normal body weight
Culling et al 2009 8 1 .3 3 (0 .6 8 ) 8 1 .1 1 (0 .6 8 )
Hudgins et al 2000 12 1 .5 8 (0 .5 9 ) 12 1 .0 2 (0 .3 7 )
Marckmannetal2000 20 0 .9 6 (1 .3 0 ) 20 0 .8 1 (0 .2 2 )
Moore et al 2000 11 1 .0 6 (0 .3 0 ) 11 0 .9 6 (0 .5 0 )
Parks et al 2008 6 1 .2 2 (0 .5 5 ) 6 0 .6 1 (0 .0 5 )
Rabenetal2001 18 0 .9 5 (0 .3 0 ) 18 0 .8 1 (0 .2 1 )
Subtotal (95% CD 75 75
SMD (fixed) 
95% Cl
SMD (fixed) 
95% Cl
Test for heterogeneity: ChF=5.45, df = 5 (P=0.36), F = 8.2% 
Test for overall effect 2=2.92 (P=0.004)
02 Overweight/obese
Brynesetal2002 10 1 .1 0 (0 .1 0 )
Hudgins et al 2000 7 2 .0 8 (1 .1 5 )
Subtotal (95% Cl) 17
Test for heterogeneity: ChF=0.15, df = 1 (P = 0.70), F =0%  
Test for overall effect 2=2.76 (P = 0.006)
Total (95% CD 92
Test for heterogeneiy: ChF=7.31, d f=7  (P =0.40), F = 4.3%
Test for overall effect 2 = 3.80 (P=0.0001)
0 .9 8 (0 .1 0 )
1 .2 8 (0 .4 3 )
9 .2 7
1 1 .96  
2 3 .44  
1 2 .83
5 .0 9
20 .37
82 .96
9 .7 6
7 .2 9
17 .04
100.00
0 .3 1  [ - 0 . 6 8 ,  1 .2 9 ]  
1 .1 0  [0 .2 3 ,  1 .9 7 ]  
0 .1 6  [ - 0 . 4 6 ,  0 .7 8 ]  
0 .2 3  [ - 0 . 6 1 ,  1 .0 7 ]
1 .4 4  [0 .1 1 , 2 .7 7 ]  
0 .5 3  [ - 0 . 1 4 ,  1 .1 9 ]  
0 .4 9  [0 .1 6 ,  0 .8 2 ]
1 .1 5  [0 .1 9 ,  2 .1 1 ]  
0 .8 6  [ - 0 . 2 5 ,  1 .9 8 ]  
1 .0 3  [0 .3 0 ,  1 .7 5 ]
0 .5 8  [0 .2 8 ,  0 .
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(C) Effect of sucrose dose or level of Intake on plasma TAG
study High sucrose diet Low sucrose diet
or sub-category N Mean(SD) N Mean(SD)
02 20-40%  total energy
Brynes et al 2002 10 1 .1 0 (0 .1 0 ) 10 0 .9 8 (0 .1 0 )
Marckmannetal2000 20 0 .9 6 (1 .3 0 ) 20 0 .8 1 (0 .2 2 )
Parks et al 2008 6 1 .2 2 (0 .5 5 ) 6 0 .6 1 (0 .0 5 )
Rabenetal2001 18 0 .9 5 (0 .3 0 ) 18 0 .8 1 (0 .2 1 )
Subtotal (95% CD 54 54
Test for heterogeneity: ChF = 4.74,df = 3(P =: 0.19), F = 36.8%
Test for overall effect 2  = 2.81 (P=0.005)
03 >40% total energy
Culling 2009 8 1 .3 3 (0 .6 8 ) 8 1 .1 1 (0 .6 8 )
Hudgins et al 2000 19 1 .8 3 (0 .8 7 ) 19 1 .1 5 (0 .4 0 )
Subtotal (95% Cl) 27 27
Test for heterogeneiy. ChF = 123,df = 1(P = 027), F = 18.6%
Test for overall effect 2=2.89  (P=0.007)
Total (95% CD 81 81
Test for heterogeneiy. ChF = 8.31,df = 5(P = 028), F = 20.8%
SMD (fixed) 
95% a
Weight
95% Cl
Test for overall effect 2  = 3.85 (P =0,0001)
1 1 .13
2 6 .76
5 .8 1
2 3 .25
6 6 .95
10 .58
22 .48
33 .05
100.00
1 .1 5  [0 .1 9 ,  2 .1 1 ]  
0 .1 6  [ - 0 .4 6 ,  0 .7 8 ]
1 .4 4  [0 .1 1 ,  2 .7 7 ]  
0 .5 3  [ - 0 . 1 4 ,  1 .1 9 ]  
0 .5 6  [0 .1 7 , 0 .9 6 ]
0 .3 1  [ - 0 . 6 8 ,  1 .2 9 ]  
0 .9 8  [0 .3 1 , 1 .6 6 ]  
0 .7 7  [0 .2 1 , 1 .3 3 ]
0 .6 3  [0 .3 1 , 0 .9 5 ]
-2 0 2
(D) Effect of sucrose feeding format on plasma TAG
study
or sub-category
hsucrose 
Mean(SD)
Low sucrose 
N Mean(SD)
SMD (fixed) 
95% a
Weight
%
SMD (fixed) 
95% a
01 Liquid diet 
Brynes et al 2002 
Moore et al 2000 
Parks et al 2008 
Subtotal (95% Cl)
1 . 10 (0 . 10)
1 .0 6 (0 .3 0 )
1 .2 2 (0 .5 5 )
Test for heterogeneity: ChP=3.14, d f=2  (P=021 ), F =36.4% 
Test for overall effect 2=2.67  (P=0.008)
02 Solid diet
Test for overall effect 2 = 3.79 (P=0.0002)
0 .9 8 (0 .1 0 )
0 .9 6 (0 .5 0 )
0 .6 1 (0 .0 5 )
Culilngetal2009 8 1 .3 3 (0 .6 8 ) 8 1 .1 1 (0 .6 8 )
Hudgins et al 2000 19 1 .8 3 (0 .8 7 ) 19 1 .1 5 (0 .4 0 )
Marckmannetal2000 20 0 .9 6 (1 .3 0 ) 20 0 .8 1 (0 .2 2 )
Raben et 812001 18 0 .9 5 (0 .3 0 ) 18 0 .8 1 (0 .2 1 )
Subtotal (95% Cl) 65 65
Test for heterogeneiy: ChF = 328,d f = 3(P = 0.35), F = 8.5%
Test for overall effect 2  = 2.80 (P=0.005)
Total (95% CD 92 92
Test for heterogeneiy ChF = 7.08,df = 6(P = 0.31),F = 15.1%
9 .7 1
1 2 .77
5 .0 7
27 .55
1 00 .00
1 .1 5  [0 .1 9 ,  2 .1 1 ]  
0 .2 3  [ - 0 . 6 1 ,  1 .0 7 ]  
1 .4 4  [0 .1 1 ,  2 .7 7 ]  
0 .7 8  [0 .2 1 ,  1 .3 5 ]
9..22 0 .3 1 [ - 0 . 6 8 ,  1 .2 9 ]
19..60 0 .9 8 [0 .3 1 ,  1 .6 6 ]
23.,34 0 .1 6 [ - 0 .4 6 ,  0 .7 8 ]
20..28 0 .5 3 [ - 0 . 1 4 ,  1 .1 9 ]
72.,45 0 .5 0 [0 .1 5 ,  0 .8 6 ]
0 .5 8  [0 .2 8 , 0 .
Paired analysis was applied to all studies [212]. Data are SMDs with 95% Cl. The 
interpretations of SMD and heterogeneity (Chi^) are as described in previous footnote 
(Fig. 2.7). Study quality was assessed by the Jadad Scale, where score 3-5 is 
considered high quality (range 0-5) [208]. Because there was no description of the 
method used in the randomisation and blinding, all studies were scored as low quality 
(score 1-2). SD, standard deviation; SMD, standardised mean difference; 01, 
confidence interval; df, degree of freedom; n, number of participants.
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2.6.6 Meta-analysis for fructose feeding intervention studies
The findings from this systematic review, were substantiated statistically by 
undertaking a meta-analysis on the same set of studies. The effect of fructose 
feeding on plasma TAG was analysed in 6/20 studies (n=88). There was moderate 
heterogeneity between fructose studies, but since this was not significant (p=0 .10; 
l^=45.2%), a fixed-model was used for the analysis to determine the SMDs. Of six 
studies, four studies [234, 238, 241, 244] showed positive associations, one study 
showed no association [240] and one study showed a negative association [235] 
between high fructose feeding and plasma TAG. The overall effect of high fructose 
feeding on plasma TAG was significant and moderate, [effect size 0.43 (95% 01; 
0.13, 0.73; p=0.006)] (Fig. 2.9). Data were also analysed within subgroups to 
examine the impact of gender, menopausal status, duration of intervention and dose 
on plasma TAG in response to fructose feeding (Fig. 2.10).
Figure 2.9: Forest plot of total effect of isocaloric high fructose vs low fructose 
diet on plasma TAG in 88 participants reported in six studies.
Si
ofsub-cÉgory N iean(SD) N llean(SD) 95%Ci % 95%CI
Baidal 2000 24 1.03 (0 .29 ) 24 0 .96(0 .29) - E - 28.11 0.44 [-0 .1 3 , 1.011
tehepin eta! 2008 16 1.32 (0 .30 ) 16 0 .95 (0 .24 ) 15.37 1.33 [0 .5 5 , 2.101
iactald dal 1968 11 1 .00 (0 .36 ) 11 0 .72 (0 .33 ) _ s _ 12.10 0.78 [ -0 .0 9 , 1.651
Sod! dal 2010 11 1.20 (0 .66 ) 11 1 .20 (0 .66 ) . 13.22 0.00 [ -0 .8 4 , 0 .84]
Swanson dal 1892 14 0.96(0 .37) 14 0 .91 (0 .37 ) 16.79 0 .13 [ -0 .6 1 , 0 .87]
Ieffdal2004 12 0.82 (0 .31 ) 12 0 .85 (0 .24 ) 14.40 -0 .10  [ -0 .9 1 , 0 .70]
Idal(95%CI) 88 88 + 100.00 0.43 [0 .1 3 , 0 .73]
lest for hderogenely: CbP=9.12, til=5 (P=0.10), F=46.2%
lest for overall effect Z=2.77(9=0.006)
4 - 2  0 2 4
Paired analysis was applied to all studies [212]. Data are SMDs with 95% Cl. The
interpretation for SMD and heterogeneity (Ghi^) are as described previously (Fig. 2.7). 
Study quality was assessed by the Jadad Scale, where score 3-5 is considered high
quality (range 0-5) [208]. SD, standard deviation; SMD, standardised mean
difference; 01, confidence interval; df, degree of freedom; n, number of participants.
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2.6.7 Subgroup meta-analyses for fructose feeding intervention studies
Of the six fructose feeding studies examined, four subgroups were analysed on the 
basis of gender and menopausal status, and two methodological factors; duration of 
intervention and fructose dose (Fig. 2.10). Subgroup analyses for gender, dose of 
fructose and duration of intervention showed ‘substantial’ to ‘considerable’ 
heterogeneity within subcategories (p<0.10; 1^ = 69% to 84%), and hence required 
the use of a random-model to calculate SMDs. Subgroup analysis for menopausal 
state failed to show any evidence of heterogeneity, so was analysed using a fixed- 
model.
Four studies, showed a significantly greater positive effect of a high fructose diet on 
plasma TAG in 36 men [effect size’ 1.20 (95% Cl; 0 .21, 2.19)] [238, 240, 241, 244], 
compared to 38 women [effect size’ 0.12 (95%CI; -0.34, 0.58] [235, 238, 241, 244] 
(Fig. 2.10(A)). Women in these studies were also subdivided according to 
menopausal status. Three studies, which included 26 pre-menopausal participants 
[235, 238, 244], showed small non-significant, positive effects of a high fructose diet 
on plasma TAG, [‘effect size’ 0.26 (95% Cl; -0.29, 0.82)] (Fig. 2 .10(B)). In 
comparison, one study showed a large but non-significant positive in three post­
menopausal participants [effect size 2.96 (95% Cl; -0.32, 6.24)] [244].
Figure 2.10(C) shows the subgroup analysis for the effects of study duration. Two 
short-term studies (^ 1 day) (n=28) [235, 238], two intermediate-term studies (> 1 day 
< 2 weeks) (n=22) [240, 244] and two long-term studies (> 2 weeks) (n=38) [234, 241] 
were included in this subgroup analysis. The short-term studies showed a large 
positive effect, [effect size 0.62 (95%CI; -0.79, 2 .02)], whilst both the intermediate- 
term and long-term studies showed small positive effects, [effect size 0.38 (95% Cl; - 
0.38, 1.14)] and [effect size, 0.33 (95% Cl; -0.13, 0.78)], respectively, all were non­
significant. To determine the effect of fructose dose, these studies were subdivided 
according to percentage of total energy from fructose (%E) incorporated in the test 
meals (Fig. 2 .10(D)). One study (n=14) used fructose < 20%E [234], three studies 
(n=52) incorporated fructose at 20% - 40%E [235, 238, 241] and one study (n=11) 
used > 40%E of fructose [240]. In contrast to sucrose, the study that used the largest 
amount of fructose produced no effect on plasma TAG. Studies that incorporated 
fructose at 20%E to 40%E, showed moderately positive effects on plasma TAG,
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[effect size 0.55 (95%CI; -0.19, 1.30)]. The study that used < 20%E of fructose 
showed small positive effect, [effect size 0.13 (95% Cl; -0.61, 0.87)]. Once again, all 
of the findings were non-significant.
In conclusion, the overall effect of high fructose was to produce a consistent increase 
in the concentration of plasma TAG. In contrast, the results from the subgroups 
analysis were more variable and less conclusive. Gender and menopausal status 
produced substantial differences in effect size of high fructose diet on plasma TAG, 
whereas differences in methodology, particularly dosage and duration of intervention 
had less impact.
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Figure 2.10: Forest plots of subgroup analyses of the effect of Isoenergetic 
high fructose vs low fructose diet on plasma TAG (A-D). (See next page for 
footnote)
(A) Impact of gender on the effect of fructose feeding on plasma TAG
study High fructose diet Low fructose diet
or sub-category N Mean(SD) N Mean(SD)
01 Men
BantleetalZOOO 12 1 . 2 6 ( 0 . 2 1 ) 12 0 . 9 5 ( 0 .2 1 )
Couchepinetal2008 8 1 . 3 5 ( 0 . 3 1 ) 8 0 . 7 9 ( 0 .1 7 )
Macdonald et a ll 966 S 1 . 0 1 ( 0 . 1 8 ) 5 0 . 6 6 ( 0 . 2 0 )
Sooketal2010 11 1 . 2 0 ( 0 . 6 6 ) 11 1 . 2 0 ( 0 .6 6 )
Subtotal (95% Cl) 36 36
Test for heterogeneiy ChF = 9.73, df = 3(P = 0.02),F = 692%
Test for overall effect Z =2.37 (P =^ 0.02)
St®  (random) 
95% Cl
S I®  (random)
% 95% Cl
1 3 .7 2 1 . 3 8 [ 0 . 4 7 ,  2 . 2 9 ]
1 0 .0 8 2 .1 2 [ 0 . 8 2 ,  3 . 4 1 ]
8 .2 0 1 . 6 6 [ 0 . 1 1 ,  3 . 2 1 ]
1 4 .4 8 0 . 0 0 [ - 0 . 8 4 ,  0 .8 4 ]
4 6 .4 9 1 .2 0 [ 0 . 2 1 ,  2 . 1 9 ]
02 Women
Bantle et al 2000 12 0 . 9 3 ( 0 . 2 1 ) 12 0 . 9 7 ( 0 . 2 1 )
Couohepinetal2008 8 1 . 2 8 ( 0 . 2 8 ) 8 1 . 1 0 ( 0 .3 1 )
Macdonald et al 1966 6 0 . 9 9 ( 0 . 3 4 ) 6 0 . 7 8 ( 0 .2 7 )
Teffetal2004 12 0 . 8 2 ( 0 . 3 1 ) 12 0 . 8 5 ( 0 . 2 4 )
Subtotal (95% CD 38 38
Test for heterogeneity; O f =237, d f=3  (P = 0.50), F =0%  
Test for overall effeot Z =0.52 (P=0.61)
Total (95% CD 74
Test for heterogeneity: ChF=18.19, d f=7  (P = 0.01), F =61.5%
Test for overall effect Z = 2 20  (P=0.03)
1 4 .8 4 - 0 . 1 8 [ - 0 . 9 9 ,  0 . 6 2 ]
1 2 .6 9 0 . 5 8 [ - 0 . 4 3 ,  1 . 5 8 ]
1 1 .1 2 0 . 6 3 [ - 0 . 5 4 ,  1 .8 0 ]
1 4 .8 6 - 0 . 1 0 [ - 0 . 9 1 ,  0 .7 0 ]
5 3 .5 1 0 . 1 2 [ - 0 . 3 4 ,  0 .5 8 ]
1 0 0 .0 0 0 . 6 4 [ 0 . 0 7 ,  1 . 2 1 ]
(B) Impact of menopausal status on the effect of fructose feeding on plasma 
TAG
study
or
High fructose diet Low fructose diet
95% Cl 95% Cl
Couchepinetal2008 8 1 .28 (0 .2 8 ) 8 1 .10 (0 .3 1 )
Macdonald et a ll  966 6 0 .99 (0 .3 4 ) 6 0 .78 (0 .27 )
Teffe tal2004 12 0 .82 (0 .3 1 ) 12 0 .85 (0 .2 4 )
Subtotal (95% Cl) 26 26
Test for heterogeneity ChF=1.56, d f= 2  (P =0.46), F =0%
Test for overall effect 2 = 0 .9 4  (P =0.35)
02 Post-menopausal
Macdonald et al 1966 3 2 .12 (0 .3 1 ) 3 1 .11 (0 .2 3 )
Subtotal (95% Cl) 3 3
Test for heterogeneity not applicable
Test for overall effect Z =1.77 (P =0.06)
Total (95% Cl) 29 29
Test for heterogeneity: ChF=4.09, d f= 3  (P = 0 2 5 ), F =26.6%  
Test for overall e ffect Z = 1 2 2  (P = 0 2 2 )
29.32  
21.50
46.32  
97.23
0.58 [ -0 .4 3 , 1 .58 ] 
0.63 [ -0 .5 4 , 1 .80] 
-0 .1 0  [ -0 .9 1 , 0 .70] 
0.26 [ -0 .2 9 , 0 .82]
4  2 .77 2 .96  [ -0 .3 2 , 6 .24]
2 .77 2 .96 [ -0 .3 2 , 6 .24]
100.00 0 .34  [ -0 .2 1 , 0.
-4 -2 2 4
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(C) Effect of duration of intervention of fructose feeding on plasma TAG
study
or sub-category
Higti fructose diet 
N Mean (SD)
Low fructose 
N lilean (SD)
SMD (random) 
95% a
Weight
%
SMD (random) 
95%  a
01 Short-term
Couchepin eta! 2008 1 6  1 . 3 2 ( 0 . 3 0 )
T e ffe ta l2 0 0 4  12  0 . 8 2 ( 0 . 3 1 )
Subtotal (95% 0 )  28
Test for heterogeneiy: ChF = 6.34, df = 1 (P = 0.01), P = 8 4 2%  
Test for overall e ffec t 2  = 0.86 (P = 0 3 9 )
02 Wermediate-term
Macdonald et al 1966 11 1 . 0 0 ( 0 . 3 6 )
Sock et al 2010 1 1  1 . 20 ( 0 . 66)
Subtotal (95% Cl) 22
Test for heterogeneity: ChF = 1.60, df = 1 (P = 0 2 1 ), F = 37.5%  
Test for overall effect 2  = 0.97 (P = 0.33)
03 Long-term
Bantle et al 2000 24 1 . 0 9 ( 0 . 2 9 )
Swanson et a l l 992 1 4  0 . 9 6 ( 0 . 3 7 )
Subtotal (95% Cl) 38
Test for heterogeneiy; ChF = 0.42, df = 1 (P = 0.52), P = 0%  
Test for overai effec t 2  = 1.40 (P = 0.16)
Total (95% CO 88
Test for heterogeneiy: ChF = 9.12, df = 5 (P = 0.10), F = 4 5 2%
Test for overai e ffec t 2  = 2.02 (P = 0 3 4 )
0 . 9 5 ( 0 . 2 4 )
0 . 8 5 ( 0 . 2 4 )
0 . 7 2 ( 0 . 3 3 )
1 . 20 (0 . 66)
0 . 9 6 ( 0 . 2 9 )
0 . 9 1 ( 0 . 3 7 )
1 6 .2 9
1 5 .6 9
3 1 .9 8
1 4 .1 4
1 4 .9 2
2 9 .0 6
2 1 .8 6
1 7 .1 0
3 8 .9 6
1 . 3 3  1 0 .5 5 ,  2 .1 0 )  
- 0 . 1 0  ( - 0 . 9 1 ,  0 . 7 0 )  
0 . 6 2  [ - 0 . 7 9 ,  2 . 0 2 )
0 . 7 8  [ - 0 . 0 9 ,  1 . 6 5 )  
0 . 0 0  [ - 0 . 8 4 ,  0 .8 4 )  
0 . 3 8  [ - 0 . 3 8 ,  1 . 1 4 )
0 . 4 4  [ - 0 . 1 3 ,  1 . 0 1 )  
0 . 1 3  [ - 0 . 6 1 ,  0 . 8 7 )  
0 . 3 3  [ - 0 . 1 3 ,  0 .7 8 )
0 . 4 3  [ 0 . 0 1 ,  0 .8 5 )
(D) Effect of fructose dose on plasma TAG
study High fructose diet 
or sub-category N Mean (SD) N
Low fructose diet 
Mean (SD)
SMD (random) 
95% Cl
Weight
%
SMD (random) 
95% Cl
01 < 20 %  total energy 
Swanson et a l l 992 14  
Subtotal (95% CD 14  
Test for heterogeneity: not applicable 
Test for overall effec t 2  = 0 3 5  (P = 0.73)
0 . 9 6 ( 0 .3 7 ) 14
14
0 . 9 1 ( 0 . 3 7 )
-4►
1 9 .9 6
1 9 .9 6
0 . 1 3
0 . 1 3
[ - 0 . 6 1 ,  0 . 8 7 )  
[ - 0 . 6 1 ,  0 . 8 7 )
02 2 0 -4 0 %  total energy 
Bantle et al 2000 24  
Couchepin et al 2008 16  
Teffe ta l2 0 0 4  1 2 
Subtotal (95% CD 52  
Test for heterogeneity: ChF = 6.57, df = 2  (P = 
Test for overall effect 2  = 1.45 (P = 0.15)
1 . 0 9 ( 0 .2 9 )
1 . 3 2 ( 0 . 3 0 )
0 . 8 2 ( 0 . 3 1 )
0.04), F = 69.6%
24
16
12
52
0 . 9 6 ( 0 . 2 9 )
0 . 9 5 ( 0 . 2 4 )
0 . 8 5 ( 0 . 2 4 )
2 4 .7 6
1 9 .1 2
1 8 .4 9
6 2 .3 6
0 . 4 4
1 . 3 3
- 0 . 1 0
0 . 5 5
[ - 0 . 1 3 ,  1 . 0 1 )  
[ 0 . 5 5 ,  2 . 1 0 )  
[ - 0 . 9 1 ,  0 . 7 0 )  
[ - 0 . 1 9 ,  1 . 3 0 )
03 > 40% total energy 
Sock et al 2010 11  
Subtotal (95% CD 11  
Test for heterogeneity: not applicable 
Test for overall effect: 2  = 0.00 (P = 1.00)
1 . 2 0 ( 0 . 6 6 ) 11
11
1 . 2 0 ( 0 . 6 6 ) 1 7 .6 7
1 7 .6 7
0 . 0 0
0 . 0 0
[ - 0 . 8 4 ,  0 . 8 4 )  
[ - 0 . 8 4 ,  0 . 8 4 )
Total (95% Cl) 77  
Test for heterogeneity: ChF = 8.42, df = 4 (P = 
Test for overall effec t 2  = 1.52 (P = 0.13)
0.08), F = 52.5%
77 1 0 0 .0 0 0 . 3 7 [ - 0 . 1 1 ,  0 . 8 5 )
Paired analysis was applied to all studies [212]. Data are SMDs with 95% Cl. The 
interpretation of SMD and heterogeneity (Chi^) are described previously (Fig. 2.7). 
Because there was no description of the method used in the randomisation and 
blinding, all studies were scored as low quality (score 1-2). SD, standard deviation; 
SMD, standardised mean difference; 01, confidence interval; df, degree of freedom; n, 
number of participants.
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2.7 Discussion
The consumption of dietary sugars, particularly that of sucrose and high fructose corn 
syrup, has increased in parallel with rising obesity and the incidence of metabolic 
syndrome, in developed countries. The relationship between sugar and CVD risk has 
been studied extensively in recent years. Sugars have been associated with raised 
plasma TAG, reduced HDL-C and, to a lesser extent, a predominance of small dense 
LDL. Several attempts have been made to systematically review the relationships 
between sugary drinks, especially soft drinks and added sugar, and body weight [38, 
246-248]. However, understanding of the relationship between sugar intake and 
dyslipidaemia is still very much in its infancy. This chapter aimed to systematically 
review the available evidence from cross-sectional and intervention studies to 
determine the effect of dietary sugars on plasma TAG and HDL-C in healthy adults. A 
meta-analyses of intervention studies was undertaken to determine the total effect 
size of dietary sugars on plasma TAG and to determine the effects of biological (i.e. 
BMI, menopausal state and gender) and methodological factors (i.e. dose and format 
of sugar and duration of intervention) on the response of plasma TAG to dietary 
sugars. A meta-analysis on the effects of sugars on plasma HDL-C was not 
performed due to an insufficient number of studies measuring this variable included in 
this review.
The findings from cross-sectional studies were consistent in showing a positive 
relationship between sugar intake and plasma TAG, and an inverse relationship 
between sugar intake and plasma HDL-C. The two largest studies showed strong 
positive relationships between sugar intake and plasma TAG. Both included large 
sample sizes which provided sufficient strength in terms of study power, nonetheless 
they differed in their methods for assessing sugar intake. In the study by Dinghra et 
al. [214] sugar intake was assessed by number of soft drinks, whereas Welsh et al. 
[41] measured sugar intake by the amount of added sugar. In the former study, the 
actual intake of sugar was unknown, whereas in the latter, sugar intake did not 
include sugars in processed food, soft drink and fruit juices. In addition, the method of 
dietary assessment was found to be critical to the interpretation of the final outcome. 
Food frequency questionnaires (FFQ), as used in the ‘Framingham Heart Study’ are 
considered to be a feasible tool to record habitual intake of sugar over time in such a 
large number of participants [214]. In comparison, 24-hour diet recall, as used in the
100
‘NHANES’ [41], is less reliable to assess individual intakes since it only records food 
intake during the previous 24 hours. This could introduce an underestimate of the 
actual intake of sugars in the habitual diet. This also may explain the non-significant 
relationship between serum TAG and intake of sugar that was found in the Tecumseh 
population study by Nichols etal. [213].
A considerable amount of randomised clinical trials have been undertaken to 
determine the effects of sugars on plasma lipids, mainly plasma TAG. In contrast to 
cross-sectional studies, the findings from intervention studies are still inconclusive. 
There were inconsistencies between studies in terms of methodology. More than 80%  
of the dietary sugars intervention studies, and 95% of the studies that used fructose 
feeding, showed a significant plasma TAG-raising effect. Nevertheless, the meta­
analyses revealed a significantly moderate effect size that was higher in dietary 
sucrose relative to fructose feeding studies on plasma TAG, effects size 0.58 and 
0.43, respectively. This suggests that dietary sucrose may exert a greater effect on 
plasma TAG, but an effect that is less consistent between studies compared to the 
impact of fructose feeding on plasma TAG.
There was evidence of an increase in plasma TAG in response to a longer-term 
sugar intervention study (six months), though this was not significant due to poor 
dietary compliance over time. Compliance rate was a major confounding factor 
associated with longer-term dietary interventions, with subjects losing motivation, 
becoming disinterested, and as a result, non-compliant with the dietary intervention 
over time. A lack of adherence to the diet in a free-living setting might help to explain 
the decrease in effect size with the increase in duration of both sucrose and fructose 
intervention studies included in the meta-analyses. In addition, misreporting also 
could be influenced by variation in the participants’ characteristics, such as BMI, 
gender, socio-demographic profile (i.e. economic, educational background, 
occupation) and lifestyle factors (i.e. smoking status and physical activity), though 
misreporting in relation to these factors was not analysed in these studies. Frequent 
contact with participants and the provision of a broad choice of study foods, were 
recognised as two important aspects of the study design that could help to maintain 
dietary compliance. Nonetheless, the outcome of long-term studies relied on fasting 
plasma TAG whilst in contrast, the outcome of acute studies were on the basis of 
post-prandial plasma TAG.
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A greater number of fructose feeding studies showed significant positive outcomes on 
plasma TAG compared to studies in sugar. It conceivable that this finding is due to 
19/20 (95%) of fructose feeding studies having used liquid fructose formula in their 
dietary interventions. This is further supported by the meta-analysis in which effect 
size of a high sucrose diet was greater in short-term, experimental studies that 
employed liquid diets relative to studies using solid food. A liquid diet has a simpler 
matrix and composition than solid foods, the latter of which can include other macro- 
and micronutrients such as dietary fat and fibre which could modify the effects of 
dietary sugar. Liquid-based formulations have been favoured in metabolic studies, 
because the composition can be tightly controlled, and they are convenient to deliver, 
but they can also be unpalatable and fail to promote satiety. Conversely, alternative 
solid-based foods are inherently complex for ascertaining the effects of individual 
nutrients. In contrast to the finding from the meta-analysis, Mustad et al. [249] found 
no difference in the response of plasma cholesterol to changes in saturated fat, total 
fat and cholesterol intake between liquid-based and solid-based diets. Whether this 
response translates to dietary sugars is uncertain. Nevertheless, whilst well controlled 
liquid formula may not be representative of diets consumed by free-living individuals 
and populations, it can provide valuable metabolic and mechanistic information. More 
evidence on the relationship between sugar and fructose and GVD risk in the 
population is required to develop appropriate dietary guidelines. Dietary fat and fibre 
are two major potential confounding factors for studying the effect of dietary sugar in 
whole diets on plasma TAG [91, 250]. Only studies with a moderate intake of dietary 
fat and fibre were included in this analysis. This cautionary step was undertaken to 
prevent the potential confounding influence of dietary fat and fibre on lipid 
metabolism.
The cross-sectional studies also demonstrated a positive dose-response effect of 
sugar intake on plasma TAG. These results are consistent with the findings from the 
meta-analysis on the effect of sucrose dose on plasma TAG, in which a higher dose 
of sucrose or level of intake produced greater effect size on plasma TAG. This is 
further supported by studies that produced a greater effect size when fructose 
contributed between 20-40% of energy relative to studies were its energy contribution 
was less than 20% (Fig. 2.8D). Interestingly, in contrast to the findings from sucrose 
intervention studies, the study which intervened with the largest dose of fructose (> 
40%E) showed no difference in its effects on plasma TAG between high and low
102
fructose diets. However, this was only one study which cannot necessarily reflect the 
‘true’ effect of the intervention. The majority of studies that found significant effects of 
dietary sugars on plasma TAG, used liquid forms of sugar that were not 
representative of that normally consumed 7%E). However, according to NDNS, the 
upper 2.5'^ percentile of the UK population are reported to consume up to 30% of 
their energy as sugar [251].
Another factor that is worthy of consideration as a confounding influence is variation 
in the analytical performance of laboratory measurements. Although standard assays 
are described in the methods, information on the accuracy, precision and quality 
control of assays was often lacking. Three sugar intervention studies and three 
fructose feeding studies reported acceptable levels of precision for their lipid assays 
(CV < 2%). The sensitivity of the assays was reported to be able to detect < Ipmol/L, 
and claimed to analyse all samples within a single batch [220, 228, 231, 234, 236, 
245].
Small sample sizes provide wide confidence intervals and thus, an inability to 
discriminate between a change in a variable that is reproducible (as determined by 
significant probability) or that which has occurred by chance. A conventionally 
acceptable variance (SD) in the measurement of plasma TAG is ± 0.23mmol/L [221]. 
A high sugar diet (25%E) has been previously shown to increase plasma TAG by 
0.32mmol/L in 16 non-diabetic participants [171]. This provides an 80% probability of 
detecting a difference of 0.3mmol/L in plasma TAG. Of the selected sugar and 
fructose intervention studies, only 25% had sample size in excess of 16 participants 
with one study by Saris et al. having a sample size of 290 participants [29]. This 
suggests that 75% of the intervention studies may have been underpowered due to 
inadequate sample size.
The inconsistency in results between studies may also be explained by biological 
variability among participants. The lipid response to dietary sugars depends on 
numerous metabolic and genetic determinants, that vary between individuals. It has 
been speculated that BMI, gender, age, ethnicity, menopausal status, genetic 
variants and body composition could all be potential determinants of the plasma lipid 
response to dietary sugars [213, 216, 241, 252, 253]. BMI has been shown to 
produce a substantial impact on the effect of dietary sucrose on plasma TAG, with
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obesity being associated with a greater effect size than being overweight. This finding 
may be related to difference in body composition and the degree of insulin sensitivity 
and de novo lipogenesis (DNL) in the liver. However, the effect size in the meta­
analysis for the obese participants was calculated on the basis of only two studies, 
involving a total 17 participants and was probably underpowered. Variation in 
response between genders could be ascribed to differences in body composition 
between men and women. While men show a greater tendency to deposit fat in their 
abdomen, pre-menopausal women tend to deposit fat in the thighs and hips. 
Abdominal obesity is an established independent risk factor of CVD [4] and also 
commonly associated with insulin resistance-related to hepatic DNL, which may help 
to explain the greater effect size, and thus sensitivity, of men to fructose relative to 
women [169]. There was disparity in the effect of dietary sucrose on plasma TAG 
between pre- and post-menopausal women, with the latter showing a very large effect 
size relative to the former (Fig. 2.8B). This finding may be explained by the 
substantial role of sex hormones on whole-body lipid metabolism, including body fat 
deposition [252]. However, whilst the number of post-menopausal studies in this 
review was limited, the menstrual cycle in pre-menopausal women and the use of 
hormone-replacement therapy (HRT) in post-menopausal women are potential 
confounding factors to be considered in intervention studies with sugar in women. 
Studies that involved pre-menopausal women included in this review were performed 
during the same cycle, thus reducing the impact of variation in sex hormones.
With respect to the effect of age on outcome, only one study by Bantle et al. stratified 
their data and compared the effect of fructose according to age. They found no 
significant influence of age on the response to fructose intake on plasma TAG [241]. 
However, aging has been associated with increased body fat and plasma TC and 
decreased basal metabolic rate (BMR), LDL particle size and plasma HDL-0 [254, 
255].
Another major confounding factor which has been recognised to influence the 
response to dietary sugars on plasma TAG is a change in body weight [256]. 
Previous studies have indicated that a 5-10% change in body weight may produce a 
substantial effect on plasma TAG and HDL-C [257, 258]. In this analysis, six 
intervention studies reported non-significant weight loss, another six studies reported 
a weight increase [29, 175, 229, 238, 240, 242], three studies reported no weight
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change [163, 243, 244], whilst others failed to measure body weight. The evidence 
from these studies suggests that variation in body weight needs to be in excess of 5%  
before this will exert a significant confounding effect upon the influence of dietary 
sugars on plasma TAG, but this will also depend on the nature of the dietary 
intervention.
In recent years, there has been increased interest in the possible influence of genetic 
polymorphism on the lipid response to diet. Apo E genotype is an example of one 
such polymorphism which can potentially modulate the effects of dietary sugars on 
the formation of TAG-rich lipoproteins (VLDL and chylomicrons), and thus HDL and 
LDL [91]. Apo E2 and E4 are recognised as the alleles that have the most influential 
effect on plasma lipoproteins relative to E3 [253]. However, the studies included in 
this review did not consider apo E polymorphisms, and can therefore draw no 
conclusions about the impact of this polymorphism.
Since more than 80% of the intervention studies in this analysis had a cross-over 
design, there was a potential confounding influence from order and carry-over effects. 
Randomisation and appropriate wash-out periods of between three to five weeks 
seemed to be adequate to eliminate the effect of the first intervention by allowing 
plasma TAG to return to baseline values [239]. Eleven from 29 cross-over studies 
applied wash-out periods of between two to six weeks [171, 191, 217, 218, 221, 223, 
226, 228, 238, 240, 245]. Even so, there were no reports of any significant 
relationship in plasma TAG at baseline and after the intervention, and thus no 
adjustments for baseline values were reported. While in a cross-over study by Szanto 
& Yudkin, participants were not randomised to treatments, it was claimed that the 
effect of the high sucrose diet was independent of the sequence of diets, and that the 
order effects of the diet was eliminated by the wash-out period between treatments 
[226].
Many possible confounding influences on the response of plasma TAG to dietary 
sugars were not analysed or documented in these studies. These could include the 
composition of the meal prior to the study day, and levels of physical activity. 
Furthermore, a number of studies have suggested that ad libitum  diets were more 
beneficial than energy-fixed diet when comparing experimental diets as they create 
more realistic physiologically situation [235, 245].
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2.8 Conclusion
In conclusion, the systematic review provides independent evidence for a positive 
relationship between sugar consumption and plasma TAG, and an inverse 
relationship with plasma HDL-C. These findings were confirmed by a meta-analysis of 
the same studies, that also identified several, potentially confounding variables that 
influence the lipid response to dietary sugars. The overall outcome may have 
implications for future dietary guidelines by reinforcing advice to limit the intake of 
dietary sugars, especially in overweight and obese populations.
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Chapter 3
DEVELOPMENT OF A DIETARY EXCHANGE MODEL TO EXAMINE THE EFFECT 
OF DIETARY SUGARS ON PLASMA TRIACYLGLYCEROL 
( C H O r Study Part I)
3.1 Introduction
Despite ail efforts to prevent and treat CVD, it remains the main cause of mortality in 
most countries in the world, and contributes to nearly 4.3 million deaths in Europe 
every year [259, 260]. Since the 1960s, dietary factors, mainly high saturated and 
trans fat, cholesterol, and more recently a low fibre intake, have been recognised as 
major contributors to CVD [17, 18, 261, 262]. Epidemiological studies have shown 
that diets low in saturated fat and cholesterol are associated with lower rates of CVD  
risk [263-265]. A previous meta-analysis has shown that a low fat intake reduced 
CVD events by 16% and reduced CVD mortality by 9% [266]. Hence, the reduction of 
dietary fat intake has been the main target for CVD dietary intervention for over two 
decades [267, 268]. However, two more recent studies have shown that a reduced 
total fat intake had no significant effect in reducing CHD and stroke in post­
menopausal women [178, 269]. Moreover, replacing dietary fat with dietary CHO, 
especially in the form of sugar, may be inadvisable due to unfavourable effects on 
plasma TAG, HDL-C and obesity, leading to increased CVD and T2DM risks.
Chapter 2 has established the positive and negative associations between a high 
intake of sugar, and plasma TAG and HDL-C, respectively. A high intake of sugar in 
both short and intermediate-term studies was accompanied by significant increases in 
plasma TAG, whereas, the effects of the long-term intake of sugar were less 
conclusive. Several studies have shown that the effects were greater in obese 
compared to lean participants, and in participants with hyperinsulinaemia compared 
to healthy participants. These findings are believed to be associated with insulin 
resistance, a common clinical feature observed in individuals with abdominal obesity 
and metabolic syndrome. While the systematic review described in Chapter 2 
concluded that a high intake of sugar, especially in the form of fructose, increased 
plasma TAG and decreased HDL-C, the impact of the quality of CHO, in real foods
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and in free-living people at increased cardio-metabolic risk, over a period of months is 
unknown.
Controlled dietary intervention studies are difficult to perform and interpret, mainly 
because of the need to replace one nutrient with another using a dietary exchange 
strategy with real foods. In addition, long-term studies in free-living settings suffer 
from poor dietary compliance. Nevertheless, two recently undertaken, long-term 
studies have successfully achieved dietary manipulation, with good compliance, in 
free-living participants using a dietary exchange model. Both ‘RISCK’ [270] and 
‘LIPGENE’ [271] studies are good examples of successful dietary intervention trials, 
which implemented extensive changes in the intake of dietary fat and CHO in free- 
living participants ‘at risk’ of, and with metabolic syndrome, respectively. The 
following chapter describes the development of a dietary exchange model for 
evaluating the effect of dietary sugar on the expression of an ALP, whilst Chapter 4
describes the application of this model within the limited context of its effect on
plasma lipids and lipoproteins. The dietary exchange was a central component of a 
larger metabolic study funded by the Biotechnology and Biological Sciences 
Research Council (BBSRC) to address the impact of dietary sugars on plasma 
lipoprotein kinetics (Ethics approval. Appendix 1).
3.2 Study aim
To develop a dietary exchange model for the purpose of testing the effects of two 
experimental diets, high and low in dietary sugars on plasma lipid metabolism.
3.3 Study objectives
• To design two diets that were high and low in sugars by manipulating the ratio 
of starch to sugar. This was achieved by the careful selection, and provision to 
participants, of a wide range of supermarket foods of an appropriate 
composition.
•  To test the efficacy of the dietary exchange model in altering the concentration 
of plasma TAG in subjects at increased cardio-metabolic risk.
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3.4 Study hypothesis
It was hypothesised that a selection of appropriate foods will achieve an exchange of 
dietary sugars for starch, thus delivering two diets high and low in sugars, the former 
of which will promote an increase in plasma TAG and formation of an ALP.
3.5 Methods
3.5.1 Study power and sample size justification
The study power and sample size were calculated on the basis of the primary 
endpoints in the main metabolic study (BBSRC Grant No. BB/G009899/1), which
were the production rates of VLDLi, apoprotein B and VLDL-TAG. The main
lipoprotein kinetic study initially aimed to recruit 36 participants with an allowance for 
a 20% drop-out rate (which was equal to three participants per intervention arm).
3.5.2 Study participants
The participants in this study were at increased cardio-metabolic risk, (according to 
the cardio-metabolic risk score adapted from the ‘RISCK’ study [272]) and were all 
homozygous for the apo E3 genotype. Participants who were carriers of apo E2 and 
apo E4 alleles were excluded from the study, since there is evidence that the 
presence of apo E2 is potentially cardio-protective, whereas apo E4 predisposes to 
CHD [253]. The detailed description of the study participants including the method of 
recruitment, inclusion and exclusion criteria, are described in Chapter 4.
3.5.3 Dietary intervention
i) Dietary exchange model
The dietary exchange model (DEM) was designed according to the mean intakes of 
two groups of men, aged 35 to 49 and 50 to 64, as published by the National Diet & 
Nutrition Survey (NDNS) [30]. Mean data were used to provide the intakes for men 
aged 40 to 65 (Table 3.1). The survey showed that dietary CHO accounted for 47%  
food energy (%E), whilst non-milk extrinsic sugar (NMES) accounted for 13%E.
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Table 3.1 : Mean energy and macronutrient intakes of men (NDNS)
Mean intakes/age 3 5 - 4 9 5 0 - 6 4 Mean
Total energy (MJ) 9.93 9.55 9.74
Protein (g) [%E] 90 [15] 89 [16] 90 [15]
Total CHO (g) [%E] 279 [47] 269 [47] 274 [47]
NMES (g) [%E] 78[13] 70 [12] 74 [13]
Fat (g) [%E] 88 [34] 85 [33] 86 [34]
Saturated fat (g) [%E] 33 [13] 32 [13] 33 [13]
Dietary fibre (g) 16 16 16
CHO, carbohydrate; NMES, non-milk extrinsic sugar; %E, percentage of food 
energy. Data are mean [%E]. Source: Food Standard Agency and the 
Department of Health. Summary Report on The National Diet & Nutrition Survey: 
adults aged 19 to 64 years. Volume 5 [30].
This dietary exchange model aimed to replace two-thirds (66%) of habitual total CHO  
intake with study foods («180 g/day). The remaining balance of 33% of total CHO  
was derived from the participants’ habitual diet (usual CHO foods). A database was 
developed from the nutritional information that was available on the labels of foods 
and beverages from local supermarkets (including the total energy, CHO, sugar, 
protein, total fat, saturated fat, fibre and sodium) (Fig. 3.1). The sugar to starch ratio 
and the percentage of total sugar in the total CHO per portion were calculated. From 
this database, the average content of CHO per portion was approximately 30g. The 
exchangeable CHO divided by the average content of CHO per portion, provided six 
portions per day. CHO foods with a sugar content > 40% of total CHO per portion 
were classified as high sugar foods, whereas foods with < 10% of total CHO were 
classified as low sugar foods. Foods with a sugar content of between 10 to 40% of 
total CHO per portion were excluded from the list. A full list of study foods, including 
the portion size, is provided in Appendices 2 and 3. Information on the content of 
NMES in foods was unavailable, and thus could not be used in the study. Data on 
total sugar content was available in all foods, and was used throughout the study as a 
surrogate of NMES. Table 3.2 shows the target energy and macronutrient contents in 
one portion of study food for the high and low sugar diets.
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Table 3.2: Target content of CHO, sugar and starch per portion for both diets
High sugar diet Low sugar diet
Total energy (MJ) 1.07 1.07
Protein (g) 9.84 9.84
Total CHO (g) 30.14 30.14
Sugar (g)* 20.00 2.00
Starch (g)* 10.10 28.10
Fat (g) 9.50 9.50
Saturated fat (g) 3.60 3.60
Dietary fibre (g) 1.77 1.77
On average, high sugar foods contained 41 %E from sugar and 18%E from fat. In 
contrast, high sugar drinks contained »100%E from sugar and 0.2%E from fat (Table 
3.3). Low sugar foods contained 5%E from sugar and 18%E from fat. Although low 
sugar drinks contained 100% sugar, the sugar content was low (approximately 
1.2g/portion) and provided a minimal energy value (0.03 MJ/portion), and so were not 
included as study foods. Nevertheless, low sugar drinks and foods, such as diet fizzy 
drinks and free sugar jelly, were included to increase compliance on the low sugar 
dietary intervention, but were not counted as a portion. Other foods that were 
provided in the low sugar diet, but not counted as a portion, are presented in Italics in 
Appendix 3. If the foods on the list were unacceptable to the participants, they were 
provided with alternative foods with a similar energy and macronutrient content. Since 
dietary fat and fibre are known to exert influences on lipid metabolism [273], 
participants were advised to choose foods with a low content of fat (< 9g/1 OOg food’s 
weight) and fibre (< 3 g/IOOg food’s weight), and match their intakes for these 
constituents on both dietary interventions.
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Table 3.3: Average macronutrient content per portion of food or drink
High sugar Low sugar
Food Drink Food
Energy (MJ) 0.72 0.41 0.70
Protein (g) 2.47 0.21 3.00
Total CHO (g) 32.32 23.21 30.45
Total sugar (g) 17.65 23.18 1.90
%E 41.2 99.9 4.6
Starch (g) 14.67 0.03 28.51
% sugar 54.59 99.87 6.25
Fat (g) 3.41 0.02 3.38
%E 18 0.2 18.3
Fibre (g) 1.11 0.07 1.51
On the high sugar diet, participants were provided with foods and drinks, and were 
advised to include both in their six portions a day. Participants were given options to 
consume four portions of high sugar foods, and two portions of high sugar drinks or 
five foods and one drink (Fig. 3.1). Switching from five to four portions of high sugar 
foods, and increasing drinks from one to two, increased the total intake of sugar by 5 
grams, but decreased energy intake by 0.3 MJ.
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Figure 3.1 : The average energy and macronutrient content for six portions, and
examples of the study foods 
High sugar diet
KILLING
W arbu iM
5 foods 1 drink
Energy (MJ) 3.99
Protein (g) 12.58
CHO (g) 184.81
Sugar (g) 111.4
Starch (g) 73.41
% sugar from CHO 60.28
Fat (g) 17.07
Fibre (g) 5.61
%YuamiBrat!
KCk^Ê
J ^ ^ o c o idiocoutcchip
4 foods 2 drinks
Energy (MJ) 3.69
Protein (g) 10.31
CHO (g) 175.71
Sugar (g) 116.95
Starch (g) 58.76
% sugar from CHO 66.56
Fat (g) 13.68
Fibre (g) 4.57
Low sugar diet
r  ~
6 foods
Energy (MJ) 4.18
Protein (g) 18.0
CHO (g) 182.68
Sugar (g) 11.41
Starch (g) 171.08
% sugar from CHO 6.25
Fat (g) 20.29
Fibre (g) 9.08
High sugar diet: foods and drinks were counted and provided as study foods; low 
sugar diet: only foods were counted and provided as study foods. Low sugar drink, 
free sugar jelly and artificial sweetener were provided but not counted in the six 
portions.
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ii) Study design
The efficacy of the dietary exchange model, in terms of its ability to affect plasma 
lipids and lipoproteins, was tested using a randomised cross-over design for 12 
weeks. However, plasma TAG is the only outcome measure described in this chapter. 
Details of the study design, study protocols, and results on plasma lipids, lipoproteins, 
including lipoprotein subclasses and apolipoproteins, are described and presented in 
Chapters 4 and 5.
Participants were randomised into dietary intervention 1 (high or low sugar diet) for 12 
weeks and then crossed-over to the alternative dietary intervention 2 (high or low 
sugar diet). The dietary intervention diets were separated by a wash-out period of 4 
weeks [239]. Five home visits were made every fortnight during each intervention. 
The purposes of these visits were to supply two weeks of study foods, to measure 
body weight and to check on dietary compliance. Participants were instructed to avoid 
any deviations from the study protocol in an attempt to maintain their body weight to 
within ± 0.5 kg. A food portion sheet and their body weight were checked to monitor 
adherence to the study protocol. ‘Home’ visits were carried-out at participants’ homes 
or places of work or at the University, according to individual preference. A wide 
variety of foods was offered to the subjects, as a means of maintaining their interest 
in the study and adherence to the dietary intervention.
iii) Dietary assessment
To increase dietary compliance, participants were provided with a ‘Participants Study 
Handbook’ which contained information about the study, including the role of 
participants, the intervention diets, examples of foods and portion sizes (Appendix 
8). They were also provided with a target nutritional card with the average energy, 
CHO, fat and fibre content per lOOg of food’s weight, and per portion, for both dietary 
interventions (Appendix 7). The purpose of these cards was to facilitate an 
appropriate selection of foods for each diet when eating outside of their home. 
Participants were advised on how to read labels on the packaging of food and how to 
make comparisons between study and non-study foods. The target nutritional cards 
were pocket sized, so that they could be carried with a minimum of inconvenience in
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pockets and wallets. Dietary intake was assessed using 3-day diet diaries and food 
portion sheets.
a) Measurement of dietary intake by 3-day diet diaries
During the run-in period and both dietary interventions, participants were required to 
complete 3-day diet diaries, one during the run-in phase, and two for each 
intervention phase, (Appendix 4). In order to ensure that usual intake of food were 
recorded and to avoid bias, participants were advised to record their intake on two 
weekdays and one weekend day, and to avoid recording their dietary intake during 
holidays or on days that involved special events, such as celebrations or parties. Diet 
diaries were analysed using a nutrition software package 'DietPlanG' (version 6.50, 
Forestfield Software Ltd). The software consisted of a database of nutrient 
composition of foods consumed in the UK based on McCance and Widdowson’s The  
Composition of Foods’, with additional data being obtained from food labels and food 
manufacturer websites [274]. To attain accurate dietary intakes, participants were 
required to provide the packaging and labels from foods they had consumed, and 
detailed recipes for homemade foods. They were also required to estimate and 
describe portion sizes as accurately as possible. Although weighed dietary intakes 
would have been more accurate, this method was considered to be unfeasible due to 
the participants working and eating outside of the home and being unwilling to carry 
weighing scales.
b) Measurement of the intake of study foods by food portion sheets
Participants were required to complete food portion sheets on each day of the 
interventions (Appendices 5 and 6). These food portion sheets were supplied to 
participants together with the study foods every two weeks. Participants were 
required to indicate the number of portions of each study food and drink they had 
consumed each day, and were advised to consume a maximum of six portions per 
day. The sheets were checked every two weeks to assess dietary compliance.
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3.5.4 Determination of piasma TAG
Plasma TAG was measured using ABX Pentra Triglycerides CP kit by Horiba Group 
(Kit ref: A11A01640; Horiba ABX, UK) on the GOBAS Mira auto-analyser (Roche 
Diagnostics, USA). The analysis was based on colorimetry enzymatic method and the 
absorbance was measured bichromatically at 500 nm wavelength. Intra-assay 
precision gave OVs for N (low) and P (high) QGs of 3.0% and 5.9%, respectively. 
Details for the measurement of all other plasma analytes are described in Chapter 4.
3.5.5 Statisticai analyses
All data were checked for normality of their distribution using Shapiro-Wilk analyses. 
Since the total sample size was less than 50, it was checked by normal and 
detrended normal probability plots [275]. Homogeneity of the variance was assessed 
by Levene’s statistic. All data were presented as means [± SEM] or as otherwise 
indicated. Skewed parameters were transformed as appropriate before analyses. 
Plasma TAG and dietary intake data were asymmetrically distributed, so were log- 
transformed before statistical analyses and are represented as medians with 
interquartile ranges (Box and whisker plot. Fig. 3.2). Dietary data are shown in graphs 
as means [± SEM]. All other data in tables are shown as mean [± SEM] or as 
otherwise indicated in the footnotes. Untransformed data were analysed using non- 
parametric tests. A paired Student T- test or the non-parametric alternative, Wilcoxon 
Signed Rank Test, were used to analyse difference between pre and post-diets of all 
variables. The mean daily intakes of energy and nutrients were calculated from an 
average of the 3-day diet diaries collected during the run-in, and on both dietary 
intervention phases. Associations between variables were determined by calculating 
Pearson’s correlation (or non-parametric equivalent; Spearman’s rho). Differences 
between dietary treatments in the total group, and differences between three or more 
subgroups, were examined by Analysis of Variance (ANOVA) with a post-hoc Tukey’s 
test for pair-wise comparisons (Kruskal-Wallis as non-parametric alternative). 
Analysis of Govariates (ANGOVA) was used to determine the difference between 
diets with adjustment for significantly associated covariates. Statistical significance 
was defined as p<0.05. Statistical analyses were performed using SPSS statistical 
package version 18 (SPSS for Windows, Ghicago, USA).
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Figure 3.2: General description of a box and whisker plot
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3.6 Results
From 163 potential participants who were pre-screened by a telephone interview, 63 
were booked for a screening visit at the CEDAR Centre. From these 63 participants, 
34 were scanned for their percentage of liver fat. Seven participants were excluded, 
which left 27 participants being enrolled onto the study. Two participants dropped-out 
from the study during the first intervention leaving 25 completers. A summary of the 
recruitment process is shown in Figure 3.3.
Figure 3.3: A schematic flow of the participant’s recruitment throughout the
study
29 participants were 
excluded due to:- 
- 21 were not ApoEs 
homozygous 
2 participants did not have 
apo E results
- 3 had BMI > 32kg/m^
-1  did not complete blood 
test
- 2 had unstable body 
weight for past 3 months
2 participants 
dropped out during^ 
the first 
intervention
163 participants 
were interviewed 
via telephone
63 met the 
eligible criteria 
and were 
screened at the 
CEDAR Centre
34 participants 
were scanned 
for liver fat
27 participants 
were included
25 participants 
completed both 
interventions
100 participants were 
excluded 
-B M I < 2 6  kg/m^or 
> 3 2  kg/m^
- could not give 
commitment for long­
term study
7 participants 
were excluded 
due to liver fat 
> 30%
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3.6.1 Baseline characteristics
The anthropometric characteristics and blood biochemistry of the participants at 
screening are shown in Table 3.4. Only 54% of screened participants were 
homozygous for the Apo E3 genotype, excluding two participants on which there was 
no data. Details of the cardio-metabolic score are presented in Chapter 4.
Table 3.4: Characteristics of participants at screening
visit (n=25)
Characteristics Mean [SEM]
Age (Year) 56.8 [1.3]
Body weight (kg) 89.6 [1.7]
Body mass index (kg/m^) 28.6 [0.3]
Waist circumference (cm) 103.9 [1.1]
Systolic blood pressure (mmHg) 132.9 [3.1]
Diastolic blood pressure (mmHg) 83.7 [2.1]
Body fat (%) 25.4 [0.6]
Fat mass (kg) 23.0 [0.8]
Free fat mass (kg) 67.1 [1.1]
Triacylglycerol (mmol/L) 1.74 [0.2]
Total cholesterol (mmol/L) 5.68 [0.2]
HDL-Cholesterol (mmol/L) 1.34 [0.1]
LDL-Cholesterol (mmol/L) 3.54 [0.1]
Fasting blood glucose (mmol/L) 5.58 [0.1]
Insulin (pmol/L) 56.1 [4.8]
3.6.2 Intake of energy and macronutrients
Table 3.5 shows the habitual intake, and the actual intake on each diet, versus the
predicted target intake for total energy, and energy from each macronutrient. The
ratio of starch to sugar is shown in bold in the bottom row of the table. On average,
the percentage of energy intake from sugar was 4% higher than the target on the high
sugar diet (starchisugar ratio; intake=1:1.1 ; target 1:1.2), but 3% higher than the
target on the low sugar diet (starch:sugar ratio; intake=4:1 ; target 6:1). There was no
difference in total energy and protein intakes between the intervention diets. There
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were significant differences in the intake of dietary CHO, sugars, fat, saturated fat and 
sodium intakes between the high and low sugar diets.
Table 3.5: Composition of the habitual, high and low sugar diet Intakes
Nutrient
Habitual
diet
High sugar diet Low sugar diet
Intake Target Intake Target
Energy (MJ/d) 9.8 [0.5] 10.6 [0.5] - 9.9 [0.4] -
CHO (g/d) 264 [15.1] 329 [14.9] - 257 [12.0] -
%Total energy 45 [1.1] 53 [1 .3 r 47 44 [1.3]' 47
Sugar (g/d) 120 [10.1] 173 [10.0] - 56 [4.0] -
%Total energy 21 [1.2] 28 [^ .3 ^ 24 9 [0.5]^' 6
Protein (g/d) 90 [5.3] 92 [4.5] - 97 [4.8] -
%Total energy 16 [0.7] 15 [0.5] 15 16 [0.5] 15
Fat (g/d) 87 [6.2] 77 [6.4] - 89 [5.0] -
%Total energy 33 [1.3] 27 [1 .5 r 34 34 [1.2]' 34
Saturated fat (g/d) 33 [2.8] 30 [3.0] - 35 [2.8] -
%Total energy 13 [0.7] 1 0 [0 .8 f 13 13 [0.8] 13
Fibre (g/d) 26 [1.4] 21 [1 .2 f 16 24 [1.5] 16
Sodium (g/d) 3.0 [0.2] 2.9 [0.2]' - 3.7 [0.2]^ -
Starch :sugar 1 :0.9 1 :1.1 1 :1.2 4 :1 6 :1
L ^ a ic i  a i  ^  111^0.11 [v -J L - iv ij d i i u  a i i a i y o ^ u  u o i i i y  / - v iN w  v /-v  v v i i i i  p u o L  i i u u  i u r \c ? y  i c o i .
Habitual vs High sugar diet, '^p<0.05 Habitual vs Low sugar diet, ^p<0.05 High vs Low 
sugar diet. n=25.
i) Intake of total energy
The mean intake of energy on the habitual and low sugar diets was similar to the 
mean energy intake for middle-aged men (35 -  65 years old) from NDNS (Fig. 3.4, 
Appendix 18) (refer to Table 3.1 for the NDNS data). Total energy intake increased 
by 0.8 MJ on the high sugar diet relative to habitual intake, but this was not 
significant. Total energy intake on the low sugar diet was 0.7 MJ lower than total 
energy intake during the high sugar diet (n.s.).
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ii) Intake of carbohydrate and sugar
Energy from CHO for the habitual and low sugar diets was 2% and 3% lower, and for 
the high sugar diet 6% higher, than the mean population intake (Fig. 3.5A) [30]. The 
high sugar diet increased energy intake from CHO by 8% (p<0.05) relative to the 
habitual diet, whilst energy intake from CHO on the low sugar diet was similar to that 
of the habitual diet. Energy from CHO intake during the high sugar diet was 9%  
greater than low sugar diet (p<0.05). Intake of energy from sugar on the habitual diet 
was 62% greater than the mean intake of the UK population [30] (Fig. 3.5B). The high 
sugar diet almost met the target ratio of starch to sugar, but exceeded the predicted 
energy contribution from sugar (achieved vs target, 1:1.1 vs 1:1.2). The low sugar diet 
fell short of the target starch to sugar ratio by 2:1 (achieved vs target, 4:1 vs 6:1), but 
still produced a three-fold increase in starch relative to sugar, and reduced the energy 
from sugar by 57%, relative to the habitual intake (Table 3.5).
122
Figure 3.5: Percentage of total energy (%E) from CHO (A); and sugar (B) for the 
middle-aged male population (NDNS data) and the habitual, high and low sugar 
diet of participants.
B
Z  20
NDNS 2004
□  Habitual diet
□  High sugar diet
□  Low sugar diet
Data are mean±SEM and analysed using ANOVA with post-hoc Tukey test. ^p<0.05 
high sugar diet different from habitual, ^p<0.05 low sugar different from baseline, 
'p<0.05 high sugar diet different from low sugar diet. n=25.
iii) Total fat and dietary fibre intakes
The energy contribution from total fat was similar on the habitual and low sugar diets 
33 vs 34%E, and met the mean population intake (34%E) (Fig. 3.6A). Energy intake 
from fat on the high sugar diet was 6% lower (p<0.01) and 7% lower (p<0.01) 
compared with the habitual and low sugar diets, respectively. The reduction in energy 
intake from fat on the high sugar diet was inversely proportional to the increase in 
energy intake from CHO.
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The intakes of fibre on the high and low sugar diets were not significantly different 
(Fig. 3.6B). While the high sugar and low sugar diets were both accompanied by a 
decrease in fibre intake by 5g and 2g respectively, both diets still exceeded the target 
fibre intake of 16g/day. The mean intake of fibre in the habitual diet of the participants 
was 10g greater than the population intake [30].
Figure 3.6: Percentage of total energy (%E) from dietary fat (A); and dietary 
fibre intake (AOAC method) (B) for the middle-aged male population (NDNS 
data) and the habitual, high and low sugar diet of participants.
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Data are mean[SEM] and analysed using ANOVA with post-hoc Tukey test. ®p<0.05 
high sugar diet different from habitual, 'p<0.05 high sugar diet different from low 
sugar diet. n=25.
iv) Intake of protein, saturated fat and sodium
There was no substantial difference in energy contribution from protein between the 
habitual, high and low sugar diets relative to the population intake (Fig. 3.7A) [30]. 
Figure 3.7B shows that energy from saturated fat on the high sugar diet was lower by 
23%, relative to the habitual diet and was also significantly lower than the low sugar 
diet (p<0.05). Sodium intake was also significantly higher in the low sugar diet relative
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to the high sugar diet (p<0.01). The habitual intake of sodium was 0.8g lower than the 
population intake (Fig. 3.7C) [30]. This lower sodium intake was maintained on the 
high sugar diet, but significantly increased on the low sugar diet relative to the 
habitual intake (p<0.05).
Figure 3.7: Percentage of total energy (%E) from protein (A); saturated fat (B); 
and sodium intake (g/day) (C) for the population (NDNS data) and the habitual, 
high and low sugar diet of participants.
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'p<0.05 high sugar diet different from low sugar diet. n=25.
3.6.3 Underreporting of energy intake
The amount of underreporting expressed as a percentage of underreporting in each
diet, based on the Goldberg cut-off point [276], are shown in Table 3.6. The mean
basal metabolic rate (BMR) of all participants was 7.6±0.7 MJ (habitual), and 7.9±0.4
MJ (for the high and low sugar diets), and the mean physical activity level (PAL) was
1.6±0.1 [277, 278]. The average energy intake to BMR (ELBMR) ratio of the
participants was 1.30±0.31 (habitual diet), 1.29±0.37 (high sugar diet) and 1.20±0.33
(low sugar diet), indicating that 58%, 50% and 63% of all participants underreported
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their energy intake on the habitual, high and low sugar diets, respectively, according 
to a cut-off of 1 [276]. The latter, which was equal to 1.35, was the lowest value for 
habitual energy intake of an individual that was compatible with a normal, very light, 
but not bedbound, lifestyle [276, 279]. Adjustment to a cut-off of 2 (< 1.55) increased 
the number of underreporting cases to 79%, 71% and 92% for the habitual, high and 
low sugar diets, respectively. A cut-off of 2 was the lowest value for the EI:BMR ratio 
that could reflect actual energy intake over the period of diet-recording [279]. The 
results also revealed that 46% (habitual diet), 42% (high sugar diet) and 63% (low 
sugar diet) of participants had a reported energy intake that was below the minimal 
intake required for life survival (1.27xBMR) [278].
Underreporting was also analysed on the basis of sociodemographic factors such as 
age, BMI, PAL and smoking status. Surprisingly, there was no significant difference in 
ELBMR between age groups, BMI, PAL and smoking status. Although there was no 
overall significant difference, the prevalence of underreporting was higher in 
overweight relative to obese participants, (ages 50 -  59 compared to 40 -  49 and 60 
-  65), in participants with moderate or higher physical activity level (PAL) relative to 
participants with light PAL, and in non-smokers compared to smokers. There was 
also strong associations between ELBMR on the habitual and high sugar diets 
(r=0.635, p<0.01), habitual and low sugar diets (r=0.551, p<0.01) and between high 
and low sugar diets (r=0.478, p<0.05).
1 2 6
Table 3.6: BMR, PAL and E[:BMR of the participants on the habituai, high and
Habitual High sugar Low sugar
BMR (MJ/d) 7.6 ± 0.7 7.9 ± 0.4 7.9 ± 0.4
PAL (mean ± SD) 1.6 ± 0.1 1.6 ±0.1 1 .6 ± 0 .1
EiiBMR (mean ± SD) 1.30 ±0.31 1.29 ± 0 .3 7 1.20 ±0 .33
< 1.27 46 42 63
<1 .35  (%)b 58 50 63
<1 .55  (% )' 79 71 92
Aae (Year)
4 0 -4 9 (1 7 % ) <1 .27  (%) 50 25 50
< 1.35 (%) 50 25 50
<1 .55  (%) 75 75 75
50 -  59 (46%) < 1.27 (%) 64 45 64
< 1.35 (%) 64 55 73
< 1.55 (%) 82 100 100
60 -  65 (38%) <1 .27  (%) 22 22 44
<1 .35  (%) 56 22 44
<1 .55  (%) 75 56 67
BMI
< 30 kg/m^ (79%) <1 .27  (%) 47 32 63
<1 .35  (%) 63 37 63
<1 .55  (%) 90 84 84
> 3 0  kg/m^ (21%) < 1 .2 7  (%) 40 40 20
<1 .35  (%) 40 40 40
<1 .55  (%) 40 60 80
PAL
Light (79%) < 1.27 (%) 33 17 33
<1 .35  (%) 50 17 50
< 1 .55  (%) 67 83 67
Moderate and higher < 1.27 (%) 50 39 61
(21%) < 1 .35  (%) 61 44 61
< 1 .55  (%) 83 78 94
Smokina habits
Smoker (28%) < 1.27 (%) 37 32 47
< 1 .35  (%) 53 32 47
< 1 .55  (%) 79 74 79
Non-smoker (72%) < 1 .27  (%) 80 40 80
< 1 .35  (%) 80 60 100
< 1.55 (%) 80 100 100
BMR, basai metabolic rate; PAL, physical activity level; El, energy intake; SD, 
standard deviation; ®1.27xBMR minimal energy intake for survival (FAOAA/HO/UNU) 
[278]; ^1.35xBMR Cut-off 1 of Goldberg equation [276]; ®1.55xBMR Cut-off 2 of 
Goldberg equation [279]. BMR was calculated using Schofield equation [277]. PAL 
was based on FAO/WHO/UNU [278]. n=25.
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3.6.4 Effects of the high and low sugar diets on plasma TAG
Of the total cohort, 84% showed an increase, and 60% showed a decrease in plasma 
TAG after the high sugar and low sugar diets, respectively (Fig. 3.8). Figure 3.9 
shows the medians (with interquartile ranges) of plasma TAG on the high and low 
sugar diets. Plasma TAG increased significantly after the high sugar diet (mean 
change±SEM = +0.26±0.07; p=0.001) and decreased after the low sugar diet (mean 
changeiSEM = -0.35±0.16; n.s.). There were strong associations between the 
concentrations of plasma TAG at baseline and after the intervention on both diets 
(p<0.001). After normalisation and adjustment of the data for baseline values, there 
was a significant difference in plasma TAG following the high and low sugar diets, 
that was independent of BMI, percentage of body fat, plasma NEFA and plasma TO
(p<0.001).
Figure 3.8: Plasma TAG for individual participants, before and after; high sugar 
(A); and low sugar (B) diets. n=25.
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Figure 3.9: Plasma TAG concentration (mmol/L) before and after the high and 
low sugar diets.
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Statistical test were analysed using geometric values. ^Change from baseline 
(p<0.01), ^Difference between diets adjusted for baseline values (p<0.01). n=25.
3.6.5 Association between intake of sugar and plasma TAG
Previous cross-sectional studies have found significant strong relationships between 
sugar intake and plasma TAG, as described in Chapter 2 [41, 214]. The relationships 
between energy intake from dietary sugar and changes in plasma TAG for the high 
and low sugar diets in this study are shown in Figure 3.10. Subdivision of group into 
intervals of energy intake from sugar (according to the ‘NHANES’ study) [41]: 5%E, 5 
- < 10%E, 10 - < 17.5%E, 17.5 - < 25%E and > 25%E, showed that plasma TAG  
generally increased with the increase in energy intake from sugar on the high sugar 
diet (n.s.).
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Figure 3.10: Changes in piasma TAG across increasing energy intake from 
dietary sugar on the high and iow sugar diets.
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Percentage of energy from dietary sugar
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□  Low sugar diet
Data are mean±SEM. "Subgroup 10 - < 17.5 for the high sugar diet has no arrow bar 
(SEM) as it contains only one case. n=25.
3.7 Discussion
The purpose of the present study was to develop and investigate the efficacy of a 
dietary exchange model based on the manipulation of the dietary ratio of starch to 
sugar, primarily on plasma TAG. The other principal objective of this study was to 
investigate the effect of high and low sugar diets on CVD risk, chiefly on plasma 
lipids, lipoproteins and apolipoproteins in a population at increased cardio-metabolic 
risk, the results of which are described in Chapters 4 and 5.
3.7.1 Development of a dietary exchange model
The main aim of this study was to develop a model for the dietary exchange of starch 
and sugar that would achieve high and low intakes of sugar that were representative 
of the actual intake of subgroups of the free-living UK population. A similar approach 
has been used previously to manipulate dietary fats in two human dietary intervention 
studies, that employed isocaloric diets and specific nutrient exchanges [271, 280]. In 
the present study, a dietary exchange model (DEM) was developed according to 
population intakes as described by NDNS [30]. It was designed to represent the 
upper 95^ and lower 5^^^ percentiles of sugar intakes in the UK population. This DEM  
enabled the manipulation of the starch to sugar ratio, whilst maintaining matched
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intakes of energy, total CHO, fat and fibre. This was achieved by selecting foods and 
drinks which delivered similar amounts of energy from CHO, especially sugar, fat and 
fibre. The difference in the starchisugar ratio for both diets was also achieved by 
excluding foods that contained moderate amounts of sugar, and by only including 
foods with either a minimum amount, and above 40% of sugar per 100g of a food’s 
weight. This DEM was developed in a free-living environment, in which participants 
had free access and ad libitum  intake to other foods within their own homes.
3.7.2 Intake of energy and macronutrients
The mean intake of energy increased by 8% on the high sugar diet, but showed no 
change on the low sugar diet. The former increase, produced no effect on body 
weight. There was also no relationship between body weight and energy intake. A 
possible explanation for this might be that participants were less active during the 
high sugar diet and more active during the low sugar diet. Although participants were 
advised to maintain their usual physical activity during both diets, physical activity 
was not measured during the dietary interventions. Another possibility is misreporting, 
mainly underreporting [26, 31, 32], which is discussed subsequently.
The starch to sugar ratio for the high sugar diet came close to achieving the target 
intake: (1:1.1 [Intake] and 1:1.2 [Target]), whilst the ratio for the low sugar diet was 
slightly lower than the target; (4:1 [Intake] and 6:1 [Target]). Although the percentage 
of energy from sugar was 17% more than the target on the high sugar diet, the exact 
target starch:sugar ratio was not achieved, primarily because the participants also 
increased their consumption of starch in addition to sugar, which also resulted in a 
higher intake of total CHO relative to the target. Nevertheless, participants also 
consumed high sugar foods during the low sugar diet. Even though the total CHO  
intake was less than the target on the low sugar diet, due to a higher sugar intake, the 
desired proportion of starch to sugar ratio was not attained, suggesting a lack of 
adequate dietary compliance from the participants. Several methods were used to 
maximise dietary compliance, such as having regular contact with the participants, 
providing a broad choice of study foods, home visits and use of other aids, like the 
provision of Participant Handbook and nutritional cards. Nonetheless, these devices 
helped to increase both interest and understanding of the study, avoid boredom, and 
reduce the attrition rate.
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In addition to achieving the target starchisugar ratio, the other main aim of this DEM 
was to match the intakes of total CHO, fat and fibre for both diets. CHO intake 
increased significantly on the high sugar diet to more than the Dietary Recommended 
Value (DRV); 50% [58]. This was probably due to an increased intake of CHO-rich 
snacks. Based on personal communication, greater than 80% of the participants 
claimed to have a preference for the high sugar diet over the low sugar diet, which 
may have contributed to over-consumption. Even though there was a significant 
increase in body weight after the high sugar diet, it was not associated with the 
increase in CHO intake. This finding was contrary to that found in a previous study in 
which 54-57% energy was supplied from CHO and BMI decreased, whilst a lower 
intake of energy from CHO (43-46%) resulted in an absolute increase in BMI [195]. A 
similar finding was reported in another study, in which a high CHO diet also seemed 
to decrease rather than increase body weight [281].
The increase in CHO intake on the high sugar diet in the present study was directly 
proportionate to the fall in intake of dietary fat. Fat intake was 21% lower than the 
target on the high sugar diet but successfully achieved the target intake on the low 
sugar diet (34%E). It is possible that this finding resulted, in part, from the 
composition of the high sugar drinks that were included as part of the study foods on 
the high sugar diet. The high sugar drinks contained no fat, but similar amounts of 
CHO with 100% sugar relative to foods. Participants who consumed more high sugar 
drinks and fewer foods had a lower intake of fat compared to participants who 
consumed high sugar foods only. The intake of high sugar drinks might also help to 
explain the lower intake of fibre on the high sugar diet, relative to the low sugar diet. 
The high sugar drinks, such as soft drinks and fruit juices, contained traces of fibre, 
which contributed to a lower fibre intake on the high sugar diet. However, fibre intakes 
were 15g/day and 8g/day more than the target intake on the high and low sugar diets, 
respectively. So in effect, the high sugar drinks could have been displacing both 
dietary fat and fibre. High sugar drinks also did not stimulate satiety leading to an 
increase in body weight and BMI on the high sugar diet [37, 38, 282, 283].
Another issue of concern on the low sugar diet was the sodium intake in relation to 
blood pressure. Even though it was similar to the population intake, sodium intake 
increased significantly by 0.7g relative to the habitual intake after the low sugar diet
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[30]. This was due, in part, to the high sodium content of the low sugar foods to 
compensate for the sweet taste.
3.7.3 Underreporting of energy intake
The underreporting of energy intake is very common in self-recorded diet diaries, and 
can seriously confound the interpretation of dietary composition [279]. Many factors 
may explain the underreporting of energy intake in free-living populations, such as 
physiological (body weight and BMI status), socio-demographic (age) and 
psychological factors [284, 285]. Lifestyle and the environment may also impact 
negatively on the participants’ level of motivation, resulting in under-recording or 
under-eating or both [286-288]. Underreporting can also be influenced by a lack of 
accuracy in the tool of assessment, as for example there being insufficient food items 
in the FFQ or misleading information in food portioning guidelines for a specific food 
[286]. The present study evaluated the prevalence of underreporting of energy intake 
by using 3-day diet diaries for each phase. After underreporting had been assessed 
by Goldberg’s equation, 46%, 33% and 54% of participants reported an intake below 
1.27, which is considered as the survival limit, on the habitual, high sugar and low 
sugar diet, respectively [276]. This means that it was highly improbable that their 
reported energy intake would actually reflect their actual intake. These results are 
consistent with a previous study that estimated the underreporting of energy intake by 
24-hour diet recall using the same Goldberg equation [288]. The interpretation of the 
Goldberg equation can be misleading if the BMR calculation is biased or 
overestimated due to an inaccurately self-reported body weight and height. Unlike the 
previous report [286], this factor was minimised in the present study, as body weight 
and height were measured by the researcher and were not self-reported. There was 
evidence of a strong association in underreporting between the habitual, high and low 
sugar diets. This suggests that the same participants who underreported in the 
habitual diet, also underreported in their high and low sugar diets, though evidence 
for this possibility is only based on a small sample size (n=25).
In contrast to previous studies, the present study found no significant difference in 
underreporting between different age and BMI groups or with PAL and smoking 
status [286, 288]. These findings also differ from a previous study by Johansson et al.
[288] with respect to the underreporting and BMI, and smoking status, but are
133
consistent with a later study by Bedard et al. [286], in which the prevalence of 
underreporting was higher in overweight relative to obese participants, and also 
higher in non-smokers compared to smokers. The present study failed to find any 
significant relationships between the physiological (BMI), sociodemographic (age) 
and lifestyle factors (PAL and smoking status) and underreporting. This has been 
reported previously, and may be a consequence of the small sample sizes (n=25) or 
lack of accuracy of the assessment tool. More than 80% of participants estimated 
their dietary intake, rather than preferring weighed food intake, which probably 
contributed to an underestimation of the actual intake. Another possible explanation 
for this finding is through a lack of motivation or adherence, or inability or 
unwillingness on the part of the participants to report the correct intake. Novothy eta l.
[289] linked underreporting to personality characteristics, such as body image and 
fatness. This could explain why the prevalence was higher in women compared to 
men, though in this respect, the findings of other studies have been contradictory 
[286, 288].
3.7.4 Effects of the high and low sugar diets on piasma TAG
Elevated plasma TAG is the most common lipid abnormality in participants at 
increased cardio-metabolic risk, and may exert direct and indirect effects on CVD  
risk; via increased oxidative stress on remnants within vascular endothelial, and/or 
reduced plasma HDL-0 and formation of sdLDL, respectively, [143, 290]. Elevated 
plasma TAG is also an important marker that influences the development of an ALP. 
There are a large number of published studies that describe the role of dietary CHO  
in inducing hypertriacylglycerolaemia [24, 26, 187, 217, 291]. Previous studies which 
restricted CHO as a treatment for T2DM and metabolic syndrome, showed that 
limiting energy from CHO to 12%E reduced plasma TAG by 51% and increased HDL- 
C by 13% [292, 293]. One of these studies also observed a 10% loss in body weight 
[293]. It is arguable that the impact on plasma TAG was produced by either the diet or 
the weight lost. A diet that consists of 12%E from CHO also seems to be impractical 
and unfeasible for the treatment of atherogenic dyslipidaemia, especially in a free- 
living setting.
There is a convincing body of evidence to suggest that an increased intake of dietary 
sugar intakes (> 20% of energy) raises plasma TAG by « 60% [170]. The systematic
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review in Chapter 2 concluded that dietary sugars, especially in the form of fructose 
increased plasma TAG significantly in the majority of the previous studies. The 
present study produced results which corroborated these findings. The effect of 
dietary sugars on plasma TAG were mostly significant in short and intermediate term 
studies 2 weeks), whereas evidence from long-term studies was still lacking. Saris 
et al. observed a non-significant increase in plasma TAG after six months of = 29%E  
sugar intake [222]. This non-significant increase may have been related to metabolic 
adaptation to a high intake of sugar in same participants, and a metabolic effect of 
dietary sugar that is dissipated over time [170]. It is reasonable to speculate that 
metabolic compensation to the high sugar diet, results in the reduction of fat oxidation 
in the liver, which promotes the accumulation of fat in this organ [190, 196]. Another 
possible explanation may be through reduced compliance on the long-term dietary 
intervention in some participants [294, 295]. This latter possibility is supported by a 
meta-analysis of the effect of the duration of exposure to sugar on plasma TAG 
(Chapter 2). The present study, which employed a high sugar intake for 12 weeks, 
produced a significant increase in plasma TAG, suggesting that the effect of dietary 
sugars on plasma TAG becomes evident within three months.
While an increase in energy from sugar was consistently associated with increased 
plasma TAG, there was no statistically significant association between energy derived 
from sugar and plasma TAG. This was in accord with previous cross-sectional data 
that showed a strong positive relationship (r^=0.76, p<0.001) between energy from 
added sugar and plasma TAG [41]. The present findings were also in agreement with 
the meta-analysis in Chapter 2, in which the effect of dietary sugars on plasma TAG  
was shown to be dose-dependent. Nonetheless, no statistical relationship was 
observed between sugar intake and plasma TAG, perhaps because of the small 
sample size in this study, which would favour a false negative finding i.e. a ‘Type II 
Error’.
Changes in plasma TAG after the high sugar diet were also associated with the 
degree of obesity. This is consistent with the finding in a meta-analysis of obese 
participants who showed a pronounced increase in plasma TAG, relative to 
overweight participants, in response to a high sugar diet (Chapter 2). One possible 
explanation for this observation might be because of greater insulin resistance in the 
obese group, especially in such organs as the liver, and as a result, a higher
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percentage of TAG in this organ [5, 296]. There is evidence to suggest that liver fat is 
positively associated with insulin sensitivity and abdominal obesity [5, 103, 297]. In 
contrast to the potentially adverse effect of a high sugar diet, mediated through 
increased plasma TAG, a diet low in dietary sugars produced the opposite, and 
potentially beneficial, effect on CVD risk by lowering plasma TAG. This finding may 
be explained by the fact that a low sugar diet (9%E from sugar) decreased the 
production of TAG and glucose in the liver via increased insulin sensitivity, together 
with a limitation on the availability of plasma NEFA from the periphery for TAG 
production [91, 169, 188].
It has been well established that a weight loss of between 5-10% is required to elicit 
changes in lipid metabolism [257, 258]. In spite of significant changes in body weight, 
and associations between body weight and plasma TAG, after the high sugar diet, the 
changes on body weight in the present study were small (+0.8±0.4% and -2.4±0.6%  
on the high and low sugar diets, respectively). After adjusting for the interaction 
between diet and body weight change, the difference between plasma TAG remained 
significant after both diets. This finding further supports the idea that the weight 
changes achieved in the participants were insufficient to affect plasma TAG [257, 
258]. Correlation analysis also revealed associations between baseline and post­
intervention plasma TAG, suggesting an order-effect on plasma TAG, though further 
analysis indicated that the post-diet plasma TAG was significantly different between 
the high and low sugar diets, and were independent of baseline values. Consideration 
has also been given to other dietary confounding factors, such as dietary fat (p<0.01) 
and fibre (n.s.), since these were significantly different between the two diets [170]. 
However, there was no significant relationship between plasma TAG and energy 
derived from fat or dietary fibre intake in both diets.
In the meta-analysis described in Chapter 2, it was clear that short-term or acute 
exposure to high dietary sugars produced a more marked effect on plasma TAG  
compared to a gradual increase of sugar intake. However, this finding may not be 
generally applicable, since there is evidence to suggest that genetic factors may play 
a role in influencing inter- and intra-variability in the TAG response to sugars [253]. 
The apolipoprotein E (apo E) polymorphism has been recognised to exert functional 
effects on lipoprotein metabolism, and it is critical in the formation of VLDL and 
chylomicrons [253, 298]. Apo E2, E3 and E4 are well known to exert genotypic
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influences on lipoprotein concentrations. Of these alleles, apo E3 has been shown to 
be the most prevalent (> 60%) in all populations, especially in Caucasians [253], and 
has an intermediate effect on lipid metabolism relative to E2 and E4 [298]. For this 
reason, this study excluded carriers of E2 and E4 alleles to remove any confounding 
effects of these genetic polymorphisms.
3.8 Conclusion
The present study was successful in developing a practical and feasible dietary 
exchange model for the design of two isoenergetic, experimental diets with specific 
targets for sugar and starch intakes. The dietary manipulation was effectively 
achieved, and produced modest effects on plasma TAG; with the high and low sugar 
diets increasing and decreasing plasma TAG, respectively, independent of baseline 
values and body weight changes. In conclusion, the TAG-raising effects of the high 
sugar diets would suggest that substituting starch with simple sugars is not advisable, 
and that reducing sugar intake may be advantageous in managing cardio-metabolic 
risk. The impact of these two diets on other biomarkers of cardio-metabolic risk, 
including liver fat, are described in Chapter 4.
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Chapter 4
APPLICATION OF DIETARY EXCHANGE MODEL IN AN INTERVENTION WITH 
HIGH AND LOW SUGAR DIETS, IN INDIVIDUALS WITH LOW AND 
MODERATELY RAISED LIVER FAT (‘CHOT Study Part II)
4.1 Introduction
In the late 1960s and 1970s, Yudkin and colleagues proposed that a higher 
consumption of CHO, mainly in the form of sugars, was associated with increased 
CVD risk [22, 161]. More recently, the replacement of dietary fat with CHO of mixed 
quality has been linked to increased CVD risk, primarily through the elevation of 
plasma TAG and reduction in plasma HDL-C [24, 26, 178]. The increase in plasma 
TAG may occur as a result of increased synthesis and secretion of TAG (VLDL) from 
the liver and/or through the impaired clearance of VLDL, whilst the reduction of 
plasma HDL-C is thought to occur with the altered TAG metabolism and the 
remodelling of HDL into smaller particles [121, 132]. Variation in the lipid response to 
dietary CHO has been attributed to the amount of CHO ingested, the presence of 
other nutrients in foods, and the existence of underlying metabolic disturbances, such 
as insulin resistance [174, 299]. Yudkin and others speculated that the effect of sugar 
was associated with hyperinsulinaemia, and that it may vary from one person to 
another [21, 108]. Hyperinsulinaemia and insulin resistance have both been 
implicated in the pathophysiology of T2DM, metabolic syndrome and CVD, and more 
recently fatty liver disease [28, 100, 104, 300]. The latter, shows strong associations 
with increased fasting serum insulin and other features of the metabolic syndrome 
including hypertriacylglycerolaemia, abdominal obesity and an inverse association 
with plasma HDL-C [103]. In addition, fatty liver is currently one of the most common 
liver disorders in westernised countries that can lead to CVD, irreversible liver 
damage (cirrhosis) and hepatic cancer [301-303]. Dietary sugars have a long­
standing relationship with the accumulation of fat and development of insulin 
resistance in the liver [101, 119, 304-306]. Raised liver fat has been associated with 
insulin insensitivity in many previous cross-sectional studies [7, 28, 103, 297], and 
may represent a surrogate marker of insulin resistance in this organ. While a high 
intake of sugar, which is known to increase de novo lipogenesis (DNL) in the liver 
[168], in the presence of hepatic insulin resistance, may be a potent combination for
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promoting the accumulation of fat in the liver [29, 232, 242, 307], whether insulin 
resistance in liver is a cause or effect of a high sugar diet is unclear.
Chapter 4 presents the application of the dietary exchange model from Chapter 3, in 
an intervention with two diets, high and low in dietary sugars, in individuals at 
increased cardio-metabolic risk, with low or moderately raised liver fat. Outcome 
measures described in this chapter include plasma lipids, and percentage liver fat.
4.2 Study aims
•  To apply the dietary exchange model developed in Chapter 3 to a dietary 
intervention, in volunteers at increased cardio-metabolic risk.
•  To determine the impact of liver fat on the response to dietary sugars on 
lipids, lipoproteins and cardio-metabolic risk factors, and the influence of the 
two diets on the percentage of liver fat.
4.3 Study objectives
•  To recruit human participants at increased cardio-metabolic risk with 
moderately raised and low percentage of liver fat, as determined by HMRS.
• To perform a crossover intervention trial using the dietary exchange model in 
human participants, over 12 weeks for each arm.
• To evaluate the endpoint lipid markers (ALP status; fasting plasma TAG, HDL- 
C and predominance of small dense LDL), other cardio-metabolic risk markers 
and liver fat.
4.4 Study hypothesis
A group with moderately raised liver fat (> 4.2%, (median of liver fat)) will show a 
greater response to a high sugar diet, in terms of the predicted change in plasma
lipids, lipoproteins and percentage of liver fat relative to a group with low liver fat.
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4.5 Methods
4.5.1 Participants
i) Recruitment strategies
The recruitment process involved several different approaches. The principal method 
was through an existing Clinical Research Network with GP surgeries in the county of 
Surrey. This method was used effectively in a previous study when it provided a 
valuable pre-screening tool for such characteristics as BMI, fasting blood glucose, 
plasma lipids, blood pressure, current health, medication, and socio-demographic 
status [280]. The process was co-ordinated by staff members at the GP surgery and 
was observed by the study co-ordinator. Patients with a known history of T2DM or 
other endocrinological diseases, renal impairment and hepatic diseases, except fatty 
liver disease, were excluded from the search. A letter of invitation to participate in the 
study from the GPs, and a Participant Information Sheet was given to selected 
patients. Other methods of recruitment included direct contact with local authorities, 
companies, schools and colleges via email and letters, plus direct approaches to 
offices and shops to distribute leaflets, and display posters on local community notice 
boards, and leaflet drops in local residential areas.
ii) Inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
Caucasian men •  Participants with T2DM or related
Aged 4 0 - 6 5  diseases
BMI 2 6 - 3 2  kg/m^ •  Participants who were taking lipid
Cardio-metabolic risk score 4 - 1 0  lowering medications
Apo E3 homozygous genotype • Participants who had unstable body
• Liver fat < 5% or 1 0 -  30% weight for the past three months
• Participants who consume alcohol 
more than 20g/day
• Participants who have metal implant 
in the body
• Participants who have claustrophobia
141
The health status and screening test results of all participants, were checked and 
approved by the medical consultant prior to their entry into the study.
4.5.2 Study design
The study was of a controlled, randomised cross-over design with two 12 week 
dietary interventions, high and low in sugar (Fig. 4.1). Participants who expressed 
interest in taking part in the study were pre-screened by a telephone interview. 
Suitable participants were screened at the Royal Surrey County Hospital (RSCH) to 
determine their cardio-metabolic risk score and apo E genotype. The cardio- 
metabolic risk score (Table 4.1) was an adapted version of on ATP III definition of 
metabolic syndrome, as previously described in the ‘RISCK’ study [280, 308]. Unlike 
the other characteristics, BMI and waist circumference had two levels. Participants 
who met all of the criteria, were sent for magnetic resonance spectroscopy (MRS) at 
the Robert Steiner MRI Unit at the Hammersmith Hospital, London, to ascertain their 
percentage of liver fat. Participants who met the entry criterion for the percentage of 
liver fat; either < 5% or between 10% to 30%, were enrolled onto the study. 
Participants who did not meet this criterion were notified by a letter, and their 
screening biochemistry results were forwarded to their GP. Before commencing the 
dietary intervention, participants underwent four weeks of a run-in diet, during which 
they consumed their habitual diet and maintained their habitual level of physical 
activity. At the end of the four weeks, participants were randomised to receive either 
the high or low sugar diet for 12 weeks. At the end of the first intervention, 
participants returned to their habitual diet for 4 weeks of wash-out, at the end of which 
they crossed-over to the alternative diet. The duration of the wash-out period was 
judged to be adequate to eliminate the effects of the first intervention on plasma 
lipids, on the basis of a similar study [239]. Five home visits were conducted, at 
fortnightly intervals, on both dietary interventions, to deliver study foods, measure 
body weight and to check-on dietary compliance.
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Table 4.1 : The cardio-metabolic risk score
Characteristics Value Score
Body mass index (kg/m^) - Level 1 2 5 - 3 0 1
Body mass index (kg/m^) - Level 2 > 3 0 2
Waist circumference (cm) -- Level 1 > 9 4 1
Waist circumference (cm) -- Level 2 > 102 2
Systolic BP (mmHg) > 140 1
Diastolic BP (mmHg) > 9 0 1
Fasting glucose (mmoi/L) > 5.5 3
insulin (pmoi/L) > 4 0 3
HDL-Choiesteroi (mmoi/L) < 1.0 2
Triacyigiyceroi (mmoi/L) > 1.3 1
BP, blood pressure. Participants with total score of 4 -  10 and ApoEs homozygous 
were eligible for a liver fat scan by ^H-MRS. Score was adapted from the ‘RISCK’ 
study[280].
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4.5.3 Study procedures
i) Screening visits 1 and 2
Participants were required to fast overnight before attending the first screening visit, 
and all subsequent visits to the CEDAR Centre. At screening visit 1 (CEDAR), 
participants completed a socio-demographic questionnaire form and provided written 
consent to take part in the study. Anthropometry and blood pressure were measured 
and fasting blood samples were taken by the research nurse. The screening blood 
samples were promptly dispatched to the pathology department at the RSCH for 
analysis. Detailed information about the study objectives and procedures were 
explained to the participants, and a study handbook was provided (Appendix 3). To 
avoid any changes in behaviour, participants were advised that any results from the 
study would not be revealed to them until completion of both dietary interventions. If a 
participant was eligible to proceed to the second screening visit, they were notified by 
telephone and e-mail, booked-in for MRS at the Hammersmith Hospital (Visit 2).
ii) Randomisation and first pre-dietary intervention visit (visit 3)
Participants attended an initial visit at the CEDAR centre after an overnight fast. 
Anthropometry and blood pressure were measured, and fasting blood samples were 
taken. Participants were supplied with a quantity of study foods that was sufficient for 
two weeks, after which, foods were delivered to their homes at fortnightly intervals. 
Participants were given food portion sheets to complete on a daily basis for two 
weeks (Appendix 4). Participants were advised to notify the researcher of any 
problems or queries concerning the study. During the interventions, participants were 
instructed to maintain their habitual level of physical activity. An identical set of 
procedures were followed at the start of second intervention (Visit 5).
ill) End of first dietary intervention (visit 4)
Since liver fat was to be included as an end-point measure in the study, participants 
were given the choice of optional second and third liver scans on a week before or 
after the kinetic study day to examine the effects of the dietary intervention on this 
variable (Visits 4/6). On the night before the kinetic study day, participants were
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provided with a limited choice of standard evening meal (Appendix 16). The meal 
consisted of main meal, a side dish and a dessert and was to be consumed between 
6 and 7 pm on the night before the clinical study day (Visits 6/10). After this meal, 
participants fasted until the next morning. Participants were also instructed to abstain 
from any exercise and alcohol consumption for 24-hours prior to the study day. An 
identical set of procedures were followed before each kinetic study day (Visits 4 and 
6).
iv) Anthropometries and measurement of blood pressure
Height was measured using a wall-mounted stadiometer (SEGA) with shoes off and 
feet precisely in the designated area on the device. Body weight, BMI and body 
composition (including body fat, fat mass and free fat mass) were measured by 
electrical bio-impedance, using a Body Composition Scale (Tanita Body Composition 
Analyzer BC-418MA). Waist circumference was measured using a SEGA 
Circumference Measuring Tape to the nearest 0.1 cm at the narrowest point between 
the iliac crest and the lowest rib. Blood pressure was measured using an electronic 
sphygonometer (Dynoscope Fukuda Denshi DS-7100) with the participants resting in 
a seated position for five minutes; the average of three readings obtained on the 
participant’s left arm constituted the examination blood pressure. A SEGA mobile 
body weight scale was used to measure body weight at home visits.
v) Procedures for the collection of blood samples
Blood samples were taken by venepuncture of an antecubital vein in the forearm, 
from all participants after they had fasted overnight for a minimum of 12 hours. The 
blood was collected into several different tubes (vacutainers) containing the following 
anticoagulants; K2EDTA for the determination of TC, TG, HDL-C, LDL-C, Apo B and 
NEFA; fluoride oxalate for plasma glucose, and lithium heparin for plasma insulin. 
Blood samples were immediately centrifuged at 2500rpm for 10 minutes at 4 'C  in a 
low speed centrifuge for the separation of plasma. Aliquots of plasma (0.5 ml) were 
dispensed into appropriately labelled cryovials, and stored at -80°C before analysis. 
All analyses were completed within 6 weeks (Sections 3.7.4 and 4.5.5).
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4.5.4 Proton magnetic resonance spectroscopy (Week 1/4/8)
Percentage liver fat was determined in all participants by proton magnetic resonance 
spectroscopy (^H-MRS) (Philips Medical Systems) at screening (n=25) and at week 
11 on each intervention (n=17). This was conducted at the Robert Steiner, MRI Unit 
at the Hammersmith Hospital in London. "'H-MRS is a non-invasive, safe, reliable and 
sensitive method for the detection of hepatic steatosis, down to a fat percentage (by 
volume) of less than 5%. It also provides a more accurate (CV=6%) [309] and 
reproducible estimate of percentage liver fat in comparison to other methods, such as 
liver biopsy (gold standard) or ultrasound and computed tomography (CT) [310-313]. 
The ’’H-MRS method has been used extensively to measure intra-hepatic fat in 
studies investigating non-alcoholic fatty liver disease (NAFLD) in cross-sectional 
studies in the general adult population, in prospective studies of obesity and in 
patients at risk of T2DM [313-316]. Two techniques of ^H-MRS are currently 
available; techniques based on differences in the signal phases of water and fat, and 
those based on frequency selective excitation. The present study, used the former or 
so-called ‘in-phase/opposed-phase (IP/OP)’ technique.
4.5.5 Measurement of plasma lipids, lipoproteins, insulin and glucose
All consumables and reagents/chemicals used in the laboratory analyses were 
supplied by Alpha Laboratories, UK unless otherwise stated for specific analysis.
i) Materials
Biochemical analyses (fasting plasma lipids, lipoproteins and giucose)
M aterials/Equipm ents Chemicals/Reagents
- ABX Mira Plus analyser (Roche 
Diagnostic Ltd. USA)
- Refrigerated swing bucket centrifuge 
(Thermo Electron Corporation, UK)
- ABX Mira cups
- Plastic cuvettes
- ABX Pentra Apo B, TAG CP, HDL-C  
Direct CP, TC CP and Glucose PAP CP 
kits (RTU) (Horiba ABX S.A.S, 
Northampton, UK)
- NEFA-C kit (WAKO) (Alpha 
Laboratories Ltd, Eastleigh, UK)
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Radioimmunoassay (RIA) (piasma insuiin)
M aterials/Equipm ents Chemicals/Reagents
- Gamma counter
- Borosilicate glass tubes (Fisher 
Scientific, UK)
- Absorbent paper
- Human Specific RIA kit (Merck Millipore, 
MA, USA)
ii) Methods; plasma lipids, apo B, glucose and Insulin
Assays for plasma TAG, TC, HDL-C, apo B, NEFA and glucose were performed on 
an ABX Mira auto-analyser (Roche Diagnostics, USA). Pre-calibrations for each 
assay and low and high quality controls (QCs) were included within each test. Assays 
were only performed if the QCs values were within acceptable confidence limits, as 
defined by the manufacturer. All samples (pre and post-dietary interventions were 
analysed within a single batch. Intra-assay CVs (within-run precision) were calculated 
using six duplicates. Plasma LDL-C was not measured directly on isolated LDL, but 
was calculated by the Friedewald Equation (LDL-C = [TC] -  [HDL-C] -  ([TAG] /  2.2)) 
[317].
Plasma TAG
Plasma TAG was measured using a colorimetric/enzymatic method (Kit ref: 
A l 1A01640; Horiba ABX, UK). The absorbance was measured bichromatically at 500 
nm wavelength. Intra-assay precision gave CVs for N (low) and P (high) QCs of 3.0%  
and 5.9% respectively.
Plasma TC
Plasma TC was measured using a colorimetric/enzymatic photometric method using 
colorimetric indicator (Kit ref: A11A01634; Horiba ABX, UK). The absorbance of the 
quinoneimine pigment was measured bichromatically at 500 nm wavelength. The 
intra-assay CVs gave 9.0% and 2.5% for N (low) and P (high) QCs, respectively.
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Plasma HDL-C
The method used to measure plasma HDL-C was based on accelerating the reaction 
of cholesterol oxidase (CO) with non-HDL unesterified cholesterol and dissolving HDL 
selectively using a specific detergent called ‘Accelerator Selective Detergent’ (Kit ref: 
A11A01636; Horiba ABX, UK). The intensity of the colour development was 
measured at a wavelength of 600 nm. The within assay precision gave CVs 12.9%  
and 3.5% for low and high quality controls, respectively.
Plasma apo B
Plasma total apo B was measured by immunoturbidimetry (Kit ref: A11A01688; 
Horiba ABX, UK). The principle of this technique is based on the relationship of direct 
proportionality between the degree of turbidity produced by the immunoprécipitation 
of apo B and plasma apo B concentration. Test results were calculated from a 
standard curve produced by the MIRA. Tests of precision tests were carried out on 
both QCs. The intra-assay CVs gave 1.5% and 2.4% for low and high QCs, 
respectively.
Plasma NEFA
The concentration of plasma non-esterified fatty acids (NEFA) was determined by a 
colorimetric/enzymatic assay (Kit ref: 0207 D4; Alpha Laboratories Ltd, UK). The 
intensity of the red pigment was directly proportional to the concentration of NEFA in 
the sample. Ascorbic acid was removed by ascorbic oxidase from the sample, and 
the intensity of colour was measured at a wavelength 550 nm. The intra-assay 
precision, which was tested using Control Serum 1 (Alpha Laboratories Ltd, 
Eastleigh, UK), produced a CV of 0.6%.
Plasma glucose
Plasma glucose concentration was determined enzymatically using Trinder method 
with the presence of glucose oxidase (Kit ref: A11A01668; Horiba ABX, UK). The 
absorbance of quinoneimine dye was quantified bichromatically at a wavelength of 
500 nm. Intra-assay CVs were 4.3% and 5.9% for low and high QCs, respectively.
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Plasma insulin
Plasma insulin was measured by radioimmunoassay (RIA) that had four basic 
requirements; a specific antiserum to the antigen to be measured, the availability of a 
radioactive labelled form of the antigen, a method whereby antibody-bound tracer can 
be separated from the unbound tracer, and finally, the RIA to count radioactivity (Kit 
ref: HI-1AK; Merck Millipore, MA, USA). A standard curve was set up. The Millipore 
Human Insulin assay (Merck Millipore, MA, USA) utilised ^^^l-labeled Human Insulin 
and Human Insulin antiserum to determine the level of insulin in plasma using the 
double antibody/PEG technique.
4.5.6 Statistical analyses
All data were checked for the normality of their distribution using Shapiro-Wilk 
analysis (since total participant number < 50) and normal and detrended normal 
probability plots. Homogeneity of the variance was assessed by Levene’s statistic. All 
data were presented as medians with interquartile ranges in box-and-whisker plots 
(Fig. 3.2; Chapter 3), and as means [± SEM] in tables or as otherwise indicated. 
Asymmetric data were transformed as appropriate before analyses. Plasma TAG, 
HDL-C and NEFA concentrations and dietary intakes were asymmetrically distributed, 
and were thus log-transformed before analyses. Data for age, BMI, liver fat, systolic 
BP and percentage of liver fat were asymmetrically distributed but could not be 
normalised by transformation and were thus analysed by non-parametric tests. A 
paired Student T- test or non-parametric alternative Wilcoxon Signed Rank Test were 
used to examine the difference in variables before and after each diet. Differences 
between diets over time were examined by a two-way Analysis of variance (ANOVA) 
or Kruskal Wallis (non-parametric alternative) was used for determining differences 
between diets over time. The mean daily intake of energy and nutrients were 
calculated from an average of the 3-day diet diaries collected in the run-in, and during 
both intervention phases. Pearson correlation coefficients (or non-parametric 
alternative Spearman’s rho) tests were used to evaluate associations between 
variables. Analysis of variance (ANOVA) with a Post-hoc Tukey test for pair-wise 
differences, was used to analyse the difference between three or more groups. 
Analysis of covariates (ANCOVA) was used to determine the difference between 
diets in adjustment for significantly associated covariates. All data for plasma lipids.
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lipoproteins, glucose and insulin are presented as box and whiskers plots (Fig. 3.2; 
Chapter 3). All other data in tables are shown as mean [± SEM] or as otherwise 
indicated in the footnotes. Statistical significance was defined as p<0.05. The median 
of 4.2% for liver fat was used as the cut-off, to create two groups of equal size that 
were representative of having low and moderately raised liver fat. All analyses were 
performed using SPSS package version 18 (SPSS for Windows, Chicago, USA).
4.6 Results
4.6.1 Cardio-metaboiic risk score
The rank order of the components in the cardio-metaboiic risk score, in terms of 
prevalence, is shown in Table 4.2. The component of the risk score with the highest 
prevalence (88%) was a raised BMI (25-30kg/m^), followed by a raised insulin (76% > 
40pmol/L) and waist circumference (60%, > 94cm). More than half of the participants 
expressed a plasma TAG in excess of 1.3mmol/L (56%) and plasma glucose of 
greater than 5.5mmol/L (52%).
Table 4.2; Prevalence (% of total group) of cardio-metaboiic features 
contributing to overali score
Characteristics Value % Value %
Body mass index (kg/m^) 2 5 -3 0 88 > 3 0 8
Waist circumference (cm) > 9 4 60 > 102 36
Systolic BP (mmHg) > 140 28
Diastolic BP (mmHg) > 90 28
Fasting giucose (mmoi/L) > 5.5 52
Fasting insulin (pmol/L) > 4 0 76
HDL-Choiesteroi (mmol/L) < 1.0 4
Triacylglyceroi (mmoi/L) > 1.3 56
BP, blood pressure
151
4.6.2 Effects of high and low sugar diets on in anthropometric variables 
and blood pressure
Body weight and BMI both increased (0.8% and 0.7%, p<0.05) and decreased (2.4%, 
p<0.05 and 2.5%, p<0.01) after the high and low sugar diets, respectively (Table 4.3). 
There was no relationship between body weight or BMI and total energy intake on 
either the high or low sugar diets. Waist circumference, percentage body fat, fat 
mass, and free fat mass all increased relative to baseline, after the high sugar diet, 
but all three of these variables decreased after the low sugar diet. There were 
significant positive associations between changes in BMI, waist circumference and fat 
mass on the high sugar diet and negative associations on the low sugar diet, and also 
an inverse relationship between the changes in BMI and free fat mass on the low 
sugar diet (p<0.05). There was no significant change in systolic or diastolic BP after 
either diet.
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Table 4.3: Anthropometric variables and blood pressures at baseline and after the high
and low sugar diets (n=25)
Variable Time-point High sugar diet Low sugar diet
Body weight (kg) Baseline 88.5 [1.7] 89.3 [1.8]
12 weeks 89.2 [1.8] 87.2 [1.9]
Changes +0.7 [0.3]^ -2.1 [0 .5 f
BMI (kg/m"") Baseline 28.3 [0.3] 28.5 [0.4]
12 weeks 28.5 [0.3] 27.8 [0.4]
Changes +0.2 [0.1]' -0.7 [0.2]"
Waist (cm) Baseline 102.6 [1.1] 103.9 [1.4]
12 weeks 104.0 [1.3] 101.9 [1.2]
Changes +1.4 [1.0]' -2.0 [0.8 ]"
Body fat (%) Baseline 25.7 [0.5] 25.9 [0.7]
12 weeks 26.1 [0.5] 25.0 [0.7]
Changes +0.4 [0.3] -1.0 [0.2]"
Fat mass (kg) Baseline 22.8 [0.7] 23.3 [0.9]
12 weeks 23.3 [0.7] 21.9 [0.9]
Changes +0.5 [0.3]" -1.4 [0.3]"'
Free fat mass (kg) Baseline 65.7 [1.2] 66.2 [1.3]
12 weeks 65.9 [1.2] 65.2 [1.3]
Changes +0.2 [0.2] -0.9 [0.3 ]"
Systoiic BP (mmHg) Baseline 127.2 [3.1] 129.0 [2.8]
12 weeks 133.5 [3.3] 127.6 [3.6]
Changes +4.0 [2.3] +0.3 [2.3]
Diastoiic BP (mmHg) Baseline 81.7 [2.2] 82.3 [2.0]
12 weeks 83.7 [2.1] 80.2 [2.3]
Changes +1.2 [1.8] -1.7 [1.5]
Values are mean [SEM]. Changes = 12 weeks -  baseline. Statistics shows changes 
from baseline; ^p<0.05, ^p<0.01; ®p<0.05, ^p<0.01 (Wilcoxon Signed Rank Test); 
Correlation with change in BMI, ®p<0.05 (Spearman’s Rho)
4.6.3 Effects of high and low sugar diets on plasma HDL-C
For the effects of high and low sugar diets on plasma TAG, see Chapter 3. Mean 
plasma HDL-C decreased after the high and low sugar diets, by 8.5% (p<0.01) and 
10.8% (p<0.01), respectively (Fig. 4.2). In contrast to plasma TAG, plasma HDL-C 
decreased consistently with an increasing contribution of energy from sugar, on the
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high sugar diet, whereas HDL-C increased in response to a decreasing contribution 
of energy from sugar on the low sugar diet.
Figure 4.2: Effects of high and low sugar diets on plasma HDL-C.
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Statistical test were analysed using geometric mean. 'Changes from baseline 
(p<0.01). n=25.
4.6.4 Effects of the high and low sugar diets on plasma lipids and 
lipoproteins
Plasma TC was significantly lower after the low sugar diet relative to the high diet (by 
0.3mmol/L, p<0.05) after adjustment for baseline values. Plasma TC decreased 
significantly after the low sugar diet by 10% (p<0.05) relative to baseline (Fig. 4.3A). 
Plasma LDL-C also decreased significantly after the low sugar diet by 4.6%  (p<0.05) 
(Fig. 4.3B). Plasma apo B decreased significantly after the low sugar diet by 9.9%  
(p<0.05) (Fig. 4.3C). There was also a significant difference in plasma apo B between 
the high and low sugar diets (0.07g/L, p<0.05), after adjustment for baseline values. 
Plasma apo B was positively associated with plasma TC and plasma LDL-C after the 
high and low sugar diets (p<0.01). Plasma NEFA increased markedly after both the 
high and low sugar diets by 56% and 47%, respectively (p<0.01), but there was no 
difference in plasma NEFA between the diets after 12 weeks (Fig. 4.3D). There was 
evidence of positive associations between changes in plasma TAG, TC and plasma 
insulin after the high sugar diet, and a positive association between the changes in 
plasma TAG and plasma glucose after the low sugar diet (p<0.05).
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Figure 4.3: Effects of high and iow sugar diets on plasma concentrations of
plasma TC (A); LDL-C (B); apo B (C); and NEFA (D).
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4.6.5 Effects of high and iow sugar diets on plasma glucose and insulin
Plasma glucose increased by 4.4% relative to baseline after the high sugar (Fig. 
4.4A). There was no significant difference in plasma glucose between the high and 
low sugar diets after 12 weeks, and no change in plasma insulin after the high and 
low sugar diets (Fig. 4.4B).
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Figure 4.4: Effects of high and iow sugar diets on piasma giucose (A) and
insuiin (B).
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A summary of the blood biochemistry results (mean ± SEM) is shown in Table 4.4.
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Table 4.4: Plasma concentrations of lipids, lipoproteins, giucose and insuiin 
before and after the high and iow sugar diets (n=25)
High sugar 
diet
Low sugar 
diet
Mean SEM
Paired
T-test Mean SEM
Paired
T-test
Piasma TAG® Pre 1.49 0.14 1.83 0.25
(mmoi/L) Post 1.74 0.15 1.48* 0.13
Changes 0.26 0.07 p=0.001 -0.35 0.16 n.s.
Plasma TC Pre 5.47 0.17 5.57 0.19
(mmol/L) Post 5.31 0.20 5.01* 0.20
Changes -0.16 0.12 n.s. -0.56 0.13 p=0.04
Piasma NEFA® Pre 0.34 0.03 0.36 0.03
(mmoi/L) Post 0.53 0.03 0.54 0.03
Changes 0.19 0.03 p=0.000 0.17 0.03 p=0.000
Piasma HDL-C® Pre 1.30 0.06 1.30 0.05
(mmol/L) Post 1.19 0.06 1.16 0.05
Changes -0.11 0.03 p=0.002 -0.14 0.02 p=0.000
Piasma Apo B Pre 1.09 0.04 1.11 0.04
(g/L) Post 1.07 0.04 1.00* 0.04
Changes -0.02 0.03 n.s. -0.11 0.03 p=0.001
Plasma LDL-C Pre 3.49 0.14 3.44 0.16
(mmoi/L) Post 3.33 0.15 3.18 0.17
Changes -0.16 0.11 n.s. -0.26 0.11 p=0.035
Piasma giucose Pre 5.67 0.15 5.73 0.13
(mmol/L) Post 5.91 0.11 5.85 0.12
Changes 0.25 0.09 p=0.014 0.12 0.11 n.s.
Piasma insuiin Pre 126.89 8.26 113.35 6.17
(pmoi/L) Post 115.94 6.20 115.92 8.52
Changes -10.94 7.35 n.s. 2.57 8.10 n.s.
®Data were tested using log transformed values, n.s., not significant. "Difference 
between diets adjusted for baseline values (p<0.05).
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4.6.6 Influence of liver fat on the plasma lipids and lipoproteins in 
response to the high and low sugar diets
There was a total of 13 participants in the low liver fat group (< 4.2% liver fat) and 12 
participants in the moderately raised liver fat group (> 4.2% liver fat) (Table 4.5). 
Participants from both groups were matched for age and BMI. As expected, 
participants with moderately raised liver fat expressed a significantly higher 
percentage of body fat, plasma TAG and plasma fasting blood glucose (FBG) relative 
to the participants with low liver fat. However, there was no significant difference in 
other cardio-metaboiic risk components, such as systolic and diastolic blood 
pressures, waist circumference and plasma insulin concentration.
Table 4.5: Baseline characteristics of participants in low and moderately raised
liver fat groups
< 4.2% > 4.2% p-value
Age (years) 54.7±2.1 59.1 ±1.4 n.s.
Body weight (kg) 90.1 ±2.6 89.1 ±2.2 n.s.
BMI (kg/m )^ 28.3±0.4 29.0±0.4 n.s.
Liver fat (%) 2.3±0.3 16.1 ±2.6 0.000
Waist circumference (cm) 131.1 ±3.7 135.0±5.3 n.s.
Systolic BP (mmHg) 104.7±1.3 103.1 ±1.7 n.s.
Diastolic BP (mmHg) 82.2±2.5 85.4±3.5 n.s.
Body fat (%) 24.2±0.8 26.7±0.6 0.02
Fat mass (kg) 22.0±1.3 24.0±0.8 n.s.
Free fat mass (kg) 68.2±1.4 66.0±1.6 n.s.
Triacylglyceroi (mmol/L)* 1.4±0.2 2.1 ±0.2 0.03
T-Cholesterol (mmol/L) 5.4±0.3 6.0±0.2 n.s.
HDL-C (mmol/L) 1.3±0.1 1.4±0.1 n.s.
LDL-C (mmol/L) 3.4±0.2 3.7±0.2 n.s.
Fasting blood glucose (mmol/L) 5.4±0.1 5.8±0.1 0.04
Insulin (pmol/L) 50.4±5.5 61.8±7.8 n.s.
HOMA-IR 1.63±0.24 2.28±0.30 n.s.
Data are mean±SEM. n.s., not significant; HOMA-IR, homeostatic model 
assessment-insulin resistance. ^Difference between groups was tested using 
geometric means, n, <4.2%=13; >4.2%=12.
Table 4.6 shows the rank order of the components in the cardio-metaboiic risk score, 
in terms of prevalence (% of liver fat group). In the moderately high liver fat group.
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92% had a raised BMI (25-30kg/m^), 75% had elevated fasting plasma insulin (> 
40pmol/L), glucose (> 5.5mmol/L) and TAG (> 1.3mmol/L), and 50% had a waist 
circumference in excess of 102cm (Table 4.6). The most prevalent feature in the low 
liver fat group (85%) was also a raised BMI (25-30kg/m^, followed by a raised fasting 
plasma insulin (75%) and waist circumference (69%). Only one participant with a low 
liver fat (< 4.2% liver fat) had a plasma HDL-C below 1 .Ommol/L, and all participants 
with moderately raised liver fat (> 4.2%) had plasma HDL-C > 1 .Ommol/L.
Table 4.6 Prevalence (% of liver fat group) of cardio-metaboiic features
contributing to overaii score
Characteristics Value % Value %
<4.2% >4.2% <4.2% >4.2%
Body mass index (kg/m^) 2 5 -3 0 85 92 > 3 0 8 8
Waist circumference (cm) > 9 4 31 38 > 102 69 50
Systoiic BP (mmHg) > 140 31 25
Diastoiic BP (mmHg) > 9 0 31 25
Fasting giucose (mmoi/L) > 5 .5 31 75
Fasting insuiin (pmoi/L) > 4 0 75 75
HDL-Choiesteroi (mmoi/L) < 1.0 8 -
Triacyigiyceroi (mmoi/L) > 1.3 38 75
BP, blood pressure, n, <4.2%=13; >4.2%=12.
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i) Dietary intake in groups with iow and moderateiy raised iiver fat
There was no significant differences in the intake of energy or any macronutrients 
between the liver fat groups on either diet (Table 4.7).
Tabie 4.7: Dietary intake on habituai, high and iow sugar diets in groups with iow
and moderateiy raised iiver fat 
Habitual diet High sugar diet Low sugar diet
< 4.2% > 4.2% < 4.2% > 4.2% < 4.2% > 4.2%
Energy
(MJ/day)
10.4±0.7 9.0±0.6 10.8±0.6 10.3±0.8 10.2±0.4 9.5± 0.6
CHO
(g/day)
289.2±22.1 234.7±16.8 348.3±20.7 307.2±20.3 273.8±18.8 237.6±12.4
%E 46.8±1.9 43.7±1.1] 54.4±1.S 50.8±1.8 44.6±1.8 42.4±1.8
Sugar
(g/day)
135.2±16.1 102.9±9.3 179.8±14.8 165.4±13.4 59.4±5.8 51.715.4
%E 21.7±1.9 19.1 ±1.1 28.3±2.0 27.2±1.5 9 .7±0 .7 9.1 ± 0 .7
Protein
(g/day)
98.5±8.5 79.0±4.4 93.6±5.0 90.2±8.2 97.2±4.9 95.819.0
%E 16.1 ±1.1 14.9±0.e 14.7±0.7 14.7±0.7 16.0±0.6 16.8±0.9
Fat
(g/day)
90.5±9.1 82.8±8.5 76.8±6.5 77.5±12.0 94.2±4.9 83.619.3
%E 32.4±2.0 34.1 ±1.5 26.5±1.7 27.5±2.6 34.8±1.3 32.5±2.2
Fibre
(g/day)
28.3±2.2 23.3±1.3] 21.5±1.5 20.4±2.0 25.9±1.8 22.612.4
Saturated 
fat (g/day)
33.9±3.3 32.7±4.9 28.2±2.5 32.1 ±5.8 35.6±2.5 34.415.6
%E 12.2±0.9 13.1 ±1.1 9.8±0.7 11.3±1.4 13.1±0.8 13.1 ±1.5
Sodium
(g/day)
2.8±0.1 3.2±0.3 2.9±0.2 2.9±0.4 3.9±0.3 3.510.2
>4.2%=12.
<4.2%=13;
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ii) Effects of high and iow sugar diets on anthropometric variabies and
biood pressures in groups with iow and moderateiy raised iiver fat
The group with moderately raised liver fat showed a significant increase in body 
weight after the high sugar diet (+1.6%, p<0.05. Table 4.8). Body weight decreased 
after the low sugar diet by 2% and 3%, in the low and moderately raised liver fat, 
respectively (p<0.05). Waist circumference decreased after the low sugar in the low 
liver fat group (-3%, p<0.05), whilst fat mass decreased after both diets, in both liver 
fat groups (p<0.05). The percentage of body fat was significantly higher in the 
moderate raised liver fat group compared to the low liver fat group after both diets 
(p<0.05), but this significance was not maintained after adjustment for body weight. 
Diastolic blood pressure showed a significant increase in the low liver fat group (+2%, 
p<0.05) and a significant decrease after the low sugar diet in the moderately raised 
liver fat group (-7%, p<0.05). After adjusting for baseline values, only waist 
circumference after the high sugar diet, and diastolic blood pressure after the low 
sugar diet, were significantly different between the liver fat groups (p<0.05).
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Table 4.8: Anthropometric variables and blood pressures In two liver fat groups before
Liver fat <4.2%(n=13) >4.2% (n=12)
Diet Pre Post Pre Post
Body weight High sugar S9.0±2.8 89.3±2.9 87.912.1 89.312.3
(kg) Changes +0.210.4 +1.410.5'=
Low sugar 89.212.8 87.213.0 89.512.5 87.212.4
Changes -2.010.7'= -2.310.8®
BMI High sugar 27.910.5 28.010.5 28.610.4 29.010.4
(kg/m )^ Changes +0.110.1 +0.410.2'=
Low sugar 28.010.5 27.410.6 29.110.5 28.310.5
Changes -0.610.2'= -0.710.2'=
Waist High sugar 103.011.7 102.411.8“ 102.111.5 105.811.8
circumference Changes -0.610.5 +3.711.7^
(cm) Low sugar 102.812.3 100.011.7 105.111.8 103.911.6
Changes -2.811.4'= -1.210.9
Body fat High sugar 24.710.6® 24.810.7® 26.710.8 27.410.6
(%) Changes +0.210.2 +0.610.5
Low sugar 24.210.8® 23.610.9® 27.810.7 26.510.8
Changes -0.610.3 -1.310.3'=
Fat mass High sugar 22.111.1 22.311.1 23.610.9 24.410.9
(kg) Changes +0.210.2 +0.810.5
Low sugar 21.911.3 20.811.3 24.911.0 23.111.0
Changes -1.110.4'= -1.810.4'=
Free fat mass High sugar 66.911.8 67.111.8 64.411.6 64.611.6
(kg) Changes +0.210.2 +0.110.5
Low sugar 67.711.7 66.511.9 64.611.8 63.911.6
Changes -1.210.4 -0.710.5
Systolic BP High sugar 124.714.8 131.614.5 133.915.8 134.315.4
(mmHg) Changes +6.913.0® +0.313.3
Low sugar 123.014.1 126.814.3 133.515.1 128.916.6
Changes +3.812.6 -4.613.9
Diastolic BP High sugar 79.112.5 80.212.5 86.114.8 87.513.4
(mmHg) Changes +1.112.4 +1.413.0
Low sugar 77.912.9 79.412.5 87.313.9 81.414.4'=
Changes +1.4611.4'= -6.012.3®
^Difference between groups (p<0.05); ^Difference between groups adjusted for 
baseline values (p<0.05); ^Changes from baseline (p<0.05). Data are m eanlSEM . 
^Statistical tests were performed using geometric values. BMI, body mass index; BP, 
blood pressure.
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iii) Effects of high and low sugar diets on plasma TAG in liver fat groups
A similarly high proportion of both the low liver fat group (85%) and moderately raised 
liver fat group (83%) showed an increase in plasma TAG, relative to baseline, after 
the high sugar diet (p<0.05) (Fig. 4.5). In contrast, only 46% of the low liver fat group 
and 75% (p<0.05) of the moderately raised liver fat group, showed a decrease in 
plasma TAG in response to the low sugar diet. Overall, the moderately raised liver fat 
group expressed greater changes after both diets relative to the group with low liver 
fat. Across increasing quintiles of liver fat, plasma TAG increased and decreased 
consistently on the high and low sugar diets, respectively (Fig. 4.6).
There were significant differences in plasma TAG between liver fat groups after the 
high and low sugar diets (by 0.92mmol/L and 0.75mmol/L, p<0.01). Flowever, 
correlation analysis revealed significant associations between baseline and post­
intervention plasma TAG values for both diets, and between plasma TAG and BMI, % 
body fat (%BF), plasma TC and NEFA (p<0.05). After adjusting for baseline values, 
plasma TAG were significantly different between liver fat groups after the high sugar 
diet (p<0.01, ANCOVA), independently of BMI, % BF, plasma TC and NEFA, but not 
after the low sugar diet.
Figure 4.5: Effects of high and low sugar diets on plasma TAG in liver fat 
groups.
Liver fat group 
E=] <4.2%  (n=13)
E=] >4.2%  (n=12)
K - 2 -
Low sugar dietHigh sugar diet-3^
Analysis was performed using geometric values. "Changes from baseline (p<0.05). 
""Difference between liver fat groups (p<0.05).
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Figure 4.6: Effects of high and low sugar diets on plasma TAG across 
increasing quintiles (Q) of liver fat (%).
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Data are mean ± SEM. Q1=1.0±0.2%; Q2=2.8±0.2%; Q3=4.8±0.8%; Q4=12.4±0.9%; 
Q5=23.8±3.9%. n, <4.2%=13; >4.2%=12.
iv) Effects of high and low sugar diets on plasma HDL-C in liver fat
groups
Interestingly, both the high and low sugar diets were accompanied by decreases in 
plasma HDL-C in both liver fat groups (p<0.05) (Fig. 4.7). There was evidence of 
significant associations for plasma HDL-C between baseline and post-intervention 
values for both diets, but not after adjustment for baseline values.
Figure 4.7: Effects of high and low sugar diets on plasma HDL-C in liver fat 
groups.
Liver fat group 
d  <4.2% (n=13) 
d  >4.2% (n=12)
0.4n
0 .2 -
^  - 0 .2 -
iS -0.4-
-0.6-* High sugar diet Low sugar diet
Statistical tests were performed on geometric means. ^Changes from baseline 
(p<0.05).
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V) Effects of high and low sugar diets on other plasma lipids and 
lipoproteins after the high and iow sugar diets in iiver fat groups
Plasma TC, LDL-C and apo B decreased relative to baseline values, after the high 
and low sugar diets in both liver fat groups (Fig. 4.8A, B and D). In contrast, plasma 
NEFA increased significantly after the high and low sugar diets (low liver fat=52%; 
raised liver fat=63%; and low liver fat=63%; raised liver fat=34%, p<0.05), 
respectively, and showed a significant difference between liver fat groups after the 
high sugar diet (p<0.001) (Fig. 4.8C).
Figure 4.8: Effects of high and low sugar diets on plasma TC (A); LDL-C (B); 
NEFA (C); and apo B (D) in liver fat groups.
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Analysis was performed on geometric means for plasma NEFA. ^Changes from 
baseline (p<0.05). ""Difference in post-diets values between liver fat groups (p<0.05).
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Vi) Effects of high and low sugar diets on fasting plasma glucose and 
insulin in liver fat groups
Plasma glucose increased after both diets relative to baseline, in both liver fat groups 
(Fig. 4.9A). Plasma glucose was higher (by 0.63mmol/L) in the group with moderately 
raised liver fat relative to the low liver fat group after the high sugar diet (p<0.01). 
Baseline values were significantly associated with post intervention values (p<0.05). 
The significant difference in plasma glucose after the high sugar diet between liver fat 
groups was not maintained after adjustment for baseline values. Surprisingly, plasma 
insulin decreased by 6.7% and 10.7% after the high sugar diet in the low and 
moderate raised liver fat groups, respectively, and increased by 5.6% after the low 
sugar diet in the low liver fat group (Fig. 4.9B).
Figure 4.9: Effects of high and iow sugar diets on plasma glucose (A); and 
insuiin (B) in iiver fat groups.
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□  <4.2%(n=13)
□  >4.2%(n=12)
*Changes from baseline (p<0.05). **Difference between liver fat groups (p<0.01).
A summary of mean values and changes of plasma lipids, lipoproteins, glucose and 
insulin in liver fat groups is shown in Table 4.9.
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Table 4.9: Mean differences in plasma lipid and glycaemic profiles in liver fat groups
Liver fat <4.2%(n=13) >4.2% (n=12)
Diet Pre Post Pre Post
Plasma TAG* High sugar 1.16±0.12^ 1.30±0.1f 1.8410.23 2.2210.22"=
(mmol/L) Changes +0.14±0.06 +0.3810.14"=
Low sugar 1.12±0.12^ 1.12±0.08 2.6010.41 1.8710.2
Changes O.OOiO.10 -0.7310.28"=
Plasma High sugar 1.31 ±0.10 1.16±0.07 1.3010.05 1.2310.08
HDL-C* Changes -0.1510.04"= -0.0710.05
(mmol/L) Low sugar 1.2910.08 1.1610.08 1.3010.06 1.1510.06
Changes -0.1310.03"= -0.1510.03"=
Plasma TC High sugar 5.2710.24 5.0110.25 5.6810.24 5.6410.31
(mmol/L) Changes -0.2610.11"= -0.0510.22
Low sugar 5.2110.22^ 4.8110.28 5.9510.28 5.2210.27
Changes -0.4010.14"= -0.7310.24"=
Plasma High sugar 0.2910.03 0.4310.03^ 0.4010.05 0.6410.03"=
NEFA* Changes +0.1510.03"= +0.2510.04"=
(mmol/L) Low sugar 0.3210.03 0.5210.04^ 0.4110.06 0.5610.04
Changes +0.2010.04"= +0.1410.05"=
Plasma apo B High sugar 1.0710.05 1.0310.05 1.1210.05 1.1210.07
(g/L) Changes -0.0410.03 +0.0010.05
Low sugar 1.0510.04 0.9710.05 1.1810.07 1.0510.07
Changes -0.0810.03"= -0.1410.05"=
Plasma LDL-C High sugar 3.4310.18 3.2610.21 3.5510.24 3.4010.23
(mmol/LO Changes -0.1710.12 -0.1510.20
Low sugar 3.410.19 3.1410.23 3.4710.26 3.2210.25
Changes -0.2610.14 -0.2510.19
Plasma High sugar 5 .3 1 l0 .2 f 5.6110.13^ 6.0510.18 6.2410.14
glucose Changes +0.3010.16 +0.1910.10
(mmol/L) Low sugar 5.3710.16^ 5.6510.15 6.1310.12 6.0710.17
Changes +0.2810.12"= -0.0510.19
Plasma High sugar 117.3918.56 104.8618.58 137.1818.35 127.95114.08
insulin Changes -12.5319.82 -9.23111.44
(pmol/L) Low sugar 100.8916.68 106.50115.35^ 126.8519.40 126.1315.78
Changes +5.61113.03 -0.7319.79
Data are meaniSEM. "Analyses were performed using geometric values. ^Difference 
between groups (p<0.05); ^Difference between groups adjusted for baseline values 
(p<0.05); ^Changes from baseline (p<0.05).
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4.6.7 Effects of high and low sugar diets on the percentage of iiver fat
The percentage of liver fat was measured at screening on all participants and in a 
total of 17 participants after each dietary intervention. Overall, the percentage of liver 
fat increased from a median of 4.17% at baseline to a median of 7.30% after the high 
sugar diet and decreased significantly to a median of 2.20% after the low sugar diet 
(p<0.05) (Fig. 4.10). The percentage of liver fat was significantly higher after the high 
sugar diet relative to the low sugar diet (p<0.05).
Figure 4.10: Liver fat percentage at baseline, after the high and low sugar diets 
for the total cohort (n=17).
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There were significant differences between the high and low sugar diets with respect 
to the change in the percentage of liver fat in each of liver fat group, and a significant 
difference in changes between liver fat groups by 2.5% following low sugar diet 
(p<0.05) (Fig. 4.12). Overall, the group with moderately high liver fat was more 
responsive in terms of changes in liver fat; showing greater increases and decreases 
on the high and low sugar diets (+3% and -3%), respectively. Two participants with 
moderately raised liver fat at baseline demonstrated a dramatic increase in the 
percentage of liver fat to nearly 46% and 54% after the high sugar diet.
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Figure 4.11 : The percentage of liver fat after the high and low sugar diets in two
liver fat groups.
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"Difference between diet (p<0.05, Wilcoxon Signed Rank Test). ""Difference between 
liver fat groups (p<0.05, Mann-Whitney U Test).
4.7 Discussion
The present study was undertaken to determine the effects of two high and low sugar 
diets on other variables of cardio-metaboiic risk, including anthropometric, blood 
pressure, fasting lipid profiles, glucose and insulin. A secondary objective of this 
study was to determine the influence of the percentage of liver fat on the response to 
dietary sugars, and conversely the effects of diets high and low in sugars on the 
percentage of liver fat.
4.7.1 Effects of high and low sugar diets on anthropometric variables and 
blood pressure
One aim of the study was to maintain body weight throughout each intervention. 
While body weight should be maintained by a balance between energy intake and 
expenditure [318], paradoxically, there was a significant increase and decrease in 
body weight after the high and low sugar diets, respectively, without any significant
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change in energy intake. It is possible that the observed changes in body weight were 
influenced by a lower and higher energy expenditure on the high and low sugar diets, 
respectively. Unfortunately, energy expenditure was not measured. Another obvious 
explanation would be because of the underreporting of energy intake.
The effects of high-CHO diets on body weight in previous studies have been highly 
variable [222, 256, 319, 320]. The increase in body weight and fat mass after the high 
sugar diet in the present study was in contrast to that of previous studies, which 
showed significant reductions in body weight and fat mass with a similar contribution 
of energy from CHO (52-54%) [194, 222]. In comparison, Krauss et al. [321] found 
that a diet with 54% energy as CHO produced no effect on body weight. It has been 
suggested that changes in body weight may be associated with the type of CHO  
rather than the energy contribution from total CHO [256]. Animal and human studies 
seem to suggest that glycaemic index (Gl) may be a factor that influences body 
weight and body fat [322, 323], through its association with insulin sensitivity [319, 
324]. In accordance with these studies, the increase and decrease in body weight 
following the high and low sugar diets may be explained by an increased intake of 
high and low Gl foods in these diets, respectively. While it is possible that the 
changes in body weight confounded the effects on plasma lipids and glycaemic 
control, a weight loss of between 5-10% has been shown to be required to influence 
plasma lipids and glycaemic control [257, 258], and the present study only reported 
changes of around 2%.
The reciprocal changes in body weight after each diet were paralleled by an increase 
in waist circumference, body fat and fat mass after the high sugar diet, and a 
decrease in the same variables after the low sugar diets. This might suggest that the 
changes in adiposity were regionalised in the intra-abdominal area, which is more 
relevant with respect to the generation of cardio-metaboiic risk [4, 325]. Increased 
abdominal obesity has been frequently associated with insulin resistance, increased 
intracellular lipolysis and elevated postprandial plasma NEFA, which, in theory, may 
increase lipid substrate availability for TAG synthesis in the liver [91, 326]. In addition, 
visceral obesity, mainly in non-diabetic obese individuals, has also been associated 
with increased TAG-rich lipoprotein remnants which may provide a source of ectopic 
fat, to fuel VLDL production in the liver [327, 328]. Conversely, a reduction in 
abdominal adiposity has been associated with beneficial effects on plasma lipids and
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insulin [329, 330]. Abdominal obesity has also been linked to high blood pressure, 
whilst a decrease in waist circumference has been associated with reduced blood 
pressure [331-334]. Previous studies have indicated that an increased intake of sugar 
might raise blood pressure [335, 336], though there was no evidence for this in the 
present study.
It is possible that an increase in both systolic and diastolic blood pressures after the 
high sugar diet was associated with the increased BMI and waist circumference. It is 
also possible that any favourable effect of the weight loss and reduced waist 
circumference on blood pressure (diastolic BP only) on the low sugar diet was 
counter affected by the increased intake of sodium on this diet [337, 338]. An 
increase in salt intake of 1 g/day (0.4g/day of sodium) has been previously associated 
with an increase of 0.4 mmHg in systolic blood pressure [337]. In the present study, 
an increase in sodium of 0.7g/day, resulted in an increase of 0.3mmHg of systolic 
blood pressure, but there was no evidence of an association between the degree of 
weight loss and changes in blood pressure.
Despite the potentially confounding effect produced by the changes in body weight, 
there was evidence to suggest that the low sugar diet improved cardio-metaboiic risk, 
whilst the high sugar diet had the opposite effect. To determine the independent 
effect of the diets on plasma lipids, anthropometric covariâtes were adjusted 
accordingly in the statistical analysis. This is discussed in section 4.7.2.
4.7.2 Effects of high and low sugar diets on plasma lipids, lipoproteins, 
glucose and insuiin
Plasma HDL-C is well known to be inversely associated with CVD risk, and a low 
HDL-C concentration has been established as an independent negative risk factor of 
CVD [20, 339, 340]. Findings from the present study are consistent with previous 
studies [222, 320, 341], in showing a non-significant decrease in HDL-C after a high 
sugar diet. While a decrease in plasma HDL-C after the high sugar diet was an 
expected outcome, HDL-C also decreased after the low sugar diet. The HDL-lowering 
effect of a high sugar diet is believed to be mediated through the increase in plasma 
TAG and the subsequent remodelling of HDL into smaller particles, which are then 
cleared from the plasma more rapidly [27, 132, 342-344]. The effect of the low sugar
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diet on HDL-C is more difficult to interpret, and may be linked to changes in body 
weight or other diet and lifestyle factors that were not assessed. In contrast to a 
previous study [345], there was no association between age, BMI, physical activity 
level, smoking status and plasma HDL-C in the present study, perhaps suggesting a 
direct effect of the high sugar diet on the reduction on plasma HDL-C.
A moderate loss of body weight (5-10%) has been previously associated with 
elevated HDL-C [346, 347]. A low intake of sugars has also been associated with 
raised HDL-C [153, 348, 349]. However, despite a loss of body weight and reduction 
in TAG and sugar intake in the present study, HDL-C was, unexpectedly, decreased 
after the low sugar diet. This finding is not unique, and has been reported previously 
[350, 351], and possibly confounded by a loss of body weight, as has been described 
previously [352]. Possible explanations for the fall in HDL-C include; a decrease in 
apolipoproteins associated with HDL, and/or an increase in plasma insulin [353]. This 
situation would decrease the synthesis and secretion of HDL, leading to a reduction 
in plasma HDL-C [308], though there was no evidence to support either of these 
effects.
Plasma LDL-C is a classic biomarker of CVD risk. The AHA recommended the 
lowering of LDL-C, as a primary target for decreasing CVD risk, via a reduction in 
saturated fat intake [2]. In the present study, the high sugar diet was accompanied by 
reductions in both plasma TC and LDL-C. This finding would be consistent with an 
LDL-lowering effect produced by a lower intake of saturated fat which was evident on 
the high sugar diet (-23%), and as previously reported by Mensink & Katan and 
others [24, 26, 354]. However, there was also evidence of a significant reduction in 
plasma LDL-C after the low sugar diet, but no change in the intake of saturated fat. It 
is possible that this finding was due to a high intake of dietary fibre on the low sugar 
diet, particularly in the form of soluble fibre [57, 355, 356]. One gram of soluble fibre 
has been previously reported to decrease plasma TC and LDL-C by 0.045 mmol/L 
and 0.057 mmol/L, respectively, but have no significant effect on plasma TAG and 
HDL-C [57].
Plasma apo B is another established marker of CVD risk [357, 358] which is 
associated with atherogenic lipoproteins (VLDL and LDL) [91, 158]. The fall in apo B 
after the high sugar diet was unexpected, especially when plasma TAG increased
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which, in theory, should translate into an increase in VLDL-TAG [135, 158]. This may 
suggest that the liver is producing larger, TAG-rich VLDL rather than more VLDL 
particles. The significant reductions in apo B after the low sugar diet, was a more 
predictable outcome that might be explained by the reduction in hepatic TAG and the 
significant decrease in waist circumference. This may support the view that apo B is 
very sensitive to changes in abdominal adiposity leading to a decrease in lipid 
substrate supply to the liver contributing to reduced hepatic secretion of apo B [359, 
360].
In contrast to LDL-C, TC and apo B, plasma NEFA increased significantly after both 
diets. Higher plasma NEFA has been associated with hypertriacylglycerolaemia in 
numerous studies [176, 221, 361]. In agreement with these findings, plasma NEFA in 
the present study, was significantly increased in parallel with the increase in plasma 
TAG after the high sugar diet. Since this diet was associated with an increase in waist 
circumference, it is possible that the elevation in plasma NEFA arose from an 
increase in lipolysis in the newly acquired adipose tissue [192, 362].
An increase in the intake of high Gl foods has been linked to insulin resistance [363], 
whereas low Gl foods may increase insulin sensitivity [364]. In the present study, both 
diets produced unexpected, non-significant changes in plasma insulin. A high intake 
of sugar has also been shown to impair glucose tolerance, especially in population at 
increased cardio-metaboiic risk [214, 365]. An increase in fasting glucose after the 
low sugar diet was an interesting finding. However, the change was small (2%) and 
insignificant, and may be not reflecting the actual effect.
4.7.3 Influence of liver fat on the lipid response to dietary sugars and the 
effect of diets on the percentage of liver fat
A major part of the general hypothesis of the 'CHOT' study was to determine how 
liver fat influences the plasma lipid response to dietary sugars and, visa-versa\ how 
the diets high and low in sugars affected the percentage of liver fat. A secondary aim 
was to increase understanding of the interrelationship between liver fat and cardio- 
metaboiic risk factors. Two liver fat groups were established by a subdivision around 
the median of liver fat (4.2%) at screening. In a previous, population-based study, that 
used the same method of liver fat quantification in > 2,000 participants, the upper limit
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of ‘normal’ liver fat content was set at 5.56%, whilst the median of liver fat in 
participants with metabolic syndrome was 8 .2% [103]. The present study was 
probably the first of its kind to examine the effect of percentage liver fat on the 
responsiveness of plasma lipids, lipoproteins, and cardio-metaboiic risk and liver fat 
to dietary sugars.
In accordance with other studies [103, 111, 121, 366, 367], the percentage of liver fat 
in the present study was associated with higher plasma TAG and plasma glucose 
[121, 366, 367] at baseline. However, in contrast to these other studies, the group 
with moderately raised liver fat in this case showed higher plasma HDL-C compared 
to the participants with low liver fat. There was no significant relationship between 
liver fat and cardio-metaboiic risk factors, such as abdominal obesity, fasting insulin 
and blood pressure, most probably because of the small sample size. However, the 
group with moderately raised liver fat still expressed greater cardio-metaboiic risk 
factors including abdominal obesity, increased fasting plasma insulin, raised diastolic 
BP, and increased percent body fat and fat mass, relative to the group with low liver 
fat [103, 111, 121].
The group with moderately raised liver fat showed greater sensitivity to both high and 
low sugar diets in terms of changes in plasma lipids, mainly plasma TAG, relative to 
the low liver fat group. The percentage of liver fat has been associated with hepatic 
insulin resistance and increased fasting serum insulin [103, 111, 366]. This suggests 
that the greater insulin resistance, presented as a higher percentage of liver fat, may 
have contributed to the increase sensitivity of this group to the dietary sugars. 
Whether this resulted from an increase DNL and subsequent increased output of 
TAG-rich VLDL (see Fig. 1.16), will be determined by the stable isotope tracer studies 
in the main project.
There was evidence of an order or carry-over effect for the high sugar diet, possibly 
introduced by an inadequate length of washout period (4 weeks), so that the 
participants had insufficient time to return to their habitual diet which prevented their 
plasma lipids from returning to baseline values. However, appropriate statistical 
adjustments were made, and the difference of plasma TAG between the liver fat 
groups still remained significant after the high sugar diet, independent of baseline 
values. In addition, the percentage of liver fat increased and decreased after the high
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and low sugar diets, respectively, an effect which was greater in the group with 
moderately raised liver fat relative to the low liver fat group. These findings provide 
evidence for greater responsiveness in participants with moderately raised liver fat in 
terms of the changes in plasma lipids and percentage of liver fat. The implications for 
these findings are that this group may achieve greater benefits in terms of 
improvements in cardio-metaboiic risk factors when placed on a low sugar diet.
4.8 Conclusion
This study presents evidence to suggest that the manipulation of sugar and starch 
can produce modest effects on cardio-metaboiic risk. The high sugar diet was 
associated with adverse effects on plasma HDL-C, BMI, waist circumference, fasting 
glucose and the percentage of liver fat, leading to increased CVD risk, whilst the low 
sugar diet was associated with benefits on these risk factors. Participants with 
moderately raised liver fat showed increased sensitivity to both high and low sugar 
diets, the metabolic origin of which will be determined in the stable-isotope tracer 
studies. In conclusion, substituting starch with simple sugars may not be advisable 
because of the potentially adverse effects on plasma lipids and liver fat. Nonetheless, 
reducing sugar intake may be useful in managing CVD risks, especially in people with 
moderately raised liver fat, who stand to gain greater benefits from this dietary 
modification.
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Chapter 5
EFFECTS OF HIGH AND LOW SUGAR DIETS ON THE DISTRIBUTION OF LDL 
AND HDL PARTICLE SIZES AND APOLIPOPROTEINS
5.1 Introduction
It is well documented that plasma LDL-C and HDL-C are associated with increased 
and decreased CVD risk, respectively. An increase of 0.26mmol/L in plasma LDL-C 
has been linked to an increase in CVD risk of 12% [368], whilst a plasma HDL-C in 
excess of 1.79mmol/L was reported to reduce CVD mortality of 64% in women and 
44% in men [345]. However, LDL and HDL exist in plasma as a heterogeneous group 
of discrete subclasses, that differ in size, density and chemical composition, and 
express variable atherogenic potential and associations with CVD risk [369].
A predominance of small, dense LDL (sdLDL) (LDL subclass phenotype ‘B’) is 
recognised to be a major feature of an atherogenic lipoprotein phenotype (ALP), a 
condition which has been associated with a three-fold increase in CHD risk (Fig. 5.1), 
and may occur in up to 25% of middle-aged men [27, 130, 370-372]. Small, dense 
LDL particles have been found to be more prevalent in men with ischeamic heart 
disease (IHD) in case-control studies [27, 145, 373-375], and have been shown to be 
independently predictive of CHD in large prospective cohorts [376-381]. The 
increased atherogenicity of sdLDL has been ascribed to their physiochemical and 
metabolic properties, including a reduced binding affinity for the LDL receptor [382, 
383], greater infiltration into the subendothelial space, by virtue of their small size 
[384], increased affinity for to arterial wall proteoglycans [385], and increased 
susceptibility to undergo oxidative modification [132, 386-388]. A sequential 
combination of these mechanisms promotes arterial damage and atherosclerosis, 
especially in individuals with diabetes [389]. Small LDL particle size has also been 
associated with metabolic syndrome, and inversely correlated with plasma TAG [390]. 
An elevation of the number of sdLDL particles, as indicated by the concentration of 
LDL apo B (hyper-apoprotein B > 1.3g/L), has been shown to be a better predictor of 
CHD in an ALP relative to the particle size of sdLDL [391, 392]. Hyper-apoprotein B 
may also be associated with the overproduction and secretion of apo B in VLDL, and 
subsequent formation of sdLDL, via the remodelling of LDL by CETP-mediated
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neutral lipid exchange [135], especially when plasma TAG exceeds 1.5mmol/L [27, 
393, 394]. Hence, a predominance of sdLDL and hyper-apoprotein B have been 
found to co-exist in individuals with metabolic syndrome [158, 390].
Figure 5.1: The association between sdLDL and progression of coronary 
atheroscierosis.
o
O )
<u
CD
O  ^
CD CO
^  (Ô o
CD CD 
COC3
2o
CO
LDL-C
tertile
sm all
m e d iu m
la rg e
LDL size tertile
high  
m e d iu m  
low
Adapted from Vakkilainen et a i from The Diabetes Atherosclerosis Intervention Study 
(DAIS) [371].
HDL has long been ascribed cardioprotective properties, which include its roles in the 
promotion of cholesterol efflux from the cells, and as an anti-oxidative and anti­
inflammatory lipoprotein [132]. In common with LDL, HDL particles are 
heterogeneous with multiple subclasses differing in diameter and density, ranging 
from the small HDLsc, HDLsb, and HDLsa to the larger HDLab and HDL^ [395]. A 
predominance of small HDL particles are commonly found in individuals with diabetes 
and CHD [396], and in individuals with visceral obesity and insulin resistance [397], 
and have been linked to the progression of CHD risk in prospective cohort studies 
[398-400]. A reduction in HDL particle size may occur through a remodelling of HDL 
particles via the neutral lipid exchange of cholesterol between HDL and TAG-rich 
lipoproteins, and/or through a reduced synthesis of HDL [132]. The larger, TAG-rich 
HDL particles are believed to have only a transient existence, before being 
hydrolysed by hepatic lipase, and cleared from plasma, which normally manifests as 
a reduction of larger HDL particles (HDL2b) and an increase in relative proportion of 
smaller HDL particles (HDLsb and HDLsc) [132, 401].
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A low-fat, high-CHO diet has been associated with a shift in LDL subclass phenotype 
from pattern ‘A’ to ‘B’, in healthy men and women in a previous cross-sectional study 
[402], and in clinical trials [165-167, 403]. Results from previous studies also suggest 
that the induction of pattern ‘B’ by a high CHO diet may be associated with genetic 
factors relating to the LDL receptor [404]. While there is data to show that a low CHO  
diet can increase LDL size, and both large and small HDL [405], evidence for the 
effect of dietary CHO on LDL and HDL subclasses in individuals at increased cardio- 
metabolic risk is still lacking. In the previous chapter, a diet high in dietary sugars was 
shown to increase plasma TAG to a greater extent in participants with moderately 
raised liver fat (> 4.2%) relative to a group with low liver fat. This finding was 
accompanied by a significant reduction in plasma HDL-C, an effect that was 
speculated to be due to a shift in HDL size, towards smaller and denser particles.
As described in Chapter 1, the formation of sdLDL, low HDL and, in some cases, the 
overproduction of apo B, have been associated with moderately-raised plasma TAG 
(in excess of 1.5mmol/L) [27]. The catabolism of TAG-rich lipoproteins is regulated, in 
part, by lipoprotein lipase (LPL), and endothelial lipase which is activated by apo CM, 
and inhibited by apo CHI. Hypertriacylglycerolaemia (HTAG) has been linked to a 
reduction or absence of apo CM and/or overexpression of apo CHI in previous studies 
[406-408]. The mean concentration of apo Cl I in VLDL fractions was also found to be 
significantly lower in subjects with HTAG relative to controls [409]. There is evidence 
from animal studies that an increase in the plasma concentration of apo CHI of 40%, 
may result in more than a doubling of plasma TAG [407, 408]. It follows, that the ratio 
of apo CH to CHI may be an important determinant of LPL-mediated lipolysis, and of 
the susceptibility to develop HTAG [91]. Animal and in vitro studies, have shown that 
the transcription of the apo C-HI gene is down-regulated by insulin, and that failure of 
insulin action results in an overexpression of apo CHI, and HTAG [408, 410]. The ratio 
of plasma apo CH-CHI, may therefore provide an indirect marker of lipolytic activity 
that may be useful in interpreting the effects of high and low sugar diets on plasma 
TAG.
The relationship between apo E and HTAG in humans has not been well studied. 
However, the overexpression of hepatic apo E in transgenic mice has been shown to 
induce a three-fold increase in plasma TAG, raise VLDL, lower HDL, and markedly 
decreased apo E-enriched VLDL in apo CH [411]. Apo E is associated with large.
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TAG-rich VLDU, a lipoprotein which produces TAG [412]. In theory, apo E should be 
essential for the metabolic conversion of VLDL into LDL, but apo E also inhibits LPL- 
mediated lipolysis which could elevate plasma TAG [413]. In humans, plasma and 
VLDL apo E have been positively associated with HTAG, but negatively associated 
with VLDL apo CH levels and LPL-mediated VLDL lipolysis [411]. Therefore, the 
quantification of plasma apo E might also be informative with respect to 
understanding how dietary sugars influence plasma TAG, particularly in people at 
increased cardio-metabolic risk. Despite our existing knowledge and understanding of 
how plasma lipoproteins contribute to the development of HTAG and an ALP, the 
extent to which this is influenced by dietary sugars and the percentage of liver fat, is 
largely unknown.
5.2 Study aims
• To determine the metabolic effects of high and low sugar diets on sdLDL-C, 
LDL and HDL particle sizes and plasma apos CH, CHI and E.
• To determine the inter-relationships between LDL and HDL particle sizes and 
apos CH, CHI and E and liver fat.
5.3 Study objectives
• To isolate total lipoproteins from plasma using preparative ultracentrifugation.
• To separate LDL and HDL subclasses on the basis of their particle size using
gradient gel electrophoresis (GGE).
• To quantify plasma sdLDL-C concentrations in plasma using a commercially 
available enzymatic/colourimetric assay.
• To determine the plasma concentration of plasma apos CH, CHI and E.
5.4 Study hypothesis
Individuals with moderately raised liver fat, will express a greater proportion of both 
plasma sdLDL and small HDL particles, a reduced ratio of plasma apo CILCHI and 
elevated apo E at baseline, in comparison to individuals with low liver fat. A diet high 
in sugar will exacerbate the dyslipidaemic profile of participants with moderately 
raised liver fat to a relatively greater extent than those with low liver fat.
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5.5 Materials and methods
5.5.1 Materials
This chapter describes a laboratory-based investigation of plasma LDL and HDL 
subclasses. All methods and materials relating to participant recruitment, the dietary 
intervention and study design, have been described previously in Chapters 3 and 4. 
All consumables and reagents/chemicals used in the laboratory analyses were 
supplied by Sigma-Aldrich Co, Germany unless otherwise stated for specific analysis.
Gradient gei eiectrophoresis (LDL and HDL subciasses)
Materiais/Equipments Chemicais/Reagents
- Pore Gradient Lipoprotein Electropho­
resis system (PGGE) (C.B.S Scientific 
Co. California, USA)
-1 3  wells sample applicator (C.B.S 
Scientific Co. California, USA)
- Optima L-100 XP Ultracentrifuge (Beck­
man Coulter, Buckinghamshire, UK)
-1 2  wells rotor type 70.1TI (Beckman 
Coulter, Buckinghamshire, UK)
- Polyallomer centrifuge tubes (Beckman 
Coulter, Buckinghamshire, UK)
- 4/30% and 2/16% pore-gradient 
polyacryla-mide gel (C.B.S Scientific Co. 
California, USA)
- Scanjet G3010 (HP, USA)
- Total Lab ID gel-scan software (Non­
linear Dynamics, Newcastle upon Tyne, 
UK)
- DMA 40 Anton Parr Digital Density 
Meter (Parr Scientific Ltd, London, UK)
- Sodium bromide
- AnalaR-5-suplhosalicylic acid
- Bromphenol blue
- Methanol
- Acetic acid
- Tris base
- Boric acid
- EDTA
- Coomasie blue
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Small dense LDL-C analysis
Materials/Equipments Chemicals/Reagents
- ILAB 650 (Instrumentation Laboratory, 
USA)
- sLDL Direct Kit (Randox Laboratories, 
Ltd, Antrim, UK)
Apollpoprotein analyses (Apo 0  II, Apo 0  III and Apo E)
Materials/Equipments Chemicals/Reagents
- ILAB 650 (Instrumentation Laboratory, 
USA)
- Apo CH, Apo CHI and Apo E Kits 
(Randox Laboratories Ltd, Antrim, UK)
5.5.2 Methods
I) Measurement of LDL and HDL subclasses
i) Isolation of lipoproteins
LDL and HDL were isolated from stored plasma (-80°C) by preparative, sequential 
flotation ultracentrifugation (Beckman Optima L100-XP) at densities of 1.063 and 1.21 
kg/L, respectively [414]. Prior to ultracentrifugation, whole plasma was adjusted to a 
density 1.225 kg/L by the addition of a solution of sodium bromide (NaBr). The 
density of NaBr solution was adjusted by adding a pre-determined amount of solid 
NaBr and checking the density with a digital densitometry (Parr Scientific Ltd, 
London, UK). A =9.5ml volume of plasma was dispensed into polyallomer tubes and 
the volume was adjusted to 10 ml with NaBr solution to give a final density of 
1.225kg/L. Aluminium caps were secured, and tubes were subjected to 
ultracentrifugation in the 70Ti fixed-angle head rotor at 40,000 rpm for 24 hours at 
4°C (G-force=125,394xg). Following ultracentrifugation, 200 pL of the upper yellow 
supernatant, containing total plasma lipoproteins was aspirated, stored at 4°C and 
used for subsequent GGE in 48 hours. Pre and post-dietary plasma samples for each 
individual were isolated in the same rotor.
ii) Gradient gel electrophoresis (GGE)
Electrophoresis was performed on a Pore Gradient Gel Lipoprotein Electrophoresis 
system (PGGE) using 2/16% and 4/30%, non-denaturing, pore-gradient 
polyacrylamide gels for LDL and HDL subclasses, respectively. Gel cassettes were
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fitted with sample applicators and positioned in the GGE apparatus. Pre and post­
dietary samples from each participant, containing total plasma lipoproteins, were 
applied to single gels for LDL (2/16%) and HDL (4/30%). The electrophoresis tank 
was filled with 3 litres of buffer (0.09M Tris base /  0.08M boric acid /  2.5mM EDTA) 
and a coolant water supply was circulated. Any air bubbles from the sample 
applicator wells were excluded and the gels were pre-equilibrated at 70V for 20 
minutes. A small volume of each sample (10 pL), containing total plasma lipoproteins 
(~12-20pg protein), was applied, together with 2.5 pL of bromphenol blue solution 
(final concentration 5% w/v), to separate wells in the gel applicator. After the 
application of the samples, electrophoresis was carried-out, initially for 70V for 30 
minutes, and then for 120V for 24 hours. During electrophoresis, buffer was circulated 
between the upper and lower vessels, together with the coolant water supply in the 
lower tank. After 24 hours, the gels were removed from the cassettes and fixed in 
suplhosalicylic acid (10% w/v) for 30 minutes, followed by staining with coomasie blue 
for 1 hour (Coomasie R250 in 0.1% w/v methanol:acetic acid:H20 (5:1:4)) and 
destained in methanol:acetic acid:H20 (5:7.5:87.5) until the background was 
completely clear and the lipoproteins were visually well resolved.
ill) Gel scanning and assessment
Destained gels were scanned using a Scanjet scanner (HP, USA) for a semi- 
quantitative, qualitative assessment of the distribution of LDL and HDL subclasses 
using Total Lab ID gel software (Non-linear Dynamics, UK). The software generated 
LDL and HDL subclass profiles, from which it was possible to measure the relative 
distance of migration of the highest peak of the LDL and HDL bands on the basis of 
their Relative front (Rf). For HDL (4/30%), the Rfs for HDL subclasses were 
measured relative to albumin (Rf=1.0), which was clearly resolved at the end of the 
gel. The percentage areas under the subclass profile (%AUCB) for specific HDL 
subclasses, were calculated according to a previously described classification of 
these HDL particles on 4/30% gels (Fig. 5.2) [395]. The HDL2 subclass consists of 
HDL2a and HDL2b, the HDL3 subclass of HDLsa, HDLsb and HDLsc. Since there was no 
albumin for LDL, the end of the 2/16% gel (Rf=1.0) was used as a point of reference 
to determine Rfs. There are no commercially available high molecular weight markers 
for the determination of LDL particle size on a 2/16% gel. While high-molecular 
weight markers for the determination of HDL size are available, the non-linearity of
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pore distribution in the 4/30% gradient has been shown to confound the estimation of 
HDL particle size by this method [415]. it was not possible to determine the inter- and 
intra-variance associated with GGE method, due to a constraint on the amount of 
plasma that was available for this analysis.
Figure 5.2: Rf intervals for HDL subciasses from GGE.
2b 2a 3a 3b 3c
#
Rf intervals 1:0.445-0.627; 2:0.627-0.712; 3:0.712-0.781; 4:0.781-0.845; 5:0.845- 
0.960. Adapted from Berkeley HeartLab Reference Manual [416].
II) Plasma small dense LDL-Cholesterol (sdLDL-C) measurement
Plasma sdLDL-G was quantified by a commercially available precipitation method 
(Randox Laboratories Ltd) on the ILab 650. This assay consists of two steps, and is 
based on the selective precipitation of lipoproteins by surfactants, coupled with the 
enzymatic detection of cholesterol in the lipoproteins remaining in solution. The 
biochemical principle of the assay is as follows:
Step 1
Chylomicrons, VLDL, IDL, — CHE & CO ^ Cholestenone + Fatty acid 4- H2O2
LDL and HDL ,
catalase
2 H2O2------------------------^  2H2O 4- O2
Step 2
CHE & CO
sdLDL-C--------------------- ► Cholestenone 4-  Fatty acid 4-  H2O2
POD
2 H2O2 4-  4-aminoantipyrine 4-  T O O S ---------------------- ► Purple-red colour 4 -  4H2O
(CHE, cholesterol esterase; CO, cholesterol oxidase; TOOS, N-Ethyl-N-(2-hydroxy-3- 
sulfopropyl)-3-methylaniline; POD, peroxidase)
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The absorbance of the purple-red colour was measured bichromatically at 600 - 700 
nm. Pre-calibrations for each standard and specific quality controls (QCs) were 
performed before and after the test. Two QCs were applied (low and high) for each 
test. Assays were only performed if the QCs were within accepted confidence limits, 
as defined by the manufacturer. All samples were analysed within one analysis. The 
intra-assay CVs before the test were 1.6% and 1.7% for the low and high QCs, 
respectively. The intra-assay CVs after the test were 1.4% and 1.0% for the low and 
high QCs, respectively.
Ill) Measurement of plasma apollpoprotelns (apo) Oil, Oil! and E
Plasma apos CH, CHI and E were measured on the ILab 650 by commercially 
available, immuno-precipitation assays. The absorbance was measured 
turbidimetrically at a wavelength of 340 nm. Pre-calibrations for each standard and 
specific quality controls (QCs) were performed prior to each test. All samples were 
analysed within a single batch. The intra-assay CVs for apo CH was 1.1% and 2 .1%  
for low and high QCs, respectively. The intra-assay CVs for apo CHI was 0.9% and 
0.1% for low and high QCs, respectively. The intra-assay CVs for apo E was 0.5% for 
low and 1.8% for high QCs.
5.5.3 Statistical analyses
All statistical analyses were performed using SPSS (version 18 SPSS for Windows, 
Chicago, USA). The normality of data distribution, homogeneity of the variance and 
transformation of the data for plasma sdLDL-C, apo CH and apo CHI were performed 
as previously described (Chapter 3). A paired T-test or Wilcoxon Sign Rank Test 
(non-parametric alternative) were used to test for differences over time (pre vs post 
intervention), and the difference between diet treatments (high vs low sugar diet) over 
time was tested using Analysis of Variance (ANOVA) or Kruskal-Wallis (non- 
parametric alternative). Independent T-Test or Mann-Whitney (non-parametric 
alternative) was used to test the difference between liver fat groups. Analysis of 
Covariates (ANCOVA) was used to test the difference between liver fat groups, whilst 
controlling for significantly associated covariates. Results are represented as box- 
and-whisker plots, that show medians and interquartile ranges (Fig. 3.3). The level of 
statistical significance was set at p<0.05.
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5.6 Results
5.6.1 Effects of high and low sugar diets on the distribution of LDL
subclasses
LDL subclasses were separated on both 2/16% and 4/30% gels (Fig. 5.3 (A) and (B), 
and the relative migration distance, as determined by Rf, was measured on each gel. 
Figures 5.4 - 5.7 show representative examples of scans of LDL subclasses on both 
gels, for each diet. The data on LDL subclasses from the two gels was not 
comparable because samples from the participants were not matched between gels. 
The mean particle size of LDL decreased (increased Rf) after the high sugar diet 
(2/16% gel, p<0.05) and increased (decreased Rf) after the low sugar diet on both 
gels (Table 5.1 A and 5.1 B).
Figure 5.3 (A): The 2/16% polyacrylamide gel
LD L 1
LDL 2
LDL 3
LD L 4
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Figure 5.3 (B): The 4/30% polyacrylamide gel
LDL 1 
LDL 2 
LDL 3 
LDL 4
a
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Figure 5.4: Distribution of LDL subclasses before and after the high sugar diet.
Pre high sugar diet 
Post high sugar diet
.A
I
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□ 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.1
Example of representative scans for the migration distance of peak Rfs of LDL 
particle on 2/16% gel, before and after the high sugar diet. An increase in migration 
distance from 0.831 (pre high sugar diet) to 0.847 (post high sugar diet) (016).
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Figure 5.5: Distribution of LDL subclasses before and after the low sugar diet.
Pre low sugar diet
Post low sugar diet
>6 *
0 0.1 0.2 0.3 0.4 0..5 0.6 0.7 0.8 0.9 1.1
Example of representative scans for the migration distance of peak Rfs of LDL 
particle on 2/16% gel. A reduction in migration distance from 0.893 (pre low sugar 
diet) to 0.851 (post low sugar diet) (014).
Figure 5.6: Distribution of LDL (and HDL) subclasses before and after the high 
sugar diet.
Î ^
Pre high sugar diet 
Post high sugar diet
i
0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.1
Example of representative scans for the migration distance of peak Rfs of LDL 
particle on 4/30% gel. An increase in migration distance from 0.132 (pre high sugar 
diet) to 0.148 (post high sugar diet) (015).
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Figure 5.7: Distribution of LDL (and HDL) subclasses before and after the low 
sugar diet.
1^ ^ ^  Pre low sugar diet
Post low sugar diet
%888g
0  0 .1  0 .2  0 .3  0 .4  0 .5  0 .6  0 .7  0 .8  0 .9  1.i
Example of representative scans showing the migration distance of peak Rfs of LDL 
and HDL particles on 4/30% gel. A reduction in migration distance from 0.169 (pre low 
sugar diet) to 0.145 (post low sugar diet) (015).
Table 5.1(A): Mean peak Rfs of LDL from 2/16% gel on high and low sugar diets
Pre
High sugar diet (n=11)
Post Change
Low sugar diet (n=11)
Pre Post Change
0 .908±0 .016  0 .913±0 .015  +0.006±0 .002* 0 .896±0 .019  0 .895±0 .020  -0.001 ±0 .002
Table 5.1(B): Mean peak Rfs of LDL from 4/30% gel on high and low sugar diets
Pre
High sugar diet (n=23)
Post Change
Low sugar diet (n=23)
Pre Post Change
0.137±0 .004  0 .139±0 .004  +0.001 ±0.002 0 .134±0 .006  0 .132±0 .006  -0 .003±0 .007
Rf, relative front; HS, high sugar diet; LS, low sugar diet. *Change from baseline (p<0.05).
5.6.2 The migration distance of LDL particles in groups with moderately 
raised and low liver fat
The migration distance of LDL on the 2/16% gel increased and decreased after the 
high and low sugar diets, respectively, in both liver fat groups, but increased 
significantly in the moderately raised liver fat group after the high sugar diet (p<0.05) 
(Table 5.2A). On the 4/30% gel, the mean migration distance (Rf) of LDL decreased 
and increased after the high sugar diet, in the low and moderately raised liver fat 
groups, respectively, and decreased after the low sugar diet in both liver fat groups 
None of these changes reached statistical significance (Table 5.2B).
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Table 5.2(A): Mean peak Rf of LDL from 2/16% gel in liver fat groups
< 4.2% (n=6) > 4.2% (n=5)
Pre Post Change Pre Post Change
HS
LS
0.907±0.028
0.909±0.024
0.910±0.024
0.907±0.026
+0.003±0.004 
-0.001 ±0.004
0.908±0.018
0.882±0.032
0.917±0.018
0.880±0.033
+0.009±0.003* 
-0 . 0 0 1  ±0 . 0 0 2
Table 5.2(B): Mean peak Rf of LDL from 4/30% gel in liver fat groups
<4.2% (n=11) >4.2% (n=12)
Pre Post Change Pre Post Change
HS
LS
0.137±0.004
0.137±0.005
0.135±0.005
0.135±0.05
-0 . 0 0 1  ±0 . 0 0 2  
-0.002±0.003
0.138±0.006
0.132±0.01
0.142±0.005
0.129±0.01
+0.004±0.002
-0.003±0.014
Rf, relative front; HS, high sugar diet; LS, low sugar diet. *Change from baseline (p<0.05).
5.6.3 Effects of high and low sugar diets on the distribution of HDL 
subclasses
HDL subclasses were separated on 4/30% gels (Fig. 5.4B) and classified by Rf 
intervals as previously described (Figs. 5.10-5.13) [395, 416]. Overall, there was no 
significant effect of the diets on the distribution of HDL subclasses, but there were 
consistent reductions in the relative abundance of HDL2 and HDL2b subclasses after 
the high sugar diet, and consistent reductions in small HDL (HDL3  and HDL2a+3a+sb+3c) 
after the low sugar diet (Table 5.3). The distribution of HDL particle size based on Rf 
was assessed on 4/30% gradient gel (Figs. 5.8 and 5.9). The particle size decreased 
(n.s.) and increased (by 1.4%, p<0.05) after the high and low sugar diets, respectively 
(Table 5.3).
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Figure 5.8: Distribution of HDL subclasses before and after the high sugar diet.
Pre high sugar diet -  
Post high sugar diet
0 . 3 0 . 4 0 . 5 1 .10 0.1 0.2 0.6 0 . 7 0.8 0 . 9
Example of scans showing migration distance of peak Rfs of HDL particles on 4/30%  
gel. An increase in migration distance from 0.680 (pre high sugar diet) to 0.699 (post 
high sugar diet) (016).
Figure 5.9: Distribution of HDL subclasses before and after the low sugar diet.
Pre low sugar diet
Post low sugar diet
0 0.1 0.2 1.10 .3  0 .4  0 .5  0 .6  0 .7  0 .8  0 .9
Example of representative profile showing migration distance of peak Rfs of HDL 
particles on 4/30% gel. A reduction in migration distance from 0.718 (pre low sugar 
diet) to 0.704 (post low sugar diet) (008).
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Table 5.3: Mean percentage areas under HDL subclass profile and peak Rf of HDL particles 
before and after the high and low sugar diet (n=20)
%AUCB High sugar diet Low sugar diet
Pre Post Change Pre Post Change
HDL2 61.2±1.6 60.8±1.7 -0.5±1.1 59.8±1.5 61.011.5 + 1.2±1.0
HDL3 38.8±1.6 39.2±1.7 +0.5±1.1 40.311.5 39.011.5 -1.2±1.0
HDL2b 34.5±1.7 34.4±1.5 -0.1±1.2 33.711.6 35.611.5 +2.0±1.1
H D L2a+3a+3b+3c 66.5±1.7 65.6±1.5 0.1±1.2 66.311.6 64.411.5 -2.0±1.1
Peak Rf 0.71 ±0.01 0.72±0.00 +0.01 ±0.01 0.7210.00 0 .7 0 l0 .0 f -0.01 ±0.01*
Rf, relative front. Peak Rf, n=23. "Change from baseline (p<0.05); ^Difference between diets 
(p<0.05).
5.6.4 Distribution of HDL subclasses in groups with low and moderately 
raised liver fat, after the high and low sugar diets
There was no significant difference in the distribution of HDL subclasses between 
liver fat groups, after both diets, as measured by area under the HDL subclass 
profiles (Figs. 5.10-5.13). However, the group with moderately raised liver fat showed 
a greater decrease in large HDL subclasses (HDL2 and HDL2b) and small HDL 
subclasses (HDL3 and HDL2a+sa+3b+3c) after the high and low sugar diets, respectively, 
relative to the low liver fat group (Table 5.4). There was no significant difference in 
particle size distribution of HDL particles, after both diets, between the two liver fat 
groups (Table 5.4).
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Figure 5.10: An example of the distribution of HDL subclasses profiles in a 
moderately raised liver fat participant before and after the high sugar diet.
HDL3Ü HDL3CHDL2a ; HDL3aHDL2b
0 0.1 P,;2, .^,.0.3 0.4 0.5 0.6 0.7 0.8 0.9 1
^ 0 #  P re  h ig h  s u g a r  d ie t
^ ^ 0  P o s t h ig h  s u g a r  d ie t
A  re d u c t io n ; in HDL2 fro m  5 9 .6 %  to  5 0 .8 % ; a n d  an  in c re a s e  in  HDL3 fro m  4 0 .4 %  to  
4 9 .2 %  (0 0 8 ).
Figure 5.11: An example of the distribution of HDL subclasses profiles in a 
moderately raised liver fat participant before and after the low sugar diet.
HDL2b. HDL2a HDL3C
0 0.1 0,2 .0.3 0.4 0.5 0.6 0.7 0.8 0.9 1
^ ^ 0  P re  lo w  s u g a r  d ie t
P o s t lo w  s u g a r  d ie t
rV W W V ^  ^
A  re d u c t io n ; in HDL3 fro m  4 7 .0 %  to  3 7 .8 % ; a n d  an  in c re a s e  in HDL2 fro m  5 3 .0 %  to  
6 2 .2 %  (0 0 7 ).
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Figure 5.12: An example of the Distribution of HDL subclasses in a low liver fat 
participant after the high sugar diet.
I
M l
0.1 0.2 0.3 0.4 0.5 0.6 0.7
Pre high sugar diet 
Post high sugar diet
0.9 1
Example of scans showing migration distance of peak Rfs of HDL particles on 4/30%  
gel. Figure shows a reduction; in HDL2b from 46.27% to 36.11%; and an increase in 
HDL2a+3a+3b+3cfrom 53.72% to 63.9% (016).
Figure 5.13: An example of the distribution of HDL subclasses in a low liver fat 
participant after the low sugar diet.
HDL2b HDL2a HDL3a
0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1
Pre low sugar diet 
Post low sugar diet
Example of scans showing migration distance of peak Rfs of HDL particles on 4/30%  
gel. Figure shows a reduction; in HDL2a+3a+sb+3c from 64.35% to 63.43%; and an 
increase in HDL2b from 35.65% to 36.56% (016).
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Table 5.4: HDL subclasses and peak Rfs in two liver fat groups
Pre
<4.2%(n=10)
Post Change Pre
>4.2%(n=10)
Post Change
HDL2(%) HS 65.0±1.9 64.1 ±1.9 -0.9±1.4 57.4±1.9 57.4±2.4 -0.0±1.7
LS 64.3±1.9 63.3±2.2 ■1.0±1.0 55.2±1.3 58.7±1.7 +3.4±1.5
HDL3(%) HS 35.0±1.9 35.9±1.9 +0.9±1.4 42.6±1.9 42.6±2.4 +0.0+1.7
LS 35.7±1.9 36.7±2.2 +1.0+1.0 44.8±1.3 41.3±1.7 -3.4+1.5
HDL2b(%) HS 37.9±2.2 37.7±1.7 -0.2±1.7 31.1 ±2.0 31.2±2.1 +0.1 ±1.6
LS 38.6±1.8 38.6±1.9 -0.03±1.5 28.8±1.3 32.7±1.8 +3.9±1.6
H D L2a+3a+3b+3c HS 62.1 ±2.2 62.3±1.7 +0.2±1.7 68.9±2.0 68.8±2.1 -0.1 ±1.8
(%) LS 61.4±1.8 61.4±1.9 +0.03±1.5 71.2±1.3 67.3±1.8 -4.0±1.6
Peak Rfs HS 0.69±0.01 0.72±0.01 +0.02±0.01 0.72±0.00 0.72±0.01 0.00±0.00
LS 0.72±0.01 0.71 ±0.00 O.OOiO.01 0.72±0.00 0.70±0.01 -0.02±0.01
HS, High sugar diet; LS; Low sugar diet; Rfs, relative fronts.
5.6.5 Effect of high and low sugar diets on plasma small, dense LDL-C in 
the total cohort, as measured by a commercially available 
precipitation assay
Plasma small, dense LDL-C (sdLDL-C) decreased markedly by 16.5% after the low 
sugar diet (p<0.001) (Fig. 5.13). There was no significant difference in plasma sdLDL- 
0  after the high sugar diet. Plasma sd LDL-C was significantly higher after the high 
sugar relative to the low sugar diet (21%, p<0.01) (Fig. 5.14). Plasma sdLDL-C was 
also associated with both plasma apo B and plasma TAG, after both diets (p<0.01).
5.6.6 Effect of high and low sugar diets on plasma small, dense LDL-C in 
groups with low and moderately raised liver fat
Plasma sd LDL-C decreased significantly after the low sugar diet in the groups with 
moderately raised liver fat (-40%, p<0.05), and low liver fat (-26%, p<0,05) (Fig. 5.15). 
Plasma sdLDL-C also decreased after the high sugar diet in both liver fat groups, 
though these changes did not reach statistical significant. In addition, there was a 
significant difference in post-diet plasma sdLDL after the low sugar diet between the 
liver fat groups, after the adjustment for baseline values (p<0.05).
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Figure 5.14: Plasma sdLDL-C concentrations before and after the high and low
sugar diets in total cohort (n=25).
4n
^  34
g  
Ü 
Ji
3  2  ^
gc
(A
1 -
0 -
cm  High sugar diet 
CZI Low sugar diet
Pre Post Pre Post
Data are medians with inter-quartiie ranges. Statistical tests were performed using 
geometric values. *Change from baseline (p<0.01). ""Difference between diets 
adjusted for baseline values (p<0 .01).
196
Figure 5.15: Plasma sdLDL-C concentrations before and after the high and low
sugar diets in groups with low and moderately raised liver fat.
4-1
d  34
E
o
Jj 
3 2
gc
CD
T3
(0 1 -
0-
nzi P re  H igh s u g a r d ie t 
□H ] P o s t H igh s u g a r d ie t 
C Z I P re  Low  s u g a r d ie t 
□OH P o s t Low  s u g a r d ie t
< 4 .2 % > 4 .2 %
D a ta  a re  m e d ia n s  w ith  in te r -q u a r t i ie  ra n g e s . < 4 .2 % , lo w  l iv e r  fa t  g ro u p  (n = 1 3 ) ; > 4 .2 % , 
m o d e ra te ly  ra is e d  liv e r  fa t  g ro u p  (n = 1 2 ). S ta t is t ic a l te s ts  w e re  p e r fo rm e d  u s in g  
g e o m e tr ic  v a lu e s . "C h a n g e s  fro m  b a s e lin e  (p < 0 .0 5 ). " "D if fe re n c e  b e tw e e n  l iv e r  fa t  
g ro u p s  (p < 0 .0 5 ).
5.6.7 Effect of high and low sugar diets on plasma apos CH and CHI in the 
total cohort (n=25)
P la s m a  a p o  CH in c re a s e d  a n d  d e c re a s e d  a fte r  th e  h ig h  a n d  lo w  s u g a r  d ie ts , (n .s .; 
F ig . 5 .2 0 , Appendix 19) re s p e c t iv e ly , w h e re a s , p la s m a  a p o  CHI d e c re a s e d  a n d  
in c re a s e d  a fte r  th e  h ig h  a n d  lo w  s u g a r  d ie ts , re s p e c t iv e ly , (n .s .) (F ig . 5 .1 6 ) . P la s m a  
a p o  CHI w a s  s ig n if ic a n tly  g re a te r  a fte r  th e  h ig h  s u g a r  d ie t re la t iv e  to  th e  lo w  s u g a r  
d ie t, b u t o n ly  a fte r  a d ju s tm e n t fo r  b a s e lin e  v a lu e s  (p < 0 .0 5 ).
T h e re  w a s  no  s ig n if ic a n t c h a n g e  in th e  ra t io  o f p la s m a  a p o  C IL C H I a fte r  b o th  d ie ts . 
O v e ra ll,  th e  ra tio  d e c re a s e d  a n d  in c re a s e d  a fte r  th e  h ig h  a n d  lo w  s u g a r  d ie t, 
re s p e c t iv e ly  (T a b le  5 .5 ).
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Figure 5.16: Plasma apo Cili concentrations before and after high and low
sugar diets in the total cohort (n=25).
25i
p
20-
Ü  1 5 -
o 10-
Q.
P re P o s t P re P o s t
[ = ]  H igh  s u g a r  d ie t 
□  L o w  s u g a r  d ie t
D a ta  a re  m e d ia n s  w ith  in te r -q u a r t i ie  ra n g e s . S ta t is t ic a l te s ts  w e re  p e r fo rm e d  o n  
u n tra n s fo rm e d  d a ta . * * D if fe re n c e  b e tw e e n  d ie ts  w e re  a d ju s te d  fo r  b a s e lin e  v a lu e s  
(p < 0 .0 5 ).
5.6.8 Effect of high and low sugar diets on plasma apos Cii and Clii in 
groups with low and moderately raised liver fat
T h e re  w e re  s ig n if ic a n t d if fe re n c e s  in p la s m a  a p o  C II b e fo re  a n d  a fte r  th e  lo w  s u g a r  
d ie ts  a n d  a fte r  th e  h ig h  s u g a r  d ie t  b e tw e e n  l iv e r  fa t  g ro u p s  (p < 0 .0 5 )  (F ig . 5 .1 8 ) . A f te r  
a d ju s t in g  fo r  b a s e lin e  v a lu e s , p la s m a  a p o  C II, re m a in e d  s ig n if ic a n t ly  d if fe re n t  
b e tw e e n  th e  l iv e r  fa t  g ro u p s  a fte r  th e  h ig h  s u g a r  d ie t, (p < 0 .0 5 ). P la s m a  a p o  CHI w a s  
a ls o  s ig n if ic a n t ly  g re a te r  in  th e  g ro u p  w ith  m o d e ra te ly  h ig h  liv e r  fa t  re la t iv e  to  th e  lo w  
l iv e r  fa t  g ro u p  a fte r  th e  h ig h  s u g a r  d ie t. T h is  f in d in g  w a s  in d e p e n d e n t o f b a s e lin e  
v a lu e s  (p < 0 .0 5 ) (F ig . 5 .1 7 ).
T h e re  w a s  no  s ig n if ic a n t d if fe re n c e  in  c h a n g e s  o f th e  ra t io  o f a p o  C IL C H I a f te r  b o th  
d ie ts , th o u g h , th e re  w e re  c o n s is te n t re d u c t io n s  in th is  ra t io  a f te r  th e  lo w  s u g a r  d ie t  
(T a b le  5 .5 ) . W h ile  th e re  w a s  n o  c h a n g e  in th is  ra t io  a f te r  th e  h ig h  s u g a r  d ie t  in  th e  lo w  
l iv e r  fa t  g ro u p , th e  p la s m a  a p o  C IL C H I ra t io  d e c re a s e d  a fte r  th e  h ig h  s u g a r  d ie t  in  th e  
m o d e ra te ly  ra is e d  liv e r  fa t  g ro u p  (3 % , n .s .).
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Figure 5.17: Plasma apo CI! concentrations before and after high and low sugar
diets in groups with low < 4.2% n=13 and moderately raised liver fat > 4.2%
n=12).
CL
<4.2% > 4 .2 %
d  P re  H igh s u g a r d ie t 
nm  P o s t H igh s u g a r d ie t 
d  P re  L o w  s u g a r d ie t 
m n  P o s t L ow  s u g a r d ie t
D a ta  a re  m e d ia n s  w ith  in te r -q u a r t i ie  ra n g e s . "D if fe re n c e  b e tw e e n  l iv e r  fa t  g ro u p s  
(p < 0 .0 5 ). " "D if fe re n c e  b e tw e e n  liv e r  fa t g ro u p s  w e re  a d ju s te d  fo r  b a s e lin e  v a lu e s  
(p < 0 .0 5 ).
Figure 5.18: Plasma apo Clii before and after high and low sugar diets in 
groups with low < 4.2% n=13 and moderately raised liver fat > 4.2% n=12).
25-1
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d  P re  H igh s u g a r d ie t 
CUD P o s t H igh s u g a r  d ie t 
d  P re  L o w  s u g a r d ie t 
CUD P o s t L o w  s u g a r  d ie t
<4.2% >4.2%
D a ta  a re  m e d ia n s  w ith  in te r -q u a r t i ie  ra n g e s . S ta t is t ic a l te s ts  w e re  p e r fo rm e d  u s in g  
u n tra n s fo rm e d  d a ta . "D if fe re n c e  b e tw e e n  liv e r  fa t  g ro u p s  (p < 0 .0 5 ) . " "D if fe re n c e  
b e tw e e n  liv e r  fa t g ro u p s  a d ju s te d  fo r  b a s e lin e  v a lu e s  (p < 0 .0 5 ).
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Table 5.5: Plasma apo CII/CIII ratio for the total cohort, and two liver fat 
groups, at baseline and after the high and low sugar diets
High sugar diet Low sugar diet
Pre Post Pre Post
T o ta l (n = 2 0 ) 0 .7 2 ± 0 .0 4 0 .7 0 ± 0 .0 3 0 .7 2 ± 0 .0 4 0 .7 5 ± 0 .0 4
L iv e r  fa t  <  4 .2 %  (n = 1 0) 0 .6 8 ± 0 .0 7 0 .6 8 ± 0 .0 5 0 .7 0 ± 0 .0 6 0 .7 4 ± 0 .0 7
L iv e r  fa t  >  4 .2 %  (n = 1 0 ) 0 .7 5 ± 0 .0 4 0 .7 3 ± 0 .0 4 0 .7 3 ± 0 .0 5 0 .7 6 ± 0 .0 4
5.6.9 Effect of high and low sugar diets on piasma apo E in the totai cohort 
(n=25)
P la s m a  a p o  E d e c re a s e d  s ig n if ic a n t ly  b y  1 3 %  a fte r  th e  le w  s u g a r  d ie t  (p < 0 .0 5 ) . A fte r  
a d ju s tin g  fo r  b a s e lin e  v a lu e s , th e  p la s m a  a p e  E w a s  s ig n if ic a n t ly  h ig h e r  a fte r  th e  h ig h  
s u g a r  d ie t  re la tiv e  tc  th e  le w  s u g a r  d ie t (p < 0 .0 5 ) (F ig . 5 .1 9 ) .
5.6.10 Effect of high and low sugar diets on plasma apo E concentration in 
groups with iow and moderateiy raised iiver fat
D e s p ite  e v id e n c e  c f  c o n s is te n t in c re a s e s  a n d  d e c re a s e s  in  p la s m a  a p e  E in  b o th  l iv e r  
fa t  g ro u p s  a fte r  th e  h ig h  a n d  lo w  s u g a r  d ie ts , re s p e c t iv e ly , th e re  w e re  no  s ig n if ic a n t  
d if fe re n c e s  in p la s m a  a p o  E in  re s p o n s e  to  th e  tw o  d ie ts , e ith e r  b e tw e e n  o r  w ith in  
th e s e  g ro u p s  (F ig . 5 .2 1 , Appendix 19).
Figure 5.19: Piasma apo E concentrations before and after high and low sugar 
diets in the totai cohort (n=25).
■5 4 -
.9 - 2-
Pre P ost P re P ost
a  H igh su g a r d ie t 
EZ3 Low  su g a r d ie t
D a ta  a re  m e d ia n s  w ith  in te r -q u a r t i ie  ra n g e s . "C h a n g e  fro m  b a s e lin e  (p < 0 .0 5 ) . 
" "D if fe re n c e  b e tw e e n  d ie ts  w e re  a d ju s te d  fo r  b a s e lin e  v a lu e s  (p < 0 .0 5 ) .
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5.6.11 Relationships between LDL and HDL subciasses, sdLDL-C, apo Cii, 
apo Clii and apo E, apo B and HDL-C with piasma TAG
T o  e x a m in e  th e  p o s s ib il ity  o f  a  d if fe re n tia l re s p o n s iv e n e s s  to  th e  h ig h  s u g a r  d ie t  in  
p a r t ic ip a n ts  w ith  a n d  w ith o u t m o d e ra te ly  ra is e d  p la s m a  T A G , th e  c o h o r t  w a s  
s u b d iv id e d  in to  tw o  s u b g ro u p s ; p la s m a  T A G  <  1 .5 m m o l/L  a n d  ^  1 .5 m m o l/L  a t 
b a s e lin e  (T a b le  5 .6 ) . P la s m a  a p o  C II a n d  GIN w e re  s ig n if ic a n t ly  d if fe re n t b e tw e e n  th e  
s u b g ro u p s  (b y  3 .6 5 m g /d L  a n d  4 .9 8 m g /d L , p < 0 .0 1 ). T h e re  w a s  no  s ig n if ic a n t 
d if fe re n c e  in  o th e r  v a r ia b le s  b e tw e e n  th e s e  s u b g ro u p s . H o w e v e r , th e re  w a s  a  
c o n s is te n t tre n d  o f a  h ig h e r  p la s m a  a p o  B , p la s m a  in s u lin  a n d  p la s m a  a p o  E a n d  th e  
a b u n d a n c e  o f s m a ll H D L  p a r t ic le s  in  th e  s u b g ro u p  w ith  p la s m a  T A G  > 1 .5 m m o l/L .
Table 5.6: Plasma lipoproteins and apolipoproteins in subgroups with and 
without moderateiy raised piasma TAG before the high sugar diet
<  1 .5 m m o l/L > 1 .5 m m o l/L p -v a lu e
M e a n S E M M e a n S E M
P la s m a  a p o  B (g /L ) 1 .0 4 0 .0 5 1 .1 3 0 .0 8 n .s .
P la s m a  in s u lin  (p m o l/L ) 1 1 0 .4 0 9.21 1 2 5 .8 0 1 6 .3 5 n .s .
P la s m a  s d L D L -C  (m m o l/L ) 1 .0 3 0.1 1 .5 4 0 .2 4 n .s .
P la s m a  H D L -C  (m m o l/L )* 1 .1 6 0 .0 7 1 .2 5 0 .1 0 n .s .
HDLzb (% ) 3 5 .91 1 .9 4 3 2 .2 4 2 .3 6 n .s .
H D L2a+3a+3b+3c ( % ) 6 4 .0 9 1 .9 4 6 7 .7 6 2 .3 6 n .s .
H D Ls (% ) 62 .21 1 .9 9 5 8 .5 9 2 .9 7 n .s .
H D Ls (% ) 3 7 .7 9 1 .9 9 4 1 .4 2 2 .9 7 n .s .
L D L  m ig ra t io n  d is ta n c e  (R f) 0 .1 4 0 .0 0 4 0 .1 4 0 .01 n .s .
H D L  m ig ra t io n  d is ta n c e  (R f) 0 .7 2 0 .0 0 5 0 .7 2 0.01 n .s .
P la s m a  a p o  E (m g /d L )* 2 .8 6 0 .1 4 3 .5 0 0 .4 2 n .s .
P la s m a  a p o  C II (m g /d L )* 5 .7 8 0 .4 4 9 .4 3 0 .9 5 * * 0.000
P la s m a  a p o  CHI (m g /d L )* 8 .1 8 0 .5 7 1 3 .1 6 1 .3 9 * * 0.002
P la s m a  a p o  C IL C III ra tio 0 .6 8 0 .0 4 0 .7 4 0 .0 4 n .s .
^ S ta t is t ic a l te s ts  w e re  p e r fo rm e d  u s in g  g e o m e tr ic  
s u b g ro u p s  (p < 0 .0 5 ).
v a lu e s . * * D if fe re n c e  b e tw e e n
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5.7 Discussion
T h is  s tu d y  a im e d  to  d e te rm in e  th e  e ffe c ts  o f tw o  e x p e r im e n ta l d ie ts  h ig h  a n d  lo w  in 
s u g a rs  o n  th e  d is tr ib u tio n  o f L D L  a n d  H D L  s u b c la s s e s , p la s m a  c o n c e n tra t io n  o f 
s d L D L -C , a p o  C II, a p o  CHI a n d  a p o  E. It a ls o  a im e d  to  d e te rm in e  w h e th e r  th e s e  
e ffe c ts  w e re  in f lu e n c e d  b y  th e  p e rc e n ta g e  o f l iv e r  fa t.
A  h ig h  s u g a r  d ie t  h a s  b e e n  a s s o c ia te d  w ith  a n  e le v a te d  c o n c e n tra t io n  o f p la s m a  T A G  
re d u c e d  p la s m a  H D L -C , a n d  th e  fo rm a tio n  o f s d L D L , e s p e c ia lly  w h e n  p la s m a  T A G  
e x c e e d s  1 .5 m m o l/L  [2 7 , 1 5 8 , 3 9 4 ]. In th e  p re s e n t s tu d y , L D L  a n d  H D L  s u b c la s s e s  
w e re  s e p a ra te d  o n  2 /1 6 %  a n d  4 /3 0 %  p o ly a c ry la m id e  g e ls  u s in g  G G E . T h e s e  g e ls  
c o n s is te d  o f a  g ra d ie n t o f d e c re a s in g  p o re  s iz e , w h ic h  e ffe c t iv e ly  fu n c t io n s  a s  a  
m o le c u la r  s ie v e , s o  th a t s m a lle r  l ip o p ro te in s  m ig ra te  fu r th e r  in to  th e  g e l p ro d u c in g  a  
h ig h e r  re la t iv e  f ro n t (R f) . O v e ra ll,  th is  in v e s tig a t io n  p ro d u c e d  s o m e  e v id e n c e  to  
s u p p o r t  th e  p o te n t ia l ly  a d v e rs e  e ffe c t o f a  h ig h  s u g a r  d ie t  o n  L D L  a n d  H D L  
s u b c la s s e s . T h e re  w a s  e v id e n c e  to  s u g g e s t th a t th e  h ig h  s u g a r  d ie t  d e c re a s e d  L D L  
p a r t ic le  s iz e . T h is  f in d in g  is  in  a g re e m e n t w ith  p re v io u s  f in d in g s  o f K ra u s s  &  D re o n 's  
[4 0 3 ] a n d  o th e r  c lin ic a l t r ia ls  b y  D re o n  et al. [1 6 5 -1 6 7 ], w h ic h  s h o w e d  a  s h if t  in  th e  
d is tr ib u t io n  o f L D L  s u b c la s s e s  fro m  p a tte rn  ‘A ’ ( la rg e , l ip id -e n r ic h e d  p a r t ic le s )  to  
p a tte rn  ‘B ’ (s m a ll, l ip id -d e p le te d  p a r t ic le s )  fo llo w in g  a  lo w  fa t /h ig h  C H O  d ie t. In  th e  
p re s e n t s tu d y , th e  lo w  s u g a r  d ie t  w a s  a s s o c ia te d  w ith  a n  in c re a s e  in  L D L  p a r t ic le  
s iz e . T h is  re s u lt  is  c o n s is te n t w ith  o th e r  s tu d ie s  th a t s h o w e d  a  p o s it iv e  e ffe c t o f  a  lo w  
C H O  d ie t (<  3 0 % E ) in in c re a s in g  L D L  p a r t ic le  s iz e  [4 1 7 , 4 1 8 ]. M o re o v e r , in  th e  
p re s e n t s tu d y , th e re  w a s  e v id e n c e  th a t th e  re d u c t io n  in  L D L  p a r t ic le  s iz e  a f te r  th e  
h ig h  s u g a r  d ie t w a s  g re a te r  in  th e  g ro u p  w ith  m o d e ra te ly  ra is e d  l iv e r  fa t . T h e s e  
f in d in g s  p ro v id e  fu r th e r  s u p p o r t  fo r  th e  id e a  th a t a  h ig h  s u g a r  d ie t  p ro m o te s  th e  
re m o d e llin g  o f L D L  in to  s m a lle r  a n d  d e n s e r  p a rt ic le s . H o w e v e r, th e  m a g n itu d e  o f th e  
c h a n g e  in  L D L  p a r t ic le  s iz e  a fte r  th e  lo w  s u g a r  d ie t, w a s  u n re la te d  to  th e  p e rc e n ta g e  
o f l iv e r  fa t  a n d  p la s m a  T A G  a t s c re e n in g , a n  o b s e rv a t io n  th a t h a s  b e e n  re p o r te d  b y  
o th e rs  [6 2 ].
In a c c o rd a n c e  w ith  th e  re s u lts  fo r  L D L , th e  h ig h  s u g a r  d ie t  w a s  a ls o  a s s o c ia te d  w ith  a  
re d u c t io n  in  H D L  p a r t ic le  s iz e , a n d  th e  re la t iv e  a b u n d a n c e  o f th e  la rg e r, H D L 2 a n d  
H D L 2b s u b c la s s e s . T h e s e  f in d in g s  a re  c o n s is te n t w ith  th o s e  o f G o n e n  et ai. [4 1 9 ] w h o  
fo u n d  a  c o n s is te n t re d u c t io n  in H D L 2 m a s s  fo l lo w in g  a  v e ry  h ig h  C H O  d ie t,  a lth o u g h
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th e  in te rv e n t io n  in  th is  c a s e , e m p lo y e d  a  d ie t  th a t w a s  v e ry  h ig h  in  C H O  (>  8 0 % E ) 
th a t  w a s  n o t re p re s e n ta t iv e  o f a  fre e - l iv in g  s e tt in g  [4 1 9 ]. In  c o n tra s t, th e  lo w  s u g a r  d ie t  
in  th e  p re s e n t s tu d y  w a s  a c c o m p a n ie d  b y  a  d e c re a s e  in s m a ll HDL p a r t ic le s . In 
k e e p in g  w ith  th is , th e  lo w  s u g a r  d ie t  w a s  a ls o  a s s o c ia te d  w ith  a  re d u c t io n  in  HDL3 a n d  
HDL2a+3a+3b+3c a n d  an  in c re a s e  in  th e  la rg e r  HDL s u b c la s s e s  (HDL2 a n d  HDL2b). 
T h e s e  f in d in g s  a re  fu r th e r  s u p p o r te d  b y  W o o d  et al. [1 5 3 ] a n d  W e s tm a n  et al. [4 2 0 ] 
w h o  fo u n d  a  s ig n if ic a n t d e c re a s e  in  HDL p a r t ic le  s iz e  a s  m e a s u re d  b y  p ro to n  n u c le a r  
m a g n e t ic  re s o n a n c e  (N M R ) a n a ly s e r  a f te r  a  v e ry  lo w  C H O  d ie t (<  1 0 % E ).
T h e re  is  v e ry  lim ite d  e v id e n c e  in  th e  lite ra tu re  c o n c e rn in g  th e  in f lu e n c e  o f l iv e r  fa t  o n  
th e  c h a n g e s  in L D L  a n d  H D L  p a r t ic le  s iz e , in  re s p o n s e  to  d ie ta ry  s u g a rs  [1 6 9 , 4 2 1 , 
4 2 2 ]. T h e  im p a c t o f th e  p e rc e n ta g e  o f l iv e r  fa t  o n  H D L  s u b c la s s e s  in  th e  p re s e n t 
s tu d y  w a s  u n re m a rk a b le . T h e  m o d e ra te ly  ra is e d  l iv e r  fa t  g ro u p  e x p re s s e d  
c o n s is te n t ly  g re a te r  e ffe c ts  a fte r  th e  lo w  s u g a r  d ie t, a s  c o m p a re d  to  th e  lo w  l iv e r  fa t  
g ro u p , w ith  re s p e c t to  re d u c t io n s  in  s m a ll H D L  p a rt ic le s . H o w e v e r , th e re  w a s  no  
o v e ra ll d if fe re n c e  in  H D L  s u b c la s s  d is tr ib u t io n  b e tw e e n  th e  l iv e r  fa t  g ro u p s .
R e s e a rc h  to  d a te  h a s  te n d e d  to  fo c u s  o n  th e  e ffe c t o f h ig h  C H O /lo w  fa t  d ie ts , o n  
lip o p ro te in s  s u b c la s s e s  [1 6 5 -1 6 7 , 4 0 3 , 4 2 3 ]. A s  s u c h , th e re  is  re la t iv e ly  l it t le  e v id e n c e  
fo r  th e  e ffe c ts  o f d ie ta ry  s u g a rs . It is  a rg u a b le , th a t s in c e  th e  g e n e ra l p o p u la t io n  h a s  a  
m o d e ra te  c o n s u m p t io n  o f to ta l C H O , b u t a  h ig h e r  p ro p o r t io n  o f s u g a r , th is  m a y  re s u lt  
in  v a r ia b le  e ffe c ts  o n  p la s m a  lip o p ro te in s , re la t iv e  to  th e  h ig h e r  p ro p o r t io n  o f s ta rc h . 
N e v e rth e le s s , w h ils t  th e  p re s e n t s tu d y  p ro d u c e d  a  p re d ic ta b le  o u tc o m e  in  te rm s  o f 
th e  c h a n g e s  in  L D L  a n d  H D L  s u b c la s s e s  fo l lo w in g  th e  d ie ts , th e  c h a n g e s  w e re  o n ly  
s m a ll, a n d  in  m a n y  c a s e s  in s ig n if ic a n t, p e rh a p s  d u e  to  th e  s m a ll s a m p le  s iz e . In 
a d d it io n , th e  a n a ly s is  w a s  p e r fo rm e d  on  s to re d  p la s m a  (-8 0 °C  fo r  a t le a s t 3  m o n th s ) ,  
w h ic h  c a n  a d v e rs e ly  a f fe c t th e  s tru c tu ra l in te g r ity  o f lip o p ro te in s , e s p e c ia lly  L D L . T h e  
g e n e ra lly  p o o r  re s o lu t io n  o f L D L  o n  b o th  g ra d ie n t g e ls , l im ite d  th e  a m o u n t o f  re l ia b le  
d a ta  o n  L D L  s u b c la s s  d is tr ib u t io n  e s p e c ia l ly  o n  th e  2 /1 6 %  g e l. It is  p o s s ib le  th a t  th e  
d a ta  p ro d u c e d  b y  th is  s tu d y  w o u ld  h a v e  b e e n  m o re  c o n c lu s iv e , if p la s m a  l ip o p ro te in s  
h a d  b e e n  is o la te d  fro m  fre s h  p la s m a .
R a is e d  p la s m a  s d L D L -C  h a s  b e e n  c o n s is te n t ly  a s s o c ia te d  w ith  in c re a s e d  C V D  r is k  
[8 , 10, 1 3 0 , 4 2 4 ]. In th e  p re s e n t s tu d y , p la s m a  s d L D L -C  w a s  q u a n t if ie d  u s in g  a  
c o m m e rc ia lly  a v a ila b le  p re c ip ita t io n  a s s a y , a  m e th o d  th a t  is  g e n e ra lly  u s e d  a s  a
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s im p le r  a lte rn a t iv e  to  th e  tra d it io n a l m e th o d s  o f u lt ra c e n tr ifu g a t io n  a n d  G G E . T h e  
s tu d y  fo u n d  a  s ig n if ic a n t re d u c t io n  in p la s m a  s d L D L -G  a fte r  th e  lo w  s u g a r  d ie t  a n d  n o  
c h a n g e  a fte r  th e  h ig h  s u g a r  d ie t. L o w  s u g a r  d ie ts  h a v e  b e e n  re p o r te d  to  re d u c e  th e  
p ro d u c t io n  o f V L D L  in th e  liv e r  [1 6 4 , 4 2 2 , 4 2 5 ], w ith  th e  p o s s ib le  c o n s e q u e n c e  o f a  
re d u c t io n  in  th e  fo rm a tio n  o f s d L D L  a n d  lo w e r in g  o f C V D  r is k  [4 2 0 ]. In  a g re e m e n t w ith  
a  p re v io u s  s tu d y , th e  m o d e ra te ly  ra is e d  l iv e r  fa t  g ro u p  s h o w e d  a  g re a te r  re d u c t io n  in 
p la s m a  s d L D L -C  re la tiv e  to  th e  lo w  l iv e r  fa t  g ro u p  a fte r  th e  lo w  s u g a r  d ie t  [4 2 6 ]. 
H o w e v e r, th e  m e th o d  fo r  th e  d e te rm in a t io n  o f s d L D L -C  h a s  o n ly  b e e n  v a lid a te d  fo r  
fre s h  a n d  n o t s to re d  p la s m a  [4 2 7 ], w h ic h  c a s ts  d o u b t o n  th e  re lia b il i ty  a n d  v a l id i ty  o f 
th e s e  f in d in g s .
P la s m a  a p o  C II a n d  CHI h a v e  im p o r ta n t m e ta b o lic  ro le s  a s  c o - fa c to rs  fo r  th e  
a c t iv a tio n  a n d  in h ib it io n  o f L P L , a n d  th u s  th e  re m o d e llin g  a n d  a lte ra t io n  o f lip o p ro te in  
p a r t ic le  s iz e  [9 1 , 4 2 8 ]. In th e  p re s e n t s tu d y , th e  h ig h  a n d  lo w  s u g a r  d ie ts  w e re  
a c c o m p a n ie d  b y  n o n -s ig n if ic a n t in c re a s e  a n d  d e c re a s e  in  p la s m a  a p o  C II, 
re s p e c t iv e ly . W h ile  p la s m a  a p o  C II h a s  b e e n  fo u n d  to  b e  e le v a te d  a fte r  a  h ig h  C H O  
d ie t in  an  e a r lie r  s tu d y  w h ic h  e m p lo y e d  8 5 % E  fro m  C H O  [4 2 9 ], in c re a s e s  in  b o th  
p la s m a  a p o  C-H a n d  T A G  is  a t o d d s  w ith  re p o r ts  o f an  in v e rs e  a s s o c ia t io n  b e tw e e n  
th e s e  tw o  v a r ia b le s , a n d  th e  ro le  o f a p o  C-H a s  a  c o - fa c to r  fo r  th e  a c t iv a t io n  o f L P L . 
In te re s t in g ly , p la s m a  a p o  C-H d e c re a s e d  a fte r  th e  lo w  s u g a r  d ie t, w h ic h  is  e q u a lly  
in c o n s is te n t w ith  th e  m e ta b o lic  ro le  o f th is  a p o p ro te in . In c o n tra s t to  a p o  C -H , p la s m a  
a p o  CHI in c re a s e d  a n d  d e c re a s e d  a fte r  th e  h ig h  a n d  lo w  s u g a r  d ie ts , re s p e c t iv e ly  
(n .s .) , w h ic h  is  c o n s is te n t w ith  a  p o s it iv e  a s s o c ia t io n  w ith  p la s m a  T A G  [7 8 ] a n d  a  
s tu d y  b y  F a lk o  et al. w h o  re p o r te d  a n  in c re a s e  in p la s m a  a p o  CHI b y  « 3 0 %  a fte r  a  
h ig h  C H O  d ie t [4 2 9 ]. In th e  p re s e n t s tu d y , p la s m a  a p o  CHI w a s  c o n s is te n t ly  h ig h e r  in  
th e  m o d e ra te ly  ra is e d  liv e r  fa t  g ro u p  re la t iv e  to  th e  lo w  l iv e r  fa t  g ro u p , a  f in d in g  w h ic h  
m a y  h a v e  c o n tr ib u te d  to  th e  g re a te r  m a g n itu d e  o f c h a n g e s  in  p la s m a  T A G  in  th is  
g ro u p , a fte r  b o th  d ie ts .
A  lo w e r  ra tio  o f p la s m a  a p o  C H/CH I h a s  b e e n  a s s o c ia te d  w ith  C H D  in  p a t ie n ts  w ith  
ra is e d  p la s m a  T A G  [4 3 0 ], s u g g e s tin g  th a t th e  ra t io  o f a p o  C H /C H I m a y  b e  a  b e tte r  
m a rk e r  fo r  p ro -a th e ro g e n ic  c h a n g e s  in  p la s m a  lip id s  [4 3 1 ]. T h e  c h a n g e s  in  th e  
p la s m a  ra tio  o f a p o  C H/C H I in  th e  p re s e n t s tu d y , w e re  c o n s is te n t w ith  a  p o te n t ia l ly  
a d v e rs e  e ffe c t o f d ie ta ry  s u g a r  o n  c a rd io -m e ta b o lic  r isk .
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In  th e o ry , a n  e le v a te d  c o n c e n tra t io n  o f p la s m a  a p o  E c o u ld  p ro m o te  H T A G  b y  
s t im u la t in g  h e p a tic  V L D L -T A G  p ro d u c t io n  a n d  im p a ir in g  V L D L  l ip o ly s is  [4 1 1 , 4 2 8 ]. 
P la s m a  a p o  E w a s  s h o w n  to  in c re a s e  a fte r  th e  h ig h  s u g a r  d ie t, a  f in d in g  th a t  w a s  
m o re  p ro n o u n c e d  in  th e  g ro u p  w ith  m o d e ra te ly  ra is e d  l iv e r  fa t, a n d  h a s  b e e n  re p o r te d  
p re v io u s ly  [8 0 ]. In v ie w  o f th e  m e ta b o lic  ro le s  o f a p o  E, it is  c o n c e iv a b le  th a t  th e  
c h a n g e s  in  its  p la s m a  c o n c e n tra t io n  c o u ld  h a v e  c o n tr ib u te d  to  th e  m o re  m a rk e d  
re s p o n s e  o f th e  g ro u p  w ith  ra is e d  liv e r  fa t, a s  d e s c r ib e d  in  C h a p te r  4 .
M o d e ra te ly  ra is e d  p la s m a  T A G  (in  e x c e s s  o f 1 .5 m m o l/L )  h a s  a ls o  b e e n  a s s o c ia te d  
w ith  s d L D L  o r  p h e n o ty p e  ‘B ’ p re v io u s ly  [2 7 , 1 5 8 , 4 3 2 ]. T h e  f in d in g s  o f th e  p re s e n t 
s tu d y  a re  c o n s is te n t w ith  th e  m e ta b o lic  s ig n if ic a n c e  o f a  p la s m a  T A G  in  e x c e s s  o f 
1 .5 m m o l/L  a s  re p re s e n t in g  a  c r it ic a l th re s h o ld  fo r  th e  re d is tr ib u t io n  o f L D L  a n d  H D L  
s u b c la s s e s  [2 7 , 1 5 8 ]. In a d d it io n , o th e r  m a rk e rs  o f c a rd io -m e ta b o lic  r is k  th a t  a re  
re la te d  to  T A G  m e ta b o lis m , s u c h  a s  fa s t in g  in s u lin , p la s m a  a p o  E a n d  a p o  C H I, w e re  
a ls o  h ig h e r  w h e n  p la s m a  T A G  >  1 .5 m m o l/L . T h is  f in d in g  p ro v id e s  fu r th e r  e v id e n c e  to  
s u p p o r t  a  ro le  fo r  e le v a te d  p la s m a  T A G  in  p ro m o tin g  p ro -a th e ro g e n ic  c h a n g e s  in  
p la s m a  lip o p ro te in s .
5.8 Conclusion
T h is  s tu d y  p ro d u c e d  s o m e  e v id e n c e  to  lin k  a  h ig h  s u g a r  d ie t w ith  a d v e rs e  c h a n g e s  in  
th e  d is tr ib u t io n  o f L D L  a n d  H D L  s u b c la s s e s , a n d  th u s  g e n e ra t io n  o f a n  A L P . It a ls o  
p ro d u c e d  d a ta  th a t w o u ld  s u p p o r t  th e  p o te n t ia l ly  a d v e rs e  e ffe c ts  o f a  h ig h  s u g a r  d ie t  
o n  p la s m a  s d L D L , a p o  CHI a n d  a p o  E. N e v e r th e le s s , th e  f in d in g s  w e re  in c o n c lu s iv e  
w ith  re s p e c t to  th e  im p a c t o f l iv e r  fa t  o n  th e  p re d ic te d  re la t io n s h ip  b e tw e e n  L D L  a n d  
H D L  s u b c la s s e s  a n d  d ie ta ry  s u g a rs . A  m a jo r  lim ita t io n  o f th is  s tu d y  in c lu d e d  th e  s m a ll 
s a m p le  s iz e , w h ic h  w a s  a n  u n a v o id a b le  c o n s tra in t  im p o s e d  b y  th e  k in e t ic  
in v e s tig a t io n s  in  th e  m a in  m e ta b o lic  s tu d y . It is  q u ite  p o s s ib le  th a t  th is  c o n s tra in t  
re s u lte d  in  in s u ff ic ie n t s ta t is t ic a l p o w e r  to  d e te c t c h a n g e s  in  th e  s te a d y  s ta te  
c o n c e n tra t io n  o f lip o p ro te in  s u b c la s s e s . A n  a d d it io n a l l im ita t io n , w a s  th e  in s ta b i l i ty  o f  
l ip o p ro te in s  in  s to re d  p la s m a  fo r  th e  m e a s u re m e n t o f L D L  s u b c la s s e s  b y  G G E , a n d  
s d L D L -c h o le s te ro l b y  a  c o m m e rc ia lly  a v a ila b le  p re c ip ita t io n  a s s a y .
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Chapter 6
EVALUATION OF THREE DIFFERENT METHODS FOR THE DETERMINATION OF
NON-MILK EXTRINSIC SUGARS
6.1 Introduction
T h e  C o m m itte e  o n  M e d ic a l A s p e c ts  o f F o o d s  (C O M A ) c la s s if ie d  s u g a rs  in to  in tr in s ic  
a n d  e x tr in s ic  s u g a rs , th e  la t te r  o f w h ic h  in c lu d e d  m ilk  s u g a rs  a n d  n o n -m ilk  e x tr in s ic  
s u g a rs  (N M E S ) [3 6 ]. W h ile  th e re  is  no  e v id e n c e  to  s h o w  th a t e ith e r  in tr in s ic  o r  m ilk  
s u g a rs  a re  h a rm fu l to  h e a lth , N M E S  a re  c o n s id e re d  to  b e  d e le te r io u s  to  d e n ta l h e a lth  
[3 6 ] a n d  h a v e  b e e n  im p lic a te d  in  th e  d e v e lo p m e n t o f o b e s ity  a n d  d ia b e te s  [3 7 , 5 2 , 
4 3 3 ]. In a  re p o r t b y  W H O , it w a s  re c o m m e n d e d  th a t  th e  c o n s u m p t io n  o f s u g a rs  b e  
l im ite d  to  1 0 %  o f e n e rg y  in ta k e  [5 2 ]. In a c c o rd a n c e  w ith  th is , c u r re n t p o lic y  in  th e  U K  
re c o m m e n d s  th a t  th e  in ta k e  o f e n e rg y  fro m  ‘fre e  s u g a rs ’ s h o u ld  n o t e x c e e d  1 0 %  o f 
e n e rg y  o r  6 0 g /d a y  [5 8 ], in o rd e r  to  p re v e n t d e n ta l c a r ie s  a s  w e ll a s  o th e r  c h ro n ic  
d is e a s e s  [5 2 , 4 3 4 ]. W h ile  th e s e  re p o r ts  re -e m p h a s is e  th e  im p o r ta n c e  o f l im it in g  th e  
in ta k e  o f N M E S  o r  ‘fre e  s u g a rs ’ , in fo rm a tio n  o n  th e  c o n te n t o f N M E S  in  fo o d s  is  s till 
la c k in g .
B e c a u s e  N M E S  a re  c h e m ic a lly  in d is t in g u is h a b le  fro m  o th e r  s u g a rs , th e y  c a n n o t b e  
q u a n tif ie d  u s in g  c o n v e n tio n a l te c h n iq u e s  fo r  th e  a n a ly s is  o f s u g a rs  in  fo o d s  [4 3 5 ]. 
N M E S  h a v e  b e e n  q u a n tif ie d  in p re v io u s  s tu d ie s  w ith  m e th o d s  b a s e d  o n  th e  
e x a m in a tio n  o f re c ip e s  o r  o th e r  d a ta  fro m  a v a ila b le  fo o d  ta b le s  [4 3 6 ]. F iv e  m e th o d s  
h a v e  b e e n  d o c u m e n te d ; 1 ) th e  N D N S  m e th o d  [5 1 , 4 3 7 -4 3 9 ]; 2 ) th e  M in is t ry  o f 
A g r ic u ltu re , F o o d s  a n d  F is h e ry  (M A F F ) m e th o d  [4 4 0 ]; 3 ) th e  H u m a n  N u tr it io n  
R e s e a rc h  C e n tre  (H N R O ) m e th o d  [4 4 1 ]; 4  &  5 )  m e th o d s  b y  B o lto n -S m ith  &  W o o d w a rd  
[4 4 2 ], a n d  D ru m m o n d  &  K irk  [4 4 3 ].
C h a p te rs  3  a n d  4  d e s c r ib e d  th e  e ffe c ts  o f to ta l s u g a rs  o n  p la s m a  lip id s , a s  d e f in e d  b y  
D ie tp la n  s o ftw a re . T h is  c h a p te r  re -e x a m in e s  th e  re la t io n s h ip  b e tw e e n  N M E S  a n d  
p la s m a  lip id s  b y  q u a n tify in g  ‘s u g a r ’ in ta k e  b y  th re e  a lte rn a t iv e  m e th o d s , n a m e ly  M A F F  
1, M A F F  2  a n d  H N R C .
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6.2 Study aim and objectives
T o  re -e v a lu a te  th e  re la t io n s h ip  b e tw e e n  s u g a r  in ta k e  a n d  p la s m a  lip id s  (T A G  a n d  
H D L -C ), b y  c o m p a r in g  fo u r  d if fe re n t m e th o d s  fo r  th e  c la s s if ic a t io n  o f d ie ta ry  s u g a rs .
6.3 Study hypothesis
A lte rn a t iv e  m e th o d s  fo r  e s t im a t in g  th e  in ta k e  o f d ie ta ry  N M E S  w ill p ro d u c e  e ith e r  
h ig h e r  o r  lo w e r  v a lu e s  fo r  th e  in ta k e  o f N M E S , a s  p re v io u s ly  d e s c r ib e d  in  C h a p te rs  3 
a n d  4 . T h is  a s s e s s m e n t o f s u g a r  in ta k e  b y  d if fe re n t m e th o d s  m a y  h a v e  im p lic a t io n s  fo r  
th e  im p a c t o f th e  h ig h  a n d  lo w  s u g a r  d ie ts  o n  p la s m a  lip id s .
6.4 Methods for NMES anaiysis
N o n -m ilk  e x tr in s ic  s u g a rs  (N M E S ) w e re  e s t im a te d  b y  tw o  fu r th e r , p u b lis h e d  m e th o d s , 
a n d  c o m p a re d  w ith  th e  o r ig in a l a n a ly s is  a s  d e te rm in e d  b y  D ie tp la n  s o ftw a re . T h e  f irs t  
o f th e s e  tw o  m e th o d s  (M A F F  1) w a s  re p o r te d  b y  M A F F  in  T h e  D ie ta ry  a n d  N u tr it io n a l 
S u rv e y  o f B r it is h  A d u lts  - F u r th e r  A n a ly s is  [4 4 0 ]. T h e  s e c o n d  m e th o d  (H N R C ) w a s  
d e s c r ib e d  b y  H N R C  a t N e w c a s t le  U n iv e rs ity , U K  [4 4 1 ]. T h e s e  m e th o d s  w e re  
d e v e lo p e d  o n  th e  b a s is  o f th e  e x a m in a tio n  o f re c ip e s  o r  o th e r  d a ta  fro m  a v a ila b le  fo o d  
ta b le s . T h e  ‘s ta n d a rd ’ N D N S  m e th o d  w a s  n o t u s e d  in  th is  s tu d y  d u e  to  its  l im ite d  
a c c e s s  to  th e  F o o d  S ta n d a rd  A g e n c y  (F S A ) fo o d  c o m p o s it io n  d a ta b a s e . In a d d it io n , it 
p ro v id e d  v a lu e s  fo r  th e  in ta k e  o f N M E S  th a t  w e re  s im ila r  to  th o s e  p ro v id e d  b y  th e  
H N R C  m e th o d  [5 1 , 4 3 7 -4 3 9 ]. T h e  M A F F  1 m e th o d  a p p e a re d  to  b e  a n  u n c o m p lic a te d  
a n d  re la t iv e ly  e a s y  m e th o d  to  a p p ly , w h ic h  d id  n o t re q u ire  th e  F S A  fo o d  c o m p o s it io n  
d a ta b a s e , b u t p ro v id e d  m o re  c o m p re h e n s iv e  d a ta  o n  N M E S  fro m  w o r ld w id e  
p o p u la t io n s . In c o m p a r is o n , th e  H N R C  m e th o d  h a d  b e e n  u p d a te d  re c e n t ly , a n d  u s e d  
e x te n s iv e ly  in c ro s s -s e c t io n a l s tu d ie s  to  in v e s tig a te  d ie ta ry  tre n d s  in  s u g a r  in ta k e  in 
a d o le s c e n ts  o v e r  th e  la s t 3 0  y e a rs  [4 4 1 , 4 4 4 , 4 4 5 ]. T h e re  w e re  tw o  o th e r  p u b lis h e d  
m e th o d s  w h ic h  w e re  n o t u s e d  in th is  a n a ly s is , p r im a r i ly  b e c a u s e  th e y  w e re  c le a r ly  
d e r iv e d  fro m  th e  s ta n d a rd  N D N S  m e th o d  [4 4 2 , 4 4 3 ]. A n  a d d it io n a l a n a ly s is  o f  N M E S  
w a s  in c lu d e d  th a t u s e d  th e  M A F F  1 m e th o d , w ith  th e  e x c lu s io n  o f fre s h  f r u its  (M A F F  
2 ). T h e  im p a c t o f s u g a rs , a s  m e a s u re d  b y  th e  th re e  d if fe re n t m e th o d s ; M A F F  1, M A F F  
2  a n d  H N R C , o n  p la s m a  T A G  a n d  H D L -C , w a s  c o m p a re d  w ith  th e  o r ig in a l m e th o d  
(D ie tp la n  s o ftw a re ) .
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6.4.1 MAFF 1 method for the determination of NMES
D e ta ils  o f th is  m e th o d  w e re  o b ta in e d  fro m  th e  F S A  ( fo rm e r ly  M A F F ) . T h e  M A F F  
m e th o d  w a s  b a s e d  o n  th e  in ta k e  o f N M E S  a s  e s t im a te d  fro m  to ta l s u g a rs , m in u s  
s u g a rs  fro m  liq u id  c o w s ’ m ilk  [440]. A c c o rd in g  to  K e lly  et al. [49, 436], th e  o r ig in a l 
v e rs io n  o f th e  re p o r t s ta te d  th a t  th e  in ta k e  o f N M E S  w a s  e s t im a te d  fro m  to ta l s u g a rs , 
m in u s  s u g a rs  fro m  liq u id  c o w s ’ m ilk , f r u it  a n d  fru it  p ro d u c ts  (e x c lu d in g  f r u it  ju ic e s ) .  
H o w e v e r, th e  F S A  la te r  c o n f irm e d  (b y  p e rs o n a l c o m m u n ic a t io n )  th a t  th e  m e th o d  w a s  
a lte re d  in th e  s u b s e q u e n t p u b lic a t io n , a n d  d id  n o t s u b tra c t th e  s u g a rs  fro m  fr u it  a n d  
fr u it  p ro d u c ts . T h e re fo re , th e  o r ig in a l M A F F  m e th o d  w a s  u s e d  (N M E S  =  to ta l s u g a rs  
m in u s  s u g a rs  fro m  liq u id , w h o le , s e m i-s k im m e d  a n d  s k im m e d  c o w s  m ilk )  [49], in  
c o n ju n c t io n  w ith  a  lis t o f a s s u m p t io n s  (Appendix 18) [49].
6.4.2 HNRC method for the determination of NMES
T h is  m e th o d  w a s  o r ig in a lly  b a s e d  o n  a n  ‘a d d e d  s u g a r ’ m e th o d  th a t  w a s  f ir s t  
d e v e lo p e d  in  1 9 8 0  [4 4 1 ], a n d  e v o lv e d  o v e r  tim e . It e s t im a te s  N M E S  o n  th e  p r in c ip le  
o f a d d e d  s u g a rs , p lu s  s u g a rs  fro m  fru it  in f r u it  ju ic e s  a n d  o th e r  s o ft  d r in k s . F ru it 
s u g a rs  d e r iv e d  fro m  th e  fr u it  in  ja m s  a n d  y o g h u r ts  w e re  c la s s if ie d  a s  in tr in s ic  [4 4 1 ]. 
T h e  d e ta ils  o f a s s u m p t io n s  th a t w e re  m a d e  a b o u t fo o d s  in  th is  m e th o d , a re  s h o w n  in 
Appendix 19.
6.4.3 Statistical anaiysis
T h e  p e rc e n ta g e  o f e n e rg y  fro m  N M E S  in  th e  d if fe re n t m e th o d s  w a s  a n a ly s e d  u s in g  a  
o n e -w a y  (b e tw e e n  g ro u p s )  A n a ly s is  o f  V a r ia n c e  (A N O V A ) (S P S S  p a c k a g e  v e rs io n  
1 8 ). P a irw is e  d if fe re n c e s  b e tw e e n  th e  th re e  m e th o d s  w e re  a s s e s s e d  b y  a  p o s t-h o c  
T u k e y  te s t.  T h e  h o m o g e n e ity  o f v a r ia n c e  w a s  te s te d  u s in g  th e  L e v e n e ’s te s t .  T h e  
p e rc e n ta g e  o f e n e rg y  in ta k e  fro m  N M E S  b y  th e  d if fe re n t m e th o d s , w e re  s u b d iv id e d  
in to  f iv e  s u b g ro u p s ; < 5 , 5 -< 1 0 , 1 0 -< 1 7 .5 , 1 7 .5 -< 2 5  a n d  > 2 5 , a c c o rd in g  to  th e  
N H A N E S  s tu d y  [4 1 ]. T h e  N H A N E S  s tu d y  w a s  o n e  o f th e  la rg e s t c ro s s -s e c t io n a l 
s tu d ie s , w h ic h  e x a m in e d  th e  a s s o c ia t io n  b e tw e e n  in ta k e  o f a d d e d  s u g a rs  a n d  p la s m a  
lip id s  in  >  6 ,0 0 0  p a r t ic ip a n ts . T h e  re la t io n s h ip s  b e tw e e n  a n d  w ith in  th e  s u b g ro u p s  
a n d  p la s m a  T A G , H D L -C , w e re  a n a ly s e d  u s in g  a n  A N O V A  w ith  p o s t-h o c  T u k e y  te s t 
a n d  u n iv a r ia te  re g re s s io n  a n a ly s is . S ta t is t ic a l s ig n if ic a n c e  w a s  d e f in e d  a s  p < 0 .0 5 .
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6.5 Results
6.5.1 Estimation of NMES using four methods
T h e  in ta k e  o f N M E S , a s  e s t im a te d  b y  th e  H N R C  m e th o d , re s u lte d  in  s ig n if ic a n t ly  
lo w e r  in ta k e s  fo r  th e  h a b itu a l, h ig h  s u g a r  a n d  lo w  s u g a r  d ie ts , a s  c o m p a re d  to  th e  
o r ig in a l D ie tp la n  m e th o d  (T a b le  6 .1 ) . M A F F  1 re s u lte d  in  a  lo w e r  e n e rg y  c o n tr ib u t io n  
fro m  N M E S  re la t iv e  to  D ie tp la n  fo r  th e  h a b itu a l d ie t b y  2.1 % E  (n .s ). W h ile  th e  e n e rg y  
c o n tr ib u t io n  fro m  N M E S  e s tim a te d  b y  M A F F  1 fo r  th e  h ig h  s u g a r  d ie t  w a s  
c o m p a ra b le , th e  p e rc e n ta g e  o f e n e rg y  fro m  N M E S  fo r  th e  lo w  s u g a r  d ie t  w a s  
s ig n if ic a n t ly  lo w e r  b y  1 .8 % E  re la tiv e  to  D ie tp la n  (p < 0 .0 5 ) . A lth o u g h  th e  e s t im a t io n  o f 
N M E S  u s in g  M A F F  2  re s u lte d  in  a  lo w e r  e n e rg y  c o n tr ib u t io n  fro m  N M E S  in  a ll d ie ts  
re la t iv e  to  M A F F  1, o n ly  th e  lo w  s u g a r  d ie t  s h o w e d  a  s ig n if ic a n t d if fe re n c e  (p < 0 .0 5 ) .
A c c o rd in g  to  M A F F  1, th e  m a jo r ity  o f p a r t ic ip a n ts  (9 6 % ) e x c e e d e d  th e  W H O  
re c o m m e n d a tio n  o f < 1 0 %  e n e rg y  fro m  N M E S  o n  th e  h a b itu a l d ie t, w h e re a s  8 3 %  
e x c e e d e d  th e  re c o m m e n d a tio n  o n  th e  b a s is  o f M A F F  2 . In c o n tra s t, o n ly  2 1 %  
p a r t ic ip a n ts  e x c e e d e d  th e  W H O  re c o m m e n d a tio n  o n  th e  h a b itu a l d ie t  b y  th e  H N R C  
m e th o d . In th e  lo w  s u g a r  d ie t, 2 1 %  p a r t ic ip a n ts  c o n s u m e d  >  1 0 %  (M A F F  1), w h e re a s  
a ll p a r t ic ip a n ts  c o n s u m e d  < 1 0 %  e n e rg y  fro m  N M E S  (M A F F  2  a n d  H N R C ).
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Table 6.1 : Mean intake of NMES on the habitual, high and low sugar diets; 
comparison between the four methods of NMES estimation
Dietplan MAFF1 MAFF 2 HNRC
Habitual diet
N M E S ( g /d a y )  1 2 0 .4 ± 1 0 .1  108 .1  ± 9 .7  9 2 .2 ± 7 .9  4 6 .8 ± 6 .9
% E  (fro m  N M E S ) 2 0 .5 ± 1 .2  1 8 .4 ± 1 .2 °  1 5 .6 ± 1 .0 “ ' 7 .9 1 1 .0 “
High sugar diet
N M E S ( g /d a y )  1 7 3 .2 ± 1 0 .0  1 6 9 .7 ± 1 1 .5  1 5 8 .6 ± 9 .9  9 1 .0 ± 8 .3
% E  (fro m  N M E S ) 2 7 .8 + 1 .3  2 7 .2 ± 1 .5 “ 2 5 .5 + 1 .4 ' 1 4 .5 ± 1 . l “
Low sugar diet
N M E S (g /d a y )  5 5 .9 ± 4 .0  45 .1  ± 3 .5  3 2 .3 ± 2 .4  7 .1 ± 1 .1
% E  (fro m  N M E S ) 9 .4 1 0 .5  7 .6 1 0 .5 “ “ 5 .5 1 0 .3 " “ ' 1 .2 1 0 .2 “
% E , p e rc e n ta g e  o f e n e rg y ; N M E S , n o n -m ilk  e x tr in s ic  s u g a r; M A F F , M in is t ry  o f 
A g r ic u ltu re , F o o d  a n d  F is h e r ie s ; H N R C , H u m a n  N u tr it io n  R e s e a rc h  C e n tre . D a ta  a re  
m e a n ± S E M  a n d  w e re  a n a ly s e d  u s in g  A N O V A  w ith  p o s t-h o c  T u k e y  te s t . ^ D ie tp la n  v s  
M A F F  1 (p < 0 .0 5 ) ; “ D ie tp la n  v s  H N R C  (p < 0 .0 5 ) ; “ M A F F  1 v s  H N R C  (p < 0 .0 5 ) ;  "M A F F  2  
v s  D ie tp la n  (p < 0 .0 5 ) ; “ M A F F  2  v s  M A F F  1 (p < 0 .0 5 ) ; 'M A F F  2  v s  H N R C  (p < 0 .0 5 ) .
6.5.2 Relationships between the intake of NMES and piasma TAG, and HDL- 
C
A  s u b d iv is io n  o f p e rc e n ta g e  e n e rg y  in ta k e s  fro m  N M E S , b a s e d  o n  th a t  in  th e  N H A N E S  
s tu d y  [4 1 ], s h o w e d  p o s it iv e  a s s o c ia t io n s  w ith  c h a n g e s  in  p la s m a  T A G  a fte r  b o th  th e  
h ig h  a n d  lo w  s u g a r  d ie ts  (F ig . 6.1 a n d  6 .2 ) . O n  th e  h ig h  s u g a r  d ie t, th e  p e rc e n ta g e  o f 
e n e rg y  in ta k e s  fro m  N M E S  w a s  p o s it iv e ly  a s s o c ia te d  w ith  th e  in c re a s e  in  p la s m a  
T A G . L in e a r  re g re s s io n  a n a ly s is  re v e a le d  a  s tro n g  p o s it iv e  a s s o c ia t io n  b e tw e e n  
N M E S  in ta k e  a n d  c h a n g e s  in  p la s m a  T A G , w h e n  N M E S  w a s  d e te rm in e d  b y  M A F F  1 
(r^= 0 .9 7 ). T h e  a s s o c ia t io n  w a s  w e a k e r  w ith  M A F F  2  (r^= 0 .7 2 ), D ie tp la n  (r^ = 0 .2 5 ) a n d  
H N R C  (r^= 0 .0 3 ). In c o n tra s t, o n  th e  lo w  s u g a r  d ie t, a  lo w e r  in ta k e  o f e n e rg y  fro m  
N M E S  re s u lte d  in  g re a te r  d e c re a s e  in p la s m a  T A G . C o n v e rs e ly , th e  p e rc e n ta g e  o f 
e n e rg y  in ta k e  fro m  N M E S  w a s  in v e rs e ly  a s s o c ia te d  w ith  p la s m a  H D L -C , m a in ly  o n  th e  
h ig h  s u g a r  d ie t fo r  a ll m e th o d s  (F ig . 6 .3 ) .
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Figure 6.1: Percentage energy from NMES, as measured by four different
methods, in relation to the change in piasma TAG on the high sugar diet.
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Figure 6.2: Percentage energy from NMES, as measured by three different 
methods, in relation to the change in piasma TAG on the low sugar diet.
10-<17.5< 5
iS -0.4
- 0.6 -
c  -0.8
Percentage of energy from NMES
Dietplan 
MAFF1 
MAFF 2
N M E S , n o n -m ilk  e x tr in s ic  s u g a rs ; T A G , tr ia c y lg ly c e ro l.  D ie tp la n = to ta l s u g a r . D a ta  a re  
m e a n iS E M . n = 2 5 .
212
Figure 6.3: Percentage energy from NMES, as measured by four different
methods, in relation to the change in piasma HDL-C on the high sugar diet.
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Figure 6.4: Percentage energy from NMES, as measured by three different 
methods, in relation to the change in plasma HDL-C on the low sugar diet.
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6.6 Discussion
In th e  o r ig in a l p u b lic a t io n  [4 4 0 ], M A F F  1 w a s  d e s c r ib e d  a s  a  re la t iv e ly  s tra ig h t fo rw a rd  
m e th o d , b a s e d  o n  ‘to ta l s u g a r ’ m in u s  s u g a rs  fro m  liq u id  m ilk . A s  a  c o n s e q u e n c e , th is  
le d  to  a n  o v e re s t im a te  fo r  th e  in ta k e  o f N M E S  fo r  a ll th e  d ie ts , b e c a u s e  th e  m e th o d  
a s s u m e d  a ll s u g a rs  w e re  in te g ra te d  a s  N M E S , e v e n  if th e  fo o d  d id  n o t c o n ta in  a d d e d  
o r  e x tr in s ic  s u g a rs  a n d  in c lu d e d  a ll fre s h  fr u it  s u g a rs  a s  N M E S  [4 9 , 4 3 6 ]. A s  a  re s u lt, 
th is  p ro v id e d  a  s ig n if ic a n t o v e re s t im a te  fo r  th e  n u m b e r  o f p a r t ic ip a n ts  w h o  e x c e e d e d  
th e  W H O  re c o m m e n d a tio n  fo r  th e  in ta k e  o f ‘fre e  s u g a r ’ o n  th e  h a b itu a l d ie t  [5 2 ]. M A F F  
2  p ro v id e d  a  m o re  s p e c if ic  e s t im a te  o f N M E S , b y  e x c lu d in g  s u g a rs  in  fre s h  fru its , 
w h ic h  w e re  c o n s id e re d  to  b e  ‘ in tr in s ic ’ s u g a rs . T h is  m e th o d  p ro v id e d  lo w e r  v a lu e s  fo r  
th e  in ta k e  o f N M E S , a n d  a p p e a re d  to  b e  a  m o re  re lia b le  m e th o d  th a n  M A F F  1, 
e s p e c ia lly  w ith in  a  p o p u la t io n  c o n s u m in g  la rg e  a m o u n ts  o f fru it .  W h ile  th is  m ig h t b e  a  
fa ir  s ta te m e n t, s in c e  M A F F  2  e x c lu d e s  th e  m ilk  a n d  in tr in s ic  s u g a rs  b a s e d  o n  th e  b a s ic  
d e fin it io n  o f N M E S , it is  a n  u n p u b lis h e d  m e th o d , a n d  b a s e d  o n  th is  re s e a rc h e r ’s 
a s s u m p t io n s  th a t fru its  s h o u ld  be  e x c lu d e d . T h e  s ig n if ic a n t d if fe re n c e  in  th e  
p e rc e n ta g e  o f e n e rg y  fro m  N M E S  b e tw e e n  M A F F  1 a n d  M A F F  2  o n  th e  lo w  s u g a r  
d ie t, s u g g e s ts  th a t p a r t ic ip a n ts  c o n s u m e d  s ig n if ic a n t ly  h ig h e r  a m o u n t o f fre s h  fru its  in  
th is  d ie ta ry  p h a s e . C o n v e rs e ly , th e re  w a s  e v id e n c e  th a t  p a r t ic ip a n ts  c o n s u m e d  le s s  
fre s h  fru its  d u r in g  th e  h ig h  s u g a r  d ie t. O n e  p o s s ib le  e x p la n a t io n  fo r  th is  m a y  b e  th a t 
p a r t ic ip a n ts  re p la c e d  th e ir  h a b itu a l in ta k e  o f fre s h  fr u it  w ith  s tu d y  fo o d s  a fte r  th e ir  m a in  
m e a l.
In  c o n tra s t to  M A F F  1, th e  H N R C  m e th o d  a p p e a re d  to  b e  a  re la t iv e ly  th o ro u g h  a n d  
c o m p le x  m e th o d , th a t w a s  a t v a r ia n c e  w ith  th e  o r ig in a l d e f in it io n  o f N M E S . F o r  
e x a m p le , s u g a rs  in pu  re e d  fru its , f ru it  s u g a rs  in  p ie  f i l l in g s  a n d  ja m s  w e re  c la s s if ie d  a s  
in tr in s ic  in s te a d  o f e x tr in s ic . T h is  c o u ld  h a v e  c o n tr ib u te d  to  a n  u n d e re s t im a te  o f 
N M E S , p a r t ic u la r ly  o n  th e  h ig h  s u g a r  d ie t, w h e n  m o s t o f th e  s tu d y  fo o d s  c o n ta in e d  
p ro c e s s e d  fru its , s u c h  a s  fr u it  p ie s  a n d  ja m s  [4 3 6 ]. It c o u ld  a ls o  h a v e  re s u lte d  in  a n  
u n d e re s t im a te  o f th e  n u m b e r  o f p a r t ic ip a n ts  (2 1 % ) w h o  e x c e e d e d  th e  W H O  
re c o m m e n d a tio n  [5 2 ].
T h is  s tu d y  re v e a le d  e v id e n c e  fo r  b o th  p o s it iv e  a n d  n e g a tiv e  e ffe c ts  o f d ie ta ry  N M E S , 
a s  m e a s u re d  b y  th e  fo u r  d if fe re n t m e th o d s , o n  p la s m a  T A G , a n d  H D L -C . T h e s e  
e ffe c ts  s e e m e d  to  b e  s tro n g e r  w h e n  N M E S  in ta k e  w a s  >  1 0 %  e n e rg y . In  l in e  w ith  th e
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W H O  re c o m m e n d a tio n , th e  in ta k e  o f N M E S  s h o u ld  b e  re d u c e d  to  <  1 0 %  o f to ta l 
e n e rg y  to  lo w e r  C V D  r is k s  a r is in g  th ro u g h  ra is e d  p la s m a  T A G  a n d  lo w  p la s m a  H D L -C  
[4 1 , 5 2 ,2 1 4 ] .
6.7 Conclusion
B o th  M A F F  1 a n d  H N R C  p ro v id e d  v a lu e s  fo r  th e  in ta k e  o f N M E S  th a t  d e v ia te d  fro m  
th e  o r ig in a l D ie tp la n  m e th o d , w ith  M A F F  1 o v e re s t im a tin g  in ta k e  a n d  H N R C  
u n d e re s t im a t in g  in ta k e  o f N M E S . M A F F  2  w a s  a  m o re  a c c e p ta b le  c o m p ro m is e  o u t o f 
th e  th re e  a lte rn a t iv e  m e th o d s , in te rm s  o f its  p ra c t ic a l u ti l ity  a n d  h o w  it c o n fo rm e d  to  
th e  o r ig in a l d e fin it io n  o f N M E S  [3 6 ]. O v e ra ll,  a ll m e th o d s  c o n firm e d  th a t  a  h ig h  in ta k e  
o f N M E S  w a s  a s s o c ia te d  w ith  ra is e d  p la s m a  T A G , re d u c e d  H D L -C  a n d  th u s  in c re a s e d  
C V D  risk .
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Chapter 7
GENERAL DISCUSSION
D e s p ite  th e  fa ll in g  tre n d  in  C V D  m o r ta lity  ra te s  in th e  U K  o v e r  th e  la s t 10  y e a rs , th e  
m o rb id ity  o f  C V D  is  in c re a s in g  a s  a  re s u lt o f  in c re a s e d  c a rd io -m e ta b o lic  r is k , a r is in g  
f ro m  o b e s ity , m e ta b o lic  s y n d ro m e  a n d  T 2 D M  [2 5 9 ]. A  c o n v e n t io n a l n u tr it io n a l a n d  
p u b lic  h e a lth  s tra te g y  fo r  re d u c in g  th is  r is k , is  to  re p la c e  d ie ta ry  fa t , m a in ly  s a tu ra te d  
fa t, w ith  C H O  [2 0 , 4 4 6 ]. H o w e v e r , o n  th e  s tre n g th  o f th e  e x is t in g  e v id e n c e , th e  
e x c h a n g e  o f d ie ta ry  fa t  w ith  C H O s , e s p e c ia l ly  w h e n  in  th e  fo rm  o f s u g a rs , w o u ld  
a p p e a r  to  b e  a s s o c ia te d  w ith  in c re a s e d  C V D  ris k , w h ic h  m a y , in  p a r t, b e  m e d ia te d  
th ro u g h  a n  e le v a tio n  o f p la s m a  T A G  a n d  re d u c e d  H D L -C  [1 7 8 , 1 7 9 , 4 4 6 ]. M o re o v e r , 
w h e n  th e  a m o u n t a n d  q u a lity  o f  C H O  is  u n c o n tro lle d , an  e x c h a n g e  o f fa t  fo r  C H O  c a n  
in c re a s e  r is k  th ro u g h  in s u lin  re s is ta n c e , a n d  its  re la te d  c o n d it io n s  s u c h  a s  m e ta b o lic  
s y n d ro m e  a n d  im p o r ta n tly , fa t ty  l iv e r  d is e a s e  [5 , 6 , 1 8 5 ]. T h is  re s e a rc h  th e s is  h a s  
fo c u s e d  a tte n tio n  o n  th e  e v id e n c e  fo r  a  re la t io n s h ip  b e tw e e n  d ie ta ry  s u g a r  a n d  
p la s m a  lip id s , a n d  o n  th e  d e v e lo p m e n t a n d  a p p lic a t io n  o f a  d ie ta ry  e x c h a n g e  m o d e l 
to  s tu d y  th e  im p a c t o f d ie ta ry  s u g a r  o n  p la s m a  lip id s  a n d  l ip o p ro te in s  [1 0 4 , 1 0 7 , 4 4 7 ]. 
It a ls o  a d d re s s e d  th e  im p a c t o f l iv e r  fa t  o n  th e  re s p o n s e  to  d ie ts , h ig h  a n d  lo w  in 
d ie ta ry  s u g a rs .
7.1 Systematic review on the effects of dietary sugars on piasma TAG
and HDL-C
C h a p te r  2  d e s c r ib e s  an  in d e p e n d e n t, s y s te m a tic  re v ie w  to  e s ta b lis h  th e  a s s o c ia t io n s  
b e tw e e n  d ie ta ry  s u g a rs  a n d  tw o  in d e p e n d e n t C V D  r is k  fa c to rs , n a m e ly  p la s m a  T A G  
a n d  H D L -C . T h is  w a s  u n d e r ta k e n  to  p ro v id e  fu r th e r  s c ie n tif ic  ra t io n a le  to  s u p p o r t  th e  
d e v e lo p m e n t an  a p p lic a t io n  o f a  d ie ta ry  e x c h a n g e  m o d e l in  a  la rg e  m e ta b o lic  s tu d y  
fu n d e d  b y  th e  B B S R C . It w a s  a ls o  u n d e r ta k e n  fo r  th e  p u rp o s e  o f s tu d y in g  fa c to rs  th a t  
m a y  in f lu e n c e  th e  p la s m a  lip id  (T A G  a n d  H D L -C ) re s p o n s e  to  d ie ta ry  s u g a rs . T h e  
re v ie w  c o n firm e d  th a t d ie ta ry  s u g a rs , e s p e c ia lly  in  th e  fo rm  o f fru c to s e , in c re a s e  
p la s m a  T A G  a n d  d e c re a s e  p la s m a  H D L -C . C ro s s -s e c t io n a l s tu d ie s  w e re  m o re  
c o n s is te n t re la tiv e  to  th e  in te rv e n t io n  tr ia ls  in s h o w in g  p o s it iv e  a n d  n e g a t iv e  
a s s o c ia t io n s  b e tw e e n  d ie ta ry  s u g a rs  a n d  p la s m a  T A G  a n d  H D L -C , re s p e c t iv e ly .  
W h ile  th e  o v e ra ll f in d in g s  fro m  th e  d ie ta ry  in te rv e n t io n  s tu d ie s  w e re  in c o n c lu s iv e .
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in te rv e n t io n s  w ith  d ie ta ry  fru c to s e  p ro v id e d  m o re  c o n s is te n t o u tc o m e s  th a n  s tu d ie s  
w ith  d ie ta ry  s u g a rs . T h e  e ffe c ts  w e re  d o s e -d e p e n d e n t,  a n d  m o re  p ro n o u n c e d  in m e n  
th a n  w o m e n , g re a te r  in  p e o p le  w h o  w e re  o v e rw e ig h t a n d  o b e s e  c o m p a re d  to  th o s e  
w ith  n o rm a l b o d y  w e ig h t, a n d  in  p o s t-m e n o p a u s a l re la t iv e  to  p re -m e n o p a u s a l w o m e n . 
L iq u id  a n d  s h o r t- te rm , a c u te  s tu d ie s  w e re  a s s o c ia te d  w ith  g re a te r  e f fe c ts  on  p la s m a  
lip id s  c o m p a re d  to  lo n g e r - te rm  s tu d ie s , a n d  s tu d ie s  th a t  in te rv e n e d  w ith  s o lid  fo o d s . 
T h e  fo o d  m a tr ix  a n d  o th e r  c o m p o n e n ts  in  s o lid  fo o d s , m e ta b o lic  a d a p ta t io n , a n d  
re d u c e d  d ie ta ry  c o m p lia n c e  o v e r  tim e , w e re  a ll id e n tif ie d  a s  p o te n t ia l ly  im p o r ta n t 
in f lu e n t ia l fa c to rs  on  th e  p la s m a  lip id  re s p o n s e  to  d ie ta ry  s u g a rs . T h e  a n a ly s is  o f 
s u b g ro u p s  o f b io lo g ic a l fa c to rs  s u c h  a s  g e n d e r , B M I a n d  m e n o p a u s a l s ta tu s , 
p ro v id e d  e v id e n c e  fo r  th e  p o te n t ia l e ff ic a c y  o f in d iv id u a l d ie ta ry  in te rv e n t io n  s tra te g ie s  
to  re d u c e  c a rd io v a s c u la r  r is k  in  th e  g e n e ra l p o p u la t io n . T h e  f in d in g s  fro m  th is  re v ie w  
a ls o  re v e a le d  a  n u m b e r  o f c o n fo u n d in g  fa c to rs  th a t  in f lu e n c e  th e  d ie ta ry  re s p o n s e , 
n a m e ly ; a  c h a n g e  in  b o d y  w e ig h t, le n g th  o f w a s h -o u t p e r io d  b e tw e e n  d ie ta ry  
tre a tm e n ts , a n d  d u ra t io n  o f th e  d ie ta ry  in te rv e n t io n . It w a s  re c o g n is e d  th a t  d ie ta ry  
in te rv e n t io n  s tu d ie s  a re  m o re  d if f ic u lt  to  p e r fo rm , p a r t ic u la r ly  in  f r e e - l iv in g  in d iv id u a ls , 
a n d  f r e q u e n t ly  s u f fe r  fro m  p o o r  d ie ta ry  c o m p lia n c e , e s p e c ia lly  in  lo n g - te rm  re la t iv e  to  
s h o r t- te rm  s tu d ie s . T h is  m a y  h a v e  c o n tr ib u te d  to  th e  v a r ia b le  o u tc o m e s  o f th e  
in te rv e n t io n  s tu d ie s . O n  th e  o th e r  h a n d , w h ile  m a n y  o f th e  c ro s s -s e c t io n a l s tu d ie s  
e x a m in e d  m u c h  la rg e r  c o h o r ts  o f p a r t ic ip a n ts , w h ic h  in c re a s e d  th e ir  s ta t is t ic a l p o w e r  
to  d e m o n s tra te  a s s o c ia t io n s  th e  e v id e n c e  w a s  in s u ff ic ie n t to  s u p p o r t  a  c a u s a l 
re la t io n s h ip , th u s  w a r ra n t in g  th e  n e e d  fo r  m o re  ra n d o m ly  c o n tro lle d  tr ia ls  w ith  re a l 
fo o d s  ra th e r  th a n  e x p e r im e n ta l te s t m e a ls  [4 4 8 , 4 4 9 ]. T h is  re v ie w  w a s  c o n d u c te d  
in d e p e n d e n t ly  b y  th e  re s e a rc h e r , w h ic h  in  tu rn , m a y  h a v e  in tro d u c e d  s ig n if ic a n t  
s e le c t io n  b ia s , th a t re s u lte d  in th e  lim ite d  n u m b e r  o f s tu d ie s  c o v e re d  b y  th is  re v ie w .
7.2 Development of dietary exchange model for the high and low sugar 
diets
T h e  e ffe c t o f th e  q u a lity  o f C H O  on  p la s m a  lip id s  a n d  l ip o p ro te in s  w a s  e x a m in e d  b y  
th e  a p p lic a t io n  o f a  d ie ta ry  e x c h a n g e  m o d e l, th a t  w a s  d e v e lo p e d  o n  th e  b a s is  o f 
d ie ta ry  in ta k e s  in  th e  U K  p o p u la t io n  [3 0 , 3 6 ]. T h e  d ie ta ry  e x c h a n g e  m o d e l w a s  s h o w n  
to  b e  p ra c t ic a lly  fe a s ib le  in  a  fre e - liv in g , d ie ta ry  in te rv e n t io n  s e tt in g . A n  a im  o f  th e  
d ie ta ry  e x c h a n g e  w a s  to  d e s ig n  tw o  d ie ts , th a t w e re  h ig h  a n d  lo w  in  s u g a r ,  a n d  
re p re s e n ta t iv e  o f th e  u p p e r  95 '^ a n d  lo w e r  2 5 ^  p e rc e n t ile s  o f s u g a r  in ta k e  in  th e  U K
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p o p u la t io n , a c c o rd in g  to  N D N S  [3 0 ]. A n  a d d it io n a l a im  w a s  to  m a tc h  th e  in ta k e  o f 
e n e rg y  a n d  m a c ro n u tr ie n ts  in c lu d in g  to ta l C H O , fa t  a n d  f ib re . S in c e  lo w  s u g a r  fo o d s  
m a y  b e  in h e re n tly  h ig h e r  in  s a lt  to  c o m p e n s a te  fo r  th e ir  la c k  o f s w e e t ta s te , it w a s  
im p o r ta n t to  a v o id  a n y  a d v e rs e  e ffe c t o f th e s e  fo o d s  o n  o th e r  C V D  r is k  fa c to rs ,  s u c h  
a s  b lo o d  p re s s u re . In p ra c t ic a l te rm s , it w a s  c ru c ia l to  k e e p  re -e m p h a s iz in g  to  th e  
p a r t ic ip a n ts  th e  n e e d  to  s u b s t itu te  tw o - th ird s  o f th e ir  u s u a l C H O  in ta k e  w ith  s tu d y  
fo o d s , a n d  n o t to  s im p ly  a d d  th e m  a s  a  s u p p le m e n t to  th e ir  h a b itu a l in ta k e  to  a v o id  
w e ig h t g a in . T h e  d ie ta ry  in te rv e n t io n  s tu d y  w a s  d if f ic u lt  to  p e r fo rm , e s p e c ia l ly  in  m a le  
p a r t ic ip a n ts . A  c r it ic a l a s p e c t o f th e  s tu d y  d e s ig n  w a s  to  p ro v id e  a  b ro a d  c h o ic e  o f 
fo o d s , p r im a r i ly  to  m a in ta in  th e  s u b je c ts ’ in te re s t th ro u g h  fo o d  c h o ic e , to  re d u c e  th e  
a ttr it io n  ra te , a n d  to  m a in ta in  c o m p lia n c e  th ro u g h o u t th e  in te rv e n t io n  [3 4 6 ]. In a d d it io n  
to  d ie ta ry  c o m p lia n c e , u n d e rre p o r t in g  w a s  a ls o  re c o g n is e d  to  b e  a  m a jo r  c h a lle n g e  
fo r  th e  a c c u ra te  a s s e s s m e n t o f d ie ta ry  in ta k e , a n d  w a s  d if f ic u lt  to  a v o id  in  a  m a in ly  
s e lf- re p o r te d  d ie ta ry  in te rv e n t io n  s e tt in g  [4 5 0 -4 5 2 ]. It w a s  e s s e n t ia l to  p ro v id e  
a d e q u a te  in fo rm a tio n  fo r  d ie ta ry  a s s e s s m e n t, s u c h  a s  g u id e lin e s  fo r  p o r t io n  s iz e , a n d  
if p o s s ib le , a  w e ig h in g  s c a le s , to  m in im iz e  u n d e rre p o r t in g . O v e ra ll,  th e  d ie ta ry  
e x c h a n g e  m o d e l w a s  s u c c e s s fu l in  a c h ie v in g  s ig n if ic a n t c h a n g e s  in  th e  re la t iv e  
p ro p o r t io n  o f s ta rc h  to  s u g a r, w h ic h  fo r  th e  h ig h  s u g a r  d ie t, c a m e  v e ry  c lo s e  to  th e  
ta rg e t in ta k e  (1 :1 .1  v e rs u s  a  ta rg e t o f 1 :1 .2 ). W h ile  th e  s ta rc h  to  s u g a r  e x c h a n g e  fo r  
th e  lo w  s u g a r  d ie t  w a s  le s s  s u c c e s s fu l (4:1 v e rs u s  a  ta rg e t o f 6 :1 ) , it s t il l p ro d u c e d  a  
s u b s ta n t ia l c h a n g e  in th e  ra t io  o f s ta rc h  to  s u g a r. A n  im p o r ta n t a s p e c t o f  th is  d ie ta ry  
m a n ip u la t io n , w a s  th a t  it w a s  a c h ie v e d  w ith  s ta p le , s u p e rm a rk e t fo o d s , th a t  w e re  w e ll 
to le ra te d  b y  a ll p a r t ic ip a n ts .
7.3 Application of dietary exchange modei in a dietary intervention study 
on plasma lipids, iipoproteins, apoiipoproteins and the impact of 
iiver fat on these responses
T h e  a p p lic a tio n  o f th e  tw o  d ie ts , h ig h  a n d  lo w  in s u g a rs , in  12  w e e k s  o f  d ie ta ry  
in te rv e n t io n , re s u lte d  in a  s ig n if ic a n t in c re a s e  (p < 0 .0 1 ) a n d  a  d e c re a s e  (n .s .)  in  
p la s m a  T A G , re s p e c t iv e ly . T h e  h ig h  s u g a r  d ie t  w a s  a ls o  a s s o c ia te d  w ith  c h a n g e s  in  
o th e r  c o m p o n e n ts  o f a  c a rd io -m e ta b o lic  r is k  p ro f ile , in c lu d in g  re d u c e d  p la s m a  H D L -C , 
in c re a s e d  B M I, w a is t  c irc u m fe re n c e , p la s m a  g lu c o s e  a n d  p e rc e n ta g e  o f l iv e r  fa t .  
C o n v e rs e ly , th e  lo w  s u g a r  d ie t w a s  a s s o c ia te d  w ith  fa v o u ra b le  e ffe c ts  o n  c o m p o n e n ts  
o f C V D  ris k s , in c lu d in g  re d u c e d  B M I, p la s m a  T C , L D L -C , a p o  B a n d  p e rc e n ta g e  o f
219
l iv e r  fa t. T h e  g ro u p  w ith  m o d e ra te ly  ra is e d  liv e r  fa t, e x p re s s e d  m o re  p ro n o u n c e d  
c h a n g e s  to  b o th  th e  h ig h  a n d  lo w  s u g a r  d ie ts , re la t iv e  to  th e  g ro u p  w ith  lo w  l iv e r  fa t, 
s u g g e s tin g  th a t in d iv id u a ls  w ith  ra is e d  liv e r  fa t  m a y  g a in  g re a te r  b e n e f it  fro m  re d u c in g  
th e  s u g a r  c o n te n t o f th e ir  d ie t. T h e  h ig h  s u g a r  d ie t  w a s  a s s o c ia te d  w ith  p o te n t ia l ly  
u n fa v o u ra b le  c h a n g e s  in o th e r  e n d p o in t m e a s u re s  in c lu d in g  s m a lle r  L D L  a n d  H D L  
p a r t ic le  s iz e s , an  in c re a s e  in  p la s m a  a p o  CHI a n d  a p o  E, a n d  a  d e c re a s e  in  p la s m a  
a p o  C II/C III  ra tio . In c o n tra s t, th e  lo w  s u g a r  d ie t  w a s  a s s o c ia te d  w ith  o p p o s ite  e ffe c ts  
o n  a ll o f th e s e  v a r ia b le s , th e  re s p o n s e s  o f w h ic h  w e re  m o re  p ro n o u n c e d  in 
p a r t ic ip a n ts  w h o s e  p la s m a  T A G  a t b a s e lin e  e x c e e d e d  1 .5 m m o l/L . T h is  c h a p te r  
p ro v id e s  e v id e n c e  o f th e  p o te n t ia l ly  a d v e rs e  e ffe c ts  o f a  h ig h  s u g a r  d ie t  o n  p la s m a  
lip id s  a n d  th e  p e rc e n ta g e  o f l iv e r  fa t, p a r t ic u la r ly  in  p e o p le  w ith  a  p re -e x is t in g , 
m o d e ra te  e le v a tio n  o f p la s m a  T A G  a n d  liv e r  fa t.
N o t u n s u rp r is in g ly , b o d y  w e ig h t w a s  n o t m a in ta in e d  th ro u g h o u t th e  in te rv e n t io n . 
A lth o u g h  s tr ic t  in s tru c t io n s  w e re  g iv e n  n o t to  a lte r  th e ir  p h y s ic a l a c t iv ity  le v e ls  
th ro u g h o u t th e  s tu d y , th e re  w a s  e v id e n c e , th ro u g h  p e rs o n a l c o m m u n ic a t io n , o f  n o n - 
c o m p lia n c e . A s  a  c o n s e q u e n c e , th e re  w a s  v a r ia t io n  in  w e ig h t d u r in g  th e  
in te rv e n t io n s , m o s t n o ta b ly  w e ig h t lo s s  a fte r  th e  lo w  s u g a r  d ie t.  C h a n g e s  in  b o d y  
w e ig h t h a v e  c o n fo u n d e d  th e  in f lu e n c e  o f d ie t  o n  lip id  m e ta b o lis m  in  p re v io u s  s tu d ie s  
[3 3 0 , 3 4 6 , 4 5 3 , 4 5 4 ]. H o w e v e r, th e  w e ig h t c h a n g e s  in  th e  p re s e n t s tu d y  w e re  
re la t iv e ly  s m a ll a n d  n o t a s s o c ia te d  w ith  c h a n g e s  in  o th e r  v a r ia b le s , n o ta b ly  p la s m a  
T A G , H D L -C  a n d  in s u lin . In c o n tra s t w ith  p re v io u s  s tu d ie s  [4 5 5 -4 5 7 ], b o th  th e  h ig h  
a n d  lo w  s u g a r  d ie ts  in th e  p re s e n t s tu d y  p ro d u c e d  n o  e ffe c t o n  p la s m a  in s u lin , 
th o u g h , in s u lin  s e n s it iv ity  w a s  n o t m e a s u re d .
T h is  s tu d y  p ro v id e d  c le a r  e v id e n c e  o f th e  a d v e rs e  e ffe c ts  o f d ie ta ry  s u g a rs , 
p a r t ic u la r ly  o n  p la s m a  lip id s  a n d  lip o p ro te in s , a n d  th u s  re in fo rc e s  th e  n e e d  o f d ie ta ry  
g u id e lin e s  to  re c o m m e n d  a  lim it o n  th e  in ta k e  o f s u g a r  to  re d u c e  d y s l ip id a e m ia  a n d  
its  a s s o c ia te d  c a rd io -m e ta b o lic  r is k  [1 6 4 , 1 9 2 , 2 6 8 , 4 5 8 , 4 5 9 ]. W h ile  th is  s tu d y  w a s  
c o n d u c te d  in  m id d le -a g e d  m e n , th e  p u b lic  h e a lth  o u tc o m e s  a re  a p p lic a b le  to  w o m e n , 
a n d  e s p e c ia lly  p o s t-m e n o p a u s a l w o m e n  e x p re s s in g  in c re a s e d  c a rd io -m e ta b o lic  r is k . 
In a d d it io n , th is  s tu d y  w a s  u n iq u e  in c o m p a r in g  th e  lip id  re s p o n s e  to  h ig h  a n d  lo w  
s u g a r  d ie ts  in  g ro u p s  w ith  lo w  a n d  m o d e ra te ly  ra is e d  liv e r  fa t. A s  a  c o n s e q u e n c e , it 
p ro v id e s  e v id e n c e -b a s e d , d ie ta ry  in fo rm a tio n  fo r  th e  m a n a g e m e n t o f c a rd io v a s c u la r  
h e a lth  in p a tie n ts  w ith  fa t ty  l iv e r  d is e a s e , a n d  m o re  s p e c if ic a lly , th e  p o te n t ia l fo r
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in c re a s e d  s e n s it iv ity  o f  th e s e  p a tie n ts  to  d ie ts  c o n ta in in g  in  e x c e s s  o f 2 7 %  o f to ta l 
e n e rg y  a s  s u g a r. T h e s e  f in d in g s , re in fo rc e  th e  c u r re n t re c o m m e n d a tio n s  fro m  th e  
A H A  [4 6 0 ], w o m e n  a n d  m e n  w h ic h  is  to  lim it th e ir  a d d e d  in ta k e  o f s u g a r  to  le s s  th a n  
s ix  a n d  n in e  te a s p o o n s  p e r  d a y  (e q u iv a le n t to  1 0 0  a n d  15 0  k c a l/d a y ) , re s p e c t iv e ly , to  
p ro m o te  a  h e a lth y  a n d  b a la n c e d  d ie t.
7.4 Re-analysis of non-milk extrinsic sugars (NMES) using the published 
methods
T h e  in ta k e s  o f n o n -m ilk  e x tr in s ic  s u g a rs  (N M E S ) w e re  e s t im a te d  u s in g  tw o  p u b lis h e d  
m e th o d s , th e  M A F F  1 a n d  H N R C , p lu s  a  c o m b in a tio n  o f M A F F  1 a n d  th e  b a s ic  
d e fin it io n  o f N M E S  w h ic h  e x c lu d e s  fre s h  fru its  (M A F F  2 ) [3 6 , 4 9 , 4 4 0 , 4 4 1 ]. T h is  
s tu d y  w a s  c o n d u c te d  to  re -e v a lu a te  th e  re la t io n s h ip  b e tw e e n  N M E S  a s  d e te rm in e d  
b y  th re e  o th e r  m e th o d s , a n d  p la s m a  T A G  a n d  H D L -C . W h ile  th e  p u b lis h e d  m e th o d s  
w e re  e ffe c t iv e  in d e te rm in in g  th e  in ta k e  o f N M E S , th e y  a ll p ro d u c e d  d if fe re n t v a lu e s  
a n d  e a c h  h a d  its  o w n  l im ita t io n s . N o n e th e le s s , N M E S  in ta k e  w a s  s t i l l  p o s it iv e ly  
a s s o c ia te d  w ith  p la s m a  T A G  a n d  in v e rs e ly  a s s o c ia te d  w ith  p la s m a  H D L -C , w ith  th e s e  
e ffe c ts  b e in g  m o re  p ro n o u n c e d  w h e n  e n e rg y  fro m  N M E S  >  1 0 %  o n  a ll fo u r  m e th o d s . 
T h is  s tu d y  p ro v id e d  c o n f irm a to ry  e v id e n c e  th a t  it is  v ita l to  l im it e n e rg y  in ta k e  fro m  
N M E S  o r  ‘f re e  s u g a rs ’ <  1 0 %  to  re d u c e  C V D  r is k  [3 6 , 5 2 , 5 8 ]. T h is  s tu d y  a ls o  
p ro v id e d  e v id e n c e  th a t d a ta  o n  c o n te n t o f N M E S  in  c e r ta in  c o m m e rc ia l fo o d s  is  s till 
la c k in g  a n d  th a t  m o re  re s e a rc h  h a s  to  b e  d o n e  to  im p ro v e  c u r re n t ly  a v a ila b le  
m e th o d s  fo r  m e a s u r in g  N M E S . It is  n e c e s s a ry  to  m e a s u re  in ta k e  o f N M E S  to  
d is t in g u is h  fro m  o th e r  s u g a rs  i.e . m ilk  a n d  in tr in s ic  s u g a rs , to  d e m o n s tra te  th e  
a s s o c ia t io n  w ith  C V D  r is k  fa c to rs  e s p e c ia lly  in  a  p o p u la t io n  w ith  a  c o n s id e ra b ly  h ig h  
in ta k e  o f m ilk  a n d  fru its . T h e  lim ite d  in fo rm a tio n  o n  th e  c o n te n t o f N M E S  in 
s u p e rm a rk e t fo o d s , c o m b in e d  w ith  th e  in c o n s is te n c y  b e tw e e n  m e th o d s  fo r  c a lc u la t in g  
N M E S , a re  lik e ly  to  h a v e  in tro d u c e d  a  d e g re e  o f in a c c u ra c y  a n d  u n re lia b il i ty  in  th e  
a n a ly s is . H o w e v e r, th e s e  p ro b le m s  a re  in h e re n t in  d ie ta ry  in te rv e n t io n  s tu d ie s  in  fre e -  
liv in g  h u m a n s , a n d  h e lp  to  e x p la in  th e  s ig n if ic a n t v a r ia t io n  in p u b lis h e d  s tu d ie s .
7.5 Strengths and limitations of study
T h is  re s e a rc h  p ro je c t e x a m in e d  th e  e ffe c ts  o f d ie ta ry  s u g a rs  o n  C V D  r is k  fa c to rs ,  w ith  
a  fo c u s  o n  th e  e x p re s s io n  o f an  A L P  in in d iv id u a ls  a t in c re a s e d  c a rd io -m e ta b o lic  r is k .
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T h is  s tu d y  w a s  c o n s id e re d  to  b e  re le v a n t to  th e  U K  p o p u la t io n , a s  it w a s  c o n d u c te d  in 
m id d le -a g e d  m e n , w h o  w e re  re c o g n is e d  a s  o n e  o f th e  m o s t v u ln e ra b le  p o p u la t io n  
g ro u p s  to  d e v e lo p  m e ta b o lic  s y n d ro m e  a n d  C V D  th ro u g h  a  life t im e  b u rd e n  o f 
u n h e a lth y  life s ty le  a n d  fo o d  c h o ic e s . It w a s  a ls o  c o n s id e re d  e s s e n tia l to  p ro v id e  
e v id e n c e  fo r  th e  d e v e lo p m e n t o f C V D  d ie ta ry  g u id e lin e s  fo r  g e n e ra l p u b lic  h e a lth , b y  
u s in g  ‘re a l’ s u p e rm a rk e t fo o d s  th a t w e re  c o n s u m e d  ad libitum, in  a  fre e - l iv in g  s e tt in g , 
w h ic h  d e liv e re d  re a lis t ic , a n d  p ra c t ic a lly  fe a s ib le  in ta k e  o f s u g a rs . A n  a d d it io n a l 
s tre n g th  o f th e  s tu d y  d e s ig n  w a s  th a t  th e  p a r t ic ip a n ts  w e re  w e ll- c o n tro lle d  a n d  
m a tc h e d  in te rm s  o f a g e , g e n d e r  a n d  a  p o te n t ia l ly  c o n fo u n d in g  g e n e t ic  p o ly m o rp h is m  
a s s o c ia te d  w ith  lip id  m e ta b o lis m  (a p o  E g e n o ty p e ) . T h is  h e lp e d  to  m in im is e  th e  in te r ­
s u b je c t v a r ia b il ity  in tro d u c e d  b y  th e s e  fa c to rs .
T h is  s tu d y  w a s  p a r t o f a  m u c h  la rg e r  B B S R C  fu n d e d  tr ia l to  in v e s tig a te  th e  e ffe c ts  o f 
d ie ta ry  s u g a rs  o n  l ip o p ro te in  k in e tic s . T h e  in v e s tig a t io n  o f l ip o p ro te in  k in e tic s  in vivo 
u s in g  s ta b le  is o to p e  tra c e rs , p la c e d  c o n s tra in t  o n  th e  s a m p le  s iz e  fo r  th e  d ie ta ry  
in te rv e n t io n , l im it in g  th is  to  o n ly  2 5  p a r t ic ip a n ts . W h ile  it is  p o s s ib le  in  s o m e  c a s e s , 
th a t th is  in tro d u c e d  ty p e  ‘T  o r  fa ls e  p o s it iv e  e rro rs , it is  a ls o  c o n c e iv a b le  th a t  th e  
lim ite d  s a m p le  s iz e  p ro v id e d  in s u ff ic ie n t s ta t is t ic a l p o w e r  to  d e te c t d ie ta ry - in d u c e d  
d if fe re n c e s  in  p la s m a  lip o p ro te in s  a n d  a p o p ro te in s . In a g re e m e n t w ith  a  p re v io u s  
lo n g - te rm  d ie ta ry  in te rv e n t io n  s tu d y , th e re  w a s  a ls o  th e  p o te n t ia l o f  re d u c e d  
c o m p lia n c e  o v e r  t im e  [2 2 2 ]. C h a n g e s  in  b o d y  w e ig h t  a n d  c a r ry -o v e r  e f fe c ts  b e tw e e n  
in te rv e n t io n  p h a s e s  w e re  th e  m a in  c o n fo u n d in g  fa c to rs  th a t m a y  h a v e  a d v e rs e ly  
a f fe c t th e  o u tc o m e s . H o w e v e r, a p p ro p r ia te  s ta t is t ic a l a d ju s tm e n ts  w e re  u n d e r ta k e n  to  
c o r re c t fo r  c h a n g e s  in  b o d y  w e ig h t, a n d  fo r  b a s e lin e  v a lu e s , e s p e c ia lly  a t th e  
b e g in n in g  o f th e  s e c o n d  d ie ta ry  in te rv e n t io n , a fte r  4  w e e k s  o f w a s h -o u t,  w h ic h  w a s  
in it ia lly  b e lie v e d  to  b e  o f a d e q u a te  le n g th  [2 3 9 ].
T h e  m e a s u re m e n t o f H D L  a n d  L D L  s u b c la s s  d is tr ib u t io n  b y  g ra d ie n t  g e l 
e le c tro p h o re s is  w a s  e x p e n s iv e , la b o u r  in te n s iv e , a n d  th e  d a ta  w a s  u n d o u b te d ly  
a s s o c ia te d  w ith  s ig n if ic a n t ly  g re a te r  v a r ia n c e  th a n  th e  o th e r  m e a s u re s  o f p la s m a  
lip id s . N e v e rth e le s s , it w a s  p re d ic te d  th a t a  C H O - in d u c e d  in c re a s e  in  p la s m a  T A G  
w o u ld  re d is tr ib u te  L D L  a n d  H D L  p a r t ic le  s iz e  to w a rd s  s m a lle r  a n d  d e n s e r  p a r t ic le s . 
T h e  a im  o f th is  in v e s tig a t io n  w a s  to  p ro v id e  e v id e n c e  fo r  th e  m e c h a n is m  o f a c t io n  o f 
d ie ta ry  s u g a rs  on  p la s m a  lip id s , in c lu d in g  h o w  a  ra is e d  p la s m a  T A G  re m o d e ls  L D L  
a n d  H D L , a n d  th u s  h o w  d ie ta ry  s u g a rs  c a n  in c re a s e  C V D  r is k  b y  in c re a s in g  th e
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p o te n t ia l a th e ro g e n ic ity  o f  th e s e  lip o p ro te in s , e s p e c ia lly  in  in d iv id u a ls  w h o  a re  a lre a d y  
a t in c re a s e d  c a rd io -m e ta b o lic  r is k  [3 9 9 , 4 6 1 , 4 6 2 ]. U n fo r tu n a te ly , th e  p la s m a  fo r  th e  
a n a ly s is  o f lip o p ro te in  s u b c la s s e s  h a d  b e e n  s to re d  a t -8 0 °C , w h ic h  is  k n o w n  to  
re d u c e  th e  s tru c tu ra l in te g r ity  o f  l ip o p ro te in  s u b tra c t io n s , a n d  m a y  h a v e  c o n tr ib u te d  to  
th e  re la t iv e ly  p o o r  re s o lu t io n  o f L D L  s u b c la s s e s  in c o m p a r is o n  to  H D L  s u b c la s s e s  o n  
G G E  a s  re p o r te d  in C h a p te r  5 .
7.6 Future work
T h is  re s e a rc h  p ro je c t h a s  id e n tif ie d  a  n u m b e r  o f l im ita t io n s  a n d  p ra c t ic a l c o n s tra in ts ,  
th e  c o r re c t io n  o f w h ic h  w o u ld  in fo rm  a n d  im p ro v e  fu tu re  s tu d ie s .
W e ig h e d  d ie ta ry  in ta k e s  a n d  7 -d a y  d ie t  d ia r ie s  w o u ld  im p ro v e  th e  p re c is io n  a n d  
a c c u ra c y  o f m e a s u r in g  d ie ta ry  in ta k e s . P h y s ic a l a c t iv ity  s h o u ld  a ls o  b e  m e a s u re d  to  
d e te rm in e  h o w  th is  im p a c ts  o n  v a r ia t io n  in  b o d y  w e ig h t, fa t  d is tr ib u t io n  a n d  p la s m a  
lip id s . E x te n d in g  th e  w a s h o u t p e r io d  (>  4  w e e k s  o r  s im ila r  le n g th  a s  th e  in te rv e n t io n )  
w o u ld  h e lp  to  m in im is e  a n y  o rd e r  o r  c a r ry -o v e r  e ffe c ts  b e tw e e n  d ie ta ry  t re a tm e n ts . In 
a d d it io n  to  th e  c u r re n t m e a s u re m e n ts , a  h o m e o s ta t ic  m o d e l a s s e s s m e n t (H O M A ) 
c o u ld  b e  u s e fu l to  d e te rm in e  in s u lin  s e n s it iv ity . A lth o u g h  c o n s id e ra b ly  m o re  la b o u r  
in te n s iv e  a n d  s p e c ia lis e d , th is  m e a s u re m e n t c o u ld  re f le c t th e  a c tu a l d e g re e  o f in s u lin  
re s is ta n c e  in  th e  p a r t ic ip a n ts , ra th e r  th a n  re la t iv e  c h a n g e s  in  th e  c o n c e n tra t io n  o f 
p la s m a  in s u lin  a n d  g lu c o s e . O u tc o m e s  fro m  th is  s tu d y , e s p e c ia l ly  fro m  th e  a n a ly s is  o f 
s m a lle r  s u b g ro u p s , w o u ld  a ls o  b e  m o re  re lia b le  w ith  a  la rg e r  s a m p le  s iz e .
T h e  d ie ta ry  e x c h a n g e  c o u ld  b e  a p p lie d  to  o th e r  ‘a t r is k ’ p o p u la t io n s , s u c h  a s  p o s t­
m e n o p a u s a l w o m e n , o f fs p r in g  o f p a tie n ts  w ith  T 2 D M , o r  o th e r  e th n ic it ie s  (A fr ic a n -  
C a r ib b e a n  a n d  A s ia n ) , w ith  v a r ia b le  g e n e t ic  a n d  m e ta b o lic  p h e n o ty p e s . It w o u ld  a ls o  
b e  in te re s t in g  to  o b ta in  a b s o lu te  c o n tro l o f d ie ta ry  in ta k e , b o d y  w e ig h t  a n d  p h y s ic a l 
a c tiv ity , b y  s tu d y in g  th e  e ffe c ts  o f th e  h ig h  a n d  lo w  s u g a r  d ie ts  in  a  m e ta b o lic  w a rd  
s e tt in g .
S u g a r -s w e e te n e d  b e v e ra g e s , s u c h  a s  fr u it  ju ic e s  a n d  f iz z y  d r in k s , h a v e  b e e n  
a s s o c ia te d  w ith  a d v e rs e  c h a n g e s  in c o m p o n e n ts  o f th e  m e ta b o lic  s y n d ro m e  in c lu d in g  
o b e s ity  a n d  ra is e d  p la s m a  T A G  in p re v io u s  s tu d ie s  [3 7 , 2 4 2 , 2 8 2 ]. T h e  p re s e n t s tu d y  
m a d e  no  a tte m p t to  d if fe re n t ia te  b e tw e e n  s u g a r -s w e e te n e d  b e v e ra g e s  a n d  s u g a r - r ic h
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s n a c k s  in  th e  s tu d y  fo o d s . H e n c e , an  im p o r ta n t a s p e c t o f fu tu re  in te rv e n t io n s  w o u ld  
b e  to  s tr ic t ly  c o n tro l th e  in ta k e  o f th e s e  fo o d s .
T h e re  is  a ls o  e v id e n c e  to  s u g g e s t th a t o th e r  d ie ta ry  c o n s t itu e n ts  m a y  b e  a b le  to  o f f ­
s e t th e  a d v e rs e  e ffe c ts  o f d ie ta ry  s u g a rs  o n  p la s m a  lip id s , m o s t n o ta b ly  p la s m a  T A G . 
E x a m p le s  o f th e s e  c o u n te ra c t iv e  e ffe c ts  in c lu d e  th e  T A G - lo w e r in g  e ffe c ts  o f lo n g - 
c h a in  n -3  P U P A  (L IP G E N E  s tu d y ) [2 7 1 , 4 6 3 ] a n d  f la v a n o id s  [4 6 4 , 4 6 5 ]. F u tu re  
s tu d ie s  s h o u ld  a d d re s s  th e  e ffe c ts  o f d ie ta ry  s u g a rs  o n  lip id  m e ta b o lis m , n o t ju s t  in 
is o la t io n , b u t in  c o m b in a tio n  w ith  o th e r  n u tr ie n ts  th a t  m ig h t m o d u la te  th e  e ffe c ts  o f 
d ie ta ry  s u g a rs  o n  C V D  r is k . M o re o v e r, a  h ig h  in ta k e  o f s u g a r, p r in c ip a lly  a s  N M E S , 
h a s  a ls o  b e e n  a s s o c ia te d  w ith  a  lo w  in ta k e  o f m ic ro n u tr ie n ts , s u c h  a s  c a lc iu m  a n d  
iro n  [4 6 6 ], in d ic a t in g  th a t  th e  m ic ro n u tr ie n t s ta tu s  m a y  b e  o f re le v a n c e  to  th e  o v e ra ll 
im p a c t o f d ie ta ry  s u g a rs  o n  h e a lth .
7.7 Concluding remarks
In c o n c lu s io n , th is  s tu d y  h a s  s h o w n  th a t  a  d ie ta ry  e x c h a n g e  m o d e l is  a n  e ffe c t iv e , 
p ra c t ic a l to o l fo r  m a n ip u la t in g  th e  q u a lity  o f d ie ta ry  c a rb o h y d ra te , v ia  re a l fo o d s , to  
in c re a s e  th e  in ta k e  o f s u g a rs . It p ro v id e s  e v id e n c e  to  s u g g e s t th a t a  d ie t  w ith  a  
g re a te r  p ro p o r t io n  o f s u g a r  to  s ta rc h  in c re a s e s  th e  e x p re s s io n  o f a n  A L P , a n d  h e n c e  
c a rd io v a s c u la r  r is k , b y  in c re a s in g  p la s m a  T A G . T h is  e f fe c t w a s  s h o w n  to  b e  g re a te r  
in in d iv id u a ls  w ith  m o d e ra te ly  ra is e d  l iv e r  fa t, p o s s ib ly  b e c a u s e  o f h e p a t ic  in s u lin  
re s is ta n c e  in  th is  g ro u p . M o re o v e r, th e re  w a s  a ls o  s o m e  in d ic a t io n  th a t  in d iv id u a ls  
w ith  m o d e ra te ly  ra is e d  l iv e r  fa t  e x p e r ie n c e d  m o re  p ro n o u n c e d  c h a n g e s  in  th e ir  b lo o d  
lip id s  w h e n  s w itc h in g  fro m  a  h ig h  s u g a r  d ie t  to  a  lo w  s u g a r  d ie t, s u g g e s t in g  th a t  th is  
g ro u p  m ig h t g a in  g re a te r  b e n e fits  fro m  th is  d ie ta ry  m a n ip u la t io n . T h e  s ta b le  is o to p e  
tra c e r  s tu d ie s  in th e  m a in  p ro je c t h a v e  a s s e s s e d  c h a n g e s  in th e  k in e t ic s  o f p la s m a  
l ip o p ro te in  a n d  de novo l ip o g e n e s is . T h e s e  d a ta  w ill p ro v id e  v a lu a b le  in fo rm a tio n  o n  
th e  u n d e r ly in g  m e c h a n is m s  fo r  th e  d if fe re n tia l lip id  re s p o n s e s  to  th e  tw o  d ie ts . 
B e c a u s e  th e  a d v e rs e  e ffe c ts  o f th e  d ie ta ry  in te rv e n t io n  w e re  a s c r ib e d  p r im a r i ly  to  
N M E S , it w a s  c o n s id e re d  c ru c ia l to  d e f in e  th e  in ta k e  o f th e s e  s u g a rs  b y  a ll a v a ila b le  
m e th o d s . A lth o u g h  th e re  w a s  an  in c o n s is te n c y  b e tw e e n  th e  m e th o d s , th e re  w a s  s till 
e v id e n c e  fo r  a  n e g a tiv e  re la t io n s h ip  b e tw e e n  th e  in ta k e  o f N M E S  a n d  b lo o d  lip id s , 
e s p e c ia l ly  a t in ta k e s  o f N M E S  in  e x c e s s  o f 1 0 %  e n e rg y , ir re s p e c t iv e  o f th e  m e th o d  
u s e d  to  d e te rm in e  in ta k e .
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Current dietary advice for the management of patients with fatty liver disease, 
advocates a low fat diet. However, the outcome of the present study highlights the 
need for a moderate intake of CHO (45-55% E) and to restrict sugar, as NMES, to 
less than 10% of food energy, to ameliorate risk arising from dyslipidaemia and 
hepatic steatosis. In addition, and whenever possible, dietary recommendations 
should give consideration to an individual’s predisposition to cardio-metabolic risk 
arising from increased liver fat and insulin resistance.
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This op in ion  is given on the  understand ing th a t you w ill com ply w ith  th e  University's 
Ethical Guidelines fo r  Teaching and Research,
The C om m ittee should be n o tif ie d  o f any am endm ents to  the  p ro toco l, any adverse 
reactions suffered by research partic ipants, and if  the  study is te rm in a te d  ea rlie r than 
expected w ith  reasons.
You are asked to  no te  th a t a fu rth e r submission to  th e  Ethics C om m ittee  w ill be 
requ ired in the  event th a t the  study is no t com ple ted w ith in  five  years o f th e  above 
date.
Please in fo rm  me w hen th e  research has been com pleted.
Yours sincerely 
A im ee Cox (Miss)
Secretary, University Ethics Com m ittee 
Registry
cc: Professor T Desombre, Chairman, Ethics C om m ittee
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Appendix 4: Example of 3-day diet diary
SMALL
Food portion sizes (10 inch plate) 
MEDIUM
Suitable for boiled spaghetti, other pastas and noodles
Suitable for boiled or roast potatoes\/
LARGE
\/
Suitable for mashed potatoes
w
\  /
Suitable for baked beans and peas
V
2 6 6
Appendix 4: Example of 3-day diet diary (Cont.)
SMALL
Food portion sizes (10 inch plate) 
MEDIUM LARGE
Suitable for vegetable or meat stews (not meat without vegetables)
V
. . . .
m
Suitable for fish in breadcrumbs or batter (not for chops or steaks)
\ /
Suitable for chips only
" \ i
\
\ \
»
Suitable for boiled rice and rice dishes
267
Appendix 4: Example of 3-day diet diary (Cont.)
Food portion sizes (10 inch plate) 
SMALL MEDIUM LARGE
Suitable for Corn Flakes and other breakfast cereals
ê
Suitable for Cheese (not butter or spread)
Suitable for Quiche, sweet or savoury pies and pizza (not cakes)
k ' v
\  f
/
/
xC I f
'
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Appendix 4: Example of 3-day diet diary (Cont.)
Sugar will appear on food labels as different names. Examples of ingredients that 
mean sugar are listed below.
•  Anything that says sugar e.g. granulated, brown, demerara, muscovado, 
barbados, invert, castor, icing, confectioner's, turbinado
• Anything which ends in ‘ose’ e.g. sucrose, glucose, fructose, galactose, 
maltose, dextrose
• Syrups; corn, high fructose corn syrup, maple, golden, rice syrup
• Maltodextrin, Honey, molasses, treacle
It will help to complete the food diary if you write the type of food you consume 
on a regular basis. Please circle the most appropriate option.
Food Type / amount
Milk Skimmed Semi-skimmed Whole Soya Other please specify
Bread White Wholemeal Brown Granary Seeded Other (please specify)
Size of loaf Small large
Type of slice Unsliced thin medium thick extra thick
Brand of bread
Spread Butter Margarine low fat spread v low fat spread
Brand of spread
Sugar in tea None 1 2 3 more than 3 (please specify)
Sugar in coffee None 1 2 3 more than 3 (please specify)
Milk in tea None dash average milky
Milk in coffee None dash average milky
Visible fat on meat Eat as little as possible most of it don’t eat meat
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Appendix 4: Example of 3-day diet diary (Cont.)
EXAMPLE DIARY PAGE 
Date: _1_ / _ 8 _  /  2 0 0 8 Day of the week: frC d a y
T im e /o fV ay
food/Gr VrLv\Jk/ 
Ve4/crib€/iYv<detX!U^iv\xdAAdi¥\/^hra^\â/Y\ame4/' 
wh&tvponihle/
Am oarvtGatetv
8.00(m v Tea/wi^iemX/-!,kXmm£d/mXlk/Cno-SdA^^^) 1 yyuA^
Too4( t  CHovC&'^cm4X4y thick/d/Cced/) 2 d icey
ScMyi/CTe^tCO-stroMberty) OKi/tDOôù Thick/ ypread/
Spread/ (U tterley  BiAttsrly) on/tiyaat Thlvdy ypread/
O ra n ^ fu lc e /  (Trùpicaviahmxyxyidv) 1 ymaü/çfici4fy
10.30am / Coffee/ (no-m tlk/) 1 wiaç^
S a ^ a r (in/coffee/) 1 tea4f>ooŸ\/
Chx>colate/di^eiitX^e&' CMcvCCW 2 hi&caCty
1.30pm/ Lundh/from/ Coffee&hop:
SandAvCch/
- WhCtB'hread/Cmedium/SlUced/) 2 d icey
- M arg arin e / (lAAtk^^owivhrcmd/) UnJbnowKv
- H am / CiA4dcnowy\/hrand/) 2  dicey
- Tomedxt 3 d icey
- LettiAce/ 2 lea^/ey
coke/ 330mJUcaw
Keady malted/criipy (W alkery) 2 5 g -b a ^
Ba4^ana/ 1 m edium /
3.30pm/ Twifi/ 5 8 ^
Tea/W i^iemA/-!kXmmed/yyUlk/Cno-iu^ar) I  m u ^
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Appendix 4: Example of 3-day diet diary (Cont.)
Tvme/of
V a y
food/£r Vrivik/ 
Ve^erCbe/v^detatUivudAAdiyig'hravid/ 
ncAAneywhedVpoiivble^
Am oiAntTaten/
3.30pm/ TwOii/ 580^
Teeu\oiid^iemA/-dUmmed/YyUXk/ 1  tnug'
7.00pm/ C hicken/curly (iee/reelpe/helchv) K  o f recipe/
L(>ng'grain/whitc^rOce^ -  htyüed/ M ed/portion/
^arllc/Gr C o rian d er YUAun/hread/CTefeer) ^  la rg e /n a a n /
W hite/wine/ 1 la rg e /çjlcL&y
StraAwherry y o g u rt CM a U e rlig h t) 200g'
9.30pm/ Cream/ craekery (Jaeohy) 2 cracker y
Minl/hahyhetchee&e/ 1 portion/
Whlte/wine/ 1 ymxAXigla{/y
Notes / comments / recipes:
Chlcken/caryy (ServeyZ) -  1 YyiedUAm/oniony 1 c love/
garlCci 1 tcüÂeipûtyn/yAA^flxywer oü/, 2 ta M e ^ o o n y  ouriy  I  ^  pCwty
chlcheAVytocki 3 tiMe^oxyyiyyAltaeiayj 4  tcMe^oxyn^r'loM) f a t  n a tu re ^  
yogdATt, 1 tcM e^ipoon /œ rv iP jyur
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Appendix 4: Example of 3-day diet diary (Cont.)
Day 1/2/3
Date: / / Day of the week:
Time of Day
Food & Drink
Describe in detail including brand names when 
possible
Amount Eaten
272
Appendix 4: Example of 3-day diet diary (Cont.)
Time of Day
Food & Drink
Describe in detail including brand names when 
possible
Amount Eaten
Notes / comments / recipes:
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Appendix 7: Nutritional cards
H IG H  SUGAR D IE T  
FOOD D R IN K
100  g Portion 100  g Portion
kJ 1553 708 207 411
Calories 370 169 49 98
Tot CHO 72 32 12 23
Sugars 40 18 12 23
Starch 32 14
Fat 9 3
Fibre 2 1
100 g Portion 100  g Portion
kJ 1582 713 32 35
Calories 377 170 7.6 8
Tot CHO 71 32 1 1
Sugars 4 2 1 1
Starch 67 30
Fat 7 3
Fibre 3 2
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SURREY
“THE EFFECT OF DIETARY  
CARBOHYDRATE ON 
LIPIDS
P a r t i  c i p  a n t
H A N D B O O K
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Thank you fo r vo lu n teerin g  to  ta k e  p art in th is  study.
Please take your tim e to read th is booklet, which gives you 
advice on the food we will be asking you to eat during the study.
G e n e r a l  g u id e l in e s
For the next 8  m onths you will be eating your normal d ie t but 
replace two th irds of your carbohydrate foods w ith the ones we 
provide.
All the foods provided are everyday foods bought from  a 
superm arket and do not contain any unusual ingredients.
The type of food you should avoid during the study will be explained 
in this booklet.
Y o u r  Q u e s t io n s  a n s w e r e d
W h at is th e  aim  o f th e  study?
There is an underlying relationship between dietary carbohydrate 
and increased Cardiovascular Disease (CVD) risk. The aim o f th is  
study is to determ ine the effects o f d ietary carbohydrate in 
association w ith increased CVD risk by measuring changes in your 
blood lipids and liver fat. The answer will provide valuable 
inform ation fo r influencing fu tu re  d ie tary recom m endations fo r public 
health.
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W hy is it im p o rtan t th a t I  fo llo w  th e  d ie ta ry  advice?
The success of the study is wholly dependant on people like you 
volunteering their time and complying to the dietary instructions. 
The two diets have been designed to be similar nutritionally apart 
from the sugar content. Page 11 shows a table of the average 
nutritional content of the foods of each of the diets per lOOg.
W ill I  lose any w e ig h t on th e  study?
We do not want any weight loss or gain during the study. It  is 
important that you stay as weight stable as possible as any weight 
change will confound the results. You will be weighed every two 
weeks to monitor any weight change.
W h a t support w ill I  receive to  help m e fo llo w  th is  d iet?
The diet you are required to follow is based on what you usually 
eat (background diet) with some modifications. If  you are unable 
to eat the foods we provide it is important to tell us and we will 
offer alternatives so that you can continue to take part.
W h a t changes w ill I  have to  m ake to  m y diet?
You have to exchange two thirds of the carbohydrates you eat in a 
day with the food we provide. You will incorporate six portions of 
food that contains 36g of carbohydrate in each portion into your 
diet (216g in total).
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F O O D  P R O V I D E D  O N  T H E  S T U D Y
The food will be delivered to your home every two weeks at 
the time of the monitoring appointment.
Bread. Your study centre will provide this. It 
may be stored in the freezer until you are 
ready to eat.
B reakfast cereals. Your study centre wil 
provide these.
Snacks. Your study centre will provide these.
S ugar-con tain ing  drink . Your study centre 
will provide this.
A rtific ia l S w ee ten er. Your study centre wil 
provide this.
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F O O D S  N O T  P R O V I D E D  O N  T H E  S T U D Y
You can help us by taking care when choosing foods to eat on each 
phase of the study.
During the low sugar d iet phase we would ask you to eat as little  
sugar as possible. In particu lar by not adding sugar to your drinks 
or cereal (you will be provided w ith artific ia l sweetener) and 
avoiding highly processed sweet or savoury foods. Eating whole 
fru it and vegetables instead of ju ices and soups.
M anufactured  food
Even savoury food can contain a lo t of sugar. Sugar comes in 
many form s which have d iffe ren t names.
Exam ples o f ingred ients  th a t a re  sugar and to  be avoided on
th e  low  sugar phase.
• Anything tha t says sugar e.g. granulated, brown, dem erara, 
muscovado, barbados, invert, castor, icing, confectioner's, 
turbinado
• Anything which ends in 'ose ' e.g. sucrose, glucose, fructose, 
galactose, maltose, dextrose
• Syrups; corn, high fructose corn syrup, maple, golden, rice 
syrup
• M altodextrin, stevia
• Honey
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H I G H  S U G A R  D I E T
Dally Intake; 6 portions a day. Each portion provides 36 g of 
carbohydrate meaning that the total weight of the food portions varies.
Study Foods Quantities Advice on how to achieve
Bread /  m a ltlo a f 1 portion= Replace 1 portion of the bread 
2  slices you norm ally eat w ith the
bread /  m altloaf provided.
B reakfast cereals
Snacks
Biscuits /  cakes
Sugar-contain ing
drinks
1  portion = Replace 1 portion of the cerea
40 grams you norm ally eat w ith the
cereal provided.
1  portion = Replace 1 snack you norm ally
1  slice / eat w ith the snack provided.
pack
1  portion = Replace 1 portion o f the
various; biscuits /  cakes you norm ally
see portion eat w ith the biscuit /  cakes
sheet provided.
1  portion Replace 1 portion of the drink
you norm ally drink w ith the 
drink provided.
We are not replacing all of your food. You can still ea t your usual 
d ie t w ith  th e  exchanges as above.
Please eat o ther foods (m e a t/f is h , d a iry  p ro d u c ts /fa ts /f ru it  
and vegetab les , te a , coffee or w a te r )  in the same 
quantities you usually eat them .
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H I G H  S U G A R  D I E T
Foods to Choose
Bread Breakfast cereal / Bar
Snack / Biscuit
school
SUCES
Drinks
Foods to Avoid
Other cereals 
Crisps 
Crackers
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L O W  S U G A R  D I E T
Daily Intake; 6 portions a day. Each portion provides 36 g of 
carbohydrate meaning that the total weight of the food portions varies.
Study Foods Quantities Advice on how to achieve
B read /C ru m p ets  1 portion
2  slices
B reakfast cereals 1 portion
40 grams
Replace 1 portion o f the 
bread/crum pets you
norm ally eat w ith the 
bread/crum pets provided.
Replace 1 portion o f the 
cereal you norm ally eat w ith 
the cereal provided.
Snacks
Biscuits
/B read s ticks
1 portion = Replace 1 snack you 
1  slice/pack norm ally eat w ith the snack 
provided.
1 portion = Replace 1 portion of the 
various; biscuits .you norm ally eat 
see portion w ith the b iscuit/breadsticks 
sheet provided.
S ugar-contain ing
drinks
sw eeteners
1 portion Replace 1 portion o f the 
drink tha t you norm ally d rink 
w ith the drink provided or 
water.
As required Replace any sugar on cereal 
or in drinks w ith the 
sweeteners provided
We are not replacing all o f your food. You can still e a t yo u r  
usual d ie t w ith  a fe w  exchanges as above.
Please eat o ther foods (m e a t/f is h , d a iry  p ro d u c ts /fa ts /f ru it  
and vegetab les, te a , coffee or w a te r )  in the same 
quantities you usually eat them .
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L O W  S U G A R  D I E T
Foods to Choose
Bread/Crumpet Breakfast cereal Spreads / sauces
Snacks/Biscuits
1
Foods to Avoid
Other cereals 
Sugar of any kind 
Fruit juices / smoothies / sugary drinks 
Sweets / biscuits 
Jam, marmalade, hazelnut-chocolate spread, lemon curd 
Chutneys, tomato ketchup, pickles 
Ice cream Cakes, pastries
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D A T E S  F O R  Y O U R  D I A R Y
There are 11 v is its  th a t you are required to  make in to ta l th roughou t the study period. 
8  v is its to  the Cedar Centre a t the  Royal Surrey County Hospital.
3 v is its to  Ham m ersm ith Hospital fo r the MRI scan.
The table below shows the dates o f your appointm ents
Visit D u ra t io n A p po in tm ent D ate
1
30
m inutes
Cedar Centre (screen)
2 1 hour Ham m ersm ith (MRI scan)
3
15
m inutes
Home (explain study)
4
30
m inutes
Cedar Centre (s ta rt ph 1)
5 1 hour Ham m ersm ith (MRI scan)
6
30
m inutes
Cedar Centre (g ive w ater)
7
A ll day  
( l lh o u r s )
Cedar Centre (study day)
8
30
m inutes
Cedar Centre (s ta rt ph 2)
9 1 hour Ham m ersm ith (MRI scan)
10
30
m inutes
Cedar Centre (g ive w ater)
11
A ll day  
( l lh o u r s )
Cedar Centre (study day)
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Target values of the food exchanges.
There may be tim es when you do not have access to  o r w ant to  eat 
foods o the r than the ones you have been provided; the tab le  below 
shows the nutritiona l content o f the foods in each o f the  High or 
the Low phases o f the study per lOOg and per portion.
T a rg e t n u tritio n a l co n ten t
High sugar foods Low sugar foods
lOOg portion lOOg portion
Calories 385 191 371 178
Tot CHO 71 35 70 34
Sugars 4 0 20 4 2
Fat 9 3 6 2
Fibre 2 1 4 2
T a rg e t n u tritio n a l co n ten t Per 100  g
High sugar drinks Low sugar drinks
lOOg portion lOOg portion
Calories 44 159 0.5 2
Sugars 1 0 38 0 0
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Study centre: Post Graduate Medical School, 
University of Surrey 
Daphne Jackson Road, 
Guildford, GU2 7WG
Principal
Investigator
Prof Bruce Griffin
b.griffin@ surrey.ac.uk
Study contact: Cheryl Isherwood
c.isherw ood@ surrey.ac.uk  
(01483) 688642  
07887 751198
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UNIVEFLSiTY OF
SURREY
" H d h  m '"
"vvou.Ld you, Ltfee to ta  fee p a r t  i iA . a 
food s tb tdy?”
we a n  at the effects o f eatlv^^
s>u(^ar^ s>v\.ao\zs> d\a. your body
we  dre loo\zi\A.Q for;
f-fedtthy c^ auea£,lon^  n&giA,
/A0£d( -^O- <c>5
w ith  CK wai£t m^eRsurentei^t o f m,ore thai^ 3>y- l/vohes
Rec.ru.ltliA.0 u.iA,tlL sept£m,ber 2010
We wlLL provide you. w ith  01LL the food «wd oowupewsate you. 
fo r you r tlm,e Rwd Iwoowvewlewce.
Cowtaot Cheryl: 0 1 4 g3-6gg642
E-malL: c.lsherwood@surrey .flc-.ufe.
This s tud y  hAs received favourable ethical oplwlows fro ru  the
S urrey  i^esearch Ethics Coru/ulttee awd u n iv e rs ity  o f 
S urrey Ethics Commlttee
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UNIVERSITY OF
Participant Information sheet
Study T itle : "The Effect o f D ietary Carbohydrate on Lipids,"
You are being invited to take part in a study investigating how dietary 
carbohydrate affects fat metabolism. Before you decide if you wish to participate, 
it is important for you to understand why the research is being done and what it 
will involve. Please take time to read the following information carefully and 
discuss it with your friends, relatives and anyone involved with your care. Please 
ask us if there is anything that is not clear or if you would like more information.
W hy have I  been chosen?
In this study we are looking for men, aged between 40-65, who are overweight 
but do not have diabetes. We want participants to be weight stable and not taking 
any other medication that may affect metabolism.
Do I  have to  ta k e  part?
It  is up to you to decide whether to take part or not. I f  you decide to take part 
you will be given this information sheet to keep and asked to sign a consent form. 
I f  you decide to take part you are still free to withdraw at any time and without 
giving a reason.
W h a t w ould  happen to  m e if I  ta k e  part?
If  you are interested in taking part in this study, you would come to the Cedar 
Centre at the Royal Surrey County Hospital in the morning, without having had 
breakfast, for an initial chat about the project, when we would measure your 
height, weight, take your blood pressure and take a small blood sample to 
measure your glucose, insulin, blood chemistry and fat levels. After this you will 
be provided with a snack and drink. This is a screening visit (V IS IT  1) to make 
sure you do not have diabetes or any other disorder that may affect you taking 
part in the study. We also ask you to fill in two short questionnaires about your 
general health and diet. We would normally inform you of your results within 2 
weeks of this visit.
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I f  following this screening visit, you are found to fulfil the recruitment criteria and 
you are still happy to take part we will ask you to visit the Hammersmith Hospital 
in London for a second screening visit (V IS IT 2) to measure the amount of fat in 
your liver. We are recruiting subjects with very low or moderate levels of liver fat.
I f  you fulfil these criteria we will ask you to undertake a dietary intervention for a 
period of 32 weeks. This will comprise a 4 week diet based on the average UK diet 
followed by a 12 week diet with either high or low sugar foods, followed by a 4 
week diet based on the average UK diet and finally a 12 week diet with either high 
or low sugar foods (depending on which diet you followed for the first 12 weeks). 
Half the men in the study will have the high sugar foods first and the low sugar 
diet second and the other half will have the low sugar diet first and the high sugar 
diet second. The nutritionist will give you guidance and advice on how to follow 
this diet at the Cedar Centre before you start, and on how to complete a 3-day 
diet diary (V IS IT 3). Diet diaries will be completed at the end of the run-in diet, 
and at 6 and 12 weeks during each 12 week dietary period. We will ask you to 
meet the nutritionist every 2 weeks, who will also contact you by telephone during 
the weeks you do not meet.
At the end of the first 4 week diet we will ask you to visit the Cedar Centre at the 
Royal Surrey County Hospital for a blood test to measure your blood fat levels 
(V IS IT 4 ). You will then be allocated to one of the two diets. At week 11 of the 
diet you will be asked to visit Hammersmith Hospital for another MRI scan (V IS IT  
5). This visit is identical to visit 2. At the end of the first 12 week diet we will ask 
you to visit the Cedar Centre on 2 successive days for a series of tests (VISITS 6 
and 7). At the end of the second 4 week wash-out we will ask you to visit the 
Cedar Centre for a blood test to measure fat levels (V IS IT 8) to start the next 
diet. At the end of the second 12 week diet at week 11 you will be asked to visit 
Hammersmith Hospital for another MRI scan (V IS IT 9). This visit is identical to 
visit 2 we will ask you to visit the Cedar Centre on 2 successive days for a series 
of tests (VISITS 10 and 11). These tests will be identical to the tests done at 
visits 6 and 7.
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V IS IT S  2, 4  and 7
You will be asked to go to the Hammersmith Hospital, London after a 10 hour fast 
to have an MRI (magnetic resonance imaging) scan. MRI is a body scanning 
technique, which is used in hospitals worldwide to create images of the inside of 
the body. MRI has been used safely for several decades and has no known side- 
effects. Each scan is directed to the specific requirements of the research study in 
which you are taking part. The M R I scan is pure ly  fo r th e  detectio n  o f live r  
fa t  and is not fo r th e  purposes o f a health  check.
You will be given an appointment for magnetic resonance scans at the Robert 
Steiner MRI unit and asked to come fasted (nothing to eat or drink for 10 hours 
before your scan) however you may drink some water and take any medication 
you would normally do.
As the MRI scanner uses high magnetic field we have to make sure you do not 
have any metallic object in or on your body to ensure your safety. Before starting 
the scanning we will ask you to complete a short checklist. This will ensure that 
you do not have any magnetic implant (such as a cardiac pacemaker) which will 
stop us performing the scan. These scans are safe and do not involve any 
radioactivity or X rays.
You will be in the MR scanner for up to 1 hour. None of the magnetic resonance 
imaging techniques uses ionising radiation or intravenous contrast agents and 
may be performed during a single imaging session. You lie flat in the scanner and 
are automatically moved through the scanner. Whole body anatomical MR 
scanning will be performed to determine total and regional fat volumes, and 
magnetic resonance spectroscopy (MRS) performed to measure lipid content in 
internal organs, such as liver (IHCL) and muscles (IMCL), such as soleus and 
tibialis.
You may hear a knocking noise during part of the procedure, and you will 
experience no discomfort. We will give you an alarm bell to sound at any time if 
you are upset or worried during the examination and if the procedure does not 
suit you for any reason it can be stopped at any time.
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ANTHROPOMETRY
Baseline anthropometric measurements including height, weight, waist and hip 
circumference, skinfold thickness, blood pressure, body-volume, and bioelectrical 
impedance analysis of percentage body fat. The bioelectrical impedance is a 
painless, safe procedure which involves either lying on a couch with sticky pads 
placed on a hand and foot, or standing on a metal platform for 1 minute so that 
the body's electrical resistance can be measured.
What i f  anything abnormal is discovered?
MRI is a powerful, diagnostic body scanning technique used in hospitals worldwide 
to create images of the inside of the body. MRI has been used safely for several 
decades and has no known si de-effects. These scans cannot be viewed as a health 
screening procedure. However, very rarely, unexpected information can 
be detected which may warrant further investigation. In this event, a report will 
be sent to your GP, who will arrange further tests and coordinate your further 
care. The doctor involved in the research study will also be informed.
V IS IT  3
You will be asked to come to the Royal Surrey County Hospital in the morning 
having fasted since 10 pm the previous day. At this visit we will take a blood 
sample to measure fat levels. After the sample is taken you will be provided with a 
snack and drink. You will then meet with the nutritionist who will explain about the 
12 week diet we would like you to be on. She will supply you with the food you will 
need for this period. If  you do not attend by car, we can arrange for the food to be 
delivered to your home. This visit will take about 30-45 minutes.
V IS IT  4
Hammersmith Hospital MRI scan. This visit is identical to visit 2.
V IS IT  5
This visit will take place at the end of the 12 week diet with high or low sugar 
content. We ask you to attend the Cedar Centre at the Royal Surrey County 
Hospital. A blood sample will be taken and you will be given 2 small bottles of 
water containing labelled water and one large bottle of water containing labelled 
water. You will be asked to drink one small bottle of the labelled water at 7pm
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after your evening meal and the other small bottle at 10pm the same night. After 
7pm, if you need to drink we will ask you to drink only the water in the large 
bottle without any other food. This visit will take about 20 minutes. We will 
provide you with a standard ready-meal for your evening meal (of your choice) to 
take home.
V IS IT  6
The next day you will be asked to come to the Cedar Centre at the Royal Surrey 
County Hospital at 7.30am having fasted since 8pm the previous day. We will 
provide you with a standard ready-meal for your evening meal to eat at home the 
day before the study. We ask you not to undertake any vigorous activity for 2 
days before this visit and not to drink alcohol the day before.
We will put 3 fine plastic tubes into your veins. Two will be placed in a vein in 
each elbow and one in a wrist vein. The tubes are made of a flexible plastic and 
so once placed should not cause any discomfort and will not impede your arm 
movements. After taking a baseline blood sample, we will inject a labelled 
molecule of glycerol (which is a non-harmful fat that our body normally produces) 
to measure how much fat your liver is making. We will also start pumping 
(infusing) 2 solutions at a slow rate into one of the tubes in your elbow for 10 
hours. This contains a labelled molecule of palmitic acid (another non-harmful fat 
that our body normally produces) bound to a blood protein albumin which can be 
used to measure how much fat your body is burning. This solution also contains a 
labelled amino acid which measures the number of particles of fat that your liver 
makes. At frequent time intervals during the 10 hour study blood samples will be 
taken from the vein in your elbow and the vein in your wrist. While we are taking 
blood from your wrist we will ask you to place your hand inside a "hot-box" for 20 
minutes before we take a blood sample. This box is made of Perspex and heats 
the blood in your wrist making the blood similar to blood found in arteries. It  will 
make your hand hot but this is not uncomfortable. You will not feel the blood 
samples being taken. At the end of the study we will measure the activity of 2 
enzymes which break down fat in your blood. A small amount of a substance called 
heparin will be injected which releases the enzymes then a blood sample will be 
taken 15 minutes later. The total amount of blood we will take in this test is 11 
tablespoons of blood (220mls).
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During the study you will be free to write/read or watch DVDs within the unit. 
Drinking water will be made available throughout the study although food will only 
be provided at the end of the study. Although you will be connected to an infusion 
pump, that pump can be moved so there will be no limit to going to the toilet etc. 
At the end of the study day you will be provided with a meal of your choice with tea 
or coffee. The whole procedure (from arrival to going home) would take 
approximately 11 hours.
V IS IT  7
This is before you start your second diet and identical to visit 4.
V IS IT  8
Hammersmith Hospital MRI scan. This visit is identical to visit 2.
V IS IT S  9 and 10
These are at the end of your second diet and identical to visits 6 and 7.
Expenses
All travelling expenses will be reimbursed and there will be an inconvenience 
allowance of £200 payable upon completion of the study.
W h a t do I  have to  do?
You will need to have fasted overnight (for 12 hours) for some of the visits. This 
means having no food or drink, other than water, after your evening meal the day 
before your visit. In addition, we will ask you to eat a standard ready-meal, which 
we will provide for you to eat at home, for your evening meal the night before 
visit 6 and visit 9. We also ask you to refrain from vigorous exercise for 2 days 
before these visits and to avoid alcohol.
W h a t a re  th e  possible d isadvantages and risks o f tak in g  part?
The risks of having a cannula in a vein are those associated with any blood 
sample. These are slight pain, possible bruising and, in principle, a local infection. 
We will try and avoid these problems.
In visit 5 and 8 one of the labelled molecules is bound to albumin. As this is a 
blood protein there is a small risk of allergic reaction. Albumin is a blood protein
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and is purified from human blood. As such there is a very small risk of 
transmission of infectious diseases. To minimise this, the albumin is purified from 
blood donors who have been screened for pathogenic viruses and the albumin is 
heat treated to inactivate viruses.
In visit 5 and 8 we will administer a small amount of heparin which thins the 
blood. You will be advised to avoid caffeine for 4 hours after this. You may have 
excessive bruising if you hit yourself hard within 4 hours of the procedure.
W h a t a re  th e  possible benefits  o f tak in g  part?
You will be helping medical science to understand how different types of 
carbohydrate affect fat metabolism. This will help formulate appropriate dietary 
advice for men at risk of metabolic syndrome.
W h a t if som ething goes w rong?
If  you are harmed by taking part in this research project then you may have 
grounds for legal action. Regardless of this, if you wish to complain about any 
aspect of the way you have been approached or treated during the course of this 
study, the normal University complaints mechanisms are available to you.
Com plaints
Any complaint or concerns about any aspects of the way you have been dealt with 
during the course of the study will be addressed. Please contact Prof. Bruce 
Griffin, Principal Investigator on 0 1 4 8 3  6 8 9 7 2 4 .
W ould m y tak in g  p a rt in th is  study be kep t confidential?
All information which is collected about you during the course of this research 
would be kept strictly confidential. Any information about you which leaves the 
hospital or University would have your name and address removed so that you 
cannot be recognised from it. With your permission, your GP will be notified of 
your participation in this study.
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W h a t w ould  happen to  th e  results  o f th e  research study?
The results of this study will be published in the scientific press and you will not 
be identifiable in any way. It  is our usual practice to send copies of any resultant 
publications to research participants.
W ho is organising th e  funding and research?
This research is being funded by the B io te ch n o lo g y  a nd  B io lo g ic a l Sciences
Research Council, a government funded research body.
W ho rev iew ed  th is  study?
The study was reviewed by the Surrey Research Ethics Committee.
C ontact fo r fu rth e r  in form ation?
Cheryl Isherwood (01483 688642) c.isherwood@surrey.ac.uk
Prof Bruce Griffin (01483 689724) b.griffin@surrey.ac.uk
Dr John Wright (01483 571122 ext 4844) john.wright@surrey.ac.uk
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Dietary Study at Surrey University
I am not sure who is the best person to contact; I hope that you can help me.
W e are looking for help to recruit participants for a dietary study at the University of 
Surrey.
The study is examining the effect of dietary carbohydrate on fats in the blood and liver 
in healthy, Caucasian men 40 to 65 years old, BMI 26 -  32.
It is a very interesting study. The participants we have enrolled so far are enjoying the 
experience. It gives an insight into what is happening inside their body and an 
opportunity to have an MRI scan.
I have enclosed some leaflets about the study. I would really appreciate if you would 
help me distribute the leaflets among colleagues or employees or put them up on 
display.
The study is Government funded and has ethical approval. All the food we supply are 
normal foods from the supermarket.
If you would like to know more about the study or could recommend a more 
appropriate person to contact, please contact myself a.ahmad@surrev.ac.uk or 
Cheryl Isherwood c.isherwood@surrev.ac.uk.
Kind regards 
Aryati Ahmad
32PGM00
Postgraduate Medical School
University of Surrey
Manor Park
Guildford
Surrey
GU2 7WG
Tel: 01483 688642 
Mobile: 07885241998 
Email: a.ahmad@surrev.ac.uk
Cheryl Isherwood (Nutrition Researcher)
Tel: 01483 688642
Mobile: 07887751198
Email: c.isherwood@surrev.ac.uk
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Effect of Dietary Carbohydrate on Lipids 
Participant screening sheet
L iNFORMATION
Name:
Address:
Contact telephone numbers:
Best time to call / on what number? 
Email address:
Next of kin contact name:
Next of kin telephone number:
GP Name:
GP Address:
Date of birth:
Age:
Occupation & town:
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Date informed consent obtained:
Dates of any holidays booked 
Would you like to be sent information on 
other studies carried out at The University of 
Surrey that you may be suitable for?
Yes No
VISIT 1. SCREENING VISIT Date:
Weight:
(kg/m2)
Height: BMI:
Waist circumference
Blood pressure: R1.......................  R2 R3....................  ave :.
YES NO
Lost or gained more than half a stone in the past three months
History of Type 1 or Type 2 diabetes; self and / or family
History of hormone disorders
History of liver disease
History of kidney disease
History of Heart Disease, Angina or Stroke
History of eating disorders inc anorexia or bulimia nervosa
History of drug or alcohol abuse within the last 2 years
How many alcoholic drinks consumed in a day? What kind?
Any previous surgical procedure to aid weight loss
Any known food allergies or intolerances
If yes please specify
Metal Implants / shrapnel / pacemaker
Claustrophobia
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Appendix 12: Study screening sheet (Cont.)
Medications known to alter body weight or appetite
Beta-biockers
Statins
Fibrates
Metformin
Any other medication / supplements
If yes please specify
Non-smoker / Smoker:.
Randomisation for f  phase:
Blood samples analyses:
Haematology:
Haemoglobin...............
White blood cell count. 
Platelet count..............
Clinical chemistry:
Triglyceride.
Total cholesterol 
Blood glucose... 
Insulin.................
Liver fat %
Liver fat
Suitable to participate in study:
a) Y e s  ........ No Maybe
Pease give further details:
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Appendix 13: Study consent form "
Volunteer Consent Form
UNIVERSITY O F
SURREY
I the undersigned voluntarily agree to take part in the study entitled: “How does dietary 
carbohydrate influence the formation of an atherogenic lipoprotein phenotype?”
I have read and understood the Information Sheet provided. I have been given a full 
explanation by the investigators of the nature, purpose, location and likely duration of the 
study, and of what I will be expected to do. I have been advised about any discomfort 
and possible ill-effects on my health and well-being which may result. I have been given 
the opportunity to ask questions on all aspects of the study and have understood the 
advice and information given as a result.
I agree to comply with any instruction given to me during the study and to co-operate fully 
with the investigators. I shall inform them immediately if I suffer any deterioration of any 
kind in my health or well-being, or experience any unexpected or unusual symptoms.
I agree to the investigators contacting my general practitioner about my participation in the 
study, and I authorise my GP to disclose details of my relevant medical or drug history, in 
confidence.
I consent to my personal data, as outlined in the accompanying information sheet, being 
used for the research project detailed in the information sheet, and agree that data 
collected may be shared with other researchers or interested parties. I understand that all 
personal data relating to volunteers is held and processed in the strictest confidence, and 
in accordance with the Data Protection Act (1998).
I understand that I am free to withdraw from the study at any time without needing to 
justify my decision and without prejudice.
I acknowledge that in consideration for completing the study I shall receive the sum of 
£200. I recognise that the sum would be less, and at the discretion of the Principal 
Investigator, if I withdraw before completion of the study.
I understand that in the event of my suffering a significant and enduring injury (including 
illness or disease) as a direct result of my participation in the study, compensation will be 
paid to me by the University, subject to certain provisos and limitations. The amount of 
compensation will be appropriate to the nature, severity and persistence of the injury and 
will, in general terms, be consistent with the amount of damages commonly awarded for 
similar injury by an English court in cases where the liability has been admitted
I confirm that I have read and understood the above and freely consent to participating in 
this study. I have been given adequate time to consider my participation and agree to 
comply with the instructions and restrictions of the study.
Name of volunteer (BLOCK CAPITALS)............................ ...........................................................
Signed ...........................................................
Date ...........................................................
Name of researcher/person taking consent 
(BLOCK CAPITALS)
Signed
Date
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Appendix 14; Study day sheet U N IV E R S IT Y  O F
SURREY
CHOT STUDY
VISIT 4/7 Date:
START OF THE INTERVENTION
Weight:
(kg/m2)
Height: BMI:
Waist circumference
Blood pressure: R1........................ R2 R3. ave
Blood samples analyses:
20ml total; 3 x purple tube + 1 x yellow tube + 1 x grey tube.(Vacutalners from Cedar) Spin 
samples at 3000 rpm for 10 minutes at 4 °C
Triglyceride........
Total cholesterol 
Blood glucose. .. 
Insulin.................
VISIT 6/9 Date:.
END OF THE INTERVENTION
Weight: Height: BMI:
Waist circumference
Blood pressure: R1...................... R2 R3. ave:
Blood samples analyses:
10ml total; 7 ml In purple Vacutainer + 3ml in green Vacutalner (both from PGMS). Spin 
samples at 3000 rpm for 10 minutes at 4 °C.
Triglyceride........
Total cholesterol 
Blood glucose... 
Insulin.................
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Appendix 15: Home visit sheet
Phase 1 : Home visit
VISIT DATE WEIGHT COMMENTS
1
2 Diet diary
3
4 Diet diary
5
Phase 2 : Home visit
VISIT DATE WEIGHT COMMENTS
1
2 Diet diary
3
4 Diet diary
5
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Appendix 16: Standard meal choices
r" UNIVERSITY OF
The Effect of Dietary Carbohydrate on Lipids
Menu for pre-study evening meal
The same meal has to be eaten the evening before each study day at the end of both 
parts of the study. Please choose one main and one dessert from the menu choices 
A or B and one side dish.
Option A
• Minced beef & potatoes and garlic slices
• Mushroom stroganoff and wild rice (V)
Dessert
•  Choc mousse
• Choc dessert
Option B
Sweet & sour chicken w rice and vegetable spring roll
Chicken & pasta
Chicken lasagna
King prawn & garlinguine
Tomato & cheese pasta bake (V)
Creamy mushroom pasta (V)
Dessert
Vanilla rice 
Summer fruit yoghurt
Side dish
steam rice w mixed veg 
Steam carrots cauliflower & beans 
Steam broccoli carrots and sweetcorn 
Garlic slice
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Appendix 17: Sample letter to GP for unsuitable volunteer
UNIVERSITY OF
i a  SURREY
Faculty of 
Health and Medical Sciences
Post Graduate Medical School
Daphne Jackson 
Road, Manor Park 
Guildford, Surrey, 
GU2 7WG
T. 01483 688642 
F. 01483 688501
Email c.isherwood@surrev.ac.uk
14*^  September 2010
Dear Dr,
A patient registered with your practice Mr ..................  (DOB:  ) expressed
interest in a dietary intervention I am coordinating at the University of Surrey entitled 
The Effect of Dietary Carbohydrate on Lipids’.
Mr .............. attended a screening appointment which included a blood sample to
measure biochemistry and haematology. Unfortunately he did not meet the inclusion 
criteria and therefore was not enrolled onto the trial.
I have enclosed a copy of these results for your records as doctors of participants on 
previous trials have mentioned that this kind of information useful to keep on file.
Best wishes,
Cheryl Isherwood
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Appendix 18: Figure 3.4
Figure 3.4: Total energy intake for the middle-aged male population (NDNS 
data) and the habitual, high and low sugar diet of all participants.
15n
ro 10
O)
0-
d  NDNS 2004 
d  Habitual diet 
d  High sugar diet 
d  Low sugar diet
Data are mean±SEM.
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Appendix 19: Figure 5.20 and 5.21
Figure 5.20: Plasma apo Cll concentrations before and after the high and low
sugar diets in the total cohort (n=25).
20n
3
S  15-
Ü
•5 10-
CL
Q. 5
I
0-
CZl High sugar diet 
CZl Low sugar diet
Pre Post 
Data are medians (interquartiles).
Pre Post
Figure 5.21 : Plasma apo E concentrations before and after high and low sugar 
diets in liver fat groups (< 4.2% n=13; n > 4.2% n=12).
d J  Pre High sugar diet 
mri Post High sugar diet 
1=1 Pre Low sugar diet 
Qm Post Low sugar diet
■q> 4-
Q.O
.9- 2 -
<4.2% > 4.2%
Data are medians (interquartiles).
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Appendix 20: List of assumptions for MAFF 1 method
•  The following products are described in the fifth edition as being made with milk: 
porridge, custard (made with milk), instant dessert powder, milk pudding, 
Bournvita powder, build-up powder, cocoa powder, drinking chocolate powder, 
Horlicks, milk shake powder, bread, cheese, onion and white sauce mixes. In 
these cases, the total sugars value for appropriate form of liquid milk (i.e. whole, 
semi-skimmed or skimmed) were deducted from the total sugars value for the 
foodstuff (fifth edition value).
•  This meant that in all other cases when this method was applied: NIVIES = total 
sugars. Sugars from milk were not subtracted from cheese, yoghurt, cream, ice­
cream, chocolate, soups or other recipe dishes as these were not considered to 
be in the form of ‘liquid milk’. Even yoghurt and cream do not fit the description of 
‘liquid milk’ because the description supplied by the FSA specifies ‘liquid milk’ as 
‘whole, semi-skimmed and skimmed cows milk’ and does not include the milk in 
recipe dishes that incorporate milk.
• Weight loss in recipe dishes did not apply to this method as in all recipe dishes, 
NIVIES = total sugars (Adapted from Kelly et al. [49]).
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Appendix 21 : List of assumptions for HNRC method
In bread, all sugars = intrinsic and milk 
In breakfast cereals, natural sugars = intrinsic and milk 
In biscuits, natural sugar = intrinsic and milk 
Dried fruit sugar = intrinsic and milk
Baked goods with milk component -  lactose and natural sugars = intrinsic and 
milk
Non-dairy ice-cream lactose = intrinsic and milk
Lactose (e.g. ice-cream, choc ice etc) = milk sugars (McCance and 
Widdowson’s The Composition of Foods Milk and Egg Products food table 
supplements were used where possible)
Sugars in pizza, curry, lasagne, casserole, stews = intrinsic 
Pureed foods = NMES (except mashed potato)
Purees and sauces unless milk based = NMES (if milk based, lactose = intrinsic 
and milk sugars)
Soups = lactose, intrinsic and milk; other sugars, NMES.
Baked beans, assume all sugars = NMES
Chocolate (including milk chocolate) = all sugars , NMES (in confectionery and 
biscuit categories but not ice-cream categories)
Chocolate in cakes = NMES
Apple chutney was based on values for tomato chutney. As tomato chutney = 
12.8% intrinsic and 32% NMES, apple chutney was calculated as 12.8% intrinsic 
and 38.3% NMES.
All stewed fruit sugars = NMES 
Fruit sugars in pie fillings, jams = intrinsic 
Sugars from nuts (including ground and pureed nuts) = intrinsic 
Fruit juices -  all sugars = NMES
Natural sugars were estimated to be 0.4g/1 OOg in breakfast cereals (without 
fruit) and cakes (without fruit or jam)
Tomato sauce was treated as a pureed food
Weight loss in recipe dishes was not taken into account. For recipe dishes, 
NMES content (g/IOOg) was determined on the recipe as published in McCance 
and Widdowson’s The Composition of Foods without subtracting any losses 
resulting from heating or cooking (adapted from Kelly et al. [49]).
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